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ABSTRACT 
Vascular injury and endothelial dysfunction are recognised features of atherosclerosis, transplant 
vasculopathy, SLE and rheumatoid. Heme oxygenase-1 (HO-1) and complement inhibitory proteins 
(CIP) decay-accelerating factor (DAF) limit vascular injury. There is considerable interest in 
therapeutic manipulation of cytoprotective genes and statins induce HO-1 and DAF expression, 
while rapamycin (R) enhances HO-1 and protects against post-transplant vasculopathy. A 
therapeutic regimen combining immunosuppression with vasculoprotection has the potential to 
prevent accelerated atherosclerosis in systemic inflammatory diseases. Based on previous data 
generated in the lab, my project explored the combination of atorvastatin and rapamycin, using 
DAF and HO-1 as target genes. 
A combination of AT 0.5μM and R 1μM led to a synergistic increase in EC DAF expression 24-72h 
post-treatment (>200%, p<0.05). In contrast, no change in CD59 was seen. In vivo, AT+R enhanced 
DAF expression in the murine aorta when compared to treatment with AT or R alone. The 
functional relevance of this synergy was revealed by enhanced protection against complement-
mediated lysis, when compared to EC treated with R or AT (35% v 75% and 55% respectively, 
p<0.05). The role of DAF was confirmed by loss of protection in the presence of a DAF inhibitory 
mAb. Mechanistically, AT+R increased HO-1 expression and activity, while HO-1 inhibition with 
ZnPP attenuated synergy. As a consequence of HO-1-activation, AT+R increased intracellular 
ferritin, while Fe2+ chelation with DFO suggested depletion of intracellular Fe2+ is important for 
synergy. AT+R enhanced PKCα phosphorylation, while a DN-PKCα adenovirus and a PKCα 
inhibitory peptide abrogated DAF induction (AT + R 250% v DN-adv 95%, p<0.05). AT and R-
induced p38 MAPK phosphorylation and inhibition attenuated DAF upregulation (AT+R 270% v 
120%, p<0.05). Transcriptionally, DAF induction by AT+R required activation and binding of CREB 
to the DAF promoter. Synergistic upregulation of DAF expression was reproduced by simvastatin 
and rapamycin, while combinations of AT and cyclosporine or mycophenolate were ineffective.  
Treatment with rapamycin and atorvastatin synergistically enhances DAF expression and 
protection against complement-mediated injury. Rapamycin increases HO-1 activity and 
intracellular ferritin, and this combined with HMG-CoA reductase inhibition and activation of 
PKCα, p38 MAPK and CREB, results in optimal DAF induction. Thus, rapamycin and statin 
combination therapy may represent a means by which vascular endothelium can be 
therapeutically conditioned against complement-mediated injury and is worthy of further study in 
vascular diseases.  
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CHAPTER 1 
INTRODUCTION 
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1.1 VASCULAR ENDOTHELIUM ROLE IN PHYSIOLOGY & DISEASE 
The vascular endothelium is a highly dynamic and heterogeneous tissue which principally 
maintains a physiological and physical barrier between the vascular and extra-vascular 
compartments. It actively regulates the transit of solutes, macromolecules and blood cells across 
the vascular wall, generates and integrates biological signals and plays an essential role in 
hemostasis, leukocyte traffic and vascular tone maintaining an anti-thrombotic, fibrinolytic and 
anti-inflammatory surface (Cines et al., 1998).  
1.1.1 Embryonic development  
The cardiovascular system is amongst the first systems to develop within the embryo. Vascular 
endothelial cells are mesodermal in origin and develop from angioblasts within the blood islands 
of the primitive yolk sac (Carmeliet, 2000). The development of the vascular system requires two 
recognized processes; vasculogenesis and angiogenesis. Vasculogenesis is the de novo formation 
of new vessels and requires the formation and differentiation of endothelial progenitor cells from 
the mesoderm, whilst angiogenesis is the expansion of the vascular tree by new capillary 
formation and endothelial cell sprouting from pre-existing vessels (Carmeliet, 2000;Kassmeyer et 
al., 2009). Vascular development is driven by specific growth factor-cytokine receptor 
combinations, extracellular matrix (ECM) proteins, tissue remodeling by proteinases/enzymes and 
specific cell-matrix and cell-cell interactions. Amongst the most important growth factors are 
vascular endothelial growth factor A (VEGF), basic-fibroblast growth factor (FGF) and angiopoietins 
1 and 2 (Ang-1 and Ang-2). FGF and VEGF on binding to their respective receptors trigger EC 
proliferation and migration promoting early vasculogenesis, whilst angiopoietins promote 
extension of the vascular tree and Ang-1 in particular recruits accessory cells and creates stable 
vessels (Suburo & D'Amore, 2006). The ECM components such as fibronectin, collagen and 
proteoglycans interact with endothelial cells via matrix-cell adhesion receptors such as the 
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integrins, which anchor the cell to the ECM and transmit diverse intracellular signals regulating 
cytoskeletal organization, cell migration and stability, proliferation and cell survival (Hynes, 2007). 
For vasculogenesis and angiogenesis to proceed, endothelial cells must make contact with 
neighbouring cells in order for vessels to extend and sprout.  These cell-cell interactions are 
initially mediated by distinct intercellular adhesion molecules including platelet EC adhesion 
molecule-1 (PECAM-1, CD31) and vascular endothelial cadherin (VE-cadherin). As the vessel 
matures, classical junctional complexes such as tight and gap junctions develop (Bazzoni & Dejana, 
2004). Vascular extension and remodeling requires the co-ordinated synthesis and degradation of 
various tissues by specific enzymes including the matrix-metalloproteinases and plasminogen 
activators (Cines et al., 1998;Carmeliet, 2000). Many of these molecular processes required for 
vasculogenesis and angiogenesis are also involved in maintaining vascular homeostasis within the 
adult. 
1.1.2 Functions of the vascular endothelium 
Barrier function 
The vascular endothelium is a semi-permeable barrier, regulating the transport of fluids, solutes 
and macromolecules across the vascular wall. The endothelial barrier is maintained by two main 
types of intercellular junctions; tight junctions (zona occludens) and adherens junctions (zona 
adherens), which are principally composed of VE-cadherin and PECAM-1 (CD31) (Bazzoni & 
Dejana, 2004). Small molecules and fluids tend to pass passively through the endothelial barrier 
using a paracellular route, whereas larger molecules use an active transcellular route employing 
receptor-dependent and independent mechanisms, caveolae, vesiculo-vacuolar organelles (VVO’s) 
and trans-cellular channels (Feng et al., 2002;Aird, 2007a). The endothelium exhibits a basal 
constitutive permeability during physiology but demonstrates inducible permeability during 
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periods of acute and chronic inflammation. The post-capillary venule is the main site of inducible 
permeability, although in various diseases such as atherosclerosis, other sites within the vascular 
tree may demonstrate enhanced permeability (Ross, 1999). Although mechanisms for inducible 
permeability are not fully understood, agonists such as histamine, serotonin, bradykinin, 
substance P, VEGF and TNF-α may increase EC permeability by enhancing intercellular gap 
formation through promotion of EC retraction, formation of fenestrae and increasing flow of 
macromolecules via VVO’s (Majno & Palade, 1961;Majno et al., 1961;Joris et al., 1990;Aird, 
2007a). 
Regulation of leukocyte traffic  
During the quiescent, non-active state, endothelial cells express low or negligible levels of 
leukocyte-adhesion molecules on their cell surface. Following vascular injury and/or in response to 
inflammatory stimuli the endothelium adopts an ‘active’ phenotype and rapidly upregulates its 
expression of cell surface leucocyte-adhesion molecules; E-selectin, P-selectin, vascular cell 
adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1). This enhances the 
recruitment of neutrophils, stimulates secretion of soluble mediators such as cytokines (IL-1, IL-6) 
and chemoattractants (RANTES, monocyte chemotactic protein-1 [MCP-1]), which perpetuate 
inflammation and leukocyte recruitment (Bratt & Palmblad, 1997). Consequently leukocytes are 
captured by ECs initiating the leukocyte-adhesion cascade. E-and P-selectin interact with their 
ligands; P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-1 (ESL-1) whilst, leukocyte 
activation enhances integrin affinity and avidity leading to firm adhesion to ICAM-1 expressed on 
ECs (Wagner & Frenette, 2008). Finally, leukocytes transmigrate to sites of injury via a gradient of 
chemotactic molecules which include MCP-1, complement components (C3a, C5a), cytokines and 
prostaglandins through paracellular pathways using interactions with junctional adhesion 
molecules (JAMs), CD99 and PECAM-1, or alternatively through the transcellular route. These 
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steps predominantly occur in the post-capillary venule but may also occur in large veins, capillaries 
and arterioles (Aird, 2007a;Wagner & Frenette, 2008).  
Regulation of haemostasis 
The vascular endothelium facilitates essential blood flow to all organ-systems by providing an anti-
thrombotic surface preventing platelet adhesion and inhibiting activation of the coagulation 
cascade.  However, endothelial or vascular injury secondary to trauma or inflammatory stimuli 
results in a pro-thrombotic transformation leading to platelet activation and aggregation with 
intrinsic/extrinsic activation of the coagulation cascade. These physiological processes culminate in 
the generation of thrombin, fibrin and clot formation which aims to prevent blood loss, initiate 
vascular repair and maintain vascular integrity. The vascular endothelium maintains a dynamic 
equilibrium between several pro-thrombotic and anti-thrombotic mechanisms within the vascular 
wall. Many anti-thrombotic mechanisms are directed against thrombin formation which is the 
pivotal step in the coagulation cascade. EC derived anti-thrombotic factors include nitric oxide 
(NO), prostacyclin, tissue factor pathway inhibitor, thrombomodulin which facilitates protein C 
activity, and tissue plasminogen activator (t-PA) which promotes fibrinolysis. Other anti-
thrombotic factors include anti-thrombin III, dermatan sulphate and heparan sulphate which are 
located within the connective tissue matrix surrounding ECs. Pro-thrombotic factors generated by 
ECs include tissue factor, plasminogen activator inhibitor-1 (PAI-1), platelet activating factor and 
von Willebrands factor (vWF) which promotes platelet adhesion to subendothelial surfaces by 
binding to glycoprotein 1b (Aird, 2001). The coagulation cascade may be activated by the 
complement components C3a and C5a, and by products of the kinin cascade (Amara et al., 
2008;Schmaier, 2008). Thus haemostasis is interconnected with other plasma protein cascades 
and will be activated during periods of inflammation.  
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Vasoregulation 
The vascular endothelium regulates blood flow, blood pressure and vascular hemodynamics by 
secreting vasodilators such as NO, prostacyclin, and vascoconstrictors including endothelin-1, 
angiotensin II and platelet activating factor (PAF). NO is the fundamental regulator of vascular 
homeostasis and is constitutively generated by ECs, whereas other factors are synthesized and 
released in response to extracellular stimuli. 
NO is a highly soluble, gaseous molecule which is liberated during oxidation of L-arginine to 
citrulline by the enzyme nitric oxide synthase (NOS). NO mediates its effects by rapidly diffusing to 
neighboring cells where it binds and activates soluble guanylate cyclase leading to the generation 
of cGMP which has many diverse cellular effects. NOS shares homology with the cytochrome p450 
family of enzymes and requires tetrahydrobiopterin, NADPH and calcium/calmodulin for NO 
synthesis. There are three recognized NOS isoforms which differ in their regulation and tissue 
expression; endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). eNOS is 
constitutively expressed in the vascular endothelium and constantly generates NO which diffuses 
into neighboring VSMC’s and activates guanylate cyclase leading to VSMC relaxation and 
vasodilation (Moncada & Higgs, 2006;Vanhoutte, 2009). Its liberation into the circulation also 
inhibits platelet aggregation and activation contributing to an anti-thrombotic vasculature. NO 
production is acutely regulated by substrate bioavailability and/or enzyme activity and more 
chronically it is controlled by enhanced enzyme synthesis (Napoli & Ignarro, 2009). The main 
stimulus for NO production is laminar fluid shear stress which can enhance enzyme activity as well 
as enzyme synthesis (Feletou & Vanhoutte, 2009). Other agonists include acetyl-choline, 
bradykinin, histamine, serotonin, ATP, ADP and drug therapy including statins (Moncada & Higgs, 
2006). 
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In contrast to NO, endothelin-1 is an extremely potent vasoconstrictor and promotes platelet 
aggregation in response to hypoxia, shear stress and ischemia. It is a peptide which binds to 
endothelin-A receptors, a G-protein coupled cell surface receptor expressed on VSMCs. Receptor 
activation triggers VSMC proliferation and promotes vasoconstriction (Abraham & Dashwood, 
2008).  
Prostacyclin and PAF are involved in the fine regulation of vascular tone and complement the 
effects of NO and endothelin-1. Prostacyclin, an eicosanoid derived from vascular EC COX-1 and 
COX-2, is induced by laminar shear stress and sites of EC perturbation. It promotes vasodilation, 
inhibits platelet aggregation and mediates its effects by interacting with cell surface G-protein 
coupled receptors (Simmons et al., 2004). PAF is a phospholipid and signals via a juxtacrine 
mechanism promoting vasoconstriction and leucocyte adhesion to the endothelium (von et al., 
2007). 
1.1.3 Vascular Endothelial Injury and its role in Disease 
During physiology, the endothelium must maintain a constitutive anti-thrombotic, anti-
inflammatory and vasoregulatory phenotype which maintains vascular wall integrity and function. 
In response to various extracellular stimuli, endothelial cells can selectively regulate permeability, 
haemostasis, leucocyte recruitment and vasomotor function. This dynamic role is illustrated by 
acute inflammation, which is an important physiological response of vascularised tissue to injury 
and clears pathogenic stimuli, recruits neutrophils and initiates wound repair and healing.  The 
vascular endothelium is involved in all steps of this process, increasing vascular wall permeability, 
promoting vasodilation and recruiting leucocytes to the injured tissue. However, if mal-adapted, 
endothelial cells may perpetuate inflammatory disease.  
Due to its anatomical location, the endothelium is constantly exposed to noxious stimuli including 
oxidized lipoproteins, C-reactive protein, pro-inflammatory cytokines, bacterial endotoxins, 
19 
 
autoimmune Abs, complement activation products, proteolytic enzymes and hemodynamic forces 
(Ross, 1999). These stimuli may injure, activate and switch the endothelial phenotype from an 
anti-inflammatory, anti-thrombotic and anti-proliferative surface to an ‘activated’ or dysfunctional 
one. Thus, the vascular endothelium is involved in all vascular diseases either primarily 
contributing to pathogenesis or secondarily via bystander cellular injury. Endothelial dysfunction 
(ED) is characterized by impaired endothelial-dependent vasodilation, which is largely attributed 
to diminished endothelial-derived NO bioavailability (Cines et al., 1998;Moncada & Higgs, 2006). 
ED can be measured non-invasively by assessing flow-mediated dilatation and is shown to precede 
atherosclerosis, is associated with atherosclerotic risk factors and is demonstrated in other 
vascular diseases including diabetes mellitus, systemic vasculitis and transplant vasculopathy 
(Booth et al., 2004;Wehner et al., 2007;Xu & Zou, 2009).  
Atherosclerosis, the most prevalent vascular disease, is multifactorial in origin and involves 
interplay between genetic susceptibility, dyslipidaemia, hypertension, insulin resistance and 
cigarette smoking, culminating in the formation of enzymatic/oxidatively modified LDL which 
contributes to EC injury and activation at susceptible sites marked by high oscillatory flow around 
arterial bends and branch points. Consequently the up-regulation of leucocyte adhesion molecules 
and platelet receptors on the EC surface combined with the production of pro-inflammatory and 
chemotactic cytokines results in the infiltration of platelets, monocytes/macrophages and T-
lymphocytes into the sub-endothelial intima. Activated macrophages enhance the clearance of 
modified LDL and cellular debris resulting in the formation of foam cells and fatty streaks with 
further release of free radicals, proteases and pro-inflammatory cytokines contributing to vascular 
injury. Interferon-γ producing Th1-cells, the predominant lymphocyte population within the 
evolving plaque, guide and potentiate macrophage responses, whilst collagen deposition by 
infiltrating and proliferating smooth muscle cells leads to the formation of a fibrous cap. Hence a 
complex plaque consists of a core containing lipid rich macrophages surrounded by smooth muscle 
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cells, mast cells, T-lymphocytes and a collagen rich fibrous cap protruding into the vessel lumen. 
The plaque becomes vulnerable to rupture as the collagen rich cap is degraded by enzymes 
including proteases and matrix metalloproteinases (MMP’s), resulting in fibrous cap thinning with 
increasing vulnerability to rupture and thrombosis (Ross, 1999;Hansson, 2005). 
Hyperglycemia in diabetes mellitus predisposes to the formation of circulating advanced glycation 
end products (AGE) which contributes to the pathogenesis of micro- and macro-vascular 
complications including accelerated atherosclerosis. AGE bind to various receptors on ECs leading 
to EC activation, ROS formation, activation of NF-κB and other pro-inflammatory signaling 
pathways promoting vascular dysfunction (Huang, 2005). 
Vascular endothelial injury is a recognized feature of the chronic inflammatory diseases such as 
rheumatoid arthritis, ankylosing spondylitis, vasculitides and systemic lupus erythematosus (SLE) 
(Ilowite, 2000;Bacon et al., 2002). Assessment of vascular function using pulse wave velocity 
analysis or flow-mediated vasodilation reveals significant aberrations in SLE, vasculitis and RA 
(Raza et al., 2000;Selzer et al., 2001;El-Magadmi et al., 2004;Gonzalez-Juanatey et al., 2004). 
Furthermore immunosuppressive treatment in these patients may improve vascular function 
implying a role for systemic inflammation and soluble mediators in EC injury (Bacon et al., 
2002;Booth et al., 2004;Bruce, 2005;Raza et al., 2006;Gonzalez-Juanatey et al., 2006;Gonzalez-
Juanatey et al., 2008). The complications of chronic inflammatory injury are reflected by a high 
rate of atherosclerotic disease in these patients (Bacon et al., 2002;Sattar et al., 2003;Bruce, 
2005). Thus, endothelial dysfunction in patients with SLE is an independent predictor of 
atherosclerosis, increasing the risk of myocardial infarction by 44 times in pre-menopausal 
women, and in rheumatoid arthritis there is a 3-fold excess mortality from cardiovascular disease 
and thrombosis (Manzi et al., 1997;Sattar et al., 2003). 
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Antibody-mediated EC injury is involved in the primary pathogenesis of diseases including the 
systemic vasculitides (Salama, 1999), hyperacute graft rejection and transplant vasculopathy 
(Wehner et al., 2007). In hyper-acute allograft rejection host anti-endothelial cell antibodies 
directed against endothelial antigens within the graft leads to complement and NK-cell mediated 
microvascular EC injury, lysis and apoptosis resulting in thrombosis, organ infarction and rejection. 
This complication is minimized by better tissue cross-matching protocols (Pierson, III, 2009). In 
vasculitides such as Wegener’s granulomatosis, anti-neutrophil cytoplasmic antibodies (ANCA) 
bind to the PR3 antigen within neutrophils leading to activation of complement-dependent and NK 
cell-dependent cytotoxicity and vascular injury (Little & Savage, 2008). Other diseases where ECs 
play an important role are ischemia-reperfusion injury, hemolytic uremic syndrome, thrombotic-
thrombocytopenia purpura and pre-eclampsia (Fischetti & Tedesco, 2006).  
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1.2 ENDOTHELIAL CELL CYTOPROTECTION AND ANTI-INFLAMMATORY 
PATHWAYS WITHIN THE VASCULAR WALL 
Inflammation is an important innate response to tissue injury and aids removal of the pathogenic 
stimulus, recruits acquired immune responses and initiates tissue repair and wound healing. 
Aberrations in the inflammatory response will lead to excessive tissue damage and contribute to 
disease. As the vascular endothelium is located at the interface between the intra- and extra-
vascular compartments it lies in a key position to modulate several aspects of the inflammatory 
response. The vascular endothelium has several homeostatic protective mechanisms which aim to 
limit bystander endothelial cell injury, maintaining vascular integrity during inflammation. These 
intrinsic homeostatic, protective mechanisms which prevent cellular injury, termed 
cytoprotection, encompass soluble anti-inflammatory molecules, cell surface proteins and 
receptors, intercellular adhesion molecules, protective intra-cellular signaling pathways and 
specific cytoprotective, anti-apoptotic and anti-inflammatory genes (figure 1). 
1.2.1 Soluble anti-inflammatory molecules and growth factors 
Transforming growth factor-β (TGF-β) 
TGF-β is an anti-inflammatory peptide which is synthesized and secreted by vascular endothelial 
and smooth muscle cells in response to pro-inflammatory cytokines (Dabek et al., 2006). In vitro, 
TGF-β attenuates iNOS induction inhibiting macrophage activation and function, suppresses EC 
TNF-α production and prevents IL-1β-induced VCAM-1, MCP-1 and IL-8  expression (Smith et al., 
1996;Vodovotz, 1997;DiChiara et al., 2000;Park et al., 2000).  Moreover, TGF-β restores 
endothelial function in mice treated with TNF-α (Lefer et al., 1990). The anti-inflammatory 
importance of TGF-β in the vasculature is confirmed in knockout mice which die in utero from a 
chronic inflammatory disease characterized by cardio-pulmonary inflammation and demonstrate  
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Figure 1. Vascular endothelial anti-inflammatory and cytoprotective mechanisms. The vascular
endothelium has multiple homeostatic protective mechanisms which limit bystander
endothelial cell injury and maintain vascular integrity during inflammation. These include anti-
inflammatory cytokines (IL-10, IL-13), growth factors (VEGF, Ang-1), intercellular adhesion
molecules (VE-cadherin), signalling pathways (protein kinase C, PI-3 kinase/Akt) and multiple
anti-apoptotic (Bcl-2) and anti-inflammatory proteins (HO-1).
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enhanced leucocyte adhesion to the pulmonary endothelium (Topper, 2001). Its vasoprotective 
properties are supported further by TGF-β +/-mice which, when fed a high cholesterol diet, show 
increased EC surface expression of ICAM-1 and VCAM-1 with enhanced macrophage infiltration 
into the vascular wall (Grainger et al., 2000). The multiple effects of TGF-β are mediated via cell 
surface receptors which signal via the SMAD family of proteins, activate CREB and prevent 
association with p65/Nf-κB and inhibit Nf-κB signaling (Dabek et al., 2006). 
Interleukin-10  
Interleukin-10 (IL-10) is an immunomodulatory cytokine produced by endothelial cells, smooth 
muscle cells, Th2 lymphocytes, B-lymphocytes and monocytes/macrophages. The cytokine inhibits 
antigen driven T-cell proliferation and attenuates Th1 cellular responses (Tedgui & Mallat, 2006).  
IL-10 mediates many of its described anti-inflammatory effects by inhibiting NF-KB signaling. The 
cytokine binds to its cell surface receptor, which is composed of two signaling subunits and 
belongs to the type 2 cytokine receptor family. Following receptor ligation and activation, 
intracellular signaling is initiated by JAK-1 and STAT-3 which eventually inhibits NF-KB activation. 
The cytokine also mediates its actions via other signaling cascades including the MAP kinases 
ERK1/2 (Tedgui & Mallat, 2001).  
In vitro studies on ECs demonstrate that IL-10 attenuates IL-1-induced ICAM-1 and VCAM-1 
expression, and inhibits FGF-2 induced aortic smooth muscle cell proliferation (Selzman et al., 
1998;Mallat et al., 1999). Its cytoprotective importance in atherogenesis is supported by 
observations in the IL-10 deficient mouse fed an atherogenic diet, which reveal increased 
leucocyte infiltration into the vascular wall (Mallat et al., 1999). Furthermore, IL-10 significantly 
decreases LDL-induced monocyte adhesion to endothelial cells and attenuates endothelial NF-KB 
activity, ICAM-1 and VCAM-1 expression in mice fed a high fat diet (Pinderski Oslund et al., 
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1999;Mallat et al., 1999). Several murine models of vascular disease demonstrate that IL-10 has 
multiple anti-inflammatory effects within the vasculature and is a potential therapeutic target. 
Thus IL-10 decreases ICAM-1 expression and protects against myocardial ischemia-reperfusion 
injury, and attenuates neo-intimal hyperplasia in mice subjected to balloon angioplasty (Hayward 
et al., 1997;Feldman et al., 2000).  
Vascular endothelial growth factor (VEGF) 
VEGF is made up of a number of isoforms of which VEGFA predominates. Although VEGF is 
essential for embryonic vasculogenesis, in the adult it may contribute to both pro-inflammatory 
and anti-inflammatory processes. Its importance in vascular homeostasis is suggested by its 
constitutive basal expression in all vascular endothelial cells (Maharaj et al., 2006). VEGF mediates 
its cellular effects by binding to a cell surface tyrosine kinase receptor of which there are three 
types; VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-1 and 2 are expressed on all endothelial cells, 
osteoblasts, monocytes/macrophages and hemopoietic stem cells. This differs from VEGFR-3 
which is expressed on endothelia in the developing embryo and is restricted to the lymphatic 
circulation in the adult (Testa et al., 2008).  
VEGF on binding to VEGFR-2 stimulates endothelial cell proliferation, cellular migration, inhibits 
apoptosis, enhances vascular permeability and promotes angiogenesis. Tissue hypoxia is a well 
known driver for angiogenesis and VEGF expression is enhanced by hypoxia through the 
stabilization of various transcription factors including hypoxia-inducible factor-1 (HIF). 
Angiogenesis and neovascularisation is an important contributor in many diseases including 
atherosclerosis, cancer, diabetic retinopathy and progressive rheumatoid arthritis (Walsh, 2007).  
Analysis of atherosclerotic plaques reveals that the number of inflammatory cells, degree of 
neovascularisation and the expression of VEGF and VEGF-R2 appears to correlate with the 
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complexity and severity of the plaque (Inoue et al., 1998;Belgore et al., 2004). Furthermore levels 
of VEGF are greater in patients with coronary artery disease and correlate with cardiovascular risk 
factors such as hyperlipidemia and cigarette smoking, while lipid-lowering therapy with statins 
decreases VEGF levels (Alber et al., 2002;Tsai et al., 2005;Alber et al., 2005;Trape et al., 2006). 
Further evidence for VEGF as a pro-atherogenic molecule arises from animal studies. VEGF 
infusion into the Apo-E knockout mouse enhanced atheroma formation whilst vaccination against 
VEGFR-2 in the LDL-receptor knockout mouse attenuated atherosclerosis. These observations 
suggest that VEGF plays a role in the pathogenesis of atherosclerosis (Celletti et al., 2001;Hauer et 
al., 2007). 
A supportive role for VEGF as an atheroprotective molecule is suggested by human VEGF 
polymorphisms which lead to high levels of VEGF and associates with coronary artery disease risk 
reduction (Howell et al., 2005). Similarly, therapy with anti-VEGF monoclonal antibodies disrupts 
micro-vascular homeostasis and may predispose to a thrombotic microangiopathy (Bollee et al., 
2009). Other studies demonstrate that VEGF regulates the expression and activity of several 
endothelial cytoprotective molecules. Thus VEGF enhances eNOS expression and NO production, 
the anti-apoptotic proteins bcl-2 and A1, complement regulatory proteins such as DAF and anti-
oxidant proteins including HO-1 (van der et al., 1997;Gerber et al., 1998a;Mason et al., 
2001;Bussolati et al., 2004).  
Thus, the role of VEGF as a cytoprotective molecule is complex. It may have a dual role, which is 
setting dependent. On the one hand it may be critical for vascular endothelial homeostasis, and on 
the other, in the presence of inflammation VEGF may contribute to vascular dysfunction. 
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Angiopoietin-1 
Angiopoietin-1 (Ang-1) and 2 (Ang-2), like VEGF, are growth factors which are also required for 
vasculogenesis and angiogenesis. Both molecules mediate their cellular effects by binding to the 
membrane bound tyrosine kinase receptors tie-1 and tie-2. Ang-1 is constitutively expressed in 
pericytes and endothelial cells and maintains endothelial cell homeostasis, whereas Ang-2 is 
expressed in activated endothelial cells and opposes the actions of Ang-1. The relative importance 
of the angiopoietin signaling system in vasculogenesis and embryogenesis is indicated by Ang-1, 
Ang-2, tie-1 or tie-2 gene deletion studies which lead to a poorly developed vasculature and 
embryonic death (Sato et al., 1995;Partanen et al., 1996;Suri et al., 1996;Gale et al., 2002). 
Furthermore, Ang-1 inhibits EC apoptosis and triggers cellular migration, promoting endothelial 
tube formation in vitro (Witzenbichler et al., 1998;Kwak et al., 1999;Kim et al., 2000). 
Many studies indicate that Ang-1 has an endothelial and vascular cytoprotective profile. Ang-1 
suppresses thrombin, TNF-α, and VEGF-induced EC phosphorylation of PECAM-1 and VE-cadherin, 
preserving endothelial integrity and permeability (Gamble et al., 2000;Satchell et al., 2004). 
Furthermore, Angiopoietin-1 infusion preserves intestinal and pulmonary microvascular integrity 
in radiation-treated mice, prevents apoptosis of microvascular endothelial cells in a model of 
pulmonary hypertension and inhibits VEGF-induced vascular leakage within the cutaneous and 
retinal microvasculature (Thurston et al., 2000;Zhao et al., 2003;Cho et al., 2004). An anti-
inflammatory role is indicated by the ability of Ang-1 to inhibit VEGF-induced ICAM-1, VCAM-1 and 
E-selectin expression in cultured endothelial cells (Gamble et al., 2000;Kim et al., 2001). Moreover, 
studies in vivo demonstrate that Ang-1 inhibits VEGF-induced ICAM-1, E-selectin and VCAM-1 in 
the skin microvasculature, retinal vessels of diabetic rats and within the pulmonary vasculature of 
LPS-treated mice (Thurston et al., 1999;Joussen et al., 2002;Witzenbichler et al., 2005). These 
observations are associated with a reduction in leucocyte adhesion. Finally, studies in HUVEC 
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indicate that Ang-1 suppresses TNF-α induced tissue factor expression. Thus, Ang-1 appears to 
have multiple vasoprotective effects by regulating inflammation, vascular permeability and 
possibly thrombosis.  It is suggested that these protective properties are mediated through a PI-3 
kinase/Akt and A20-dependent pathway (Brindle et al., 2006).  
1.2.2 Intracellular cytoprotective proteins 
Endothelial nitric oxide synthase 
As well as being essential for the regulation of vascular homeostasis NO has an important anti-
inflammatory role within the vasculature. NO prevents leucocyte rolling and adhesion by inhibiting 
cytokine-induced ICAM-1 and VCAM-1 expression, attenuates endothelial synthesis and 
expression of the chemokines M-CSF and MCP-1 in response to interferon-γ (Kubes et al., 1991;De 
et al., 1995;Peng et al., 1995;Zeiher et al., 1995). The anti-inflammatory importance of NO within 
the vasculature has been demonstrated using the NOS inhibitor L-NAME and eNOS deficient mice. 
Chronic in vivo inhibition of NOS with L-NAME enhances vascular infiltration by monocytes with an 
increase in ICAM-1 and VCAM-1 expression, increases expression of the pro-inflammatory 
cytokines and chemokines including IL-6 and MCP-1 (Koyanagi et al., 2000;Gonzalez et al., 
2000;Kuhlencordt et al., 2001). Furthermore, eNOS deficient mice have enhanced leucocyte 
adhesion to endothelium and accelerated atherosclerosis (Kuhlencordt et al., 2001). The anti-
inflammatory mechanism of NO is predominantly attributed to inhibition of Nf-κB (Spiecker et al., 
1997). 
Cyclo-oxygenase-2 and prostacyclin 
Prostacyclin, the predominant prostanoid produced by endothelial cells, is formed by the 
sequential activity of cyclo-oxygenases and prostacyclin synthase. Endothelial cell COX-2 may be 
induced by laminar shear stress and along with COX-1 is likely to be the main driver for vascular 
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derived-prostacyclin (Topper et al., 1996). Once generated, prostacyclin diffuses to neighbouring 
smooth muscle cells, binds to its G-protein coupled receptor (IP) and triggers VSMC relaxation, 
whilst activation of the IP receptor system on platelets prevents their aggregation (Davies et al., 
1989). Thus prostacyclin has a key role in regulating vasomotor tone and platelet aggregation, 
opposing the pro-thrombotic and vasoconstrictor effects of thomboxane A2. Furthermore, 
prostacyclin promotes fibrinolysis in vivo (Gryglewski et al., 2003), inhibits VSMC differentiation, 
proliferation and migration (Alfranca et al., 2006), protecting against neointimal proliferation 
following vascular injury (Numaguchi et al., 1999). Moreover, prostacyclin may protect against 
endothelial cell apoptosis (Liou et al., 2007) and is cytoprotective in models of transplant 
arteriosclerosis (Rudic et al., 2005). Despite these vasoprotective properties, COX-2 activity may 
promote atherogenesis. Atherosclerotic plaques express high levels of COX-2 and selective or non-
selective blockade attenuates atheroma in LDLR -/- or ApoE -/- mice (Burleigh et al., 2002;Burleigh 
et al., 2005).  However, this remains a controversial topic, fuelled by the recent recognition of 
accelerated atherothrombosis in patients treated with NSAIDs or selective COX-2 inhibitors, 
attributed by some to the unopposed activity of platelet-derived thromboxane A2. This 
explanation cannot account for the apparent equivalent atherothrombotic risk associated with the 
use of COX-2 selective and non-selective NSAIDs  (Warner & Mitchell, 2008). 
1.2.3 Anti-apoptotic genes and proteins 
 
Vascular injury resulting from oxidized LDL, oxidative stress, complement and inflammatory 
cytokines may promote endothelial cell apoptosis resulting in endothelial cell denudation, vascular 
inflammation, atheroma formation and thrombosis. The vascular endothelium expresses several 
anti-apoptotic proteins including those of the bcl-2 family (bcl-2, bcl-xl, A1), A20 and HO-1 which 
inhibit apoptosis following vascular injury.  
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Bcl-2 family 
 
The bcl-2 family of proteins are involved in the intrinsic pathway of apoptosis, regulating 
cytochrome c release from mitochondria which associates with APAF-1 leading to cleavage and 
activation of pro-caspase 9 followed by a cascade of caspases which execute the process of 
apoptosis. A balance of pro-apoptotic and anti-apoptotic mechanisms determine the execution of 
apoptosis. Various growth factors, inter-cellular interactions and extra-cellular stimuli regulate 
apoptosis by altering the expression of the bcl-2 family of proteins (Kutuk & Basaga, 2006). Many 
stimuli known to be important in promoting vascular homeostasis transmit several EC survival 
signals. Laminar shear stress, VEGF, FGF-2 and angiopoietin-1 are known to promote EC survival 
via an anti-apoptotic signaling pathway which involves the enhanced expression of bcl-2 
(Stoneman & Bennett, 2004). Furthermore integrins and CD31 in combination with VEGF promote 
EC survival by enhancing bcl-2 expression (Gerber et al., 1998a;Fujikawa et al., 1999). Nitric oxide, 
a fundamental molecule in vascular homeostasis also protects ECs from TNF-induced apoptosis by 
enhancing bcl-2 expression (Dimmeler et al., 1999).  
A20 
A20, is a cytoplasmic protein with a zinc-finger motif, is expressed at low levels in ‘resting’ ECs. 
Following cellular injury and during inflammation, A20 expression is rapidly induced and has a dual 
role regulating apoptosis and Nf-κB-dependent inflammation. A20 was first identified as an 
inhibitor of fas/fas-ligand, NK-cell or complement-dependent apoptosis by preventing cleavage of 
bid, caspases 8, 2, 3, 6 and cytochrome c release. A20 is induced following Nf-κB activation and 
serves as a negative feedback inhibitor of further Nf-κB stimulation. This occurs through A20’s 
ubiquitin editing properties which deubiquitinate and inactivate NEMO and RIP-1, accessory 
proteins required for dissociation of IKK and Nf-κB activation (Vereecke et al., 2009). The anti-
inflammatory importance of A20 is demonstrated by A20 deficient mice which are hypersensitive 
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to TNF-α and die from multi-system inflammation and cachexia (Lee et al., 2000). The role of A20 
in atherosclerosis is illustrated by combined Apo E deficient and A20 haplo-insufficient mice which 
deonstrate an increase in atherosclerotic aortic root lesion area, whilst overexpressing A20 
decreases lesion area (Wolfrum et al., 2007). The observed protection is attributed to inhibition of 
Nf-κB target genes resulting in decreased VCAM-1, ICAM-1 and M-CSF expression (Wolfrum et al., 
2007). Furthermore, specific human A20 polymorphisms resulting in decreased A20 expression 
confer increased cardiovascular risk in diabetic patients through modulation of Nf-κB activation 
(Boonyasrisawat et al., 2007). 
1.2.4 Transcription factors 
Vascular Kruppel-Like Factors (KLF’s) 
The KLF’s are a group of transcription factors with a zinc-finger binding motif which are similar in 
structure to the Sp1 family. There are 16 members of the KLF family of transcription factors and 
KLF’s 2, 4 and 6 are expressed in endothelial cells, whilst KLF’s 4 and 5 are expressed in smooth 
muscle cells (Suzuki et al., 2005).  
KLF2 is essential for vascular development, is expressed in endothelial cells and gene knockout 
results in abnormal vessel morphology with fatal premature haemorrhage, although 
vasculogenesis and angiogenesis are preserved (Kuo et al., 1997). KLF2 is induced physiologically 
by laminar shear stress and pharmacologically by statins which results in the enhanced expression 
and activity of eNOS, HO-1, thrombomodulin and CD59 (Dekker et al., 2002;Dekker et al., 2005;van 
Thienen et al., 2006;Ali et al., 2007;Kinderlerer et al., 2008). The transcription factor attenuates 
VCAM-1 and E-selectin expression in response to pro-inflammatory cytokines (SenBanerjee et al., 
2004). Thus, KLF2 appears to have an anti-inflammatory role in the vascular wall by regulating the 
expression of several cytoprotective molecules. 
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KLF4 was initially identified within the vasculature but its role in vascular function is incompletely 
understood. This transcription factor suppresses vascular smooth muscle cell differentiation in 
response to TGF-β, is also induced by laminar shear stress and it is suggested that it may be 
pathologically induced in endothelial cells (Yet et al., 1998;McCormick et al., 2001;Suzuki et al., 
2005). KLF6 is an early growth response factor which following vascular injury activates the TGF-β 
signaling network by inducing TGF-β and TGF-β receptors. It also enhances the expression of 
urokinase plasminogen activator (Kojima et al., 2000;Botella et al., 2002). Thus KLF6 like KLF2 may 
have a cytoprotective role in the vasculature. 
Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-activated transcription 
factors which belong to the nuclear receptor superfamily. On activation by a specific ligand the 
PPARs form heterodimers with the retinoic acid receptor (RXR) which then bind to a specific PPAR 
response element (PPRE) leading to target gene transcription. There are at least three members of 
the PPAR family of proteins; α, γ and β/δ. All three members are expressed in vascular endothelial 
and smooth muscle cells, have multiple biological effects and regulate vascular tone, thrombosis, 
inflammation, cellular proliferation and apoptosis (Hamblin et al., 2009).  
The natural ligands for PPARα include polyunsaturated fatty acids such as docosahexanoic acid and 
eicosapentanoic acid, oxidized phospholipids and lipoprotein products, whereas synthetic ligands 
include the fibrates. PPARα activation in ECs inhibits cytokine mediated MCP-1 synthesis, VCAM-1 
and endothelin-1 expression but enhances endothelial NOS expression and activity (Chinetti et al., 
1998;Marx et al., 1999;Goya et al., 2004). In cholesterol fed rabbits, fibrates attenuate atheroma 
formation and PPARα deficient mice have enhanced vascular inflammatory responses to LPS 
(Hennuyer et al., 1999;Delerive et al., 1999). In angiotensin II infused rats, PPARα activation 
suppresses ROS formation, decreases ICAM-1 and VCAM-1 expression and also attenuates the 
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hypertensive response (Diep et al., 2002).  The vasoprotective properties of PPARα activation are 
clinically evident. Large randomized clinical trials show that fibrates reduce coronary vascular 
events and PPARα polymorphisms associate with coronary heart disease (Frick et al., 1987;Frick et 
al., 1997;Flavell et al., 2002). Furthermore fibrates improve endothelial function in hyperlipidemic 
and diabetic patients (Evans et al., 2000;Playford et al., 2002). 
Activation of PPARγ sensitizes tissues to insulin, regulating lipid storage and adipocyte 
differentiation. The PPARγ ligands include prostaglandin J2, linoleic acid and synthetic glitazones 
including pioglitazone and rosiglitazone. PPARγ appears to have similar vasoprotective effects as 
PPARα (Hamblin et al., 2009). Thus, PPARγ activation also attenuates TNFα, IL-1 and IL-6-
dependent VCAM-1 and ICAM-1 expression, suppresses agonist induced endothelin-1 synthesis 
and enhances eNOS expression and activity (Calnek et al., 2003;Bruemmer et al., 2005). In 
macrophages PPARγ agonists suppress MMP-9 and scavenger receptor expression, whereas in 
VSMC’s they inhibit proliferation, migration, attenuate ROS formation and AT1 receptor 
expression (Ricote et al., 1999).  These potential in vitro benefits are also apparent in vivo. 
Glitazone treatment decreases the severity of atherosclerosis in the ApoE and LDL deficient 
mouse, inhibits neo-intimal formation following vascular injury and decreases iNOS synthesis, ROS 
formation and improves vascular function in rabbits fed a high cholesterol diet (Law et al., 1996;Li 
et al., 2000;Tao et al., 2003). A similar protective response is also observed in animal models of 
hypertension (Iglarz et al., 2003). Although these observations would suggest that PPARγ 
stimulation would translate to an atheroprotective benefit, recent meta-analyses fail to 
demonstrate this and indicate an increase in cardiovascular events (Nissen & Wolski, 2007). 
Like PPAR-α and γ, PPAR-β/δ has an established role in the regulation of metabolism in adipose 
tissue, skeletal and cardiac muscle (Hamblin et al., 2009). However, little is known about its role in 
vascular homeostasis and function. It may have an anti-inflammatory role as it suppresses 
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macrophage synthesis of pro-inflammatory cytokines and its activation with the synthetic ligand, 
GW0742X, retards atherogenesis in LDL receptor knockout mice, a response associated with a 
decrease in vascular MCP-1, ICAM-1 and macrophage TNF-α expression (Graham et al., 2005b). Its 
role in vascular endothelial cells is poorly understood but PPAR-β/δ agonists suppress TNF-α 
induced leucocyte-adhesion molecule expression, stimulate EC proliferation and angiogenesis and 
protect against oxidative stress by enhancing HO-1 expression (Piqueras et al., 2007;Fan et al., 
2008;Piqueras et al., 2009;Ali et al., 2010). 
NFE-2 related factor (Nrf2) 
Nrf2 is a transcription factor which regulates the expression of several anti-oxidant detoxifying 
enzymes and will be discussed in section 1.4.1. 
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1.3 OXIDATIVE STRESS & VASCULAR ANTI-OXIDANT DEFENSE MECHANISMS  
1.3.1 Reactive oxygen species and oxidative stress 
Reactive oxygen and nitrogen species (ROS) are molecules with unpaired electrons which are 
short-lived, unstable and rapidly oxidize several intra- and extracellular molecules modulating 
various biological processes. The main ROS of biological significance include superoxide, hydroxyl 
radicals and peroxynitrite. Oxidative stress occurs when ROS formation overwhelms the 
scavenging and removal capabilities of various antioxidant enzyme systems. The classic 
cardiovascular risk factors; hypertension, diabetes mellitus, cigarette smoke and 
hypercholesterolemia are strong predictors of cardiovascular disease and each of these risk factors 
increase the concentration of ROS within the vascular wall. Endothelial dysfunction is also a strong 
independent predictor of cardiovascular disease. eNOS activity and nitric oxide are key 
determinants of endothelial function and chronic eNOS dysfunction and a decrease in nitric oxide 
bioavailability leads to endothelial dysfunction. ROS may deplete tetrahydrobiopterin so 
uncoupling eNOS, switching its function to generate superoxide leading to further ROS formation, 
further endothelial dysfunction and atherosclerosis (Madamanchi et al., 2005;Forstermann, 2008).  
ROS are formed by various enzyme systems: NADPH oxidase, the mitochondrial respiratory chain, 
xanthine oxidase and dysfunctional eNOS. The main vascular source of ROS appears to be NADPH 
oxidase derived superoxide. NADPH oxidase is a membrane bound multi-complex enzyme found in 
endothelial and smooth muscle cells which generates the formation of superoxide radicals 
(Keaney, Jr., 2005). The importance of NADPH oxidase in vascular disease is illustrated by animal 
models of hypertension, diabetes mellitus and hypercholesterolemia which demonstrate higher 
levels of NADPH oxidase and greater concentrations of ROS within the aortic wall (Hink et al., 
2001;Li et al., 2006). The pathophysiological importance of NADPH-derived ROS and various 
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NADPH subunits in vascular disease is confirmed by NADPH knockout studies which decrease the 
hypertensive response to angiotensin II and ameliorates atheroma formation in ApoE knockout 
mice   (Warnholtz et al., 1999;Barry-Lane et al., 2001). Moreover, superoxide generated by NADPH 
oxidase appears to regulate xanthine oxidase and eNOS ROS formation.  
The importance of xanthine oxidase as a source of ROS is unclear. Xanthine oxidase catalyses the 
formation of superoxide and hydrogen peroxide by transferring an electron to singlet oxygen 
(Madamanchi et al., 2005). Xanthine oxidase is known to be generated in the liver but in vivo has 
been demonstrated within endothelial cells (McNally et al., 2003). In vivo studies using xanthine 
oxidase inhibitors such as oxypurinol decrease superoxide formation within the vascular wall and 
improves vascular function (Ohara et al., 1993). However, clinical studies using xanthine oxidase 
inhibitors in hyperlipidemic and diabetic patients show conflicting findings regarding 
improvements in endothelial function (O'Driscoll et al., 1999;Butler et al., 2000). 
The mitochondrial respiratory chain is an enzyme system located within the inner mitochondrial 
membrane and is required for the generation of ATP during oxidative phosphorylation. The 
enzyme complex shuttles electrons from one enzyme to another and drives a proton gradient 
leading to the generation of ATP. If electron transport becomes inefficient then electrons leak 
from this enzyme system and reduce molecular oxygen leading to the formation of superoxide 
(Gutierrez et al., 2006). The main source of electron leak is complex 1 (NADH dehydrogenase) and 
complex III (ubiquinone-cytochrome b-c) of the electron transport chain (Landar et al., 2006). The 
role of mitochondrial derived superoxide in atherogenesis is unclear but disrupting mitochondrial 
function in Apo E knockout mice accelerates atherosclerosis (Ohashi et al., 2006). 
eNOS is composed of a reductase and oxygenase domain. The reductase domain consists of 
NADPH, flavin adenine dinuceotide (FAD) and flavin mononucleotide (FMN), whilst heme is the 
main prosthetic group within the oxygenase domain. These enzymes transfer electrons from the 
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reductase to the oxygenase domain resulting in the formation of NO and citrulline from L-arginine. 
Depletion of the eNOS cofactor tetrahydrobiopterin (BH4) leads to uncoupling of the eNOS 
oxygenase and reductase domains leading to superoxide generation. Superoxide is known to react 
with NO to form peroxynitrite which may also bind and deplete BH4, uncoupling eNOS and 
promoting further superoxide formation, eNOS dysfunction and vascular dysfunction 
(Forstermann, 2008). Supporting this concept is the improvement in vascular function following 
administration of tetrahydrobiopterin to patients with hypercholesterolemia, diabetes and 
hypertension (Stroes et al., 1997;Heitzer et al., 2000;Higashi et al., 2002). 
The formation of ROS alters the redox tone within the cell and this has both direct and indirect 
impact on several redox sensitive transcription factors and protein kinases resulting in important 
biological effects. For example, ROS enhances the expression of several Nf-κb dependent 
molecules including MCP-1, VCAM-1, ICAM-1 and E-selectin which in turn facilitate leucocyte-
endothelial cell interactions promoting inflammation. Similarly, angiotensin II induced ROS 
activates p38 MAP kinase and triggers smooth muscle cell and fibroblast proliferation and 
migration contributing to atherogenesis (Liu et al., 2005a). 
1.3.2 Antioxidant mechanisms within the vascular wall 
Superoxide dismutase 
Superoxide dismutase (SOD) catalyses the breakdown of superoxide into hydrogen peroxide and 
molecular oxygen. There are three isoforms; a cytosolic isoform (copper-zinc SOD), mitochondrial 
isoform (manganese SOD) and an extracellular isoform of copper-zinc SOD. The importance of 
endothelial SOD is illustrated by genetic deletion in mice which increases their susceptibility to 
myocardial ischemia-reperfusion injury, decreases NO bioavailability and impairs endothelial 
function (Yoshida et al., 1993;Jung et al., 2007). Furthermore in man, SOD polymorphisms 
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resulting in decreased enzyme activity are associated with vascular dysfunction and a 
predisposition to ischemic heart disease (Iida et al., 2006). 
Glutathione peroxidase 
Glutathione peroxidase (GP) catalyses the formation of water, hydrogen peroxide and alcohol 
from lipid hydroperoxides. There are several isoforms of GP and GP1 is ubiquitously and 
constitutively expressed. Although GP1 knockout mice have a normal phenotype, they are 
susceptible to myocardial ischemia-reperfusion injury (Yoshida et al., 1997). In murine models of 
atherosclerosis combined ApoE and GP1 depletion accelerates atherosclerosis, and in humans 
erythrocyte GP1 activity is inversely related to vascular risk (Blankenberg et al., 2003;Torzewski et 
al., 2007). 
Catalase 
Catalase dehydrates hydrogen peroxide to form molecular oxygen. It is broadly expressed but its 
significance as an anti-oxidant defense mechanism is unclear. Genetic deletion of the enzyme has 
no adverse effects; however overexpression of the enzyme is vasoprotective and retards 
progression of atherosclerosis in mice (Yang et al., 2004a).  
Thioredoxin 
Thioredoxin peroxidase (TRX) is found within endothelial and smooth muscle cells and catalyses 
the degradation of hydrogen peroxidase leading to the formation of water and thioredoxin 
reductase. There are two recognized forms of thioredoxin peroxidase, a cytsolic form (TRX1) and a 
mitochondrial form (TRX2) (World et al., 2006). Human atherosclerotic lesions exhibit a high 
expression of TRX within the neo-intima which localizes to infiltrating macrophages and 
endothelial cells (Okuda et al., 2001). Moreover, oxidized LDL enhances TRX expression in 
macrophages, whilst in ECs of rat carotid arteries subjected to balloon injury, enhanced expression 
of TRX is observed (Takagi et al., 1998). These findings support the concept of TRX as an inducible 
39 
 
anti-oxidant protein during vascular injury. The anti-oxidant profile of TRX within the 
cardiovascular system is further illustrated by the spontaneously hypertensive and stroke-prone 
hypertensive rat which demonstrate a reduction in TRX levels within various tissues (Yamagata et 
al., 2000;Tanito et al., 2004). Furthermore, over expressing TRX1 within the murine heart 
attenuates infarct size and improves ventricular function following myocardial ischemia-
reperfusion injury (Turoczi et al., 2003). The anti-oxidant properties of TRX1 are thought to involve 
a direct scavenging effect on hydrogen peroxide and iNOS-derived peroxynitrite. However TRX1 is 
likely to have a broader cytoprotective role by interacting with various signaling proteins including 
apoptosis signaling kinase-1, Nf-κB and caspase-3 thereby promoting an additional anti-apoptotic 
and anti-inflammatory role (World et al., 2006). 
Extra-cellular circulating ant-oxidants 
Glutathione and glutathione peroxidase is the main determinant of intracellular redox status. 
However, extracellular ROS are removed by circulating anti-oxidants which include uric acid, HO-1-
derived bilirubin, glutathione and vitamins C and E. Bilirubin and uric acid can directly scavenge 
ROS but this is unproven in vivo.  Vitamin C (ascorbic acid) is a water soluble anti-oxidant which 
directly scavenges reactive oxygen and nitrogen species. Additionally, vitamin C enhances eNOS 
activity in endothelial cells by replenishing tetrahydrobiopterin (Heller et al., 1999;May, 2000). 
Vitamin C treatment to eNOS deficient mice or in patients with coronary artery disease improves 
endothelial function, NO levels and decreases levels of ROS within the vascular wall (Gokce et al., 
1999;Ellis et al., 2001). Vitamin E is composed of several tocopherols and the predominat α-
tocopherol removes lipid peroxides but in turn may become a pro-oxidant promoting oxidative 
stress. Anti-oxidant strategies involving vitamins C and E are highly attractive, however 
largeclinical trials employing these agents have been disappointing (Stanner et al., 2004;Lonn et 
al., 2005). 
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1.4 HEME OXYGENASE AND VASCULAR CYTOPROTECTION 
Heme-oxygenase (HO) is an enzyme which uses molecular oxygen, cytochrome p450 reductase 
and NADPH to catabolize heme into ferrous iron (Fe2+), carbon monoxide and biliverdin. The HO 
product biliverdin is reduced by biliverdin reductase into bilirubin, while free iron derived from 
heme activates an iron anti-porter and induces the formation of ferritin, which together decrease 
intracellular iron. The HO enzyme system is critical for heme metabolism and maintenance of iron 
homeostasis (figure 2) (Poss & Tonegawa, 1997b). Although the main source of heme is 
hemoglobin, heme is also found in several other proteins and enzymes including myoglobin, cyclo-
oxygenase, cytochrome peroxidases and nitric oxide synthases. Heme is highly cytotoxic and pro-
inflammatory as it augments the formation of lipid peroxides in response to hydrogen peroxide, 
oxidizes LDL and enhances the expression of leucocyte adhesion molecules in vascular endothelial 
cells (Soares & Bach, 2009). The vascular endothelium is constantly exposed to heme derived from 
hemoglobin and therefore is highly susceptible to heme induced vascular injury. The importance 
of HO for protection from heme-induced cytotoxicity and in heme metabolism is well recognized, 
but over the last decade several in vitro, in vivo and human studies demonstrate that the HO 
family of enzymes and the products they generate also have several anti-inflammatory, anti-
apoptotic and cytoprotective effects (Ryter et al., 2006;Loboda et al., 2008).   
There are two isoforms of heme-oxygenase which have been identified in mammals; heme 
oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Both proteins are products of different genes 
and vary in terms of tissue distribution, regulation and kinetics (Maines et al., 1986). HO-1 is a 32 
KDa protein which is expressed at low or undetectable levels in several cell types including 
endothelial cells, but is rapidly induced by multiple physiological or pathophysiological stimuli and 
aims to maintain cellular integrity (Ryter et al., 2006). Thus, HO-1 is a stress-induced protein which 
is also denoted heat shock protein 32 (hsp32)(Keyse & Tyrrell, 1989).  
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Figure 2. Heme oxygenase-1 and its role in vascular cytoprotection. Heme-oxygenase-1 (HO-1)
catalyses the degradation of heme into biliverdin, carbon monoxide (CO) and ferrous iron (Fe2+).
Biliverdin is reduced to bilirubin by biliverdin reductase (BVR) and the presence of ferrous iron
induces ferritin. Each product activates several cytoprotectve pathways. ROS- reactive oxygen
species, sGC-soluble guanylate cyclase.
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HO-2 is a 36 KDa protein which is constitutively expressed at high levels in the brain with lower 
expression levels recognized in endothelium, testes, liver and the distal nephron (Rotenberg & 
Maines, 1990).Cortisone, dexamethasone and hypoxia are amongst the very few known inducers 
of HO-2 (Maines et al., 1996;Donnelly & Barnes, 2001;Han et al., 2005). The kinetics of both 
enzymes differ as HO-1 has a km of 0.24µM and HO-2 0.67µM despite requiring identical cofactors 
and substrates (Maines et al., 1986).  
1.4.1 Regulation of HO-1 expression 
HO-1 expression is predominantly regulated at the transcriptional level and is potently induced by 
conditions which increase intra-cellular oxidative stress (Wagener et al., 2003). These stimuli may 
be physiological, such as laminar shear stress and nitric oxide, or pathophysiological which include 
heavy metals (eg. cobalt, cadmium), lipopolysaccharide, hypoxia, heat shock and cytokines 
(Wagner et al., 1997;De Keulenaer et al., 1998;Loboda et al., 2008). Similarly, various drugs induce 
HO-1 including statins, rapamycin, paclitaxel and non-steroidal anti-inflammatory drugs (Lee et al., 
2004;Choi et al., 2004;Hsu et al., 2006;Aburaya et al., 2006).  
The human HO-1 gene (Hmox-1) consists of five exons and four introns spanning 14-kb and is 
located at position 22q12 (Shibahara et al., 1989). The HO-1 promoter lacks conventional TATA or 
CAAT boxes and inter species differences within the promoter suggests species specific regulation 
of Hmox-1 (Shibahara et al., 1989). The cellular capacity to induce HO-1 by several stimuli is 
corroborated by the presence of a large number of positive regulatory response elements within 
the Hmox-1 promoter. The stress response element (StRE) plays a dominant role in the regulation 
of HO-1 by ROS and is structurally and functionally similar to the anti-oxidant response element 
(ARE) which binds the redox sensitive transcription factor, nuclear factor E2-related factor-2 
(Nrf2), a prominent driver of HO-1 induction (Prestera et al., 1995;Inamdar et al., 1996).  
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Nrf2 belongs to the cap ‘n’ collar related leucine zipper family of transcription factors and has a 
high affinity for the anti-oxidant response element (ARE) (Alam et al., 1999). The ARE is found in 
the promoters of several genes involved in anti-oxidant defense and the detoxification of 
xenobiotics, termed phase II enzymes. These genes include NADPH quinine oxidoreductase, 
glutathione transferase and thioredoxin. The regulation of Nrf2 is incompletely understood but in 
a state of low redox tone, Nrf2 is sequestered within the cytosol bound to Kelch-like ECH- 
associated protein-1 (Keap1) which prevents its translocation into the nucleus. Keap-1 is a cysteine 
rich protein which undergoes oxidative modification of its thiol groups following an oxidative 
stimulus resulting in a conformational change, with subsequent dissociation from Nrf2. Nrf2 then 
translocates into the nucleus where it binds to the Maf1 protein and activates the ARE (figure 3) (Li 
& Kong, 2009). The role of Nrf2 in detoxification is illustrated by Nrf2 knockout mice which 
demonstrate impaired induction of phase II detoxifying enzmes (Itoh et al., 1997). Many inducers 
of HO-1 including prostaglandin J2 and laminar shear stress  utilize Nrf2 for Hmox-1 transcription 
(Gong et al., 2002;Dai et al., 2007;Chen et al., 2003).  
Bach-1 is a transcriptional repressor of HO-1 which competes with Nrf2 for the transcriptional co-
activator Maf1. Thus Nrf2-Maf1 heterodimers will enhance HO-1 expression, whilst Bach-1-Maf1 
heterodimers inhibit HO-1 induction (Sun et al., 2004). Heme is known to enhance Hmox-1 
transcription in part by binding and sequestering nuclear Bach-1 and increasing Maf1 availability 
for Nrf2 binding (Ogawa et al., 2001;Sun et al., 2002). Moreover, Bach-1 knockout mice express 
higher levels of HO-1 and are protected from atherosclerosis and ischemic injury demonstrating 
the repressor function of Bach-1 in cytoprotection (Sun et al., 2002) . 
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Figure 3. NRF2/ Keap-1 interactions and HO-1 transcription. Keap-1 sequesters NRF2 within
the cytosol. Following an oxidative or electrophilic stimulus, thiol groups within keap-1 become
oxidised forming a cysteine bridge, conformational change and dissociation of NRF2.
Consequently NRF2 translocates into the nucleus and binds the anti-oxidant response element
(ARE) and transcribes several cytoprotective genes including HO-1.
Oxidative stress
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Other response elements within the Hmox-1 promoter include the cadmium response element 
(CdRE), SMAD-binding element (SmBE), AP-1, AP-2, NF-κB, CRE and STAT binding sites (Lavrovsky 
et al., 1993;Lavrovsky et al., 1994;Takeda et al., 1994;Traylor et al., 2007). Although there are 
several positive Hmox-1 regulatory elements, only two negative regulatory elements are  
recognized. One which is located at -981 and -418bp and a second which is a microsatellite GT 
repeat polymorphism (Takahashi et al., 1999) . 
1.4.2 HO-1 and vascular cytoprotection  
The importance of HO-1 in heme and iron metabolism was first demonstrated by Tonegawa and 
Poss who characterized the HO-1 deficient mouse. These mice developed a state of iron overload, 
similar to patients with hemochromatosis and demonstrate excess tissue iron deposition, 
splenomegaly, hepatitis with hepatic fibrosis and premature mortality (Poss & Tonegawa, 1997b). 
Studies on HO-1 deficient murine embryonic fibroblasts (MEFs) isolated from these mice revealed 
enhanced ROS formation and cytotoxicity in response to hemin, hydrogen peroxide and cadmium.  
Furthermore, these mice had excess LPS-induced hepatic injury and mortality compared to wild-
type mice (Poss & Tonegawa, 1997a). These initial studies showed firstly, the importance of HO-1 
in iron homeostasis; secondly, that HO-1 is an inducible anti-oxidant and finally its role as an anti-
inflammatory molecule. Other investigators using experimental models for cardiac-ischemia 
reperfusion injury, pulmonary inflammation and pulmonary hypertension also demonstrated a 
cytoprotective role for HO-1 (Minamino et al., 2001;Fujita et al., 2001;Yet et al., 2001). 
The anti-inflammatory significance of HO-1 in man was confirmed by the study of a child with HO-
1 deficiency. This patient died of a chronic inflammatory illness characterized by intravascular 
hemolysis and heme-induced diffuse endothelial damage. The inability to handle free iron results 
in iron accumulation within LDL with enhanced oxidative modification leading to endothelial 
damage, fatty streak and fibrous plaque formation within the vascular wall (Yachie et al., 
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1999;Kawashima et al., 2002). Furthermore endothelial cells obtained from this patient were more 
susceptible to oxidative stress in vitro (Jeney et al., 2002). These observations suggested that HO-1 
is a critical vascular anti-oxidant and anti-inflammatory system in man.  
Atherosclerosis is the most prevalent vascular disease and several observations and studies 
suggest that HO-1 is a readily inducible cytoprotective protein during atherogenesis. 
Histopathological analyses of atherosclerotic lesions reveal enhanced HO-1 expression in all cell 
types within the plaque and that the degree of expression correlates with the severity of the lesion 
(Wang et al., 1998;Morsi et al., 2006). Furthermore, atherogenic risk factors such as oxidized 
lipids, smoking and hypertension induce HO-1 expression (Ishizaka et al., 1997;Ishikawa et al., 
1997;Favatier & Polla, 2001). These findings in combination with several studies suggest that HO-1 
is a homeostatic cytoprotective protein within the vasculature.  
The multiple anti-oxidant, anti-inflammatory and cytoprotective properties of HO-1 are evident in 
several cell types involved in atherosclerosis. HO-1 attenuates macrophage-derived superoxide 
formation by inhibiting NADPH oxidase assembly and activity, whilst in endothelial cells HO-1 over-
expression prevents ROS-mediated cell growth and apoptosis (Abraham et al., 2003;Taille et al., 
2004). In addition, HO-1 prevents leucocyte adhesion to the vascular endothelium and inhibits 
oxidized LDL-induced transmigration of macrophages into the vascular wall. Each of these actions 
of HO-1 may be reproduced by its products biliverdin and bilirubin (Ishikawa et al., 1997;Morita et 
al., 2003). SMC migration and proliferation is an important step in atheroma formation and HO-1 
over-expression inhibits endothelin-1-induced smooth muscle cell proliferation and migration 
(Morita & Kourembanas, 1995). Thus HO-1 may modulate many different pathogenic processes 
involved in atherosclerosis. 
The protective role of HO-1 in vascular injury and atherogenesis is reinforced by animal models of 
disease. HO-1 inhibition with zinc protoporphyrin (ZnPP) enhances neointimal formation following 
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balloon injury in rat carotid arteries, whilst hemin-induced HO-1 attenuates neointimal 
proliferation (Togane et al., 2000;Tulis et al., 2001b). Similarly, in the LDL receptor knockout 
mouse HO-1 inhibition with ZnPP exacerbated atheroma formation, whereas HO-1 induction with 
hemin attenuated the severity of plaque formation (Ishikawa et al., 2001). Furthermore, HO-1 
deficiency increases atheroma formation in the ApoE deficient mouse and promotes neo-intimal 
formation in venous grafts (Yet et al., 2003). Other studies employing targeted endothelial HO-1 
overexpression have demonstrated a similar protective role. Thus, adenoviral-mediated HO-1 
overexpression attenuates neointimal formation in balloon injured rat carotid arteries and 
decreases severity of plaque formation in ApoE-/- mice (Tulis et al., 2001a;Juan et al., 2001). 
Furthermore, targeted overexpression of HO-1 in the porcine vascular wall improves vascular 
function and inhibits smooth muscle cell proliferation by activating a guanylate cyclase and cGMP-
dependent pathway (Duckers et al., 2001). 
A large number of in vitro, in vivo and human studies have shown that the cytoprotective and anti-
inflammatory functions of HO-1 are attributed to the products of heme catabolism; carbon 
monoxide, biliverdin/bilirubin and an increase in intracellular ferritin. Each of these products may 
have a direct anti-oxidant effect or modulate several signaling pathways involved in inflammation, 
complement regulation, anti-oxidant defense, apoptosis and cellular proliferation (Ryter et al., 
2006;Loboda et al., 2008).  
Carbon monoxide 
Carbon monoxide (CO) is the most extensively studied product of HO-1 and many of the 
cytoprotective benefits of HO-1 can be reproduced by CO. For example in models of cardiac xeno-
transplantation HO-1 is essential for graft survival, but in the absence of HO-1, treatment with 
carbon monoxide reproduces the effects of HO-1 and prevents graft rejection (Sato et al., 2001). 
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Similarly, in mouse models of endotoxic shock and acute lung injury, CO reproduced the 
cytoprotective actions of HO-1 (Otterbein et al., 1999;Sarady et al., 2002).  
CO functions as a gaseous signaling intermediary leading to cytoprotection by activation of several 
signaling pathways. Its mechanism of action is similar to NO, interacting with soluble guanylate 
cyclase resulting in the formation of cGMP with consequent downstream effects. p38 MAPK is an 
important downstream mediator for CO-mediated inhibition of LPS-induced TNF-α, IL-1β and MIP-
1β. Furthermore, CO also increases IL-10 synthesis and this may account for its anti-inflammatory 
properties (Ryter et al., 2006).  
CO has multiple anti-thrombotic effects. It inhibits platelet activation and aggregation using a 
guanylate cyclase/cGMP dependent pathway (Brune & Ullrich, 1987). Moreover, CO 
downregulates PAI-1 in macrophages and in HO-1 deficient cells CO attenuates ox-LDL-induced 
PAI-1 expression (Fujita et al., 2001;Matsumoto et al., 2006). The anti-thrombotic characteristics 
of HO-1 derived CO were demonstrated in vivo using the Apo E-/- mouse subjected to coronary 
angioplasty. Adenoviruses over expressing HO-1 attenuated vascular PAI-1 expression, thrombosis 
and neointimal proliferation and these observations were reproduced by CO (Chen et al., 2006). 
Furthermore, a study demonstrated that HO-1 deficiency accelerated vascular endothelial cell 
injury, apoptosis, denudation and arterial thrombosis, and this was reversed by inhaled CO (True 
et al., 2007).  
The anti-proliferative effects of HO-1 on smooth muscle cells and T-cells may also be attributed to 
CO. CO inhibits IL-2 dependent T-cell proliferation which may involve ERK and caspase-dependent 
pathways (Pae et al., 2004;Song et al., 2004). Similarly CO is shown to inhibit smooth muscle 
proliferation and migration involving a guanylate cyclase and cGMP-dependent pathway (Liu et al., 
2002).  
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The anti-apoptotic effects of HO-1 parallel those of CO, and they are observed in several cell types 
including endothelial cells, osteoblasts and fibroblasts (Ryter et al., 2006). The molecule regulates 
several anti-apoptotic proteins and pathways which is partly dependent on the pro-apoptotic 
stimulus. CO inhibits TNFα-induced EC apoptosis by a p38 MAP kinase-dependent pathway 
(Brouard et al., 2000). The p38 MAP kinase isoform may be important, as p38α is known to be pro-
apoptotic whereas p38β is anti-apoptotic (Silva et al., 2006).  CO may act to suppress NF-kB-
mediated apoptosis while enhancing the expression of several anti-apoptotic proteins such as bcl-
2, bcl-xl, A1 and A20 (Brouard et al., 2000;Ke et al., 2002;Zhang et al., 2003). Other signaling 
molecules which may regulate the cytoprotective effects of CO include STAT3 and HIF-1α 
(Otterbein et al., 2003;Zhang et al., 2006;Chin et al., 2007). Thus CO mediates many of the 
cytoprotective effects of HO-1, which in turn may be important for maintaining vascular 
homeostasis during inflammation and vascular injury. 
Biliverdin and Bilirubin 
Both biliverdin and its reduced product bilirubin are known to have a direct anti-oxidant 
scavenging profile. Stocker and colleagues first showed that bilirubin scavenged chemically 
generated peroxyl radicals to a greater extent than the potent anti-oxidant alpha-tocopherol 
(Stocker et al., 1987). Following on from this study and other observations, the concept of 
biliverdin and bilirubin as an anti-oxidant and anti-atherogenic molecule was supported by 
epidemiological studies which showed that elevated bilirubin levels were athero-protective 
(Schwertner et al., 1994;Breimer et al., 1995;Hopkins et al., 1996). The anti-oxidant properties of 
biliverdin and bilirubin are not fully understood but are also likely to involve non-scavenging 
mechanisms. For example bilirubin is shown to inhibit neutrophil NADPH oxidase leading to a 
reduction in superoxide production (Kwak et al., 1991). Although bilirubin has anti-oxidant 
properties, several lines of evidence demonstrate that biliverdin and bilirubin have other anti-
50 
 
inflammatory properties which may be independent of its anti-oxidant profile. Biliverdin/bilirubin 
inhibits hepatocytolysis and intra-vascular hemolysis by inhibiting classical complement activation 
(Arriaga et al., 1999;Arriaga et al., 2002;Basiglio et al., 2007). Recently studies from our lab have 
showed that bilirubin derived from HO-1 enhances endothelial DAF expression, protecting cells 
from complement-dependent injury (Kinderlerer et al., 2009). Bilirubin attenuates cytokine 
induced E-selectin, VCAM-1 and ICAM-1 expression, suggesting that during inflammation this 
molecule may inhibit leucocyte-endothelial interactions (Soares et al., 2004). Hence biliverdin and 
bilirubin can modulate several aspects of the inflammatory response which is best illustrated in 
various models of disease. In mouse models of dextran sodium sulphate-induced inflammatory 
bowel disease, biliverdin suppressed inflammation in the absence of HO-1 (Berberat et al., 2005). 
Similarly in a murine MHC mismatched cardiac transplant model, biliverdin significantly prolonged 
graft survival (Otterbein et al., 2003).  Exogeneous biliverdin inhibits neo-intimal proliferation in 
mice subjected to wire injury and enhances eNOS expression and endothelial function in LDL 
receptor knockout mice (Nakao et al., 2005;Kawamura et al., 2005). Oxidation of bilirubin by ROS 
leads to the formation of biliverdin which in turn is reduced by BVR to form bilirubin. This 
amplification of bilirubin production is postulated to augment the cytoprotective properties of 
biliverdin/bilirubin (Baranano et al., 2002). Recently biliverdin reductase has been identified as a 
signaling molecule in various cytoprotective pathways. Phosphorylation of BVR at the cell surface 
leads to phosphorylation and activation of Akt/PKB and enhances the production of IL-10 in 
various cell types including macrophages and endothelial cells (Wegiel et al., 2009). Moreover BVR 
also activates signaling pathways involving MAP kinases and protein kinase C (Amit & Boneh, 
1993;Hansen et al., 1996). Thus biliverdin, biliverdin reductase and bilirubin constitute a unique 
pathway with multiple anti-inflammatory effects.  
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Iron and ferritin 
Ferritin is composed of a heavy and light chain and oxidizes ferrous iron to the ferric form enabling 
intracellular iron storage. Ferritin synthesis is mainly regulated at the post-transcriptional level and 
a rise in intracellular iron enhances ferritin synthesis. Conversely a reduction in iron levels 
decreases ferritin synthesis. Free iron can augment ROS formation and promotes inflammation. 
HO-1 releases iron from heme which rapidly induces ferritin H chain expression and chelates iron 
resulting in an anti-oxidant and cytoprotective effect (Stocker & Perrella, 2006). This has been 
demonstrated in vitro where HO-1-derived ferritin protects endothelial cells from hydrogen 
peroxide and hemin-induced cytotoxicity (Balla et al., 1992). Ferritin also demonstrates anti-
apoptotic effects on endothelial cells, inhibits complement activation by enhancing endothelial 
DAF expression and may inhibit cytokine-induced leucocyte adhesion molecule expression (Pham 
et al., 2004;Soares et al., 2004;Kinderlerer et al., 2009). The benefits of HO-1 derived ferritin 
expression are unclear in vivo and appear to depend upon the disease model and cell type. In a rat 
model of endotoxic shock, ferritin and iron dosing was ineffective at offering protection (Otterbein 
et al., 1997). However, in a model of liver ischemia-reperfusion injury, over expression of the 
ferritin heavy chain attenuated injury and protected endothelial cells and hepatocytes from 
apoptosis (Berberat et al., 2003). 
In the clinical setting, the highly inducible properties of HO-1, coupled with its multiple anti-
inflammatory, anti-apoptotic and cytoprotective effects, have aroused interest in HO-1 and its 
products as a therapeutic target for several varied inflammatory diseases including 
atherosclerosis, transplant rejection and ischemia-reperfusion injury. 
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1.5 COMPLEMENT AND COMPLEMENT REGULATORY PROTEINS 
The complement system plays an important role in the host’s innate response to infection and is 
comprised of more than 30 proteins which include circulating plasma proteins and membrane-
bound regulators.  Complement proteins are predominantly synthesized within the liver and 
circulate in plasma as inactive zymogens. They are sequentially activated by proteolytic cleavage 
following stimulation by one of several factors including infectious or immune triggers. Once 
initiated, the cascade undergoes sequential activation and demonstrates amplification, generating 
protein and enzymatic products which have a role in the inflammatory process and enhance 
clearance of the invading pathogen. The complement cascade is also an effector component of 
humoral immunity, facilitating pathogen removal by acquired immune responses (Walport, 
2001a;Walport, 2001b;Mollnes et al., 2002).  
The cascade is activated by 3 distinct pathways termed; the classical, alternative and lectin (MBL) 
pathways (figure 4). The classical pathway is predominantly activated by immune complexes 
binding to the complement component C1q, which subsequently activates the serine protease C1r 
and C1s. The MBL pathway is predominantly triggered by mannose on micro-organisms, binding to 
lectin, and then activating the mannose-associated serine proteases, which is similar to the 
classical pathway. The alternative pathway is triggered by bacterial products such as 
lipopolysachharide, resulting in enhanced hydrolysis of C3. The outcomes of all three pathways are 
similar, resulting in the formation of the proteolytic complex termed C3 convertase, which cleaves 
the complement component C3 to C3a and C3b. As C3b serves as the subunit for the alternative 
pathway C3 convertase (C3bBb), the cleavage of C3 creates a self-propagation loop. Thus, this step 
is pivotal to the entire cascade and sets in motion the activation and formation of downstream 
products.  
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Figure 4: Overview of the complement cascade and its membrane bound regulators. The
cascade is activated by the classical, lectin or alternative pathways. Classical or lectin activation
will form the classical pathway C3 convertase (C4b2a) or alternative pathway C3 convertase
(C3bBb), resulting in subsequent terminal cascade activation. Decay-accelerating factor (DAF),
membrane cofactor protein (MCP) and complement receptor 1 (CR1) inhibit C3 convertase
formation. CD59 inhibits C5b-9 membrane attack complex assembly.
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 The product C3b formed by cleavage of C3 acts as a potent opsonin, facilitating removal of 
invading pathogens, immune complexes and other foreign particles by the reticulo-endothelial 
system.The complement fragments C3a and C5a also termed anaphylatoxins are potent pro-
inflammatory mediators which promote vasodilation, increase vascular permeability and are 
chemotactic for neutrophils.  The end product of complement activation is the assembly of a 
multimeric protein complex on a target cell surface composed of C5b, C6, C7, C8 and C9 (C5b-9) 
and is termed the membrane attack complex (MAC). This protein complex forms physical pores 
within the cell membrane allowing the free passage of ions and water across the membrane, 
leading to osmotic cell lysis. The MAC may assemble on any cell but typically only leads to lysis of 
non-nucleated cells or micro-organisms. Complement may also transmit stimulatory and inhibitory 
signals to several cell types including leucocytes leading to activation, proliferation and migration 
(Walport, 2001a).  
The complement system is intricately connected with the coagulation and kinin systems. Thus 
plasmin can cleave and activate C3, whilst C4 binding protein can inhibit protein S and promote a 
pro-thrombotic state (Amara et al., 2008). C1 inhibitor prevents activation of factor XII and 
kallikrien whilst carboxypeptidase N, a major bradykinin-inactivating enzyme also inhibits C3a and 
C5a (Schmaier, 2008). 
1.5.1 Complement regulation in man 
Activation of the complement cascade has the potential to inflict bystander cellular and tissue 
injury. Hence, constant inhibition is required to prevent spontaneous activation of the alternative 
and classical pathways. Multi-cellular organisms have evolved several fluid phase and membrane-
bound regulators, which inhibit complement activation at three distinct steps within the cascade, 
i.e. C1 activation (C1 inhibitor), C3 activation (Factor H, C4b binding protein, Factor I, complement 
receptor 1 [CR1/CD35], membrane cofactor protein [MCP/CD46], decay accelerating factor 
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[DAF/CD55]) or MAC formation (Apolipoprotein J/Clusterin and CD59).  The fluid phase regulators 
include C1 inhibitor, C4b binding protein, factor H, factor I, properdin, S protein and clusterin. 
Their functions are described in Table 1. In humans, the membrane-bound complement regulators 
CR1/CD35, DAF/CD55, MCP/CD46 and CD59 utilize distinct mechanisms to facilitate cytoprotection 
against complement- dependent injury (Miwa & Song, 2001;Mollnes et al., 2002). Structurally CR1, 
DAF and MCP belong to the regulators of complement activation (RCA) family of genes and 
contain short consensus repeat (SCR) domains. Following complement activation approximately 
30-100 molecules of C3 are required to generate active C5, and 1-10 molecules of C5 are necessary 
to form the terminal C5b-9 MAC (Bhakdi et al., 1988). This indicates the degree of regulation at 
various steps within the cascade and the overall efficiency of the complement regulation system. 
The studies in this thesis relate to DAF and the membrane-bound complement regulators. 
1.5.2 Membrane-bound regulators of complement activity 
 
Complement receptor 1 (CR1 / CD35) 
CR1 is a 190 KDa transmembrane glycoprotein which is encoded by the regulators of complement 
activation (RCA) located on chromosome 1. It is mainly expressed on circulating haematopoietic 
cells including B-lymphocytes, erythrocytes, polymorphonuclear cells and macrophages. It has also 
been identified on follicular dendritic cells and podocytes in the kidney. CR1 is a multi-functional 
protein which has complement inhibitor effects on both the alternative and classical pathways, 
demonstrating decay-accelerating activity for C3 and C5 convertases. It acts as a cofactor for factor 
I-mediated cleavage of C3b and C4b. The molecule also functions as a C3b/C4b receptor, which 
aids clearance of immune complexes by the reticulo-endothelial system (Miwa & Song, 2001). 
Enzymatic cleavage of CR1 from the surface of leucocytes yields a soluble form (sCR1), the 
physiological function of which is unknown (Miwa & Song, 2001). 
Regulatory Protein Main function
C1-inhibitor Inactivates C1r and C1s
C4b-binding protein Accelerates decay and inhibits classic 
pathway C3 convertase, cofactor for factor I
Factor H Accelerates decay and inhibits alternative 
pathway C3 convertase, cofactor for factor I
Factor I Cleaves and inactivates C3b and C4b in the 
presence of cofactor
Properdin Stabilizes alternative pathway C3 convertase
S protein Inhibits C5b-9 assembly
Clusterin Inhibits C5b-9 assembly
Table 1: Fluid phase complement regulators and their principal functions.
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Decay-accelerating factor (CD55) 
Decay-accelerating factor is a 70 KDa, GPI-anchored complement regulatory protein. DAF 
comprises a proximal serine/threonine enriched spacer domain, an O-glycosylated region and four 
complement control protein (CCP) repeats. It is principally glycosylphosphaditylinositol (GPI)-
anchored, although transmembrane (TM) and secreted forms have been described (Lublin & 
Atkinson, 1989). The length of the O-glycosylated region correlates with the degree of its 
complement inhibitor function (Miwa & Song, 2001). In humans, a single 35 Kb gene located at 
1q32 within the RCA encodes the GPI-anchored form and an alternatively spliced variant resulting 
in a secreted form (Ewulonu et al., 1991).  
Membrane bound DAF is broadly expressed on various tissues including several vascular and non-
vascular cell types, including epithelial cells, leucocytes and endothelial cells (Asch et al., 1986;Lin 
et al., 2001). DAF is constitutively expressed and mainly regulated at the transcriptional level by 
several mediators. Endothelial DAF expression is regulated by growth factors, including VEGF and 
basic fibroblast growth factor (bFGF), pro-inflammatory mediators such as histamine, C-reactive 
protein, LPS and cytokines as well as other agonists including thrombin and phorbol esters (Medof 
et al., 1987;Bryant et al., 1990;Tsuji et al., 1994;Mason et al., 1999;Li et al., 2004;Mason et al., 
2002b;Lidington et al., 2005). Hypoxia may also enhance DAF expression on vascular endothelium 
(Kinderlerer et al., 2006). The DAF promoter has been sequenced, characterized and response 
elements for specific transcription factors identified including those for cAMP, KLF’s, PPARs, Sp1 
and HIF (Ewulonu et al., 1991;Thomas & Lublin, 1993;Holla et al., 2005).  
DAF inhibits the formation of C3 and C5 convertases. Following binding of DAF to C3, the CCP2 and 
CCP3 domains act to both prevent the formation and accelerate the decay of the C3 convertases 
C3Bb (alternative pathway), and C4b2a (classical and mannose-binding lectin pathways)(Kuttner-
Kondo et al., 2007). Thus, DAF exerts potent cytoprotective and anti-inflammatory effects by 
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minimizing deposition of C3, C5a and C5b-9 (Lublin & Atkinson, 1989). DAF also acts as a cofactor 
for the leucocyte activation ligand CD97 (Hamann et al., 1996), is a receptor for coxsackie viruses 
and modulates adaptive immune responses by regulating T-cell function (Miwa & Song, 2001;Liu 
et al., 2005b). The secreted form is found in plasma, urine, tears, saliva, cerebrospinal fluid and its 
biological role is unknown (Medof et al., 1987) 
Membrane cofactor protein (MCP, CD46) 
MCP is a transmembrane protein with four heavily glycosylated SCR domains, STP rich regions a 
transmembrane domain and cytoplasmic domain. MCP is broadly expressed on all circulating cells 
with the exception of erythrocytes and is present in several tissues including the kidney, 
respiratory tract, brain, eyes and skin. It is also secreted into biological fluids including plasma, 
seminal fluid, and tears. MCP is a cofactor for factor I dependent proteolytic cleavage of C3b and 
C4b, thus inhibiting the formation of C3 and C5 convertases (Liszewski et al., 1991). Functionally 
MCP will inactivate C3b bound to its same cell (Miwa & Song, 2001). 
CD59  
CD59 is a 20 KDa GPI-anchored glycoprotein which is highly expressed on several cell types 
including haematopoietic and endothelial cells. The CD59 gene is located on chromosome 11 and 
encodes a molecule containing a hydrophobic signal peptide, ten cysteine residues, and a single N-
glycosylation site. It differs from other complement regulators as it is not coded by the RCA. There 
are few known inducers of CD59 on the vascular endothelium which include laminar shear stress 
and hypoxia (Kinderlerer et al., 2006;Kinderlerer et al., 2008). CD59 inhibits the formation of the 
C5b-9 MAC by interacting with C5b-8 and antagonising the incorporation of C9 into the lytic 
complex (Davies et al., 1989;Mollnes et al., 2002).  
59 
 
1.5.3 Complement and its role in disease 
The complement cascade comprises an important component of innate and adaptive immune 
responses which facilitates the removal of cellular debris, apoptotic material and foreign 
pathogens. However, if the cascade is inappropriately activated or poorly regulated it may lead to 
excessive tissue damage contributing to pathology. Thus, complement is described by some 
investigators as a ‘double edged sword’ (Taylor et al., 2000). The importance of each of the 
complement components or its regulators in the pathogenesis of infectious and inflammatory 
disease is demonstrated by various inherited complement or complement regulatory protein 
deficiencies and by animal knockout studies.  
Deficiency of the classical complement components such as C1, C2 or C4 predisposes individuals to 
SLE and C1q knockout mice are unable to phagocytose apoptotic debris, suggesting that the 
classical complement components are required for immune complex clearance, induction of 
tolerance and protection from autoimmunity (Pickering et al., 2000). Downstream complement 
components appear to be important in protection from infectious disease. C3 deficiency increases 
susceptibility to pyogenic infections, whilst deficiencies affecting formation of the MAC predispose 
to Neisseria meningitides (Pettigrew et al., 2009). 
Disorders of complement regulation are also well recognized. C1 inhibitor deficiency leads to 
complement activation via the classical pathway, resulting in the syndrome of hereditary angio-
oedema. Polymorphisms or deficiency of Factor H leads to uncontrolled C3 activation and the 
hemolytic uremic syndrome or membranoproliferative glomerulonephritis. Mutations in the 
phosphatidyl-inositol glycan (PIG) genes leads to aberrant expression of the GPI anchor, which is 
important for membrane insertion of the complement regulators DAF and CD59 leading to their 
relative deficiency on haematopoietic cells. This leads to paroxysmal nocturnal haemoglobinuria, 
which is characterized by intravascular haemolysis and thrombosis. Further knowledge of the 
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complement regulatory proteins and relevance to cytoprotection arises from animal studies. DAF 
deficient mice are more susceptible to nephrotoxic serum-induced nephritis and DAF deficiency 
exacerbates autoimmune injury in mrl/lpr mice, a model for SLE (Sogabe et al., 2001;Miwa et al., 
2002;Mollnes et al., 2002).  Similarly CD59 knockout mice are more susceptible to erythrocyte lysis 
and have exacerbated lesions in mouse models of demyelination and arthritis (Holt et al., 
2001;Mead et al., 2004;Williams et al., 2004).  
Excessive and inappropriate activation of the complement cascade leads to excessive tissue injury 
and damage which is apparent in several diseases including rheumatoid arthritis, transplant 
rejection, atherosclerosis, vasculitis, SLE and sepsis  (Walport, 2001b). The role of complement in 
vascular disease is discussed in the next section. 
Certain pathogens may exploit complement membrane proteins to gain entry into the cell. CD46 is 
a receptor for several infections including measles virus, Neisseria species, Streptococcus pyogens 
and Human Herpes virus 6. Epstein-Barr virus uses CD21/CR2 as a receptor on B-lymphocytes, 
whilst Echoviruses and Coxsackie virus B may use CD55/DAF as their receptor (Miwa & Song, 
2001).  
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1.5.4 Complement in vascular disease 
The role of endothelium in complement-dependent disease 
The vascular endothelium is constantly exposed to circulating complement and its products. 
Furthermore the endothelium is likely to be affected by inflammatory diseases where complement 
is activated at a local or remote site. Hence complement-dependent endothelial damage is likely 
to be involved in the pathogenesis of several vascular diseases. There is compelling evidence that 
complement has a role in atherosclerosis, arterial aneurysms, ischemia-reperfusion injury, 
transplant vasculopathy and the vasculitides (Oksjoki et al., 2007;Wehner et al., 2007;Haskard et 
al., 2008;Little & Savage, 2008). 
The endothelium is a large dynamic organ which is an important source of complement proteins. 
Endothelial cells produce all complement components including Factor B in vitro, and are also 
known to be a major source of circulating C7 (Langeggen et al., 2000;Fischetti & Tedesco, 2006). In 
response to pro-inflammatory cytokines or hypoxia-reoxygenation the vascular endothelium 
upregulates the production of several complement components including C1q, C3, C4, C5 and C9 
which are likely to contribute to disease at a local or distant site (Dauchel et al., 1990;Collard et al., 
1997;Vakeva & Meri, 1998). 
Disease specific factors determine the mechanism of complement activation at the endothelial 
surface. Many diseases involve activation of the classical pathway on the endothelial surface. For 
example anti-HLA class I antibodies activate complement during hyperacute rejection and anti-
phospholipid antibodies may be important during ischemia-reperfusion injury (Fleming et al., 
2004;Fischetti & Tedesco, 2006;Wehner et al., 2007). Antibody-independent activation may 
involve cell bound CRP, while hypoxia-reoxygenation may activate complement by utilizing the 
mannose-lectin pathway (Collard et al., 1997;Collard et al., 2000).  
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ECs express C1q receptors which can bind the collagen or globular component of C1q. Levels of 
free circulating C1q are determined by the presence of the components C1r, C1s and C1 inhibitor 
activity. Following classical complement activation free C1q levels rise and on binding to its 
endothelial cell receptor enhances the expression of leucocyte adhesion molecules E-selectin, 
ICAM-1, VCAM-1 and increases synthesis and release of cytokine IL-1, IL-8 and IL-6 and the 
chemokine MCP-1 (Lozada et al., 1995;van den Berg et al., 1998). ECs express G-protein coupled 
receptors for C3a and C5a. Ligation of the C5a receptor may enhance leucocyte-endothelial cell 
interactions and leucocyte transmigration by enhancing P-selectin, E-selectin and VCAM-1 
expression (Albrecht et al., 2004). It also enhances the expression of the pro-inflammatory 
cytokines IL-1, IL-6, TNF-α, IL-8 and MIP-1 and may impact on hemostasis by increasing levels of 
vWF, heparin sulfate and tissue factor (Czermak et al., 1999;Fischetti & Tedesco, 2006). Moreover, 
injecting C5a into monkey femoral arteries leads to impaired coronary blood flow and 
vasoconstriction, indicating a possible role in endothelial dysfunction (Mugge et al., 1993;Lucchesi 
& Kilgore, 1997).  
Nucleated cells have evolved several mechanisms which prevent C5b-9 dependent lysis. Thus 
endothelial cell lysis rarely occurs following complement activation and C5b-9 deposition, but 
more frequently has sublytic effects and induces an active endothelial phenotype. Sublytic C5b-9 
enhances the EC expression of P-selectin, E-selectin, ICAM-1, VCAM-1, promotes the production of 
IL-1, IL-8, MCP-1, bFGF, PDGF and augments TNFα-induced adhesion molecule expression 
(Benzaquen et al., 1994;Kilgore et al., 1995;Kilgore et al., 1996;Tedesco et al., 1997). C5b-9 
promotes leucocyte extravasation and promotes coagulation by increasing the expression of tissue 
factor and PAF formation (Tedesco et al., 1997;Dobrina et al., 2002;Lupia et al., 2003).  
Complement activation is increased during inflammation and ECs express several complement 
regulators which act to limit bystander complement-dependent injury and maintain vascular 
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homeostasis. These include the fluid phase regulators; Factor H, Factor I, vitronectin, clusterin, C1 
inhibitor, and the membrane bound regulators; CD55, CD59 and MCP. Many of these exhibit a 
basal constitutive expression. However during inflammation, specific regulators may be 
upregulated in response to growth factors, cytokines and complement components. The cytokines 
IFNγ and TNFα enhance the expression of the fluid phase regulators factor H, factor I, vitronectin, 
clusterin and C1 inhbitor (Fischetti & Tedesco, 2006). Of the membrane-bound regulators DAF and 
CD59 have relatively high expression on endothelial cells, but DAF appears to be most responsive 
to a diverse array of external stimuli. The cytokines; IFNγ, TNFα, growth factors; VEGF, bFGF and 
histamine may enhance DAF expression (Tsuji et al., 1994;Mason et al., 1999;Mason et al., 2002b). 
In addition,CD59 and clusterin may be upregulated by laminar shear stress, and both DAF and 
CD59 are responsive to hypoxia (Urbich et al., 2000;Kinderlerer et al., 2006;Kinderlerer et al., 
2008;Vlaicu et al., 1985b;Vlaicu et al., 1985a;Seifert & Hansson, 1989).  
Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of medium to large sized vessels which is 
characterized by focal areas of inflammatory plaques composed of smooth muscle cells, 
leucocytes and fibroblasts. Plaque rupture leads to superimposed thrombosis and vascular 
occlusion with consequent tissue infarction(Ross, 1999;Hansson, 2005). Evidence suggests that 
complement has a role in all stages of atherosclerosis, from early lesion formation to complex 
plaques, plaque rupture and thrombosis. Histological studies from human specimens demonstrate 
that complement activation products are present within the atherosclerotic plaque and the degree 
of C5b-9 MAC deposition correlates with the severity of the plaque (Vlaicu et al., 1985b;Vlaicu et 
al., 1985a;Seifert & Hansson, 1989).  Moreover, it is suggested that complement plays a role in 
early vascular injury based on observations made in rabbits fed a high cholesterol diet . In these 
studies complement deposition preceded lipid deposition and fatty streak formation (Seifert et al., 
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1989). Further evidence for its role in atherosclerosis arises from animal studies. C6 deficient 
rabbits fed a high cholesterol diet are protected from atheroma formation, indicating a role for 
complement and the terminal cascade (Schmiedt et al., 1998). Moreover, treating rabbits with the 
anti-complement agent, K-76COONa decreases atheroma formation in a model of diet-induced 
atherosclerosis, and injecting vaccinia virus expressing the complement control protein also 
prevents atheroma formation in C57Bl/6 mice fed a high fat diet (Thorbjornsdottir et al., 
2005;Oksjoki et al., 2007). Although these findings indicate a role for complement in 
atherogenesis, some well established murine models of atherosclerosis fail to show a clear role for 
complement. Thus combined ApoE knockout with C5 deficiency have similar degrees of 
atherosclerosis compared to C5 sufficient mice, and surprisingly mice deficient in C3 on a 
background of combined LDL and ApoE knockout have higher lipid levels and a greater degree of 
atheroma formation (Patel et al., 2001;Buono et al., 2002;Persson et al., 2004). These paradoxical 
observations may be related to inter-species differences regarding complement proteins and their 
regulation. Despite the paradoxical observations found with the distal complement pathway, it is 
apparent that the classical pathway is likely to be protective against atherosclerosis. The classical 
components are known to be important in clearing immune complexes and apoptotic bodies 
(Pickering et al., 2000). Consistent with this is the finding that C1q deficiency in LDL receptor 
knockout mice exacerbates lesion formation, with increased apoptotic cells within plaques (Bhatia 
et al., 2007). This is corroborated by the observation that C1q, C4 and C2 deficiency predisposes to 
cardiovascular disease in humans (Nityanand et al., 1999;Jonsson et al., 2005). 
The mechanism of complement activation in atherosclerosis is poorly understood. The absence of 
complement activation products in normal arteries suggests that the complement activating factor 
is either generated within or deposited into the intima. In vitro studies have shown that oxidatively 
modified LDL, necrotic and apoptotic cells can activate complement via the classical or alternative 
pathways by binding to immunoglobulin or CRP (Bhakdi et al., 1999;Gershov et al., 2000;Chang et 
65 
 
al., 2002). Furthermore, evidence for complement activation by these pathways have been 
demonstrated in vivo (Oksjoki et al., 2003). 
Abnormal function of the complement regulatory proteins may also contribute to atherogenesis. 
This is initially evident from animal models of vascular injury and atherosclerosis. Absence of DAF 
or CD59 in mouse models of diet-induced atherosclerosis may enhance complement deposition, 
leucocyte infiltration and atheroma burden (Yun et al., 2008;An et al., 2009;Leung et al., 2009). In 
a wire model of vascular injury, genetic deficiency of C1 esterase inhibitor increases neointimal 
proliferation (Shagdarsuren et al., 2008). Atherogenesis has a predilection for arterial bifurcations 
and areas of turbulent/oscillatory blood flow, whereas areas of laminar flow are protected. CD59 
and clusterin are complement regulatory proteins which are upregulated by laminar shear stress 
and the expression of CD59 has been shown to be downregulated in areas of oscillatory flow both 
in vitro and in vivo (Urbich et al., 2000;Kinderlerer et al., 2008). This observation may in part 
explain the predisposition of branch points to atherosclerosis.  
Diabetes mellitus is a major risk factor for atherosclerosis and poor glycemic control correlates 
with microvascular and macrovascular disease. Dysfunctional complement regulation is apparent 
in these patients. Diabetic patients demonstrate high levels of glycated CD59 within blood and 
urine and glycation of CD59 impairs its complement inhibitor function which is associated with 
enhanced erythrocyte lysis and growth factor release from endothelial cells in vitro (Davies et al., 
2005). Diabetic patients tend to have higher levels of circulating C5b-9 and complement 
deposition in the microvasculature. High glucose levels impair endothelial synthesis of CD55 and 
CD59. Glycated CD59 is observed in renal biopsies of patients with diabetes and colocalises with 
CD59. Finally glycated CD59 may be responsible for complement-dependent loss of smooth 
muscle cells from the arterial media (Qin et al., 2004;Fischetti & Tedesco, 2006). 
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Ischemia-reperfusion injury 
Ischemia results in tissue hypoxia, nutrient and glucose deprivation with accumulation of toxic 
products resulting in cellular injury, apoptosis and necrosis. Revascularization or reperfusion of the 
ischemic tissue results in sudden re-oxygenation with formation of ROS and perfusion of toxic 
metabolites leading to further cellular and organ injury. This phenomenon is known as ischemia-
reperfusion (I/R) injury and is recognized in coronary artery bypass surgery, arterial thrombolysis 
and transplantation (Riedemann & Ward, 2003;Eltzschig & Collard, 2004).  
Complement activation, oxidative stress and leucocyte traffic are key processes involved in I/R 
injury. Complement has multiple direct and indirect effects during I/R injury. Assembly of C5b-9 
will trigger EC activation, EC apoptosis and necrosis. Consequences of EC activation include 
leucocyte adhesion and recruitment, via upregulation of leucocyte adhesion molecules, 
production of pro-inflammatory cytokines and chemokines. Other complement components such 
as C3a and C5a directly enhance EC permeability, are chemotactic and activate neutrophils 
generating ROS (Oksjoki et al., 2007). Both ischemia and reperfusion stages activate complement, 
although the pathway for activation is unclear. C5b-9 MAC appears to be important in determining 
infarct size and damage, as C6 deficient rabbits have smaller myocardial infarcts (Ito et al., 1996). 
It is likely that both the alternative and MBL pathways are required for complement activation. 
MBL associates with C3 in vivo following myocardial I/R (Collard et al., 2000). Furthermore 
neutralizing MBL with a mAb and MBL deficiency protects against myocardial I/R (Jordan et al., 
2001;Walsh et al., 2005). A role for the alternative pathway of activation is suggested by intestinal 
I/R injury. Here factor D deficiency protects against intestinal I/R injury (Stahl et al., 2003). It is 
clear at least in animal models that there may be no role for the classical pathway of activation. 
Thus C1q, C4 and C2 deficiency offers no protection against renal or myocardial I/R injury 
(Riedemann & Ward, 2003).   
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Complement regulatory proteins are likely to limit tissue injury during ischemia-reperfusion. In a 
mouse model of renal ischemia-reperfusion injury, CD59a deficiency was associated with 
increased C9 deposition and tissue injury compared to wild type mice (Turnberg et al., 2004). In a 
second study, combined CD55 and CD59 deficiency was shown to augment neutrophil infiltration, 
C3 and C5b-9 deposition, with more severe renal injury and dysfunction compared to single CD55, 
CD59 knockout or wild type mice.  This study suggested that there was no protective role for CD59 
in I/R injury but did indicate functional co-operation between CD55 and CD59 in limiting injury 
(Yamada et al., 2004).  
The ability of activated complement products to recruit neutrophils and augment oxidative stress, 
as well as causing direct cellular injury during I/R injury, makes complement an attractive 
therapeutic target. Several approaches have been used in vivo to demonstrate this. Intravenous 
infusions of soluble CR1 significantly attenuated murine myocardial and intestinal I/R injury (Hill et 
al., 1992;Zacharowski et al., 1999). Unusually, inhibition of the classical pathway using a C1s 
inhibitor was beneficial in myocardial I/R injury (Buerke et al., 1995). A soluble complement 
inhibitor derived from CD55 and MCP was shown to be of benefit in cardiac xenotransplantation 
and mAb directed against MBL decreased myocardial damage following I/R injury in rats (Jordan et 
al., 2001). C5a is an important pro-inflammatory mediator in I/R injury. Thus mAbs directed 
against C5a have been developed and limit intestinal and myocardial injury in various species 
(Riedemann & Ward, 2003). 
Several clinical studies employing a recombinant C1 esterase inhibitor or C5 mAb have suggested a 
beneficial role in various forms of I/R injury. Thus, use of this inhibitor was shown to  attenuate 
markers of myocardial injury following thrombolysis for MI, coronary angioplasty and CABG 
(Oksjoki et al., 2007). 
68 
 
Transplant vasculopathy 
Although allograft tolerance and survival has significantly improved within the first year of 
transplantation due to better immunosuppressive protocols, long term survival following solid 
organ transplantation is generally unchanged (Mudge, Jr., 2007). Data from the Registry of the 
International Society for Heart and Lung Transplantation shows that at 8 years following 
transplantation 40% of patients will have angiographic evidence of transplant vasculopathy. 
Furthermore cardiac allograft vasculopathy and unexplained graft failure is the leading cause of 
mortality in 30% of cardiac transplant patients (Taylor et al., 2006). Cardiac transplant 
vasculopathy is characterized by diffuse, concentric, intimal hyperplasia of the coronary arteries 
leading to stenosis, ischemia and organ dysfunction. The process is multifactorial and is likely to 
involve both immune and non-immune mechanisms. Traditional Framingham cardiovascular risk 
factors such as hypertension, diabetes mellitus and hyperlipidemia are highly prevalent in the 
transplant population and aggressive treatment of these risk factors may retard vascular disease 
(Mudge, Jr., 2007). Drug therapy and immunosuppression may also have a role. Cyclosporine A 
therapy has played a significant role in preventing allograft rejection and promoting survival. 
However, cyclosporine A contributes to vascular injury and nephrotoxicity which may contribute 
to chronic allograft vasculopathy. Antibody and complement dependent processes also have a 
pathogenic role. This is demonstrated in experimental models where vascular lesions are apparent 
in allografts, but not isografts, and B-cell immunodeficiency appears to protect against vascular 
injury (Wehner et al., 2007). Histologically complement activation products such as C4d are found 
deposited within endothelium. The role of complement is further delineated by animal models of 
transplant arteriosclerosis where animals deficient in C6 are protected against transplant 
arteriosclerosis (Qian et al., 2001a;Qian et al., 2001b). 
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Anti-phospholipid antibody syndrome  
The anti-phospholipid antibody syndrome (APLS) is a thrombotic disorder characterized by 
recurrent arterial or venous thromboses, recurrent miscarriages, thrombocytopenia and the 
presence of anti-phospholipid antibodies. 40% of patients with SLE may have an associated APLS. 
The anti-phospholipid antibodies which are present in these patients include those directed 
against prothrombin and beta-2-glycoprotein-1. The mechanism of thrombosis is unclear but is 
likely to involve interactions between endothelial cells, platelets, leucocytes, antibodies and the 
coagulation cascade (Hughes, 1998). A role for the vascular wall and endothelium is indicated by 
murine studies, where infusion of prothrombotic antibodies alone fails to induce thrombosis. 
Instead, vascular injury in the form of mechanical trauma or photochemical injury is necessary to 
induce thrombosis in the presence of these antibodies (Meroni et al., 2001). An infectious trigger 
is possibly involved, based on the observation that up to 24% of patients with APLS have a 
preceding infection and LPS injection into mice in the presence of β2GP1 can trigger thrombosis 
(Asherson, 1992). Early fibrinogen deposition onto endothelium is observed prior to thrombus 
formation, suggesting a direct pathogenic role for EC in this syndrome. Complement is known to 
play a role in thrombosis which is evident in individuals with complement deficiency. Current 
evidence suggests a role for complement in the pathogenesis of APLS. C3 and C9 co-localises with 
antibody on endothelial surfaces in a mouse model of APLS. C6 deficient rabbits are protected 
from thrombosis following injection of β2GP1 antibodies, suggesting a role for the C5b-9 MAC in 
thrombosis which is supported by in vitro studies. Protection from thrombosis is also observed in 
C3 and C5 deficient animals. Finally, treating mice with C5 inhbitory mAbs prevents the formation 
of thrombosis in murine models of APLS, highlighting the role of complement in this syndrome. 
Mechanisms for complement activation remain to be investigated (Fischetti & Tedesco, 2006).  
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Systemic vasculitis 
Complement is thought to contribute to the pathogenesis of large and small vessel vasculitis. 
Vascular immune complex deposition with subsequent classical complement activation and C5b-9 
MAC-induced endothelial damage and activation is proposed as a mechanism of vascular injury 
(Little & Savage, 2008). Thus in leucocytoclastic vasculitis, patients demonstrate elevated 
circulating levels of C3dg and terminal complement components (TCC), with perivascular 
deposition of C3dg and TCC in skin lesions (Fischetti & Tedesco, 2006). Patients with Kawasaki 
disease demonstrate high levels of circulating anti-endothelial IgM antibodies, which in the 
presence of TNFα, trigger EC cytotoxicity (Takahashi, 1998). The presence of gammaglobulins 
attenuates this response. Similarly, anti-endothelial cell antibodies are also present in patients 
with Takayasu’s arteritis and polyarteritis nodosa, whilst serum from patients with Takayasu’s 
arteritis can lyse ECs (Tripathy et al., 2001). Up to 50% of patients with Wegener’s granulomatosis 
and PAN have a decrease in circulating complement levels, with demonstrable C5b-9 MAC and 
immunoglobulin deposition within the vasculature (Little & Savage, 2008). 
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1.6 PROTEIN KINASES IN ENDOTHELIAL CYTOPROTECTION  
1.6.1 Introduction to Protein kinase C (PKC) 
PKC, a large family of phospholipid-dependent serine/threonine kinases, is part of the inositol 
phospholipid signaling cascade and is prevalent in several tissues and organs (Inoue et al., 
1977;Dempsey et al., 2000). The PKC family comprises of at least 11 isozymes, which are further 
divided into 3 subgroups based on their structures and modes of activation. The classical PKCs (α, 
βI, βII and γ, cPKCs) are calcium-dependent and are activated by both phosphatidylserine (PS) and 
diacylgylcerol (DAG); the novel PKCs (δ, ε, θ and η, nPKCs) are calcium-independent and regulated 
by DAG and PS; the atypical PKCs (ζ, ι and λ, aPKCs) are calcium-independent and do not require 
DAG for activation, although PS can regulate their activity (Nishizuka, 1992;Newton, 1995;Mackay 
& Twelves, 2007). 
PKCs contain N-terminal regulatory and C-terminal catalytic domains separated by a flexible hinge 
region. In the absence of activating co-factors, the catalytic domain is subject to autoinhibition by 
the regulatory domain, mediated by a pseudosubstrate sequence motif that resembles the 
consensus sequence for phosphorylation by PKC (House & Kemp, 1987). Binding of DAG to the C1 
domain causes a conformational change leading to loss of autoinhibition followed by activation 
and translocation of the enzyme. Calcium also facilitates the translocation of cPKC’s by increasing 
the affinity of the C2 domain for anionic membranes. The lack of several aspartate residues in the 
C2 calcium binding site confers calcium independence to the nPKCs, whereas absence of part of 
the C1 DAG-binding domain and the C2 binding domain render the atypical isotypes insensitive to 
both DAG and calcium (Mackay & Twelves, 2007;Churchill et al., 2008). 
The chain of events that modulate PKC activity begins with stimulation of a G-protein-linked 
receptor (GPLR) or a receptor tyrosine kinase (RTK), which both lead to the generation of DAG. 
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Several PKC isozymes are activated independently in a redundant manner through the 
phospholipase C (PLC) and PI-3K pathways (Nishizuka, 1992;Newton, 1995;Mackay & Twelves, 
2007). Activated PKC then phosphorylates and activates a range of kinases which ultimately induce 
gene transcription via different mechanisms. The mitogen-activated protein kinase (MAPK) 
cascade and the IκB kinase (IKK) complex are the best described downstream targets of PKC. The 
interaction between PKC and these proteins has placed PKCs at the center of numerous signaling 
pathways that control DNA synthesis, cell cycle and inflammatory responses (Sugden & Clerk, 
1997;Clerk & Sugden, 2001;Oliva et al., 2005).   
1.6.2 Functions of PKC 
PKC has been implicated in regulating a range of cellular events from proliferation, differentiation, 
apoptosis and survival in many tissue types. However, remarkable heterogeneity exists within 
their tissue distribution, activation profiles, functional roles and substrate specificity (Dempsey et 
al., 2000). PKC α, β, δ, ε, ζ, η, θ are reported to be expressed by ECs and have different roles in EC 
function, inflammatory responses and cytoprotection. 
PKCα, β and θ are thought to be proangiogenic in response to VEGF-induced EC proliferation 
(Wang et al., 2002;Teicher et al., 2002). In contrast, PKCδ has been shown to retard cell-cycle 
progression and inhibit VEGF-induced EC proliferation (Shizukuda et al., 1999). Recently Steinberg 
et al demonstrated that PKCε, co-operating with Akt, protects ECs from apoptosis through 
induction of the anti-apoptotic protein bcl-2 and inhibition of caspase-3 cleavage (Steinberg et al., 
2007).  
Previous studies from our laboratory have shown that thrombin, VEGF and statins can upregulate 
EC DAF expression. It has recently been shown that the predominant pathway for thrombin-
induced DAF expression involves transactivation of proteinase-activated receptor-2 (PAR2) by 
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PAR1 and signaling via PKCε and MAPK (Lidington et al., 2005). In contrast, induction of DAF by 
VEGF utilizes a VEGFR-2, PLCγ, PKCα/ε and p38 MAPK-dependent pathway (Mason et al., 2004). 
Alternatively, DAF induction by statins is mediated through activation of PKCα and interestingly, 
inhibition of PI-3K significantly augments statin-induced DAF expression (Mason et al., 2002a). 
Finally, DAF induction by TNF-α in murine ECs is mediated via a PKCα, PI-3K, p38 MAPK and NF-κB-
dependent pathway (Ahmad et al., 2003). 
The activity of another vascular cytoprotective molecule, eNOS is closely associated with PKC 
isozymes in ECs. Phosphorylation of eNOS by PI-3K-dependent Akt stimulates its catalytic activity. 
Rask-Madsen (Rask-Madsen & King, 2008) suggested that PKCε expression is critical for activation 
of Akt and eNOS by VEGF, as downregulation of PKCε with siRNA abrogated VEGF-stimulated 
phosphorylation of Akt and eNOS. Gélinas (Gelinas et al., 2002) also demonstrated that VEGF 
mediates NO synthesis in ECs via PI-3K/Akt/PKC pathways. Likewise, thrombin activates eNOS 
using a calcium-dependent, PKC-sensitive, but PI-3K/Akt-independent pathway (Motley et al., 
2007). 
Various PKC isozymes have been implicated in HO-1 induction in ECs in response to different 
stimuli. Rojo et al (Rojo et al., 2006) suggested that HO-1 is induced by a PI-3K/PKCζ/Sp1-mediated 
pathway while Kim et al  (Kim et al., 2007) showed Phellinus Linteus-induced HO-1 expression to 
be dependent upon a PKCδ/Nrf2/ARE signaling pathway.  
Of note, activation of PKCα seems to be required for LDL receptor upregulation and the resulting 
decrease in serum LDL. In terms of myocardial protection, it is thought that protection conferred 
by ischemic preconditioning is mediated via activation of PKCε, as inhibition of PKCε by selective 
inhibitory peptides abolish the protection induced by preconditioning. In contrast, PKCδ-selective 
agonists and antagonists suggest that PKCδ contributes to tissue damage induced by ischemia 
(Gray et al., 1997;Dempsey et al., 2000).  
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PKC isozymes are also involved in the induction of pro-inflammatory genes. It has been shown that 
PKC activation results in the upregulation of P-selectin on the surface of the coronary endothelium 
(Murohara et al., 1995). The LDL constituent, apolipoprotein CIII, induces activation and 
translocation of PKCβ and increased expression of VCAM-1 and ICAM-1 (Kawakami et al., 2006). 
Phospholipase A2 activation and increased monocyte PECAM-1 expression has also been 
associated with PKCε/α (Gong et al., 2004).  
1.6.3 Mitogen-Activated Protein Kinases (MAPK) 
Mitogen-activated protein kinases (MAPK) are serine/threonine-specific protein kinases that 
respond to extracellular stimuli (mitogens) and regulate various cellular activities, such as gene 
expression, mitosis, differentiation, and cell survival/apoptosis. Extracellular stimuli lead to 
activation of a MAPK via a signaling cascade ("MAPK cascade") composed of MAP kinase, MAP 
kinase kinase (MKK or MAP2K), and MAP kinase kinase kinase (MKKK or MAP3K). A MAP3K that is 
activated by extracellular stimuli phosphorylates a MAP2K on its serine and threonine residues, 
and then this MAP2K activates a MAP kinase through phosphorylation on its serine and tyrosine 
residues (Garrington & Johnson, 1999). The MAP kinase signaling cascade is evolutionarily 
conserved from yeast to mammals. Once activated, MAPK can phosphorylate and activate other 
kinases or transcription factors in either the cytoplasm or nucleus. Three distinct subgroups of 
MAPK have been described to date: the extracellular signal-regulated kinases (ERK) family, the c-
Jun NH2-terminal or stress activated protein kinases (JNK/SAPK) and the p38 MAPK (Blenis, 
1993;Garrington & Johnson, 1999) . 
Extracellular signal-regulated kinases (ERK1/2; p42/44)  
ERK1/2 is ubiquitously and differentially expressed between different cell types and tissues. It is 
activated in response to growth factors and phorbol esters, and regulates cell proliferation and 
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differentiation (Sugden & Clerk, 1997). The ERK1/2 pathway has been closely linked with 
vasculoprotection and may be activated by laminar shear stress (Hoefen & Berk, 2002). We and 
others have demonstrated a role for ERK1/2 in resistance to complement-mediated cell lysis 
(Kraus et al., 2001;Lidington et al., 2005). 
p38 MAPK 
A relatively novel member of the MAPK cascade, p38 kinase (reactivating kinase or MAP2) is 
activated by inflammatory cytokines, endotoxins, and osmotic stress . Synthesis and activation of 
this MAPK is not ubiquitous, but is differentially regulated in various cell lineages and tissues. 
Cytokines activate p38 MAPK through two distinct pathways. The first is via MKK4 which is TNFα-
independent, and the second via MKK3 or MKK6 which is activated by TNFα (Garrington & 
Johnson, 1999). 
In mammalian cells p38 MAPK plays a central role in the regulation of a variety of responses such 
as the expression of pro-inflammatory mediators, leukocyte adhesion, chemotaxis, oxidative burst 
and degranulation (Zu et al., 1998;Cara et al., 2001;Lawrence et al., 2008). In addition, our 
laboratory has shown that p38 MAPK is involved in the upregulation of EC DAF by VEGF and TNF-α 
(Ahmad et al., 2003;Mason et al., 2004). However, the precise regulation and function of p38 
MAPK, in particular the mechanisms by which p38 regulates gene expression and the role of 
individual p38 MAPK isoforms in immune and inflammatory cell function remain to be resolved.  
JNK/SAPK 
The third family of MAPK, the JNK/SAPK, are an evolutionarily-conserved group of 
serine/threonine protein kinases. The first member to be identified was the 54 kDa protein SAPK 
(Moriguchi et al., 1995). Parallel studies using the N-terminal transactivation domain of the 
transcription factor substrate c-Jun further identified the 46-55kDa c-Jun protein kinase which is 
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activated in response to ultraviolet light (Hibi et al., 1993). These protein kinases were termed JNK 
as their activation parallels the phosphorylation of c-Jun in intact cells, suggesting an important 
role for these kinases in regulating c-Jun transcriptional activity.  
Activation of JNK has been demonstrated in response to various extracellular stimuli, including 
growth factors, cytokines and cellular stresses such as heat shock, hyperosmolarity, UV radiation 
and I/R injury (Minden et al., 1994;Moriguchi et al., 1995). A major target of the JNK pathway in 
response to these stimuli is the activation of the transcription factor AP-1 that is mediated in part 
by the phosphorylation of the transcription factor substrate c-Jun (Westwick et al., 1994). 
1.6.4 Protein kinase B/Akt 
Akt/Protein kinase B is a serine/threonine kinase with high sequence homology to protein kinase’s 
A and C. The kinase is comprised of at least three members Akt1, 2 and 3 and each contains an N-
terminal pleckstrin homology (PH) domain, catalytic domain and a C-terminal regulatory domain. 
The activity of Akt is predominantly determined by PI-3 kinase and PTEN (phosphatase and tensin 
homolog detected on chromosome 10) which regulates phosphatidyl-inositol levels. Full activation 
of Akt requires its translocation to the plasma membrane via the PH domain followed by a two 
step phosphorylation of a threonine residue by phosphoinositide dependent kinase-1 (PDK-1) and 
a serine residue (Akt Ser-473) by PDK-2. The identity of PDK2 was unclear but recently was 
recognized as mTORC2 (Abraham, 2002;Tsang et al., 2007). 
Akt/PKB is activated by receptor tyrosine kinases and G-protein coupled receptors in response to 
growth factors, cytokines and intercellular junctional contacts, which regulate several endothelial 
cell processes fundamental to vascular homeostasis. These include apoptosis, cellular proliferation 
and angiogenesis, vasomotor tone and inflammation. VEGF, basic-FGF and angiopoietin-1 activate 
Akt to promote EC survival by stimulating proliferation and inhibiting apoptosis (Gerber et al., 
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1998b;Kim et al., 2000). The central importance of Akt in vascular function is demonstrated by its 
ability to phosphorylate and activate eNOS in response to laminar shear stress (Dimmeler et al., 
1999;Boo & Jo, 2003). Furthermore several EC cytoprotective proteins and signaling pathways are 
regulated by Akt. Thus Akt regulates the expression of HO-1, Nrf-2, DAF, CD59, COX-2 and bcl-2 in 
response to growth factors, cytokines, ROS, laminar shear stress and statin therapy (Salinas et al., 
2004;Wu et al., 2006;Dai et al., 2007;Steinberg et al., 2007;Kinderlerer et al., 2008). These 
responses are mediated by interactions with other signaling mediators including PKC, MAP 
kinases, hypoxia-inducible factor, KLF’s and PPARs (Liu et al., 2001;Gliki et al., 2002;Natarajan et 
al., 2003;van Thienen et al., 2006;Jimenez et al., 2010). Finally, the protective effects of Akt are 
apparent in models of ischemia-reperfusion injury, ischemic pre-conditioning and post-
conditioning (Hausenloy et al., 2005;Hausenloy & Yellon, 2006). 
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1.7 THERAPEUTIC VASCULAR CYTOPROTECTION  
Due to its anatomical location the vascular endothelium has a pivotal role in all inflammatory 
diseases, either by primarily contributing to pathogenesis, or by facilitating disease in response to 
pathogenic stimuli arising from a remote region. In vascular inflammatory diseases such as 
atherosclerosis, transplant vasculopathy and vasculitis the endothelium is a key therapeutic target 
due to its central regulatory role in disease pathogenesis. As described in the previous section, the 
vascular endothelium is equipped with multiple homeostatic protective mechanisms which aim to 
maintain vascular integrity and function following vascular injury and during inflammation. 
Although many preventive and therapeutic strategies target the underlying aetio-pathogenesis of 
disease, an alternative or additional approach is to enhance cytoprotective and anti-inflammatory 
pathways.  Thus, novel agents which activate key cytoprotective signaling pathways and proteins 
within vascular endothelium, such as eNOS, HO-1, Nrf2, Akt and PKCε will enhance vascular 
protection against oxidative stress, complement, apoptosis, thrombosis and immune-mediated 
injury.  
 As well as providing a better insight into disease pathogenesis, progression, morbidity and 
mortality; cellular, clinical and epidemiological studies may also identify vascular cytoprotective or 
even cytotoxic properties of currently used agents. For example, recent epidemiological and 
clinical studies indicate that NSAIDs and glitazones may have adverse cardiovascular effects, whilst 
several studies indicate that statins may have additional anti-inflammatory properties within the 
vasculature (Ray et al., 2002;Grosser et al., 2006;Nissen & Wolski, 2007). Thus, the impact of 
currently used drugs in vascular injury and vascular protection are poorly understood and are 
worthy of further investigation.  
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1.7.1 Immunosuppression and vascular disease: insights from chronic 
inflammatory disease and transplant vasculopathy 
Chronic inflammatory disease 
Atherosclerosis is the most prevalent vascular disease and over the last four decades our 
understanding of pathogenesis has evolved from a lipid deposition disorder of the vascular wall, to 
the current perspective as a focal, chronic inflammatory disease of medium to large sized arteries, 
characterized by inflammatory plaques which may become susceptible to rupture and thrombosis. 
The inflammatory basis of atherosclerosis parallels other inflammatory diseases including the 
autoimmune disease rheumatoid arthritis (RA).  Furthermore, excess atherosclerosis, 
cardiovascular morbidity and mortality are well recognized in patients with RA and other chronic 
inflammatory rheumatic diseases such as SLE and systemic vasculitis. For example patients with RA 
have high standardized mortality ratios for cardiovascular disease, and cardiovascular deaths 
accounts for up to 50% of mortality, with life expectancy reduced by 10-15 years (Sattar et al., 
2003). A similar alarming trend is observed in systemic lupus erythematosus (SLE), with a marked 
increase in stroke and myocardial infarction (Esdaile et al., 2001). These outcome data reflect the 
presence of increased carotid artery intima thickening, vascular stiffness and impaired flow-
mediated vasodilation (FMD) in RA and SLE, indicating endothelial dysfunction and subclinical 
atherosclerosis (Salmon & Roman, 2008). A similar association with vascular dysfunction and 
atherosclerosis is also apparent in ankylosing spondylitis, psoriatic arthritis  and systemic vasculitis 
(Raza et al., 2000;Bacon et al., 2002;Hall & Dalbeth, 2005).  
The mechanisms for vascular injury in these diseases are unclear but epidemiological evidence 
suggests a role for disease specific factors rather than traditional Framingham risk factors. 
Furthermore, severity of disease activity and markers of systemic inflammation, such as C-reactive 
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protein (CRP), predict cardiovascular mortality in these patients, whilst systemic inflammation may 
also adversely affect lipid profiles and promote insulin resistance (Sattar et al., 2003).  
Treating the underlying inflammatory disease and suppressing inflammation appears to improve 
outcomes from cardiovascular diseasein patients with primary inflammatory diseases (Hamdulay 
& Mason, 2009). Methotrexate is the most widely used immunosuppressant in RA, and mortality 
from MI in RA has improved since its introduction in the 1980’s (Choi et al., 2002). In vitro 
evidence indicates that methotrexate can promote reverse cholesterol transport in macrophages 
and prevents foam cell formation (Reiss et al., 2008). A similar atheroprotective benefit is also 
apparent for both sulfasalazine and hydroxychloroquine (van, V et al., 2006). In addition, 
hydroxychloroquine promotes an anti-atherogenic lipid profile which may have anti-thrombotic 
effects (Munro et al., 1997;Edwards et al., 1997).  
Corticosteroid therapy may adversely affect traditional risk factors such as insulin resistance, 
hypertension and lipid profiles, and is directly associated with carotid plaque formation in RA and 
SLE (del, I et al., 2004). However, this relationship is complex and failure to use adequate 
immunosuppressive therapy including corticosteroids may predispose to accelerated 
atherogenesis (Roman et al., 2007).  
Preliminary data suggest that biologic therapies including TNFα antagonists, the interleukin-1 
receptor antagonist (IL-1ra), anti-IL-6 receptor mAb and B cell depletion may have 
vasculoprotective potential in inflammatory disease.  The  TNFα antagonists, infliximab, 
etanercept and adalumimab improve disease activity, systemic inflammation and outcomes in RA 
(Feldmann & Maini, 2008). Infliximab therapy improves flow-mediated  vasodilation 4-12 weeks 
after infusion, whilst etanercept reduces aortic stiffness which in turn correlates with a beneficial 
effect on disease activity (Hurlimann et al., 2002;Maki-Petaja et al., 2006). Similarly, IL-1 receptor 
blockade improves nitro-oxidative stress, FMD, coronary flow reserve (CFR), left ventricular 
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function and reduces IL-6 and endothelin-1 levels in patients with RA (Ikonomidis et al., 
2008).  
Transplantation 
Whilst outcomes from acute transplant rejection have improved, long term morbidity and 
mortality following transplantation are unchanged. At 8 years following transplantation all 
patients will have hypertension, 40% will have diabetes mellitus and 40% will have transplant 
vasculopathy. Renal impairment is common and 10% will require hemodialysis. Chronic allograft 
vasculopathy and late graft failure will account for mortality in 30% (Taylor et al., 2006).  
Cyclosporin A has significantly improved outcomes from acute transplant rejection. However 
cyclosporin A-induced nephrotoxicity, hypertension and vascular damage undoubtedly contribute 
to poor long-term outcomes following transplantation. Cyclosporin A binds to cyclophylin and 
inhibits calcineurin attenuating IL-2 dependent T-cell proliferation which is the basis of its 
immunosuppressive effects. However, its vasotoxic properties are attributed to its effects on 
vascular smooth muscle cells and endothelial cells. Cyclosporin A may promote pro-inflammatory 
cytokine production, ROS generation and alter VEGF expression within the renal tubule and 
vascular endothelial cells, whilst blockade of VEGF signaling exacerbates cyclosporin A-induced 
nephrotoxicity (Caramelo et al., 2004;Trapp & Weis, 2005). Moreover, cyclosporin A inhibits VEGF 
induced eNOS dephosphorylation which may contribute to vascular dysfunction (Kou et al., 2002).   
Several clinical studies show that patients immunosuppressed with mycophenolate or rapamycin 
have significantly less transplant vasculopathy than patients treated with cyclosporin A 
(Kobashigawa et al., 2006;Raichlin et al., 2007;Kofler et al., 2009). Mycophenolic acid is an inosine 
monophosphate dehydrogenase inhibitor which selectively inhibits antigen-driven T-lymphocyte 
proliferation and promotes T-lymphocyte apoptosis (van Leuven et al., 2006). However, its 
observed beneficial effects on the vasculature suggest that it may have additional vasoprotective 
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properties. Mycophenolate lowers GTP levels in monocytes/macrophages attenuating their 
function and suppressing TNFα and IL-1β induced EC adhesion molecule expression, which 
together inhibits leucocyte-endothelial cell adhesion (Laurent et al., 1996;Glomsda et al., 
2003;Huang et al., 2005). Mycophenolate may improve vascular function by decreasing iNOS 
activity, reducing endothelin-1 production and enhancing prostacyclin release (Senda et al., 
1995;Haug et al., 2002;Wilasrusmee et al., 2003). Moreover, mycophenolate attenuates NADPH-
dependent superoxide formation in endothelial cells (Krotz et al., 2007). These vasoprotective in 
vitro characteristics are supported by a limited number of in vivo studies.  Thus mycophenolate 
protects against atherosclerosis in rabbits fed a pro-atherogenic diet (Schreiber et al., 
1998;Romero et al., 2000;Greenstein et al., 2000). Another immunosuppressant drug rapamycin 
may have similar vasoprotective effects which are discussed below.  
Atherosclerosis has all the hallmarks of an inflammatory disease which includes the elaboration of 
similar macrophage activating cytokines such as tumour necrosis factor-α (TNFα), interleukin-1 (IL-
1) and interleukin-6 (IL-6), the presence of CD4+CD28- regulatory T-cells, a predominance of Th1 
cellular responses, raised inflammatory markers such as CRP and the enhanced EC expression of 
adhesion molecules including VCAM-1, ICAM-1 and E-selectin (Hansson, 2005). Insights from the 
management of primary inflammatory diseases and transplantation suggest that 
immunosuppressive agents with vasoprotective characteristics may be beneficial in 
atherosclerosis and other vascular pathologies. This is now a subject of proposed clinical trials 
(Ridker, 2009).  
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1.8 STATINS & VASCULAR CYTOPROTECTION  
1.8.1 Introduction 
Statins were initially identified within fungal extracts in the 1970’s and were subsequently shown 
to effectively lower serum cholesterol and improve cardiovascular outcomes from atherosclerosis. 
Statins bind to the active site of hydroxy-methyl glutaryl coenzyme A reductase (HMG-CoA 
reductase) with high affinity and displace its natural substrate mevalonate, so inhibiting 
cholesterol biosynthesis (figure 5). Lowering serum cholesterol is also associated with enhanced 
expression of the hepatic LDL receptor which increases clearance of LDL from the serum and 
contributes to serum cholesterol reduction (Goldstein & Brown, 1990;Liao, 2002;Mason, 2003).  
There are several statins which differ in their molecular structure, ability to inhibit HMG-CoA 
reductase, solubility and pharmacokinetics. The lipophilic statins include atorvastatin, simvastatin, 
lovastatin and cerivastatin, which are superior in permeating cell membranes compared to 
hydrophilic statins such as rosuvastatin and pravastatin. Rosuvastatin has a greater number of 
bonding interactions with HMG-CoA reductase compared to other statins and this is reflected in its 
potent cholesterol-lowering properties compared to other statins (Istvan & Deisenhofer, 
2001;Illingworth & Tobert, 2001).  
Serum cholesterol levels are strongly associated with cardiovascular disease and several landmark 
clinical trials such as  the Scandanavian Simvastatin Survival Study (4S) (1994), Long-term 
Intervention with Pravastatin in Ischemia Disease (LIPID)(Simes et al., 2002), West of Scotland 
Coronary Prevention Study (WOSCOPS)(Shepherd et al., 1995), Air Force/Texas Coronary 
Atherosclerosis Prevention study (AFCAPS)(Gotto, Jr. et al., 2000) and the Heart Protection Study 
(HPS)(Collins et al., 2002) have demonstrated that cholesterol lowering with statins  improve 
outcomes from atherosclerotic cardiovascular disease. Furthermore, recent clinical trials also  
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Figure 5. The cholesterol biosynthetic pathway. Hydroxy-methylglutaryl CoA reductase
(HMG-CoA reductase) is the rate limiting enzyme in the cholesterol biosynthetic pathway.
Statins inhibit HMG-CoA reductase and decrease synthesis of isoprenoid intermediates and
cholesterol.
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indicate that intensive cholesterol-lowering with high dose statins such as atorvastatin 80mg 
further reduces vascular risk compared to lower doses (Cannon et al., 2004). Thus statins are now 
prescribed worldwide as part of a routine treatment strategy in the primary and secondary 
prevention of cardiovascular disease. 
1.8.2 Statin Pleiotropy  
 Although effective cholesterol lowering can primarily explain the mortality benefits of statin 
therapy in cardiovascular disease, several lines of evidence indicate that statins may have 
beneficial properties which are independent of cholesterol lowering. Subgroup analyses of the 4S, 
WOSCOP, CARE and HPS trials demonstrate clinical benefits which are unrelated to baseline 
cholesterol and the degree of cholesterol reduction.  Furthermore angiographic studies show that 
the benefits of statin therapy fail to correlate with atheroma size, and the protection from 
recurrent coronary events following statin therapy occurs far too rapidly to be accounted for by 
cholesterol lowering and plaque resorption alone (Brown et al., 1993;Chan et al., 2002). Instead 
these observations may be attributed to the plaque stabilizing properties of statins. Intriguingly, 
the benefits of statin therapy extend to cholesterol-independent diseases such as ischemic stroke 
and inflammatory rheumatic disease (Crouse, III et al., 1998;McCarey et al., 2004). A recent study 
has indicated that statin therapy improves cardiac function, delays the need for cardiac 
transplantation and improves all cause mortality in patients with severe non-ischemic heart 
failure, a disorder independent of cholesterol levels (Node et al., 2003). These observations, 
together with experimental evidence from in vitro and in vivo studies have led to the hypothesis 
that statins have multiple cholesterol-independent effects, collectively termed ‘statin pleiotropy’ 
(Liao, 2002). 
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HMG-CoA reductase inhibition with statins will inevitably prevent the synthesis of several 
cholesterol intermediaries including farnesyl-pyrophosphate and geranyl-pyrophosphate (figure 
5). These isoprenoids are important lipid attachments for several signal transduction molecules, 
including the G-proteins Ras, Rac, Raf and Rho which may constitute 2% of total intra-cellular 
protein, indicating their importance in cellular function ((Maurer-Stroh et al., 2007). The Ras and 
Rho family of GTPases are the main proteins modified by isoprenylation, a mechanism necessary 
for their transfer and attachment to membranes and biological activity. Rho kinase has several 
downstream targets including Rho-associated protein kinase (ROCK) which is well known to 
phosphorylate and inhibit myosin light chain phosphatase and trigger myosin contractility 
(Burridge & Wennerberg, 2004). Enhanced Rho/ROCK activity is evident during oxidative stress, 
hypertension, pulmonary hypertension and in vascular dysfunction (Wang et al., 2008). The 
pleiotropic effects of statins are attributed to the reduction in isoprenoid levels and in part their 
effects on Rho/ROCK activity. Thus, statin therapy will lead to inhibition of Rho/ROCK by 
preventing isoprenylation of Rho. Many cellular effects of statins can be reproduced by inhibitors 
of Rho kinase and reversed by supplementing with geranyl pyrophosphate (Greenwood & Mason, 
2007). 
Proving the presence of statin pleiotropy is difficult as studies involving statins will always be 
confounded by cholesterol reduction and the evidence for the role of cholesterol in 
atherosclerosis is irrefutable. Furthermore, many of the observed benefits of statin therapy such 
as increased eNOS activity and improvement in vascular function can clearly be accounted for by a 
reduction in cholesterol and oxidized LDL. In addition, the ability of lipophilic statins to permeate 
the cell membrane would predict pleiotropy in these statins, however the benefits of statins 
including pleiotropy is apparent in hydrophilic as well as lipophilic statins (Mason, 2003). Ezetimibe 
is a potent drug which lowers serum cholesterol by inhibiting intestinal cholesterol absorption. 
Recently, a small blinded clinical trial using ezetimibe has provided evidence for statin pleiotropy. 
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Patients with chronic heart failure were randomized to ezetimibe or simvastatin and despite a 
similar reduction in cholesterol levels in each group, patients in the simvastatin group had 
improvements in flow-mediated vasodilation and oxidative stress. Furthermore, increasing the 
dose of statins to achieve a comparable cholesterol reduction to that seen with ezetimibe was 
associated with even greater improvements in vascular function (Landmesser et al., 2005). In two 
recent blinded clinical trials, patients treated with high dose statins demonstrated a reduction in 
ROCK activity and improvements in flow-mediated dilation compared to patients treated with low 
dose statin or ezetimibe (Nohria et al., 2009;Liu et al., 2009). These clinical studies support the 
possibility of cholesterol-independent properties and statin pleiotropy.  
Regardless of mechanism, statins have been shown to enhance several cytoprotective and anti-
inflammatory pathways which may account for their clinical benefits (figure 6). 
1.8.3 Statins and Endothelial Function 
Several studies demonstrate that statins improve endothelial function in diseases associated with 
atherosclerosis including diabetes mellitus and rheumatoid arthritis. As discussed above, some 
studies indicate that improvements may be independent of cholesterol lowering (Raza et al., 
2000;Sattar et al., 2003;El-Magadmi et al., 2004;Raza et al., 2006). The improvement in 
endothelial function is closely correlated with eNOS activity and NO bioavailability. eNOS activity 
can be acutely enhanced by increasing delivery of eNOS substrates and cofactors, and in the long 
term by increasing eNOS mRNA stability (Rikitake & Liao, 2005;Moncada & Higgs, 2006). Statins 
are known to enhance eNOS mRNA stability leading to increased eNOS protein expression, which 
is reversed by geranylgeranyl-pyrophosphate and reproduced by Rho kinase inhibitors (Laufs & 
Liao, 1998).  
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Other cytoprotective pathways involved in statin enhanced eNOS expression and activity are well 
described including KLF-2 and PI-3 kinase/Akt (Sen-Banerjee et al., 2005;Tesfamariam, 2006). 
Several other in vitro and in vivo studies support the role of eNOS and NO in the vasoprotective 
effects of statins (Mason, 2003). Whether the anti-inflammatory properties of statins are 
attributed to NO is unclear. Studies with eNOS deficient mice show that statins fail to inhibit 
leucocyte-EC interactions which suggest an NO-dependent mechanism (Endres et al., 1998). 
Statins also modulate other mediators of vascular function including endothelin-1 (Hernandez-
Perera et al., 2000).  
1.8.4 Statins and Haemostasis 
Statins have been shown to promote an anti-thrombotic vasculature and may have fibrinoloytic 
properties. Simvastatin and fluvastatin reduce the expression of tissue factor in monocytes, 
macrophages, endothelial cells and smooth muscle cells, both in vitro and in vivo (Aikawa et al., 
2001;Baetta et al., 2002;Colli et al., 1997;Eto et al., 2002;Ferro et al., 2000a). Statins also inhibit 
platelet activation, function and aggregation. Recently, lovastatin was shown to acutely inhibit 
porcine carotid artery thrombosis by inhibiting platelet function (Obi et al., 2009). Suggested 
mechanisms include increased eNOS activity, reduced thromboxane A2 synthesis, depletion of 
cholesterol content in platelet membranes and increased ecto 5’ nucleotidase activity (Greenwood 
& Mason, 2007). Statins demonstrate potential fibrinolytic properties by increasing levels of tissue 
plasminogen activator and inhibiting function of plasminogen activator inhibitor-1, so enhancing a 
pro-fibrinolytic state (Bourcier & Libby, 2000). Furthermore, statins upregulate the EC expression 
of thrombomodulin through a KLF-2 dependent mechanism (van Thienen et al., 2006).  
90 
 
1.8.5 Statins as anti-inflammatory agents  
Statins have been shown to modulate several aspects of the inflammatory process. Various statins 
inhibit the EC synthesis of pro-inflammatory cytokines IL-1, IL-6 and TNFα, and other proteins 
including inducible COX-2 and matrix-metallo-proteinases (Inoue et al., 2000;Aikawa et al., 2001).  
Moreover, statins attenuate EC mRNA expression of MCP-1, IL-8 and the protein expression of the 
chemokine receptors CCR1, CCR2, CCR4 and CCR5 (Ferro et al., 2000b;Romano et al., 
2000a;Veillard et al., 2006). Other important statin effects include inhibition of P-selectin and 
possibly ICAM-1, VCAM-1 and E-selectin expression (Romano et al., 2000b;Mason, 2003). 
Consequently these effects may account for inhibition of leucocyte adhesion, activation and 
migration during inflammation. The anti-inflammatory properties of statins are supported by in 
vivo models of atherosclerosis, where statins attenuate atherosclerosis with a reduction in IL-1β, 
VCAM-1 and macrophage infiltration in atherosclerotic plaques (Bustos et al., 1998;Sparrow et al., 
2001;Sukhova et al., 2002). Possible mechanisms for these effects include inhibition of NF-kB and 
activation of the nuclear receptors PPARα and PPARγ (Greenwood & Mason, 2007).  
1.8.6 Statins as modulators of oxidative stress 
Statins may inhibit ROS formation by multiple mechanisms in various vascular diseases. Statins are 
shown to inhibit angiotensin-II induced ROS generation through suppression of Rac-1 mediated 
NADPH oxidase activity (Wagner et al., 2000;Wassmann et al., 2002). In addition, statin inhibition 
of NADPH oxidase may also attenuate the activity of MnSOD and xanthine oxidase (Forstermann, 
2008). Levels of MnSOD and circulating endothelial progenitors are enhanced in individuals 
treated with statins, which restores SOD expression and inhibits accumulation of oxidized-LDL in 
the aortic arch of dyslipidemic mice (Sola et al., 2006;Verreth et al., 2007;Leone et al., 2008). 
Finally statins are known to enhance the endothelial and smooth muscle expression of HO-1 and 
its anti-oxidant actions in vitro and in vivo (Lee et al., 2004;Ali et al., 2009). 
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1.8.7 Statins as Immunomodulators 
Statins modulate multiple components of the acquired immune response. First, they inhibit the 
proliferation and/or function of various cell types necessary for the immune response including 
monocytes/macrophages, B-cells, T-cells and NK-cells (Rudich et al., 1998;Katznelson et al., 
1998;Romano et al., 2000a). Secondly, statins inhibit interferon-γ-induced MHC class II expression 
by downregulating the expression of the class II trans-activator and disrupting lipid rafts (Kwak et 
al., 2000). Finally, statins inhibit the EC expression of cytokine-induced CD40 which attenuates 
CD40 ligand induced IL-12 production. These effects are also reversed with geranylgeranyl-
pyrophosphate (Wagner et al., 2002;Lin et al., 2006). Hence statins can influence mechanisms 
required for antigen presentation and T-cell activation.  
These immunomodulatory effects of statins are recognised in various models of auto-immune 
disease. Statins attenuate nephritis and renal dysfunction in a mouse model of SLE, and are neuro-
protective in experimental autoimmune encephalomyelitis (Youssef et al., 2002;Lawman et al., 
2004). Animal models also show that combined immunosuppression with statins prolong graft 
survival and retard transplant arteriosclerosis (Kofler et al., 2009). Furthermore, statins may 
reduce disability in multiple sclerosis and suppress inflammation in rheumatoid arthritis (McCarey 
et al., 2004). 
1.8.8 Statins and complement regulation 
Statins have anti-complement properties by enhancing the EC expression of various complement 
regulatory proteins. Statins enhance the EC expression of DAF offering protection against 
complement deposition and MAC-dependent EC lysis (Mason et al., 2002a). As expected enhanced 
expression is reversed by geranylgeranyl-pyrophosphate, reproduced by inhibition of Rho kinase 
and is dependent on a protein kinase Cα-dependent pathway. Furthermore, atorvastatin enhances 
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the EC expression of CD59 and DAF during hypoxia-reoxygenation, which in turn protects against 
complement-dependent injury (Kinderlerer et al., 2006).   
In summary, statins appear to be a unique class of compound with multiple cytoprotective actions 
targeting various aspects of vascular injury and inflammation. This is strongly supported by in vitro, 
in vivo and clinical trial evidence, and treatment strategies employing statins are likely to reinforce 
the cytoprotective properties of the vasculature. 
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1.9 THE mTOR PATHWAY & RAPAMYCIN 
1.9.1 Introduction 
The mammalian target of rapamycin (mTOR) is a 289 KDa serine, threonine kinase which is related 
to the PI-3K family of enzymes, but has no intrinsic lipid kinase activity. mTOR is part of an 
important signaling network which regulates several processes including cell growth, proliferation, 
metabolism and autophagy in response to extracellular stimuli including growth factors, nutrients 
and cell stress.  It is a highly conserved molecule which has been identified in all eukaryotic 
organisms to date and its importance in embryogenesis is indicated by genetic knockout which 
leads to fetal death in utero (Hay & Sonenberg, 2004).  
The secondary structure of mTOR is outlined in figure 7. The protein consists of the C terminus 
FATC domain, FKBP12 rapamycin binding domain (FRB) and the N-terminus HEAT region. The FATC 
domain is critical for mTOR function, as amino acid deletion in this region abrogates mTOR activity. 
The FRB domain is critical for rapamycin-immunophilin interactions and the HEAT motif is 
important for interactions with other proteins (Asnaghi et al., 2004). mTOR assembles with several 
adaptor proteins to form at least two distinct signaling complexes (figure 8). Firstly mTOR, when 
assembled with the adaptor proteins raptor and GβL forms the signaling complex mTORC1, which 
transmits a growth and proliferative signal in response to growth factors, hormones and nutrients 
regulating transcription, translation, ribosome biogenesis and nutrient transport (Tsang et al., 
2007). A second complex, mTORC2, is formed when mTOR binds the proteins rictor, GβL and sin 1. 
This complex phosphorylates and stabilises protein kinase B/Akt and regulates its well recognized 
role in cell survival (Sarbassov et al., 2005). 
 
HEAT repeats FAT
FRB
PIKK
RD FATC
COOHNH2
Figure 7. Structural domains of mTOR. HEAT, Huntington-elongation factor 1A- protein
phophatase 2A-A subunit-TOR; FAT, FRAP, ATM, TTRAP2; FRB, FKBP12 rapamycin binding; RD,
regulatory domain; FATC, FAT, C terminal; PIKK, PI-3K-related kinase. See text.
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Figure 8. The mTOR signalling network. mTOR transmits multiple signals in response to
growth factors, nutrients and cellular stress regulating cell growth and proliferation. mTOR
forms two distinct signalling complexes. mTORC1 is composed of mTOR, raptor and GβL which
regulates protein synthesis and mTORC2 consists of mTOR, rictor and GβL which regulates AKT
phosphorylation and activity. Rapamycin disrupts both mTORC1 and mTORC2 function.
Rapamycin
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1.9.2 The mTOR Pathway 
The best characterized signaling pathways are those involving mTORC1 (figure 8). Cellular 
stimulation with insulin, growth factors, cytokines or nutrients activate PI-3K leading to rapid 
phosphorylation and activation of Akt /protein kinase B. This phosphorylates and inactivates the 
tuberous sclerosis complex, a heterodimeric protein consisting of TSC1 and TSC2. The TSC1/2 
complex has GTPase activity for the GTP binding protein Rheb. GTP bound Rheb activates 
mTORC1. In the resting cell TSC1/2 hydrolyses and inactivates GTP rheb to the GDP state. 
However, following growth factor or nutrient signaling, subsequent TSC phosphorylation inhibits 
GTPase activity and maintains Rheb-GTP promoting mTORC1 activation. The best characterized 
downstream targets of mTOR are p70-S6 kinase and the eukaryotic translation initiation factor. 
Activation of mTOR results in phosphorylation and activation of p70-S6 kinase and 
phosphorylation and inactivation of eukaryotic translation initiation factor. This leads to the 
enhanced translation of mRNAs which encode ribosomes necessary for protein synthesis, cellular 
proliferation and growth. The importance of mTOR in growth factor-dependent cell cycle 
progression is highlighted in growth factor and serum deprivation which inactivates mTOR and 
inhibits cellular proliferation (Asnaghi et al., 2004;Hay & Sonenberg, 2004;Young & Nickerson-
Nutter, 2005;Tsang et al., 2007). Furthermore downregulation of mTOR also triggers autophagy 
and mTORC1 is classically described as being rapamycin sensitive (Yang & Klionsky, 2009). 
Pathways involving mTORC2 are less well described but are known to be responsible for growth 
factor or cytokine-mediated phosphorylation of Akt -ser 473 which is essential for Akt /protein 
kinase B activity and its important downstream responses including cell survival (Dormond et al., 
2007).  
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1.9.3 Rapamycin 
Rapamycin (Sirolimus) is a macrolide lactone which was isolated from the bacterium Streptomyces 
hygroscopicus. It is an mTOR inhibitor which has anti-proliferative, anti-apoptotic, anti-angiogenic 
and immunosuppressive properties. After entering the cell, rapamycin exerts its effects by forming 
a complex with FKBP12 which binds to the FRB domain of mTOR, disrupts formation of mTORC1 by 
antagonizing raptor binding and inhibits mTORC1 function. Consequently, rapamycin leads to G1/S 
phase cell cycle arrest inhibiting growth factor or cytokine-induced proliferation in several cell 
types including T-cells, endothelial and smooth muscle cells (Young & Nickerson-Nutter, 2005). 
Rapamycin was previously thought to have no effect on mTORC2 function and Akt. However, 
recent studies indicate that prolonged rapamycin treatment in vitro inhibits growth factor-induced 
Akt-ser-473 phosphorylation by decreasing mTOR expression (Sarbassov et al., 2004;Dormond et 
al., 2007). Thus, rapamycin may also inhibit Akt function and its downstream effector pathways.  
Rapamycin is rapidly absorbed achieving peak concentrations within two hours of oral 
administration and systemic bioavailability is approximately 15% as it undergoes rapid first pass 
hepatic metabolism by the cytochrome p450 system and P-glycoprotein counter transport within 
the intestine. The drug undergoes oxidative metabolism generating inactive metabolites which are 
excreted in stool with minimal urinary excretion. The drug has a half life of 60 hours with efficacy 
and toxicity closely related to serum concentrations and the therapeutic range is between 10-
30nM (Augustine et al., 2007). 
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1.9.4 Pleiotropic properties of rapamycin  
The well recognized anti-proliferative effects of rapamycin on various cell types may provide 
clinical benefits in several pathological processes and diseases. 
Immunosuppression 
 Rapamycin is a potent inhibitor of IL-2-dependent T-cell activation and proliferation which is 
employed as an effective immunosuppressant in organ transplantation. In contrast to cylcosporin 
A and tacrolimus (FK506), the rapamycin/FKBP12 complex has no effect on calcineurin (Young & 
Nickerson-Nutter, 2005;Tsang et al., 2007). In addition, rapamycin is known to expand CD4 CD25 
FOX P3 regulatory T-cell populations by at least two mechanisms (Battaglia et al., 2005). First, as 
the mitogenic responses of regulatory T-cells are independent of mTOR, rapamycin selectively 
expands these T-cells whilst inhibiting proliferation of mTOR-dependent effector T-cells (Zeiser et 
al., 2008). Secondly, rapamycin’s inhibitory effect on Akt activation, upregulates the T-cell specific 
transcription factor FOX-P3 increasing regulatory T-cell populations. Rapamycin also has effects on 
dendritic cell function (Haxhinasto et al., 2008). For example rapamycin down-regulates dendritic 
cell expression of CD80/86 and CD54 inhibiting DC driven T-cell proliferation independent of 
cytokine production (Contreras et al., 2008).  
Vascular effects 
As well as its immunosuppressive properties, rapamycin may exert various beneficial effects on 
the vasculature.  
Smooth muscle cell proliferation, hypertrophy and migration are important characteristics of neo-
intimal proliferation which is apparent in atherosclerosis, pulmonary hypertension, allograft 
vasculopathy and post-stent restenosis. The proliferative response is mTOR-dependent and 
mediated by several growth factors and cytokines including VEGF, basic-FGF, and interferon-γ. 
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Studies in vitro demonstrate that rapamycin inhibits smooth muscle cell proliferation, migration 
and decreases matrix deposition by inhibiting collagen synthesis by 40-60% (Gregory et al., 
1993;Marx et al., 1995;Poon et al., 1996). Rapamycin potently induces the cytoprotective enzyme 
HO-1, which inhibits PDGF-induced smooth muscle cell proliferation and contributes to the anti-
proliferative response (Visner et al., 2003).  
The vasoprotective properties of rapamycin and its ability to inhibit neo-intimal proliferation is 
apparent in several experimental models of vascular disease, but is best demonstrated in models 
of transplant vasculopathy.  In several rat cardiac transplant models, rapamycin prevents and 
retards the progression of allograft vasculopathy in a dose-dependent manner compared to 
cyclosporine-treated recipients (Schmid et al., 1995;Goggins et al., 1996;Poston et al., 1999). 
Attenuation of neo-intimal proliferation is due to its anti-proliferative effects on smooth muscle 
cells and is likely to be independent of T-cell suppression (Raichlin & Kushwaha, 2008). In addition, 
these vasoprotective effects are reproduced with everolimus (Cole et al., 1998). A further study 
using intra-vascular ultrasound (IVUS) in a model of aortic transplant vasculopathy in non-human 
primates showed that rapamycin not only retarded progression of vasculopathy, but also led to 
lesion regression by 20% (Ikonen et al., 2000). These findings indicate that rapamycin may trigger 
smooth muscle cell death by apoptosis or autophagy. 
In vitro and in vivo studies confirm a role for rapamycin in regulating smooth muscle cell apoptosis 
by inhibiting p27 kip-1 an inhibitor of cyclin-dependent kinase (Woltman et al., 2003;Levine & 
Yuan, 2005). These experimental benefits are also apparent in several clinical studies and trials in 
cardiac transplantation. Introduction of rapamycin or everolimus 2 years after transplantation is 
superior to azathioprine, mycophenolate and cyclosporin in retarding progression of allograft 
vaculopathy and the need for percutaneous coronary intervention (Eisen et al., 2003;Mancini et 
al., 2003;Keogh et al., 2004;Vigano et al., 2007;Raichlin et al., 2007). Other benefits over 
100 
 
cyclosporin A include less nephrotoxicity, viral infections and neoplastic complications. However, a 
switch to rapamycin therapy should be delayed, as immediate prescription following 
transplantation is associated with impaired wound healing (Raichlin & Kushwaha, 2008). 
Rapamycin has also been incorporated into coronary artery stents, inhibiting neointimal 
proliferation and effectively preventing restenosis following coronary artery angioplasty (Costa & 
Simon, 2005). These stents were regarded as a major breakthrough in coronary artery 
intervention, but concerns have been raised as late stent restenosis, in stent-thrombosis and 
coronary artery dysfunction are increasingly recognized (Hofma et al., 2006;Lagerqvist et al., 
2007;Stone et al., 2007). These problems are not unique to rapamycin and have also been 
observed in paclitaxel eluted stents, and attributed to delayed healing and re-endothelialisation 
following stent implantation (Stone et al., 2007).  Studies in vitro reveal that rapamycin inhibits 
endothelial cell proliferation in response to growth factors, disrupts mTORC1 and mTORC2 with 
concomitant Akt hypophosphorylation, inhibits eNOS expression, NO bioavailability, promotes 
endothelial cell apoptosis and decreases cell viability (Mohacsi et al., 1997;Parry et al., 
2005;Contreras et al., 2008;Barilli et al., 2008). Furthermore VE-cadherin is regulated by an mTOR- 
Akt-dependent pathway and inhibition with rapamycin attenuates VE-cadherin expression 
potentially increasing vascular permeability (Bieri et al., 2009). Other studies suggest that 
rapamycin potentiates thrombin-induced ICAM-1 upregulation and tissue factor expression in ECs 
and may contribute to endothelial cell progenitor cell death (Minhajuddin et al., 2005;Steffel et al., 
2005b;Miriuka et al., 2006). Clearly, these effects are detrimental to the endothelium and vascular 
function which may account for the observed problems associated with rapamycin-eluting stents. 
However, it is suggested that the kinetics of rapamycin, the stent system, its polymer design and 
drug releasing ability may account for these problems, particularly as it is very difficult to measure 
concentrations of rapamycin in the vicinity of the stent (Costa & Simon, 2005;Stone et al., 2007). In 
support of this is a recent study which utilised biolimus, a rapamycin analog, eluting stent, 
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demonstrated improved coronary artery function when compared to rapamycin eluting stents 
(Hamilos et al., 2008).  
Although rapamycin may have toxic effects on the endothelium, several studies do indeed 
demonstrate improvements in vascular function and protection from atherosclerosis. In vivo 
studies show that rapamycin enhances eNOS expression and improves endothelial function in 
areas of oscillatory/turbulent flow and severity of atherosclerosis is markedly reduced in the Apo E 
knockout mouse (Naoum et al., 2004;Cheng et al., 2008). Furthermore rapamycin clears 
macrophages from atherosclerotic plaques via autophagy (Verheye et al., 2007). EC toxicity may in 
part account for its protective role in allograft vasculopathy. VEGF is known to promote 
endothelial cell proliferation and inflammatory angiogenesis which contributes to the 
pathogenesis of allograft vasculopathy. Thus, rapamycin’s ability to impair endothelial cell 
proliferation and its anti-angiogenic profile may contribute to the observed protection against 
chronic allograft vasculopathy (Contreras et al., 2008).  
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2. MATERIALS & METHODS 
2.1 MATERIALS  
2.1.1 Antibodies  
The following primary and monoclonal antibodies (mAb) were used:  
Anti-DAF mAb 1H4 (IgG1) and anti-MCP mAb TRA-2-10 which were gifts from Dr’s D. Lublin and J. 
Atkinson (Washington University School of Medicine, St Louis, Mo). mAbs A35 (anti-CD59), RMAC8 
(anti-endoglin) and mAb MD1 (murine anti-DAF) were kind gifts from Dr C Harris and Prof. B. P. 
Morgan (University of Wales College of Medicine, Cardiff, UK) and Dr A d’Apice (St. Vincents 
Hospital, Victoria, Australia) respectively.  
The anti-E-selectin mAb 1.2B6, anti-VCAM-1 mAb 1.4C3 and anti- ICAM-1 6.5B5 were generated in 
house. MAbs against HO-1 (1:5000), COX-2 (1:250) and Nrf2 (1:500) were purchased from 
Stressgen (Ann Arbor, MI), Cayman Chemicals (Ann Arbor, MI) and Santa Cruz Biotechnology 
(Santa Cruz, California) respectively.  
Anti-Akt and anti-phospho Akt (Ser473), were from Cell Signaling (Danvers, MA). Anti-phospho-
PKCα (Ser657), (Millipore Corporation, Bedford, MA, United States). Anti-PKCα (Santa Cruz 
Biotechnology, Santa Cruz, California). Anti-phospho-PKCδ (Thr505) polyclonal rabbit Ab , and anti-
PKCδ (New England Biolabs Ltd., Hitchin, Herts, UK). Anti-phospho PKCε (Ser729) ( Millipore). Anti-
PKCε (Santa Cruz Biotechnology). Anti-phospho-p38 MAPK (Thr180/Tyr182) and anti-p38 MAPK (New 
England Biolabs Ltd). Anti-phospho-p44/42 MAPK (Thr202/Tyr204), anti-p44/42 MAPK, anti-phospho-
SAPK/JNK (Thr183/Tyr185), and anti-SAPK/JNK, purchased from New England Biolabs Ltd. Anti-CREB 
Ab (Santa Cruz Biotechnology, Santa Cruz, California) and anti-phospho-CREB(ser133) were from 
Cell Signalling (Danvers, MA. Abs were applied at 1:2500 dilution unless specifically stated.  
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The following secondary Abs were used: Fluorescein isothiocyanate (FITC)-labeled polyclonal 
rabbit anti-mouse immunoglobulin, swine anti-rabbit-immunoglobulin/horseradish peroxidase 
(HRP), goat anti-mouse immunoglobulins were all purchased from DAKO (Glostrup, Denmark). 
2.1.2 Purification and preparation of monoclonal antibodies 
The anti-DAF mAb 1H4 (IgG1) was used to assess DAF expression in many studies within this 
thesis.  This was in the form of a hybridoma culture supernatant. The hybridoma was cultured in 
RPMI 1640, 10% heat inactivated fetal calf serum, 100iu/ml penicillin, 0.1mg/ml streptomycin and 
2mM L-glutamine at 37˚C/5% CO2 and serially passaged (1:3 split).  Established cultures in 175cm
2 
tissue culture flasks were grown until 99% of cells were dead as judged by trypan blue exclusion 
and cell debris was then removed by centrifugation. All mAbs prepared in this way were routinely 
tested for activity by ELISA. Affinity chromatography using protein G sepharose was used to purify 
mAbs from hybridoma culture supernatants. The supernatant was initially pre-cleared of non-
specific binding activity by sequential passage over 2 x 5ml sepharose 4B columns (Pharmacia 
Biotech Ltd.-Milton Keynes, UK).  The supernatant was then passed twice over a 5ml protein G 
sepharose CL-4B column (Pharmacia) equilibrated with a 20mM sodium phosphate buffer pH 7.0 
(binding buffer).  Prior to elution the column was washed through with 50ml of binding buffer and 
the mAb was eluted as 1ml fractions with 0.1M glycine buffer pH 2.5 (elution buffer), which were 
immediately neutralised with 30-50µl of 1M Tris-HCL pH 9.0 to achieve a final pH of 7.4.  The 
protein concentration of the eluted fractions was determined by spectrophotometry at 280nm 
and the appropriate fractions pooled and dialysed against HBSS/0.05% sodium azide (Sigma). The 
column was regenerated by washing with 50ml of elution buffer followed by 100ml of binding 
buffer, for prolonged storage the column was stored at 4˚C in 20% ethanol. The DAF MAb 
supernatant was stored at 4˚C with 0.05% azide whilst purified mAb were stored at -20˚C.  
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However, for functional assays sodium azide was removed by repeated dialysis and mAb passed 
through a 0.2 µm filter prior to use.  
2.1.3 Animals 
C57BL/6 mice were purchased from Harlan Olac (Bicester, Oxford, UK) and housed under 
controlled climactic conditions in microisolator cages with autoclaved bedding. Irradiated food and 
drinking water were readily available. All of the animals were housed and studied according to UK 
Home Office guidelines. Sentinel mice were housed alongside test animals and regularly screened 
for a standard panel of murine pathogens.  
2.1.4 Drugs 
Atorvastatin, simvastatin, NS-398, indomethacin and mycophenolic acid were obtained from 
Merck Biosciences Ltd. (Nottingham, UK). Celecoxib and rofecoxib were obtained from Toronto 
Research Chemicals (Toronto, Cananda), cyclosporin A and rapamycin were purchased from from 
LC laboratories (Woburn, MA, USA). All drugs were dissolved in di-methylsulfoxide (DMSO, Sigma) 
according to the manufacturer’s data sheet. 
2.1.5 Other compounds 
Zinc (II) protoporphyrin IX (ZnPPIX), cobalt (III) protoporphyrin IX and biliverdin were obtained 
from Frontier Scientific (Logan, UT, USA). Metalloporphyrins were dissolved in 0.2 M NaOH and 
the pH adjusted to 7.4. Salicyl-aldehyde isonicotinoyl hydrazone (SIH) was a gift from P. Ponka 
(McGill University, Montreal, Canada).  
The p38 MAPK inhibitor SB202190, MEK1/2 (ERK1/2) inhibitor UO126, JNK inhibitor SP600125 
(JNK-I-II), broad-spectrum PKC antagonist, bisindolymaleimide I (GF109303X), the cPKC isozyme 
inhibitor, Gö6976, were all purchased from Merck Biosciences Ltd. (Nottingham, UK). The PKC 
agonist phorbol 12, 13-dibutyrate (PBu), H-89, bilirubin, iloprost, prostaglandin E2, LY290042, N-
acetylcysteine, di-phenyl-iodonium, apocynin, rotenone, antimycin A, carbonyl cyanide p-tri-
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fluoro-methoxy-phenylhydrazone (FCCP), prostaglandin E2, desferrioxamine and H-89 was 
purchased from Sigma-Aldrich Ltd (Poole, Dorset, UK). TNFα was from R and D Systems (Abingdon, 
UK). 
Myristoylated cPKC peptide inhibitor (myr-ψ-PKC) (myr-Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-
Lys-Asn- Val) was purchased from Promega, (Southampton, UK). 
For the analysis of oxidative stress the following were purchased from Molecular Probes: 2',7'-
dichloro-dihydrofluorescein diacetate (DCFH-DA),  MitoSox™  and mitotracker were purchased 
from Molecular Probes (Invitrogen Ltd, Paisley, UK). 
2.1.6 Dominant Negative Adenovirues  
The dominant negative Akt adenovirus was a kind gift from C Wheeler Jones (Royal Veterinary 
College, University of London). The recombinant adenovirus expressing dominant-negative (DN)-
Nrf2 was provided by J Johnson (University of Wisconsin, Madison). The dominant negative (DN) 
PKC isozyme adenoviruses were a kind gift from M Ohba (Showa University, Tokyo, Japan). An 
adenovirus expression vector, Ax, was used to introduce the DN form of PKC genes into the 
HUVECs. The Ax contained a DN mutation in the gene coding PKCα, δ or ε isozymes. The gene 
product was able to block the function of the wild-type PKCα, δ or ε protein within the same cell 
by competitive inhibition. Generation of adenovirus expression vectors for DN-PKC isozymes has 
been described previously (Ohba et al., 1998). Adenoviruses with an empty vector (AdO) were 
used as control, a gift from E Paleolog (Imperial College). The recombinant adenoviruses were 
amplified in human embryonic kidney (HEK) 293A cells in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen) with 10% FCS (Sigma-Aldrich Ltd.) and grown at 37ºC in 5% CO2. When the cell 
monolayer reached 60-80% confluence, cells were infected with the appropriate adenovirus. The 
infected cells were cultured at 37ºC in 5% CO2 for 3-5 days until HEK cells showed cytopathic 
effects, characterised by a round cell morphology and detachment from the culture flask. Infected 
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HEK293A cells were then harvested by pipetting, transferred into 50 ml tubes, and pelleted by 
centrifugation. The cell pellet was resuspended in 10 ml of the supernatant and the remaining 
supernatant was decanted into a sterile container and kept at 4ºC. The cell suspension was 
freeze/thawed three times to disrupt. The cell debris was pelleted by centrifugation at 3,500 x g 
for 15 min. The supernatant was removed and the reserved supernatant added. Adenoviruses 
were then purified using the AdEasyTM Virus Purification Kit (Stratagen, La Jolla, CA, USA) following 
the manafacturers’ instructions. Purified adenoviruses were then titred using the Adeno-XTM Rapid 
Titer Kit (Clontech Laboratories Inc., Mountain View, CA, USA). The infectious units (ifu/ml) for 
each well were calculated as follows:  
(mean infected cell/field) x (fields/well) 
   volume virus (ml) x (dilution factor) 
 
2.1.7 Cell culture reagents  
Collagenase type II: purchased from Boehringer Mannheim, Lewes, UK. 2% gelatin, EC culture 
medium 199 (M199), fetal bovine serum (FBS), penicillin (100IU/ml), streptomycin (0.1mg/ml), L-
glutamine (2mmol/L) and phosphate-buffered saline with calcium and magnesium (PBS): all 
purchased from Gibco BRL Life Technologies, Paisley, UK. Heparin (10U/ml): Leo Laboratories, 
Princes Risborough, UK. EC growth supplement (ECGS, 30μg/ml): Sigma. Hank’s balanced salt 
solution with calcium and magnesium (HBSS) or without calcium and magnesium (HBSS w/o): 
Sigma. Trypsin/ethylenediaminetetraacetic acid (EDTA): ICN Biomedicals Inc, Costa Mesa, CA, USA. 
The 25 cm2 and 75 cm2 tissue culture flasks (T25 and T75) were from: Costar, Cambridge, MA, USA. 
6-well and 12-well tissue culture plates: Nunc, Thermo Fisher Scientific, Rochester, NY, USA.  
Ifu/ml = 
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2.1.8 Reagents and Apparatus for Western Blotting 
Protein lysis buffer: 4 mM EDTA, 50 mM Tris/HCl, pH 7.4, in 150 mM NaCl with 25 mM sodium 
deoxycholic acid, 200 μM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM sodium 
fluoride, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 5% protease inhibitor cocktail: 
all were purchased from Sigma. DL-Dithiothreitol Solution (DTT): purchased from Sigma. 
Protein quantification: Bio-Rad Dc protein assay kit (Bio-Rad Laboratories, Herfordshire, UK) 
containing 250 ml alkaline copper tartrate solution (solution A), 2 ml dilute Folin reagent (solution 
B), 5 ml surfactant solution (solution S) and bovine serum albumin standard (Kit II). 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE): NuPAGE® Novex System, 
Invitrogen. Reagents and apparatus included: NuPAGE® Novex 4-12% Bis-Tris Gel 1.0 mm, 10 well 
or 10% Bis-Tris Gel 1.5mm, 15 well; NuPAGE® MOPS SDS Running Buffer (20X); NuPAGE® LDS 
Sample Buffer (4X); Protein size marker: SeeBlue® Plus2 Pre-Stained Standard. (All were purchased 
from Invitrogen Ltd, Paisley, UK) 
Transfer system: Semi-dry system (Bio-Rad). Transfer membrane: ImmobilonTM-P transfer 
membrane (Millipore). Transfer buffer: 25mM Tris / 92mM Glycine / 0.1% (v/v) SDS pH8.3 / 20 %( 
v/v) Methanol (Bio-Rad).  
Signal detection: Blocking buffer and Ab dilution buffer (primary and secondary): 1×Tris buffered 
saline and Tween 20 (TBS-T) containing 5% bovine serum albumin (BSA) (all purchased from 
Sigma). Western Blotting Detection Reagents: Amersham ECL™ (enhanced chemiluminescence) 
Western Blotting Detection Reagents (GE Healthcare, USA). Developing films: Kodak XOMat film 
(Eastman Kodak, Rochester, NY, USA). Developing machine: Compact X4 X-ray film processor 
(Xograph Healthcare Ltd, Gloucestershire, UK). Densitometry: Alpha Innotech ChemiImager 5500 
(Alpha Innotech, San Leandro, CA) 
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2.1.9 DAF Promoter Construct and Luciferase Reporter Vectors 
The pGL3-Basic luciferase reporter vector containing the full length DAF promoter region was a 
kind gift from Vijaykumar R. Holla (Department of Medicine, Vanderbilt University Medical Center, 
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee). The promoter was inserted into the 
pGL3-Basic vector between the BglII and HindIII sites. The pGL3-DAF promoters were grown in 
DH5α Escherichia coli and purified by miniprep and maxiprep plasmid purification kits as per the 
manafacturers’ instructions (Qiagen). pGL3-Basic luciferase reporter vector without the promoter 
insert (Promega) was used as a control. pGL4.73[hRluc/SV40] reporter vector (Promega) 
containing an SV40 promoter and a synthetic Renilla luciferase gene was used as the control 
vector for the dual luciferase reporter assay.  
2.1.10 Reagents for Restriction Enzyme Digestion and Agarose Gel 
Electrophoresis 
Agarose: purchased from Sigma. TAE buffer: Tris base 2M, acetic acid 1M, 10% (v/v) 0.5M Na2 
EDTA (pH 8.0) (all from Sigma). Restriction enzymes Xho1, HindIII and 4-CORE Buffer System: 
purchased from Promega. HyperLadder I DNA marker: Bioline, London, UK. The cleavage sites of 
the enzymes are as follows:  
Xho1: C▼TCGA G                 HindIII:  A▼AGCT T 
G AGCT▲C                         T TCGA▲A 
2.1.11 Reagents for Dual-Luciferase Reporter Assay 
Dual-Luciferase® Reporter Assay System (DLR Assay) containing Luciferase Assay Substrate, 
Luciferase Assay Buffer II, Stop & Glo® Substrate, Stop & Glo® Buffer, 5X Passive Lysis Buffer (PLB): 
purchased from Promega. The luminescence generated by the DLR assay was measured by a 
Biotek Synergy™ 4 Multi-Mode Microplate Reader (BioTek Instruments Inc., Vermont, USA) 
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2.2 METHODS 
2.2.1 EC Isolation, Culture and Passage 
Human umbilical cords were donated by the Department of Obstetrics, Queen Charlotte’s 
Hospital. The use of human umbilical vein endothelial cells (HUVEC) was approved by 
Hammersmith Hospitals Research Ethics Committee (06/Q0406/21). 
Fresh umbilical cords obtained at normal deliveries were stored in HBSS containing penicillin and 
streptomycin at 4°C for up to 3 days. HUVECs were isolated from umbilical cords by digestion with 
collagenase type II based on a modified method from Jaffe et al (Jaffe et al., 1973). First, the 
umbilical vein was identified and washed with 50 ml of HBSS to remove blood in the lumen. The 
vein was then filled with 25 ml of 0.5mg/ml collagenase dissolved in HBSS and incubated for 8 min 
at 37°C. After incubation, collagenase solution containing the ECs was collected from the cord. The 
cord was then flushed with 25 ml of HBSS, which was added to the collagenase solution. The cells 
in these pooled solutions were recovered by centrifugation at 250g for 10 min and transferred to a 
25 cm2 1% gelatin-coated tissue culture flask containing complete HUVEC medium, which was 
composed of M199 supplemented with 20% FBS, 100IU/ml penicillin, 0.1 mg/ml streptomycin, 
2mmol/L L-glutamine, 10U/ml heparin, and 30μg/ml ECGS. The next day after isolation the cells 
were washed with HBSS and medium replaced. Once the ECs were confluent in the 25 cm2 flask, 
they were passaged into a 75cm2 culture flask with trypsin/EDTA.  The morphological and 
molecular characterization of isolated ECs used in this thesis are detailed in chapter 3. 
2.2.2 EC stimulation/ treatment 
All experiments were conducted with ECs at passage 2 to 4. For each experiment, ECs were 
harvested with trypsin/EDTA from culture flasks and plated out in 1% gelatin-coated 6 well or 12 
well plates. In general 500 000 cells were plated into each well of a 6 well plate, and 250 000 cells 
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into each well of a 12 well plate. Each well contained reduced HUVEC medium, which was 
composed of M199 supplemented with 10% FBS, 100IU/ml penicillin, 0.1 mg/ml streptomycin, 
2mmol/ L-glutamine, 10U/ml heparin, and 15μg/ml ECGS. ECs were allowed to adhere overnight 
before treatment/stimulation.  
Statins, rapamycin, celecoxib, cyclosporin A, mycophenolic acid, desferrioxamine, SIH, biliverdin, 
CORM-2 and haemoglobin were added directly to the culture medium. Where indicated, 
pharmacological and peptide inhibitors were added 30 min prior to atorvastatin, rapamycin or 
celecoxib. In all experiments, EC monolayers were treated with the appropriate drug vehicle 
controls (DMSO). The final concentration of DMSO was <0.1% in all samples. 
2.2.3 RNA interference  
HUVECs were plated at 4 X105 cells per well in six-well plates in Endothelial Cell Basal Medium 
(EBM2) (Cambrex BioScience, Wokingham, UK) to obtain 50% confluency. Test and control siRNA 
(10–50 nM) were complexed with geneFECTOR (Venn-Nova, Florida, USA), a lipid-based 
transfectant, and cultured with HUVECs for 4 hours in Optimem.  After 4 hours, HUVECs were 
washed with EBM2 and incubated overnight in EBM2 at 37oC. After 48h, HUVECs were treated 
with the indicated drugs/compounds for 6 to 24 hours, then lysed and analyzed to confirm 
knockdown and to investigate changes in target gene expression using qPCR, or protein using 
immunoblotting. Validated ferritin heavy chain siRNA (50nM) was purchased from Santa Cruz 
Biotechnology (Sc-40575, sequences not provided) and validated mTOR siRNA (30nM) was 
purchased from Dharmacon (Layafette, Colorado, siRNA sequences not disclosed by company).  A 
scrambled group of siRNA sequences was used as a negative control (All stars, RNAi, Qiagen). 
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2.2.4 Adenoviral Infection 
HUVECs were infected by incubation with the relevant adenovirus in serum-free M199 for 2 h at 
37 °C. The medium was then changed to reduced HUVEC medium, and HUVECs were incubated 
overnight prior to addition of atorvastatin, rapamycin, celecoxib or carrier control for 24 h. 
Infection of HUVEC with βgal or Ad-GFP control adenoviruses demonstrated a transfection 
efficiency of 95%. The multiplicity of infection (MOI) for the adenoviruses used in this study was 
200 virus particles per cell, which was determined by western blotting in previous experiments 
(Lidington et al., 2005).  
2.2.5 Quantitative real-time PCR  
Quantitative real-time PCR was performed using an iCycler (BioRad, Hercules, CA). β-actin was the 
housekeeping gene, with data calculated in relation to β-actin and verified using glyceraldehyde-3-
phosphate dehydrogenase. DNase-1-digested total RNA (1 μg) was reverse transcribed using 1 μM 
oligo(dT) and Superscript reverse transcriptase (Invitrogen, Paisley, UK). cDNA was amplified in a 
25 μL reaction containing 5 μL of cDNA template, 12.5 μL of iSYBR supermix, 0.5 pM sense and 
antisense gene-specific primers, and double distilled H2O. Cycling parameters were 3 min at 95°C, 
and 40 cycles of 95°C for 10 sec and 56°C for 45 sec. Primers were previously designed, optimized 
and verified by other investigators within the laboratory (Kinderlerer et al., 2006;Partridge et al., 
2007;Ali et al., 2007). Primer sequences are detailed in table 2 and representative PCR curves are 
shown in figure 9. 
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 Table 2. Primer sequences used for quantitative PCR and chromatin immunoprecipitation 
assays.  CRE- cAMP response element. 
                   
     
         
    
 
Primer 
 
 
Forward 
 
Reverse 
 
DAF 
 
CCCTCAAACAGCCTTATATCACTC 
 
AATATGCCACCTGGTACATCAATC 
 
 
HO-1 
 
CTTCTTCACCTTCCCCAACA 
 
TTCTATCACCCTCTGCCTGA 
 
 
Ferritin 
 
CGACCGCGTCCACCTCG 
 
CTTTCATTATCACTGTCTCCC 
 
 
VCAM-1 
 
GGTGGGACACAAATAAGGGTTTTGG 
 
CTTGCAATTCTTTTACAGCCTGCC 
 
 
ICAM-1 
 
GTCCCCTCAAAAGTCATCC 
 
AACCCCATTCAGCGTCACC 
 
 
E-selectin 
 
GCTCTGCAGCTCGGACAT 
 
GAAAGTCCAGCTACCAAGGGAAT 
 
 
β-Actin 
 
CTGGAACGGTGAAGGTGACA 
 
AAGGGACTTCCTGTAACAATGCA 
 
 
GAPDH 
 
CAACAGCCTCAAGATCAT 
 
GAGTCCTTCCACGATACC 
 
 
CRE (flank) 
 
GCACCTCTGACCACAACAAA 
 
CGAGGCTTCTGCTACTGC 
 
 
CRE 
(downstream) 
 
ACAGGGTAAGTTTGGGCA 
 
CCCTCTCCTCAAAGACCCTT 
A T FD
Figure 9. Representative quantitative PCR curves for actin (A), target of rapamycin (TOR), DAF
(D) and ferritin in cDNA prepared from endothelial cells. Ct- threshold cycle.
Ct
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2.2.6 Flow Cytometry 
Monolayers of endothelial cells were harvested by exposure to trypsin/EDTA and stained with the 
appropriate primary mAb for 30 minutes at 4oC. After washing, endothelial cells were stained with 
fluorescein isothiocyanate (FITC)-labeled rabbit anti-mouse Ig for 30 minutes at 4 oC followed by 
washing and fixation in 1% paraformaldehyde. Samples were analyzed on an Epics XL-MCL 
(Coulter, Hialeah, FL) by counting 10 000 cells per sample. Representative histograms and plots are 
shown in figure 10. Results are expressed as a percentage of the relative fluorescent intensity (RFI) 
of non-stimulated cells. The RFI is calculated from the mean fluorescent intensity (MFI) of the test 
antibody divided by the MFI obtained with an isotype-matched irrelevant antibody. 
2.2.7 Western Blotting  
ECs were washed with ice-cold PBS and incubated with lysis buffer (100μl per well of a 6-well 
plate) at 4°C for 10 minutes and lysed. The lysates were then collected into eppendorfs, sonicated 
for 15 seconds and centrifuged at 375g for 10 minutes. Protein concentrations for each sample 
were quantified using the Bio-Rad Dc protein assay kit to ensure equal loading of proteins from 
each sample. Proteins contained in cell lysates were separated by SDS-PAGE. The samples were 
prepared by mixing 25μg of protein, 7.5μl of 4×NuPAGE® LDS Sample Buffer and 3μl of DTT for a 
10 well (1.0mm), 4-12% Bis-Tris Gel or 15 μg of protein, 5μl of 4×NuPAGE® LDS Sample Buffer and 
2μl of DTT for a 15 well (1.5mm), 10% Bis-Tris Gel. The final volume of each sample was diluted 
with distilled water to either 30μl (10 well gel) or 20μl (15 well gel). Samples were denatured by 
boiling for 5 min, centrifuged at 4°C for 1 minute and loaded onto the gels. Gels were run at 200 
volts for 60 min. The separated proteins were transferred from gels to ImmobilonTM-P transfer 
membranes by semi-dry transfer for 1 h at 1 milliamp per membrane. The membrane was 
activated by methanol for 20 seconds and then washed with transfer buffer for 5 min before use.  
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Figure 10. Flow cytometric analysis of human umbilical vein endothelial cells. A representative
HUVEC FACS blot is shown. Gated cells were analyzed (dashed ellipse top left) for protein of
interest. Molecular characterization of these cells is described in chapter 3.2. SS-side scatter,
FS-forward scatter, FL1- fluorescent signal.
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After transfer, the membranes were blocked in 50 ml of blocking buffer at room temperature (r/t) 
for 1 hour. The membranes were then sealed in a plastic bag containing primary Abs in dilution 
buffer at the working concentration and incubated on a rotator overnight at 4°C. On the second 
day, the membranes were rinsed and washed with 50 ml TBS-T 3 times and resealed in a new 
plastic bag containing the secondary HRP-conjugated Ab in dilution buffer at the working 
concentration. After incubation on a rotator at r/t for 2 h, the membranes were washed with TBS-
T 3 times and the signals were detected by an ECL detection kit. The blots were developed by 
exposing the membranes to Kodak XOMat films for varied periods of time to obtain the optimal 
results. Each film was developed by a Compact X4 X-ray processor. Membranes were stripped 
and/or reprobed for other proteins including a housekeeping gene as a loading control. Integrated 
density values (IDV) for the test and control bands were obtained with an Alpha Innotech 
ChemiImager 5500. 
2.2.8 Complement-mediated cell lysis assay 
ECs were cultured overnight in 6-well plates at 37 oC prior to the addition of atorvastatin, 
rapamycin or both. ECs were harvested by exposure to trypsin/EDTA, opsonized with mAb RMAC8 
and incubated with 5-15% rabbit serum for 2 h at 37°C. With DAF inhibition studies, the blocking 
DAF mAb 1H4 was added at a final concentration of 25 μg/mL. Complement-mediated cell lysis 
was then analyzed by flow cytometry measuring propidium iodide uptake by lysed ECs. 
2.2.9 Quantification of HO-1 activity 
HUVEC plated in 96 well microtitre plates were treated with the relevant agonists for 24h, fixed in 
1% paraformaldeyde and permeabilized with 0.1% Triton X-100. After washing, EC were incubated 
with anti-bilirubin IXα mAb (24G7), a gift from Dr T Yamaguchi (Tokyo Medical and Dental 
University, Japan) (Yamaguchi et al., 1996), or isotype-matched control for 30 min, washed and 
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incubated with HRP-conjugated rabbit anti-mouse Ig (Jackson ImmunoResearch, West Grove, PA), 
prior to washing and addition of tetra-methyl benzidine substrate solution (Sigma-Aldrich). The 
enzyme reaction was read at 405/630nm and recorded using a 96-well plate reader (Dynex 
Technologies, Worthing, UK).  
2.2.10 Measurement of HUVEC supernatant iron concentrations 
Supernatants from HUVECs treated with desferrioxamine, atorvastatin and/or rapamycin were 
collected and analyzed for free iron concentrations (Clinical Chemistry, Hammesrmith Hospital). 
The corresponding HUVECs were lysed for protein (20mM Tris/HCl, with 0.5% NP-40, pH 7.4) and 
concentrations measured using the BioRad Dc protein assay kit. Supernatant iron concentrations 
were then normalized to protein concentrations and expressed as µmol/g. 
2.2.11 Measurement of cellular ROS 
2',7'-dichloro-dihydrofluorescein diacetate (DCFH-DA) and MitoSox™ (Invitrogen) were used to 
detect intracellular peroxides or mitochondrial-derived superoxide respectively. DCFH-DA is 
converted to DCFH, generating a green fluorescent product 2’-7’- dichlorofluorescein (DCF; 514nm 
excitation/585nm emission). MitoSox™ a specific detector of mitochondrial superoxide generates 
a red fluorescent product (514nm excitation/585nm emission). HUVEC were cultured on 
fibronectin-coated Petri dishes (Mat-Tek Corporation, MA) and pre-loaded with DCFH-DA (5μM) 
for 60 minutes, or mitochondrial dyes MitoTracker® 633 (5μM) or MitoSox™ (500nM) for 15 
minutes prior to addition of celecoxib. Images were captured using a confocal laser-scanning 
microscope (Zeiss, Oberkochen, Germany). Cellular generation of ROS was quantified by image 
analysis of EC fluorescence in 100 cells from three different fields. Cell fluorescence was corrected 
for autofluorescence and measured using a threshold intensity defined by background 
fluorescence. Results are expressed as percentage change compared to untreated cells.  
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2.2.12 immunofluorescent staining and confocal microscopy  
In vivo 
C57BL/6 mice (6 weeks) were treated for 48 hours twice daily with intra-peritoneal atorvastatin 
(5mg/kg), and/or once daily with rapamycin (5mg/kg). Mice were killed by CO2 inhalation, and the 
vasculature perfused-fixed with 1% paraformaldehyde in phosphate-buffered saline (PBS). 
Thoracic organs were removed en bloc and equilibrated in OCT for 18 h. The ascending aorta, 
aortic arch and descending aorta was dissected and the block was frozen in isopentane. Serial 
cryostat sections were cut and blocked with avidin and biotin solution, then incubated with 20% 
normal rabbit serum (Dako, Ely, UK) in PBS. Sections were then incubated with rat anti-mouse DAF 
mAb MD1 (10µg/ml) or rat anti-mouse CD31 mAb EA3 (10µg/ml) (gift from B Imhof, Geneva) for 
45 minutes at room temperature. The sections were washed and incubated with biotinylated 
rabbit anti-rat mAb (1:100) with 2% normal mouse serum for 40 minutes at room temperature. 
Sections were again washed and incubated with streptavidin-AlexaFluor 568 (Invitrogen) (1:500) 
with 2% normal mouse serum for 1 hour at room temperature in the dark. The sections were 
washed in PBS and incubated for 1 min with Draq-5 (1:1000) in PBS and mounted with 
Hydromount ((National Diagnostics, Atlanta, GA). Sections were examined with a Zeiss LSM 510 
Meta inverted confocal microscope (Thornwood, NY). Scan and photomultiplier settings were set 
to optimize signal/noise ratio for each emission wavelength. Using these photomultiplier settings, 
there was no detectable cross-over between channels. However, to eliminate any possibility of 
data skew by signal contamination, quantification was performed on DAF-only stained sections. 
Processing was with Zeiss LSM Image Browser and quantification by export of the images into 
Image J. The regions of interest were selected, and the histogram function was used to calculate 
the distribution of pixel intensities on the green channel (corresponding to AlexaFluor 568).  
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In vitro 
 
HUVEC cultured on fibronectin-coated chamber slides (Thermo-fisher Scientific, Kamstrupvej, 
Denmark) were treated with celecoxib, fixed in methanol and treated with 10% normal goat serum 
(DAKO) for 1 hour at room temperature. EC were incubated at 4oC overnight with rabbit anti-Nrf2 
(1:200) or an isotype-matched control, washed and incubated with goat anti-rabbit AlexaFluor 488 
antibody (1:200; Invitrogen) for 1 hour at room temperature. Cells were washed, stained with 
nuclear dye Draq5 and mounted with Hydromount (National Diagnostics, Atlanta, GA). Nrf2 
nuclear translocation was analyzed by confocal microscopy using images obtained at 40X 
magnification from ten fields of view per experiment. Nrf2 nuclear co-localization was quantified 
after correcting for autofluorescence and defining threshold intensity from background 
fluorescence. Results are presented as mean nuclear co-localization expressed as a percentage of 
total Nrf2 expression from three independent experiments. 
2.2.13 Restriction Enzyme Digestion and Agarose Gel Electrophoresis 
Prior to restriction enzyme (RE) digestion, the concentration of plasmid DNA was measured by 
spectrophotometry. The optical absorption was measured at λ=260, 280nm. The plasmid samples 
were diluted 1:100 in H2O. RE digestion was performed in a volume of 20μl on 1μg of plasmid 
DNA, using a 5-fold excess of RE (5u) over DNA. Buffer C of the 4-CORE Buffer System was used for 
Xho1 and HindIII double digestion because both of these enzymes have high activity in buffer C. In 
a sterile tube, the reagents for each digestion were added in the following order: Sterile, deionized 
water (required volume for each digestion), RE 10X Buffer C 2μl, Acetylated BSA, 10μg/μl 0.2μl, 
and DNA 1μg. The content was mixed by pipetting and 0.5μl of each RE (Xho1 and HindIII, 10u/μl) 
was added to each reaction. The content was then mixed gently by pipetting, centrifuged for a few 
seconds and incubated at 37°C for 3 h. After the digestion, the DNA was stored at -20°C and a 1% 
agarose gel was prepared for electrophoresis analysis. The DNA for loading was prepared by 
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mixing 5μl of digested DNA, 3μl of 6X loading buffer and 2μl of molecular grade water. After 
loading the mixture, the gel was run at 60 milliamps for 1 h. DNA HyperLadder I and corresponding 
uncut plasmid DNA were used in parallel with products of RE digestions as control. Results were 
read on an Alpha Innotech ChemiImager 5500.  
2.2.14 Transfection of HUVECs with DAF promoter constructs 
ECs were transfected with pGL3-DAF deletion constructs and pGL4.73[hRluc/SV40] or pGL3-Basic 
luciferase reporter plasmids using a lipid-based transfection protocol (Genejuice, Merck 
Bioscinces). ECs were cultured at 200 000 cells per well in a 6-well plate with reduced HUVEC 
medium. The following day a transfection mixture was prepared composed of 0.9µg of each DAF 
promoter construct combined with 0.1µg Renilla luciferase in 100µl Opti-MEM (Invitrogen). The 
DAF promoter-Renilla mixture was incubated with Genejuice (Genejuice:DNA [µg] = 2.5:1) for 15 
minutes at room temperature and this was added to ECs in Opti-MEM. After 6 hours Opti-MEM 
was replaced with reduced HUVEC medium overnight and then treated with the appropriate 
agent/compound.  Analysis for promoter activity was performed 16 h post-stimulation using the 
dual luciferase reporter (DLR) assay.  
2.2.15 Dual Luciferase Reporter Assay 
The Promega Dual-Luciferase Reporter (DLR) Assay kit was used to carry out the assay as per 
instructions. In the DLR assay, the activities of firefly (Photinus pyralis) and Renilla (Renilla 
reniformis, also known as sea pansy) luciferases are measured sequentially from a single sample. 
The firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II (LAR II) to 
generate a stabilized luminescent signal. After quantifying the firefly luminescence, this reaction is 
quenched, and the Renilla luciferase reaction is simultaneously initiated by adding Stop & Glo® 
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Reagent to the same tube. The Stop & Glo® Reagent also produces a stabilized signal from the 
Renilla luciferase, which decays slowly over the course of the measurement. 
Cell lysis buffer was prepared by adding 1 volume of 5x protein lysis buffer (PLB) to 4 volumes of 
sterile water. LAR II was prepared by adding 10ml of Luciferase Assay Buffer II to the Luciferase 
Assay Substrate; Stop & Glo reagent was prepared by adding 20μl of Stop & Glo to 1ml of Stop & 
Glo buffer. All the reagents were defrosted and warmed to room temperature in advance. Growth 
medium was aspirated from each well and the monolayer of cells were washed twice using 1ml 
PBS. 500μl of 1x PLB was added per well of a 6-well plate and was rocked at room temperature for 
15 min. The cell lysates were then collected into 1.5ml tubes. A white 96 well plate was used for 
the DLR assay. 20μl of lysate was transferred into one well for each reaction. Each sample was 
prepared in triplicate. The plate was read on a Biotek Synergy™ 4 Multi-Mode Microplate Reader 
which dispensed LARII and Stop & Glo, resulting in firefly and Renilla luminescence. Data was 
expressed as a ratio of firefly:Renilla luminescence.  
2.2.16 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed using ChIP-IT (Active Motif, Rixensart, 
Belgium). HUVECs were grown to confluence in 15 cm diameter plates and fixed in formaldehyde 
(1%) for 10 minutes, cells were scraped from the plate, lysed, and homogenized using a Dounce 
homogenizer. Chromatin was sheared by enzymatic digestion for 10 minutes at 37°C. Pre-cleared 
chromatin was then added to 2 µg CREB antibody (Santa Cruz Biotechnology, Santa Cruz, 
California) or negative control rabbit IgG and incubated overnight on a rotator at 4°C. The 
antibody-chromatin mixture was then bound to Protein G beads for 1.5 hours. At the end of the 
incubation, the beads were washed and the immunoprecipitated DNA was eluted from the beads 
and purified by reversing cross-links, removal of RNA, and treatment with Proteinase K. DNA was 
then used as the template for PCR using primers (table 2) specific for the human DAF promoter 
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sequence to amplify a region containing putative CREB-binding sites. To determine the specificity 
of the CREB-chromatin interactions, PCR amplification was performed with primers downstream of 
the promoter in a region that should not interact with transcription factors.  
2.2.17 DNA-Binding Activity of Sp1 
HUVECs were grown to confluence in 6 well plates and treated with atorvastatin and rapamycin 
for 30 minutes, 1, 2 and 4 hours. Nuclear lysates were prepared using a nuclear extraction kit 
(Active Motif, Carlsbad, CA). Sp1 binding activity was analyzed using an ELISA based kit (TransAM, 
Active Motif, Carlsbad, CA). Nuclear extracts (10 μg) were added for 1 hour to wells containing 
immobilized Sp1 consensus DNA, followed by the addition of an anti-Sp1 antibody for 1 hour 
(1:1000). Wells were washed 3 times followed by incubation with HRP conjugated-anti-IgG 
(1:1000) for a further hour. Developing solution was added for 3-5 minutes followed by stop 
solution and absorbance was measured at 450nm using a Biotek Synergy™ 4 Multi-Mode 
Microplate Reader. 
2.3 STATISTICAL ANALYSIS 
 
Data derived from individual experiments was expressed as the mean ± SD. Data were grouped 
according to treatments and analyzed using GRAPHPAD PRISM software (San Diego, CA, USA). 
Differences of the results between treatments were evaluated by analysis of variance (ANOVA) 
with Bonferroni correction, an unpaired Students t-test or Mann-Whitney test. Differences were 
considered significant at p-values <0.05. Results of western blots were quantified by the Appligene 
Image Analysis System and values were corrected with respect to the control bands. 
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CHAPTER 3 
MOLECULAR & MORPHOLOGICAL 
CHARACTERIZATION OF ENDOTHELIAL CELLS 
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3.1 INTRODUCTION 
The endothelium is a cellular monolayer which lines the vasculature and selectively regulates the 
transit of molecular and cellular elements between the intra- and extravascular compartments. It 
is a highly dynamic tissue which responds to its local environment and maintains vascular 
homeostasis by regulating vasomotor tone, hemostasis, vascular wall permeability and leucocyte 
traffic. Due to its anatomical location and its extensive distribution throughout several organ-
systems, the endothelium is involved in all diseases; either having a primary role in pathogenesis 
or facilitating disease following endothelial cell (EC) bystander injury.  
The endothelium is derived from the embryonic mesoderm via the differentiation of angioblasts 
and stem cells (Cines et al., 1998). ECs are highly responsive to their micro-environment and 
exhibit marked plasticity with the ability to trans-differentiate into other cell lineages, whilst other 
cell types may also differentiate into ECs (Aird, 2008). Although the endothelium was once viewed 
as being composed of a homogeneous, uniform cell type lining several communicating conduits, it 
is now clear that ECs display marked molecular, structural and functional heterogeneity which is 
apparent between vessels of different sizes and the vascular beds of different organs. For example 
ECs in the high endothelial venules (HEV) have a cuboidal morphology, with well developed golgi 
apparatus, rough endoplasmic reticulum, few cell-cell tight junctions and constitutively express 
lymphocyte adhesion molecules which are not found on other ECs. These characteristics account 
for their permeability and ability to guide lymphocyte traffic through the HEVs located within the 
lympho-reticular system. This profile differs from ECs making up the blood-brain-barrier which 
have highly developed cell-cell tight junctions, highly selective intracellular transport mechanisms 
and low pinocytic activity which accounts for the highly selective permeability of this membrane to 
solutes, macromolecules and cell types (Garlanda & Dejana, 1997). Although all ECs share common 
progenitors there are very few defining structural or molecular markers which can be used to 
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identify ECs and distinguish one type of EC from another in a different vascular bed. Some 
structural, molecular and functional markers used to characterize ECs are listed in table 3 
The vascular endothelium is a difficult tissue to assess and study due to its inconvenient location 
and the inability to perform direct diagnostic and experimental studies. Our understanding of EC 
biology and function has evolved over the last 50 years following advances in microscopy, cell and 
molecular biology. A major development was the ability to culture and characterize ECs in vitro 
which was initially attempted by Maruyama in the 1960’s and later developed independently by 
Jaffe and Gimbrone in the 1970’s (Maruyama, 1963;Jaffe et al., 1973;Gimbrone, Jr. et al., 1974). 
The studies in this thesis employ ECs isolated from umbilical veins adopting the techniques 
developed by Jaffe and colleagues which is detailed in chapter 2. As described in their original 
study smooth muscle cells and fibroblasts may contaminate the isolated EC population and ECs 
may also differentiate into other cell types with different molecular and functional profiles (Jaffe 
et al., 1973). Therefore this chapter details the morphological and molecular characterization of 
ECs isolated from umbilical veins which are used in studies in the forthcoming chapters. This 
chapter also documents DAF expression in various ECs following stimulation with known inducers 
further confirming the presence and functional characteristics of isolated HUVEC. 
Constitutive markers Cell Type Reference
CD31/ PECAM ECs, platelets, Lymphocytes, monocytes, 
neutrophils
(DeLisser et al., 1994;Vecchi et al.,1994)
CD102/ ICAM-2 ECs, lymphocytes, monocytes, platelets (Springer, 1990)
CD105/ endoglin ECs, moncyte-macrophages, B-lymphocytes, 
syncytiotrophoblast
(Gougos & Letarte, 1988)
Vascular endothelial cadherin ECs, trophoblasts, PLN sinus macrophages (Lampugnani et al., 1992)
Type 1 scavenger receptor ECs, macrophages, SMCs, pericytes, fibroblasts (Voyta et al., 1984)
Weibel Palade bodies ECs (WEIBEL & PALADE, 1964)
von Willebrand Factor ECs, platelets (Jaffe et al., 1974), (Wagner et al., 1982)
Ulex europaeus I agglutinin binding 
/O (H) blood-type antigen
ECs, erythrocytes (Jackson et al., 1990)
Thrombomodulin ECs, SMCs (Esmon, 1995)
Inducible markers Cell Type Reference
CD54/ ICAM-1 ECs, leukocytes, epithelium, fibroblasts (Springer, 1990)
CD106/ VCAM-1 ECs, macrophages, sinovia, dendritic cells, 
mesothelium
(Springer, 1990)
CD62E/E-selectin ECs, postcapillary venules restricted in vivo (Kansas, 1996)
CD62 P/ P-selectin ECs, platelets (Kansas, 1996)
Tie 1 ECs (Mustonen & Alitalo, 1995)
Tie 2/ Tek ECs (Mustonen & Alitalo, 1995)
VEGF receptor 1 (Flt-1) ECs (Peters et al., 1993)
VEGF receptor 2 (KDR/Flk-1) ECs (Quinn et al., 1993)
Modified from Garlanda and Dejana, 1997.
Table 3
Constitutive and inducible marker of endothelial cells
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3.2 RESULTS 
3.2.1 Morphological characterization of endothelial cells (ECs) 
Cells were isolated from umbilical veins following collagenase treatment and grown to confluence 
on gelatin-coated flasks. Phase-contrast microscopy showed cellular monolayers with a 
‘cobblestone’ appearance, composed of homogeneous, closely apposed, polygonal shaped cells 
with distinct borders and centrally located nuclei (figure 11a and b). These appearances were 
maintained beyond 5 ‘passages’. Similar appearances were found with human microvascular 
endothelial cells (HMEC) representing ECs of the microvasculature and human aortic ECs (HAoEC) 
representing ECs from the aorta (figure 11c and d). These appearances were distinctly different 
from human aortic smooth muscle cells (HAoSMC) which grew as long, slender, overlapping cells 
in parallel arrays (figure 11f). Isolated HUVECs demonstrated enhanced uptake of acetylated LDL 
labeled with 1, 1'-dioctadecyl-3,3,3’3'-teramethyl-indocarbocyanine perchlorate, which showed a 
speckled cytoplasmic fluorescence pattern (figure 11e). 
3.2.2 Expression of constitutive and inducible markers of ECs 
Isolated HUVEC monolayers were assessed for the constitutive expression of cell surface markers. 
Flow cytometric analysis of HUVECs showed that there was a significant basal expression of CD31 
(PECAM), CD105 (endoglin) and ICAM-2 on the EC surface (figure 12). Using laser scanning 
confocal microscopy HUVECs demonstrated high intracellular expression of von Willibrand factor 
(vWF) and cell surface expression of VE-cadherin (figure 13). There was no basal expression of the 
leucocyte adhesion molecules E-selectin, VCAM-1 or ICAM-1. Following the treatment of HUVECs 
with TNF-α for 6 hours there was a marked, 1000-fold increase in the expression of E-selectin, 
VCAM-1 and ICAM-1 mRNA compared to untreated cells (figure 14). A similar trend in protein 
expression was observed on the EC surface. Following 6 hours of TNF-α treatment, E-selectin  
A B
HAEC
C HMEC D HAoEC
E F
Figure 11. Morphological characterization of human endothelial cells. Human endothelial
cells (ECs) were cultured on gelatin-coated flasks and visualized using phase-contrast
microscopy. Endothelial monolayers of human umbilical vein ECs at A 20X and B 40X
magnification. Images of C human microvascular ECs (40X) and D aortic ECs (20X). E HUVEC
showing uptake of acetylated LDL labeled with 1’,1’ dioctadecyl-3,3,3'3'-teramethy-
indocarbocyanine perchlorate (40X). F Images of cultured human aortic smooth muscle cells
(20X).
Figure 12. Expression of CD31, CD105 and ICAM-2 on ECs. The expression of EC surface antigens
were assessed using flow cytometry. HUVEC monolayers were analysed for the expression of A-
CD31 (PECAM-1) using P2B1 mAb, B – CD105 (Endoglin) using RMAC8 mAb and C- ICAM-2 using
CBR-IC2/2 mAb. Data is expressed as the mean fluorescent intensity (MFI) for the antigen of
interest compared to a matched isotype control. Bar graphs show pooled data from at least 3
independent experiments with a representative FACS histogram. All data is presented as mean +/-
SEM. *p<0.05 compared to isotype control.
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Figure 13. Expression of von Willebrand factor and VE-cadherin on ECs. HUVEC were grown
onto fibronectin-coated glass slides and stained with fluorescently labeled mAb and the
nuclear stain Draq-5, then visualized with a laser scanning confocal microscope. A HUVEC
stained for von Willebrand factor (green) at (i) 20X magnification and (ii) 40X magnification
with 2.5X digital zoom. B HUVEC stained for vWF (green), VE-Cadherin (red) and nuclei
(purple) at 20X magnification.
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protein expression was significantly enhanced (relative fluorescent intensity (RFI) of 16 for TNF-α 
treated cells compared to RFI of 1.2 for untreated cells) and TNF-α treatment for 16 hours 
increased ICAM-1 (RFI of 60 for TNF-α treated compared to an RFI of 2.3 for untreated cells) and 
VCAM-1 (RFI of 1.8 for TNF-α treated compared to RFI of 12 for untreated cells) protein expression 
(figure 14).  
3.2.3 Decay accelerating factor expression on ECs 
The cell surface expression of DAF was assessed using flow cytometric analysis of cells stained with 
the 1H4 mAb obtained from a hybridoma supernatant detailed in section 2.1.2. Its binding 
specificity and DAF blocking ability was determined previously by Coyne and colleagues (Coyne et 
al., 1992). A titration of the mAb on HUVEC showed that optimal expression was detected with 
dilutions ranging from 1:1 (1) to 1:16 (0.0625) achieving a maximal RFI of 23 (figure 15a). Using the 
dilution 1:1, HUVEC, HMEC and HAoEC demonstrated constitutive DAF expression on the cell 
surface (figure 15b-d). Treatment of HUVEC with TNF-α and Ifn-Υ for 8 hours enhanced DAF mRNA 
by 3-fold, while a comparable increase was observed with VEGF treatment for 24 hours (figure 
16a). This corresponded with a 100% increase in DAF protein expression by VEGF after 48 hours of 
treatment (figure 16b). In contrast thrombin led to a 50% increase (figure 16c) and PBu led to a 
400% increase in DAF protein expression after 24 hours of treatment (figure 16d). 
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Figure 14. Inducible endothelial cell surface markers. A HUVECs were treated with TNF-α
(10ng/ml) for 6 hours and assessed for E-selectin, ICAM-1 and VCAM-1 mRNA expression using
qPCR. HUVEC were treated with TNF-α (1ng/ml) and protein expression analyzed flow
cytometrically for B E-selectin after 6 hours, C ICAM-1 and D VCAM-1 after 16 hours. Bar graphs
represent pooled data from at least 3 independent experiments with a representative FACS
histogram. All data is presented as mean +/- SEM. *p<0.05 compared to untreated cells (U).
Figure 15. DAF expression on human ECs. A Human umbilical vein ECs were treated with
decreasing dilutions of anti-DAF mAb 1H4 and DAF expression assessed using flow cytometric
analysis. B Human umbilical vein ECs, C human microvascular ECs and D human aortic ECs were
stained with anti-DAF mAb 1H4 (1:1 dilution) and expression analyzed using flow cytometry.
Data is expressed as the mean fluorescent intensity (MFI) compared to a matched isotype
control. Bar graphs show pooled data from at least 3 independent experiments with a
representative FACS histogram. All data is presented as mean +/- SEM. *p<0.05 compared to
isotype control.
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Figure 16. Up-regulation of DAF in human umbilical vein ECs. HUVECs were treated with
A (i) interferon-γ (500units/ml) and TNF-α (10ng/ml) or (ii) VEGF (25ng/ml) for indicated times and
DAF mRNA analyzed using quantitative PCR (n=3). Data is presented as fold change relative to 0
hours . HUVECs were treated with B VEGF (12.5ng/ml, 25ng/ml) for 48 hours, C thrombin
(10ng/ml) 24 hours or D PBu (50ng/ml)for 24 hours and DAF expression analyzed using flow
cytometry. DAF expression is presented as percent of untreated (U) cells (n=3). All data is
presented as mean +/- SEM. *p<0.05 compared to untreated cells.
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3.3 DISCUSSION 
The purpose of the studies in this chapter was firstly, to demonstrate the successful isolation and 
culture of ECs from umbilical veins and to confirm the identity of these cells using well described 
morphological and molecular markers. The second aim was to assess constitutive and inducible 
DAF expression on various endothelial cells using antibodies obtained from the 1H4 hybridoma, 
further supporting the successful isolation and culture of ECs and validating the antibody for 
further studies.   
Isolated umbilical vein ECs grew in monolayers with a characteristic polygonal, cobblestone 
appearance as described by Jaffe, Gimbrone and Maruyama (Maruyama, 1963;Jaffe et al., 
1973;Gimbrone, Jr. et al., 1974). These cells had a similar appearance to cultured aortic and 
microvascular ECs but differed markedly from smooth muscle cells which were spindle shaped and 
grew in overlapping parallel arrays. ECs, as well as monocytes and macrophages readily internalize 
modified lipoproteins in vitro and in vivo using a type 1 scavenger receptor-mediated pathway 
(Voyta et al., 1984). Isolated HUVECs demonstrated rapid uptake of acetylated-LDL, which is a 
characterristic feature of ECs including aortic and microvascular cell types (Voyta et al., 1984;Pitas 
et al., 1985). HUVEC expressed the cell surface molecules CD31, CD105, ICAM-2 and VE-cadherin. 
CD31 is a glycoprotein expressed at intercellular junctions and is important for the 
transendothelial migration of leucocytes (DeLisser et al., 1994;Woodfin et al., 2007). CD105 
(endoglin) is part of the TGF-β receptor complex and is important in TGF signaling, cell migration 
and cardiovascular development (Duff et al., 2003). ICAM-2 is expressed at high levels in ECs, binds 
LFA-1 and is important for leucocyte endothelial-cell interactions while VE-cadherin is expressed 
on inter-EC junctions via calcium dependant homotypic interactions and is important for 
maintaining vascular integrity (Aird, 2007a). Von Willebrand factor (vWF) is a glycoprotein 
synthesized and stored within Weibel-Palade bodies in ECs or the α-granules of megakaryocytes 
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and platelets (Wagner et al., 1982;Spiel et al., 2008). It has an important haemostatic role in 
mediating platelet-subendothelial interactions via Gp1bα, platelet-platelet interactions via 
GpIIb/IIIa and is a carrier protein for factor VIII (Spiel et al., 2008). Although the expression of vWF 
is restricted to very few cell types it is predominantly expressed on venous ECs (Aird, 2007a). 
Immunfluorescent studies using vWF antibodies showed a speckled cytoplasmic staining pattern 
confirming the presence of vWF within isolated HUVECs. E-selectin, ICAM-1 and VCAM-1 are 
leucocyte adhesion molecules which are not expressed on resting ECs but in the presence of 
cytokines including TNF-α, interferon-γ, interleukin-1 and interleukin-6 these molecules are rapidly 
induced and expressed on the cell surface (Aird, 2007b). E-selectin is among very few proteins 
where expression is highly restricted to ECs and is predominantly induced in the post-capillary 
venules during inflammation (Aird, 2007b). Isolated HUVECs demonstrated a similar E-selectin 
expression profile with no expression in the resting state, but following treatment with TNF-α 
there was a marked enhancement in E-selectin mRNA and protein. A similar trend was observed 
with VCAM-1 and ICAM-1 but in contrast to E-selectin, these adhesion molecules are also induced 
on several vascular and non-vascular cell types with differential expression patterns in different 
vascular beds and vessels of various size (Aird, 2007a).  
DAF is constitutively expressed in vitro and in vivo in several vascular beds and several cell types 
including ECs, monocytes/ macrophages, smooth muscle cells and fibroblasts (Asch et al., 1986;Lin 
et al., 2001). Its expression is transcriptionally regulated in response to several stimuli including 
inflammatory cytokines, VEGF, thrombin, statins and C-reactive protein (Mason et al., 2001;Mason 
et al., 2002a;Ahmad et al., 2003;Mason et al., 2004;Li et al., 2004;Lidington et al., 2005). Many of 
these stimuli enhance the EC expression of mRNA by 6 hours and induce maximal protein levels 
between 24 and 48 hours in vitro (Mason et al., 2002a;Mason et al., 2004). The results in this 
chapter were consistent with these studies. Cultured HUVECs, HAoECs and HMECs constitutively 
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expressed DAF at comparable levels and HUVEC displayed predictable transcriptional and 
translational responses to interferon-γ combined with TNF-α, VEGF, PBu and thrombin.   
As shown in table 1 there are very few, if any, specific morphological, structural and molecular 
characteristics that are uniformly expressed in ECs which can be used to define their identity. 
Many of these characteristics are shared with haemopoietic cells suggesting common progenitors 
(Cines et al., 1998). Instead the identity of ECs is confirmed by the presence of a variety of 
morphological, structural, molecular and functional markers. Cells isolated from umbilical cords 
using the techniques outlined in chapter 2 demonstrated several constitutive and endothelial 
markers confirming the endothelial identity of these cells. The techniques used to isolate and 
culture ECs detailed in chapter 2 will be adopted for studies in forthcoming chapters. However 
there are limitations to an in vitro approach, as it is difficult to reproduce the in vivo endothelial 
micro-environment including aspects such as flow, interactions with other cells, connective tissues 
and signaling molecules. This is evident from studies which demonstrate that culture disturbs ECs 
from their quiescent in vivo state (0.1% replications per day) to an activated one (1-10% 
replications per day)(Cines et al., 1998). Nevertheless, this approach has provided a wealth of 
knowledge in understanding endothelial cell biology and its role in physiology and disease.  
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CHAPTER 4 
STATINS & RAPAMYCIN SYNERGISTICALLY 
ENHANCE ENDOTHELIAL DAF EXPRESSION 
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4.1 INTRODUCTION 
The complement cascade plays an important role in many stages of the inflammatory, innate and 
acquired immune response. The excessive activation or dysregulation of the cascade promotes 
inflammation and contributes to the pathogenesis of several immune-inflammatory diseases 
including SLE, rheumatoid arthritis and vasculitis. The complement components C3a, C5a and C5b-
9 exert a variety of effects within the vasculature and endothelium including the upregulation of 
leucocyte-adhesion molecules, release of pro-inflammatory cytokines and the induction of pro-
thrombotic factors (Walport, 2001a;Walport, 2001b;Mollnes et al., 2002). Hence direct 
complement activation within the vascular wall or exposure to circulating complement fragments 
due to inflammation at a remote site may injure the endothelium and lead to vascular dysfunction, 
which is evident in several vascular diseases including atherosclerosis, vasculitis, inflammatory 
aortic aneurysms, ischaemia-reperfusion injury and transplant vasculopathy (Oksjoki et al., 2007).  
The complement system is regulated by several fluid-phase and membrane-bound regulators 
which inhibit complement activation within plasma or on the cell surface. The membrane-bound 
regulators include decay-accelerating factor (DAF, CD55), membrane cofactor protein (MCP, 
CD46), CD59 (protectin) and complement receptor 1 (CR1). DAF inhibits the formation and 
accelerates the decay of C3 and C5 convertases, MCP enhances factor I dependent degradation of 
C3b and C4b while CD59 inhibits the assembly of the C5b-9 membrane attack complex (MAC). 
Thus DAF and MCP inhibit the pro-inflammatory effects of C3a, C5a and C5b-9 MAC, whilst CD59 
has an impact specifically at the level of C5b-9 MAC (Miwa & Song, 2001;Kim & Song, 2006). The 
anti-inflammatory importance of complement regulators is demonstrated in paroxysmal nocturnal 
haemoglobinuria in which combined DAF and CD59 deficiency leads to diffuse vascular damage, 
intra-vascular hemolysis and thrombosis (Mollnes et al., 2002). Moreover, deficiency of CD55 or 
CD59 increases complement and leucocyte-dependant vascular injury in murine renal ischemia-
141 
 
reperfusion injury and accelerates atherosclerosis in apolipoprotein E or LDL-receptor knockout 
mice, supporting the role of these regulators in limiting vascular injury (Yamada et al., 
2004;Turnberg et al., 2004;Yun et al., 2008;Wu et al., 2009;An et al., 2009). 
Although DAF, CD59 and MCP are constitutively expressed on vascular endothelium, only DAF is 
readily induced by growth factors, cytokines and inflammatory mediators by activation of well 
defined cytoprotective pathways (Mason et al., 1999;Ahmad et al., 2003;Mason et al., 
2004;Lidington et al., 2005). In contrast CD59 is responsive to hypoxia and laminar shear-stress 
(Kinderlerer et al., 2006;Kinderlerer et al., 2008), and to my knowledge there are no known 
inducers of MCP on ECs. The range of stimuli known to enhance DAF expression on the EC surface 
illustrates the cytoprotective versatility of this molecule during inflammation and makes it an 
attractive therapeutic target. 
Statins effectively lower LDL cholesterol and are proven to improve morbidity and mortality from 
cardiovascular disease (1994). Although understanding of lipid-independent cardiovascular 
benefits of statins remain to be fully elucidated they include depletion of isoprenoid intermediates 
leading to inhibition of rho kinase and activation of anti-inflammatory, anti-thrombotic and 
immunomodulatory pathways (Greenwood & Mason, 2007).  Previous studies by Mason and 
colleagues have shown that statins enhance the EC expression of DAF which in turn offers 
protection from complement-mediated injury (Mason et al., 2002a). Furthermore this study 
showed that atorvastatin induced DAF was synergistically enhanced when PI-3 kinase was 
pharmacologically inhibited, a finding which was reproduced by others using prostaglandin E2 or 
VEGF to induce DAF in epithelial or endothelial cells (Mason et al., 2002a;Holla et al., 2005;Abid et 
al., 2007). Growth factors and hormones such as VEGF, EGF, insulin and nutrients including 
glutamine activate PI-3 kinase which transmits a growth and proliferative signal through the mTOR 
signaling cascade (Asnaghi et al., 2004). Rapamycin prevents FKBP 12 from binding to the FRB 
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domain of mTOR, attenuating its function with subsequent inhibition of proliferation of several cell 
types including T-cells and smooth muscle cells (Tsang et al., 2007). Hence, rapamycin is employed 
as an immunosuppressant for organ transplantation and prevents neointimal proliferation when 
eluted from stents following coronary artery angioplasty (Tsang et al., 2007). This led me to the 
conclusion that combining statins with rapamycin might reproduce the synergistic induction of 
DAF when statins are combined with PI-3 kinase inhibitors(Mason et al., 2002a).   
Aim of chapter 4: 
Hypothesis:  statins in combination with the mTOR inhibitor rapamycin synergistically enhance 
DAF expression on vascular endothelium.  
The experiments in this chapter investigate this hypothesis by studying the dose-response 
relationship between atorvastatin and rapamycin, alone and in combination using DAF as a target 
gene. The relevance of DAF upregulation is explored using in vitro functional assays of 
complement activation.  
143 
 
4.2 RESULTS 
4.2.1 The combination of atorvastatin and rapamycin synergistically enhances 
endothelial cell DAF expression in vitro 
Flow cytometric analysis of HUVEC revealed that DAF was constitutively expressed on the cell 
surface (figure 15)  and treatment for 24 hours with increasing concentrations of atorvastatin or 
rapamycin led to a dose-dependent increase in expression (figure 17). Atorvastatin concentrations 
of 7.5µM led to a maximal up-regulation of DAF expression to almost 300 percent, which was 
comparable to previous studies (Mason et al., 2002a). Rapamycin, in contrast achieved a maximal 
dose-response of 140% at concentrations of 5µM. The solvent for atorvastatin and rapamycin was 
di-methyl sulfoxide (DMSO), which was used at a 1:10,000 dilution and had no effect on DAF 
expression (figure 17).  
Pharmacological synergy is defined as an enhanced dose-response of two or more drug 
combinations, which is greater than the expected additive response of the individual drugs 
(Tallarida, 2001). To identify a synergistic induction in DAF expression by atorvastatin and 
rapamycin, HUVEC were treated with various dose combinations of the two for 24 hours and DAF 
expression assessed using flow cytometry. Rapamycin 1µM optimally enhanced the atorvastatin-
DAF dose-response curve by 100%, whereas concentrations exceeding this had no further effect 
on DAF expression (figure 18). An optimum synergistic increase in DAF was observed when 
atorvastatin 0.5μM was combined with rapamycin 1μM, resulting in a 170% increase in DAF above 
basal levels and 100% above the expected, additive expression of the two drugs (figure 18b and c). 
The synergistic induction in DAF at these concentrations was confirmed on an isobologram (figure 
18d). The line on an isobologram indicates the concentrations of each drug that will achieve 80% 
of the maximum dose response for DAF (rapamycin 3µM, atorvastatin 6µM). 
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Figure 17. Atorvastatin and rapamycin DAF-dose-response expression studies in HUVEC. 
HUVEC were plated at confluence and treated for 24 hours with increasing concentrations 
of A- atorvastatin or B- rapamycin with the DMSO carrier control. DAF expression was 
measured using flow cytometry and is presented as a relative percentage of untreated  cells 
(U). Data represents pooled data of 5-15 independent experiments. * p<0.05, **p<0.01 and  
*** p<0.001.
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Figure 18. Atorvastatin and rapamycin synergistically enhance DAF expression. HUVEC were 
plated at confluence and DAF expression assessed after 24 hours of treatment with A various 
combinations of atorvastatin and rapamycin, and B 0.5 µM atorvastatin (A), 1µM rapamycin
(R), or combination. C Expected additive DAF expression in A and R treated HUVEC compared 
to observed expression. D Isobologram calculated from using the 80% max of individual 
atorvastatin and rapamycin DAF dose-response curves, equivalent to atorvastatin 6µM and 
rapamycin 3µM. DAF expression is presented as relative percentage +/- SEM above untreated 
cells (U). Data is representative of 10 independent experiments. * p<0.05, **p<0.01,  *** 
p<0.001 compared to untreated unless where indicated.
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Synergy is confirmed by dose pairs which lie below the additive line and achieve 80% of the 
maximum response. The optimal dose pair is shown as a bold dot. Further experiments in this and 
forthcoming chapters used these optimal synergistic concentrations. 
 
Phase-contrast microscopy showed that atorvastatin treated HUVEC had well defined membranes 
with a more linear appearance than untreated cells. This morphology differed in rapamycin-
treated HUVEC which had irregular, round cellular margins with some loss of the characteristic 
cobblestone appearance. Cells treated with the drug combination had a morphology which was 
intermediate to cells treated with the individual drugs, but more similar to atorvastatin alone. 
Importantly, there was no evidence for cytotoxicity and confluence was preserved in cells treated 
with either atorvastatin, rapamycin or the combination (figure 19).  
VEGF, thrombin and statin-induced EC DAF expression requires de novo mRNA and protein 
synthesis, with mRNA achieving peak levels after 6-9 hours of treatment (Mason et al., 
2001;Mason et al., 2002a;Mason et al., 2004;Lidington et al., 2005). Therefore the ability of 
atorvastatin and rapamycin to synergistically enhance DAF mRNA was explored. The drug 
combination increased DAF mRNA levels by 4 hours and achieved a maximal 4.5 fold increase by 
18 hours, which did not differ significantly between 6, 8 and 24 hours post- treatment (figure 20a). 
Treatment of HUVEC with atorvastatin or rapamycin alone for 18 hours enhanced DAF mRNA by 2-
fold, however the combination led to a 6.5 fold synergistic induction (figure 20b).  Protein time- 
kinetic studies demonstrated that atorvastatin, rapamycin or synergistically enhanced DAF 
expression peaked at 24 hours, and importantly this was sustained for 72 hours post-treatment 
(figure 20c).  
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Figure 19. Phase-contrast microscopy of atorvastatin and rapamycin treated HUVEC.
HUVEC monolayers were treated with 0.5µM atorvastatin and/or 1µM rapamycin for 
24 hours or with the corresponding DMSO control and observed with a phase-contrast 
microscope and photographed at 20 X. No significant toxicity is apparent.
Figure 20. DAF mRNA and protein expression time-kinetics in atorvastatin and rapamycin-
treated HUVEC. HUVEC were treated with A 0.5µM atorvastatin and 1µM rapamycin for 0, 4, 
6, 8, 18 and 24 hours or B treated with 0.5 µM atorvastatin and/or 1µM rapamycin for 18 
hours and DAF mRNA expression assessed using quantitative real-time PCR. Data are 
expressed as fold change relative to β-actin. C Flow cytometric analysis of DAF expression in 
HUVEC treated with atorvastatin and/or rapamycin for 24, 48 and 72 hours. Data is 
presented as relative percentage +/- SEM of untreated cells (U) and derived from 3 
independent experiments. * p<0.05, **p<0.01 and *** p<0.001 as indicated. 
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4.2.2 Endothelial and smooth muscle cells differentially express DAF in response to  
atorvastatin and rapamycin 
CompIement-dependent vascular diseases have a predilection for vessels of different size and 
various vascular beds. Therefore the effects of atorvastatin and rapamycin on DAF expression in 
various endothelial and smooth muscle cells were explored. Human aortic endothelial cells 
(HAoEC) treated with atorvastain and/or rapamycin for 24 hours reproduced a 160% synergistic 
increase in DAF expression (figure 21a). Human microvascular endothelial cells (HMEC) 
demonstrated a dose-dependent increase in DAF when treated with atorvastatin, achieving a 
300% peak at concentrations approaching 5µM. Rapamycin treatment led to a peak 30% increase 
in DAF expression at concentrations of 1µM. However, combining atorvastatin and rapamycin at 
concentrations known to synergistically enhance DAF in HUVEC, led only to an additive increase in 
HMEC DAF expression (figure 21b).   
Smooth muscle cells have an important role in the pathogenesis of many vascular diseases 
including atherosclerosis, transplant vasculopathy and pulmonary hypertension. Therefore the 
DAF expression profile in human aortic smooth muscle cells (HAoSMC) was investigated. HAoSMC 
constitutively expressed DAF at levels comparable to venous, microvascular and aortic endothelial 
cells. In contrast to HUVEC, atorvastatin or rapamycin treatment alone both led to a marked 200% 
increase in DAF expression. Furthermore, combination treatment had no additional effect on 
expression (figure 21c). 
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Figure 21.. Differential DAF expression in atorvastatin and rapamycin-treated vascular cells.
DAF expression was assessed after 24 hours of treatment with 0.5µM atorvastatin (A) and/or 
1µM rapamycin (R) using flow cytometric analysis in A human aortic endothelial cells, B human 
microvascular endothelial cells (i) atorvastatin- DAF dose response (ii) rapamycin- DAF dose 
response (iii) atorvastatin and rapamycin-induced DAF and C human aortic smooth muscle cells. 
DAF expression is presented as relative percent above untreated cells (U), (n=3). All data is 
presented as mean +/- SEM. * p<0.05 and **p<0.01 where indicated. 
A
C
HAoEC
HAVSMC
B
HMEC HMEC HMEC
U 0.5 1 5 
0
100
200
300
400
R
el
at
iv
e 
D
A
F 
E
xp
re
ss
io
n
(P
er
ce
nt
 a
bo
ve
 u
nt
re
at
ed
)
U 0.5 1 5
0
20
40
60
80
100
R
el
at
iv
e 
D
A
F 
E
xp
re
ss
io
n
(P
er
ce
nt
 a
bo
ve
 u
nt
re
at
ed
)
U R A A+R 
0
50
100
150
200
R
el
at
iv
e 
D
A
F 
E
xp
re
ss
io
n
(P
er
ce
nt
 a
bo
ve
 u
nt
re
at
ed
) *
Atorvastatin (µM) Rapamycin (µM)
(i) (ii) (iii)
151 
 
4.2.3 Atorvastatin and rapamycin synergistically enhance DAF expression in vivo  
Although atorvastatin and rapamycin treatment synergistically enhanced DAF expression in vitro, I 
wished to explore whether this could be reproduced in vivo. C57BL/6 mice were intra-peritoneally 
injected with atorvastatin (5mg/kg) and/or rapamcyin (5mg/kg) for 48 hours, reflecting doses used 
in other studies (Lee et al., 2004;Cheng et al., 2008). Aortas were perfuse-fixed, removed, 
sectioned and the descending aorta analysed for DAF expression using immunofluorescence 
confocal microscopy. Atorvastatin and rapamycin treatment alone at the doses used had little 
effect on murine aortic endothelial DAF expression (Figure 22a). However, combination treatment 
resulted in a 3.5 fold synergistic induction in DAF expression on the aortic endothelium, as 
quantified by image analysis (Figure 22b). There were no observable toxic effects during the 48 
hour treatment period. 
4.2.4 DAF expression in response to other immunosuppressants and statins 
The ability of other clinically relevant statins to synergistically induce DAF expression when 
combined with rapamycin was explored next. Simvastatin dose-response studies in HUVEC led to a 
dose-dependent increase in expression with a maximal plateau of 80% at concentrations of 0.75-
1µM. The addition of rapamycin 1µM led to a marked synergistic induction in DAF to levels in 
excess of 200% above untreated cells (figure 23ai). The observed increase in DAF expression by the 
drug combination exceeded the expected additive value by greater than 125%, with simvastatin 
0.75µM the lowest optimal synergistic concentration (figure 23aii). 
Mycophenolic acid (MMF) and cyclosporine A (CsA), like rapamycin are immunosuppressant drugs 
frequently used post organ transplantation. Therefore, their ability to induce DAF when combined 
with atorvastatin was studied. HUVEC treated with a broad range of MMF concentrations led to a 
minimal 10% increase in DAF. The addition of atorvastatin to 10µM MMF led to an additive  
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Figure 22. Atorvastatin and rapamycin synergistically enhance DAF expression on murine
aortic endothelium. A. C57BL/6 mice were treated twice daily with atorvastatin 5mg/kg (A) 
and/or once daily rapamycin 5mg/kg (R) for 48 hours, and aortic endothelial DAF or CD31 
expression assessed using immunofluorescence confocal microscopy. Images are at 40X 
magnification. DAF or CD31 (green), nuclei (red), elastin (purple), arrows indicate luminal 
expression. B. Histogram showing pooled quantification data from image analysis, 
representing DAF expression as relative fluorescence v matched isotype control. Data is 
presented as fold change +/- SEM of mice treated with carrier control and derived from 3 
independent experiments. **p<0.01 and ns- not significant compared to carrier. 
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increase in expression, but at higher concentrations of MMF (50µM) DAF expression was 
synergistically  enhanced by 40% (figure 23). In contrast, all CsA concentrations attenuated DAF 
expression to 20% below basal levels. Combining atorvastatin with CsA 0.5-10µM had no further 
significant additional effect on DAF expression, however CsA 50µM reduced atorvastatin-induced 
DAF expression by 20% (figure 23).  
4.2.5 Atorvastatin and rapamycin protects ECs from complement-dependant lysis in 
vitro 
To address the functional relevance of DAF upregulation by atorvastatin and rapamycin, the 
effects of the drug combination on complement-dependent endothelial cell lysis was measured 
using assays established in the laboratory (Mason et al., 2004). HUVEC pre-treated with 
atorvastatin and/or rapamycin were opsonised with anti-endoglin mAb (RMAC8), incubated with 
rabbit serum and EC lysis quantified by measuring propidium iodide uptake using flow cytometric 
analysis (Mason et al., 2004). In comparison to untreated ECs (set at 100% lysis), rapamycin 
treatment alone decreased EC lysis by 20%, while atorvastatin monotherapy offered greater 
protection of up to 40%. However, the combination of atorvastatin and rapamycin was superior to 
the individual drugs offering protection of up to 75%. Moreover, using an inhibitory DAF antibody 
(1H4), protection from atorvastatin and/or rapamycin was abrogated, confirming the importance 
of DAF in the observed protection (figure 24a). These data suggested that increased DAF 
expression was the predominant factor in atorvastatin and rapamycin enhanced cytoprotection 
against complement. This conclusion was reinforced by comparing changes in DAF expression with 
those of surface bound CD59 and MCP (figure 24b). 
Figure 23. DAF expression in response to other statins and immunosuppressant drugs.  
DAF expression in HUVEC after 24 hours of treatment with A (i) increasing concentrations of 
simvastatin (S) 0.25- 1µM alone or in combination with rapamycin 1µM, (ii) expected 
additive (E- grey bars) and observed (O- black bars) DAF expression when simvastatin
0.75µM or 1µM is combined with rapamycin 1µM. DAF expression in HUVEC treated with 
atorvastatin 0.5µM and/or B mycophenolic acid (MMF) 10-50µM or C cyclosporin A 0.5-50 
µM. DAF expression was assessed using flow cytometric analysis and presented as relative 
percentage above untreated cells (n=3). All data is presented as mean +/- SEM. * p<0.05, 
and **p<0.01 compared to untreated unless as indicated.
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Figure 24. Atorvastatin and rapamycin protects endothelium from complement-dependent 
lysis. HUVEC were treated with atorvastatin (A) 0.5µM and/or rapamycin (R) 1µM for 24 hours 
(grey bars) and after harvesting were opsonised with anti-endoglin mAb RMAC8, with or 
without the inhibitory DAF mAb 1H4 (black bars) or plain medium alone for 30 minutes at 4oC. 
Cells were then incubated with 10% rabbit serum for 30 minutes, treated with propidium iodide 
and cell lysis assessed using flow cytometry (n=5). C1- IgG2a control, C2-heat-inactivated rabbit 
serum, RS- 10% rabbit serum and RMAC8 mAb, 1H4- inhibitory DAF mAb. B DAF, CD59 and MCP 
expression in HUVEC treated with atorvastatin (A) 0.5µM and/or rapamycin (R) 1µM for 24 
hours and analysed flow cytometrically (n=3). All data is presented as mean +/- SEM. *p<0.05 
compared to untreated cells (U).
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4.3 DISCUSSION 
The findings in this chapter demonstrate that treatment of endothelial cells with atorvastatin leads 
to a dose –dependent increase in cell-surface DAF expression, whereas rapamycin treatment 
results in a more moderate induction. I decided to explore the combination of these two drugs on 
the basis of previous data demonstrating synergy between atorvastatin and the PI-3 kinase 
antagonist Ly290042 (Mason et al., 2002a). Combining atorvastatin and rapamycin at lower 
concentrations led to a synergistic induction in DAF mRNA and protein, with optimum 
enhancement when atorvastatin 0.5 µM was combined with rapamycin 1µM, resulting in levels 
usually achieved with 5-6µM atorvastatin monotherapy. A similar synergistic response was 
observed when simvastatin was combined with rapamycin, indicating a drug class effect rather 
than an atorvastatin specific one. The therapeutic feasibility of these concentrations are difficult to 
assess as the source, purity, formulation and solubility of the drug for in vitro purposes varies 
greatly from oral preparations, and pharmacokinetic factors such as protein binding, 
pharmocogenomics, tissue distribution as well as hepatic and renal clearance cannot be predicted. 
Concentrations of atorvastatin 0.5µM are equivalent to high dose oral atorvastatin (60-80mg /day) 
(Cilla, Jr. et al., 1996). However, despite unpredictable pharmacokinetics, treating mice with 
atorvastatin and rapamycin reproduced a synergistic induction of DAF on murine aortic 
endothelium.  Many of the anti-inflammatory and pleiotropic properties of statins were identified 
in vitro or in vivo and occur at relatively high drug concentrations which are not therapeutically 
possible in man (Liao, 2002). As demonstrated here, combining rapamycin with statins may enable 
anti-inflammatory properties, such as the induction of DAF, to be achieved with safer and clinically 
relevant statin doses.  
Rapamycin inhibits mTOR at concentrations of 10-50nM and the therapeutic range in man is 
maximal at 50nM (Augustine et al., 2007). Concentrations used to achieve optimal synergy in vitro 
were 1µM, a 20-fold increase. In vitro rapamycin inhibits EC proliferation at concentrations 
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exceeding 1µM and concern has been raised regarding rapamycin eluting stents causing coronary 
artery thrombosis due to high local concentrations in the vicinity of the stent (Mohacsi et al., 
1997;Nakazawa et al., 2008). Furthermore, the relatively high concentration of rapamycin required 
for synergy also raises the possibility of an mTOR independent effect and this issue will be 
addressed in forthcoming chapters.  
Rapamycin and statins are known to synergistically affect several cellular responses when 
combined with other compounds. Marimpietri and colleagues reported a synergistic anti-
angiogenic and pro-apoptotic effect on endothelial cells when rapamycin was combined with low 
dose vinblastine (Marimpietri et al., 2005). Synergistic inhibiton of neo-intimal proliferation 
following aortic injury was observed when imatinib was combined with rapamycin (Tigerstedt et 
al., 2009). Similarly, immunomodulatory synergy occurred when atorvastatin was combined with 
glatiramer acetate reversing clinical and histological experimental autoimmune encephalitis (Stuve 
et al., 2006). Although, rapamycin has several ‘vasoprotective’ properties, it also has potential 
vasotoxic effects including hyperlipidemia, anti-proliferative effects on the endothelium and a 
predisposition to thrombosis (Mohacsi et al., 1997;Augustine et al., 2007;Aliabadi et al., 2008). 
These potential harmful effects may be countered by co-prescribing statins (a common clinical 
combination) which effectively lowers LDL cholesterol and stimulates AKT-dependent EC 
proliferation, an approach suggested by many groups (Fukuda et al., 2009). However, caution is 
required as myopathy and hepatotoxicity have been reported in patients prescribed the drug 
combination (Aliabadi et al., 2008). 
DAF mRNA expression was maximal after 18 hours of combination treatment, a delayed response 
when compared to VEGF, basic-FGF, thrombin and cytokine-induced DAF, where peak mRNA levels 
occured by 6 hours of treatment (Mason et al., 1999;Mason et al., 2002a;Ahmad et al., 
2003;Mason et al., 2004;Lidington et al., 2005). However, there was no significant difference in 
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mRNA expression between 6, 8 and 18 hour time points, which may indicate variability in the peak 
response between primary HUVEC isolates. Time-kinetic studies of DAF protein expression 
demonstrated peak levels 24 hours post-treatment, which was sustained at 72 hours and is 
comparable with DAF induction by other agonists (Mason et al., 1999;Mason et al., 2002a;Ahmad 
et al., 2003). Taken together these findings suggest that atorvastatin and rapamycin-induced DAF 
is transcriptionally regulated and this will be investigated further in chapter 5.  
VEGF, statins, cytokines and thrombin upregulate DAF expression to similar levels in human aortic, 
venous and microvascular EC (Mason et al., 2002a;Mason et al., 2004;Lidington et al., 2005). 
However, despite similar basal cell surface expression, synergistically enhanced DAF expression 
was only observed in human aortic and venous ECs but not in microvascular ECs where an additive 
response was apparent. In contrast, there was marked DAF induction in human aortic smooth 
muscle cells following treatment with atorvastain or rapamycin alone, but no synergistic or 
additive increase was observed with the concentrations used. Hence ECs and smooth muscle cells 
exhibit heterogeneity in their response to statins and rapamycin, a likely consequence of the 
differential expression of signaling proteins, transcription factors and activation of different 
signaling pathways involved in DAF regulation.  
Rapamycin, cyclosporine A (CsA) and mycophenolic acid (MMF) are immunosuppressant drugs 
frequently used to prevent allograft rejection, treat various autoimmune diseases including SLE, 
and are often co-prescribed with cholesterol-lowering agents such as statins. Therefore the 
combined effects of atorvastatin with either MMF or CsA on EC DAF expression was explored. 
MMF monotherapy minimally enhanced DAF expression, while at higher concentrations in 
combination with atorvastatin a small synergistic increase in expression was observed. MMF is an 
inhibitor of inosine monophosphate dehydrogenase and selectively inhibits T-cell proliferation. 
The mechanism for synergy in this case is unclear.  
159 
 
Although the introduction of CsA in the 1960’s had a major impact on allograft survival post-
transplantation, CsA is an important contributor to post-transplant vasculopathy, which is a late 
and important cause of allograft failure (Chadban et al., 2008). This is evident in studies post-
transplantation where CsA treated patients had greater neo-intimal proliferation compared to 
patients treated with rapamycin or MMF (Kobashigawa et al., 2006;Raichlin et al., 2007). 
Mechanisms for CsA-induced vascular injury include nephrotoxicity, hypertension and endothelial 
injury resulting in inhibition of flow-mediated eNOS activation and endothelial dysfunction (Kou et 
al., 2002;Mason et al., 2004;Caramelo et al., 2004). CsA at all concentrations decreased DAF 
expression and negated atorvastatin-induced DAF expression, a finding corroborated by Wang et 
al where CsA decreased EC DAF expression in hyperlipidemic rats and by Mason et al where CsA 
prevented DAF upregulation by VEGF (Mason et al., 2004;Wang et al., 2009). Hence a decrease in 
EC DAF expression by CsA might potentiate antibody and complement-mediated vascular damage 
post-transplantation. 
Complement has an established role in the pathogenesis of several inflammatory vascular diseases 
including atherosclerosis, transplant vasculopathy and ischemia-reperfusion injury. C1q, C3a and 
C5a via receptor binding can activate ECs leading to the release of soluble factors including IL-1, IL-
6, MCP-1, tissue factor, vWF and P-selectin. The C5b-9 MAC has similar effects but may also 
infrequently lyse EC’s (Eltzschig & Collard, 2004;Oksjoki et al., 2007;Wehner et al., 2007). These 
effects promote a pro-inflammatory and pro-thrombotic vasculature leading to 
monocyte/macrophage adhesion, chemotaxis, smooth muscle cell, fibroblast proliferation and 
thrombosis (Eltzschig & Collard, 2004;Fischetti & Tedesco, 2006;Oksjoki et al., 2007;Wehner et al., 
2007). Atherosclerotic plaques demonstrate deposition of active complement components 
including C3d, C4d and C5b-9, and the latter co-localizes with lipid deposits prior to macrophage 
infiltration suggesting that complement plays an early role in the evolution of the atherosclerotic 
plaque (Oksjoki et al., 2007;Haskard et al., 2008). In transplant vasculopathy ECs stain densely for 
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C4d, and C6 deficiency retards progression of lesions (Qian et al., 2001a;Wehner et al., 2007). 
Hence, therapeutically targeting complement appears to be a rational approach to the 
management of vascular disease. C5a receptor antagonists, over expression of C1 esterase 
inhibitor and blockade or depletion of C3 decreases C3d, C4d, C5b-9 deposition, leucocyte 
infiltration and attenuates ischemia-reperfusion injury and neo-intimal proliferation following 
vascular injury (Riedemann & Ward, 2003;Schepers et al., 2006;Shagdarsuren et al., 2008). 
Furthermore C5a blockade in man reduces infarct size and cardiac muscle enzyme release 
following infarction (Riedemann & Ward, 2003).  
DAF inhibits the formation and accelerates decay of C3 and C5 convertases, preventing formation 
of the pro-inflammatory anaphylatoxins and the C5b-9 MAC (Miwa & Song, 2001). The recent 
finding that DAF suppresses T-cell differentiation into Interferon-Υ producing cells and the rapid T-
cell mediated rejection of DAF deficient cardiac allografts supports a new role for DAF in regulating 
T-cell immunity (Lalli et al., 2007;Pavlov et al., 2008). Therefore therapeutically targeting EC DAF 
expression is an alternative approach to modulating complement activation and possibly T-cell 
function. DAF super-induction by atorvastatin and rapamycin in microvascular, aortic and venous 
ECs leading to DAF-dependent protection against both the generation of C3a, C5a and C5b-9 
mediated lysis, indicates that combination therapy may provide additional anti-complement 
benefits coupled with the known vasoprotective properties of statins and the T-cell 
immunosuppressive effects of rapamycin. Such a combination would clearly benefit patients 
requiring immunosuppression and vasculoprotection, such as those with systemic autoimmune 
diseases and transplant recipients. The following chapters investigate the molecular mechanisms 
contributing to the regulation of DAF expression by the combination of statins and rapamycin.
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CHAPTER 5 
HEME OXYGENASE-1 REGULATES 
ATORVASTATIN & RAPAMYCIN ENHANCED DAF 
EXPRESSION 
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5.1 INTRODUCTION 
The  endothelium has a variety of constitutively expressed and inducible cytoprotective genes 
which limit vascular injury during inflammation. Hemeoxygenase 1 (HO-1) is an inducible 
cytoprotective enzyme which degrades heme into carbon monoxide, biliverdin and ferrous iron. 
Biliverdin reductase reduces biliverdin to bilirubin, while ferrous iron induces ferritin and activates 
an iron anti-porter decreasing levels of intracellular iron (Ryter et al., 2006). The importance of 
HO-1 in inflammation is demonstrated by human HO-1 deficiency, which leads to fatal 
intravascular hemolysis and diffuse EC damage (Yachie et al., 1999), whilst HO-1 deficient cells are 
more susceptible to oxidative stress induced cytotoxicity (Poss & Tonegawa, 1997a), and in models 
of myocardial ischemia-reperfusion HO-1 is protective (Yet et al., 2001). The cytoprotective 
properties of HO-1 are attributed to its products bilirubin, ferritin and carbon monoxide. Bilirubin 
and ferritin are known to have anti-oxidant properties, but along with carbon monoxide may also 
activate anti-inflammatory and anti-apoptotic pathways (Otterbein et al., 2003;Ryter et al., 2006). 
Recently, Kinderlerer and colleagues demonstrated that HO-1 derived ferritin and bilirubin 
regulates DAF expression, protecting ECs from complement deposition and cytolysis in vitro, 
extending the regulatory role of HO-1 during inflammation (Kinderlerer et al., 2009). 
HO-1 may be induced by several stimuli and due to its broad anti-inflammatory profile is a novel 
therapeutic target (Ryter et al., 2006). Statins have several anti-inflammatory, immunomodulatory 
and vasoprotective properties which include HO-1 induction in endothelial, smooth muscle cells 
and monocyte/macrophages in vitro and in vivo (Lee et al., 2004;Hsu et al., 2006;Greenwood & 
Mason, 2007;Ali et al., 2007). Furthermore the pharmacological induction of HO-1 by statins has 
anti-inflammatory and vasoprotective properties as demonstrated by attenuation of liver and 
kidney ischaemia-reperfusion injury in mice, and amelioration of pulmonary hypertension in rats 
(Gueler et al., 2007;Lai et al., 2008). Rapamycin is also a potent inducer of HO-1 in smooth muscle 
and endothelial cells and inhibits PDGF induced cellular proliferation (Visner et al., 2003). In a 
163 
 
model of pulmonary hypertension, rapamycin attenuated the histological and hemodynamic 
consequences of pulmonary hypertension through HO-1 induction (Zhou et al., 2006). 
Aims of chapter 5 
As HO-1 is known to regulate constitutively expressed and inducible DAF, and statins and 
rapamycin are each known to enhance HO-1 expression, I investigated the hypothesis that: 
synergistic induction of DAF expression by statins and rapamycin is regulated by HO-1.
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5.2. RESULTS 
5.2.1 Atorvastatin and rapamycin enhances HO-1 expression and activity in endothelial 
cells 
Statins and rapamycin are each known to enhance endothelial cell HO-1 expression and activity in 
vitro and in vivo. Therefore, I investigated whether statins and rapamycin, at concentrations which 
synergistically enhance DAF expression, influenced EC HO-1 expression and activity. ECs treated 
with rapamycin or atorvastatin increased HO-1 mRNA expression up to 3-fold, whereas the 
combination generated a 4.5-fold induction which was maximal between 4-6 hours of treatment 
(figure 25a and figure 29a). There was a 2.5-fold induction in HO-1 protein with the drug 
combination, which was comparable to ECs treated with rapamycin alone, whereas atorvastatin 
had no effect on HO-1 protein expression (figure 25b).  
HO-1 enzyme activity was assessed using an ELISA which measures relative intracellular EC 
bilirubin generation (Ali et al., 2007). Low-dose atorvastatin treatment for 24 hours had no effect 
on EC bilirubin production, whereas rapamycin enhanced bilirubin levels by 25% and the 
combination treatment synergistically increased levels to 60% above that in untreated cells (figure 
25c). The role of HO-1 in the synergistic induction of DAF expression was verified using the 
competitive HO-1 antagonist zinc protoporphyrin IX (ZnPP), which decreased synergistically 
enhanced DAF from 250% to 150% above control. However, ZnPP had no effect on atorvastatin-
induced DAF expression, while a non-significant decrease in rapamycin-induced DAF was observed 
(figure 26a). 
These findings suggest first, that rapamycin is the main component of the drug combination which 
drives HO-1 expression and activity, and secondly, that rapamycin-induced HO-1 or its products 
were interacting with statin to synergistically enhance DAF expressionn. To confirm this, cobalt  
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Figure 25. Atorvastatin and rapamycin enhances HO-1 expression and activity in endothelial
cells. HUVEC were treated with 0.5µM atorvastatin (A) and/or 1 µM rapamycin (R) and
analyzed after A, 6 hours for HO-1 mRNA using quantitative PCR or B, 24 hours for HO-1
protein assessed by immunoblotting. A representative immunoblot is shown with a histogram
representing pooled quantification data relative to α-tubulin (n=3). Data is expressed as fold
change v untreated cells (U). C HUVECs were treated with atorvastatin and rapamycin for 24
hours and HO-1 activity analyzed using an intracellular bilirubin IXα ELISA. Results are
expressed as percentage change relative to untreated cells (n=3). Heat shock = 440C for 30
minutes. All data is presented as mean +/- SEM. * p<0.05 and ns- not significant compared to
untreated.
AB
Figure 26. HO-1 regulates atorvastatin and rapamycin-induced DAF. HUVEC were
treated for 24 hours with 0.5µM atorvastatin (A) and/or 1µM rapamycin (R) A in the
presence or absence of HO-1 antagonist zinc protoporphyrin (ZnPP- 10µM) or B in
the presence or absence of HO-1 agonist cobalt protoporphyrin (CoPP- 20 or 50µM).
DAF expression was analyzed using flow cytometry and is presented as percent
change relative to untreated cells (U). Dotted line represents theoretical additive
DAF expression of CoPP 50 µM and atorvastatin. All data is presented as mean +/-
SEM of 3 independent experiments. * p<0.05 compared to untreated cells unless as
shown.
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protoporphyrin IX (CoPP), a chemical inducer of HO-1 was used as an alternative to rapamycin to 
increase HO-1 expression and activity. CoPP increased EC HO-1 and cell surface DAF expression, a 
220% synergistic increase in DAF expression was observed in ECs treated with both CoPP and 
atorvastatin. In contrast, combining rapamycin with CoPP led to a 160% additive increase in DAF 
expression (figure 26b). 
5.2.2. The role of HO-1 products in synergistically enhanced DAF expression 
HO- 1 catalyses the degradation of heme into carbon monoxide, biliverdin and ferrous iron, 
consequently leading to the induction of ferritin and activation of an iron anti-porter. Ferritin and 
bilirubin, derived from biliverdin reductase, are known to regulate DAF expression (Kinderlerer et 
al., 2009). Therefore I next investigated the role of rapamycin-induced HO-1 products in the 
synergistic interaction with statins. In keeping with studies by Soares et al, ECs exposed to bilirubin 
for 24 hours attenuated TNF-α induced VCAM-1 expression (reduced from 20 to 12-fold) (Soares 
et al., 2004) (Figure 27a). ECs were treated with atorvastatin and/or biliverdin or bilirubin for 24 
hours and DAF expression analyzed using flow cytometry. Biliverdin had little effect on DAF 
expression, but when combined with atorvastatin synergistically induced DAF expression to almost 
200% above control. In contrast, bilirubin decreased basal DAF expression by 10% and attenuated 
atorvastatin-induced DAF by 20% (figure 27b).  
To explore the role of carbon monoxide in the regulation of drug-induced DAF, haemoglobin (Hb), 
a carbon monoxide scavenger was added to the EC medium prior to atorvastain and/or rapamycin. 
Hb decreased basal DAF by 20% and attenuated synergistically enhanced DAF expression by 50%, 
but had no significant effect on atorvastatin or rapamycin-induced DAF expression. As these 
findings indicated a role for carbon monoxide, ECs were treated with a short-acting carbon  
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Figure 27. Role of biliverdin, bilirubin and carbon monoxide in synergistically enhanced DAF.
A HUVEC were treated with bilirubin (B) 5 or 10µM, followed by TNF-α for 16 hours and VCAM-1
expression analyzed using flow cytometry. Data is expressed as fold change relative to untreated
cells (U). HUVEC were treated for 24 hours with B atorvastatin 0.5µM (A) and/or biliverdin (5-
10µM), bilirubin (5-10µM) or rapamycin 1µM (R) or C combinations of atorvastatin, rapamycin,
haemoglobin 10µM (Hb) and tri-carbonyl-dichloro-ruthenium 5µM (CORM) and DAF expression
analyzed by flow cytometry. Dotted line represents theoretical additive DAF expression for
biliverdin (5µM) and atorvastatin (0.5µM). DAF expression is presented as percent change
relative to untreated cells (U). All data is presented as mean +/- SEM of 3 independent
experiments. * p<0.05, **p<0.01 and ns- not significant compared to untreated cells unless as
shown.
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monoxide releasing molecule (tri-carbonyl-dichloro-ruthenium, CORM-2) which had no effect on 
basal DAF expression and in fact attenuated atorvastatin- induced DAF by 50% (figure 25c).This 
suggests that carbon monoxide on its own is insufficient to induce synergy. 
Heme degradation by HO-1 releases ferrous iron which induces ferritin and activates an iron anti-
porter leading to a decrease in intracellular iron. Desferrioxamine (DFO) and salicylaldehyde-
isonicotinoyl hydrazone (SIH) are iron chelators which can reproduce the effects of ferritin and 
cellular iron export. Treating EC’s for 24 hours with DFO or SIH increased DAF by 45% compared to 
untreated cells. Combining DFO or SIH with atorvastatin led to a 220% synergistic induction in DAF 
expression, which approached the synergistic levels achieved by combining atorvastatin and 
rapamycin (figure 28a). As an alternative to iron-chelators, the ferritin heavy chain was over 
expressed using a constitutively active adenovirus and when combined with atorvastatin a 7-fold 
synergistic increase in intracellular DAF expression was observed (figure 28b). 
5.2.3. Atorvastatin and rapamycin synergistically enhances ferritin expression 
As iron chelation with DFO/SIH, or over-expressing the ferritin heavy chain in combination with 
atorvastatin, reproduced the synergistic induction of DAF expression, the effects of atorvastatin 
and rapamycin on ferritin expression was investigated. mRNA time-kinetic studies in ECs treated 
with the drug combination showed that ferritin mRNA was increased up to 7-fold after 6 hours 
treatment, which coincided with an almost 3-fold increase in HO-1 mRNA. In contrast, a peak 4.5-
fold induction in DAF mRNA was achieved after 18 hours of treatment (figure 29a). The change in 
ferritin preceded DAF induction. A further assessment of ferritin mRNA expression at 6 hours 
showed that rapamycin led to a 3-fold and atorvastain a 2-fold increase in mRNA, whereas a 
synergistic 7.5 fold induction was observed in EC’s treated with the drug combination (figure 29b).  
 
AB
Figure 28. Iron chelation in combination with statins synergistically enhance DAF expression.
A HUVEC were treated for 24 hours with atorvastatin 0.5µM (A) and/or rapamycin 1µM (R),
the iron chelators desferrioxamine (D) (100µM), salicyl-aldehyde isocontinoyl hydrazone (S)
(100µM) and DAF expression analyzed using flow cytometry. Results are expressed as percent
of untreated cells (U). Dotted line represents theoretical additive DAF expression for
desferrioxamine and atorvastatin. B HUVEC were transduced with an adenovirus expressing
ferritin heavy chain adenovirus (FHC) (MOI 200), or a control virus (β-gal) (MOI 200) for 24
hours, and then treated with atorvastatin for 24 hours with DAF expression assessed using
immunoblotting. A representative immunoblot with a histogram showing pooled quantification
data with respect to β-actin is shown (n=3). Data is presented as fold change relative to
untreated cells (U), and expressed as mean +/- SEM of 3 independent experiments. * p<0.05
compared to untreated cells unless as shown.
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Figure 29. Atorvastatin and rapamycin enhance ferritin heavy chain expression and function.
A HUVEC were treated with atorvastatin (0.5µM) and rapamycin (1µM) for 4, 6, 8, 18 and 24 hours
and HO-1, ferritin heavy chain and DAF mRNA expression analyzed using quantitative PCR. B
HUVEC were treated with 0.5 µM atorvastatin (A) and/ or 1µM rapamycin (R) for 6 hours and
analyzed for ferritin heavy chain mRNA expression using qPCR. Data are expressed as fold change v
untreated (U) cells. C HUVEC were treated with desferrioxamine (D), atorvastatin (A) and/ or
rapamycin (R) for 24 hours and HUVEC supernatant iron concentrations determined and
normalized to cellular protein concentrations. All data is presented as mean +/- SEM of 3
independent experiments. * p<0.05 and **p<0.01 compared to untreated cells.
172 
 
The functional significance of synergistically enhanced ferritin expression was assessed by 
measuring HUVEC supernatant iron-concentration 24 hours post-treatment. Atorvastatin and 
rapamycin alone had a non-significant effect on supernatant iron concentration compared to 
untreated cells. However, the drugs in combination significantly decreased iron levels from 6.75 to 
6.0 µg/mol (11.2%), whereas DFO decreased levels to 5.4 µg/mol (20%) (figure 29c).  
To confirm the importance of ferritin in DAF induction by atorvastatin and rapamycin a strategy 
involving ferritin RNA interference (RNAi) was used. Ferritin RNAi decreased basal as well as statin 
and rapamycin induced ferritin mRNA by over 90% (figure 30a). The atorvastatin and rapamycin-
induced increase in DAF mRNA was reduced from 4 to 1.8-fold, confirming the importance of 
ferritin in synergistically enhanced DAF expression (figure 30b). 
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Figure 30. Atorvastatin and rapamycin-induced DAF is regulated by ferritin heavy chain
expression. HUVEC were transfected with 50nM ferritin heavy chain (RNAi) or scrambled
(Scr) siRNA for 48 hours, then treated with atorvastatin combined with rapamycin and then
analyzed after A 6 hours for ferritin mRNA or B 18 hours for DAF mRNA using quantitative
PCR. Data are expressed as fold change v untreated (U) cells. All data is presented as mean
+/- SEM of 3 independent experiments. * p<0.05, *** p<0.001 and ns- not significant
compared to untreated cells unless as indicated.
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5.2.4 Role of reactive oxygen species in atorvastatin and rapamycin induced 
cytoprotection 
Reactive oxygen and nitrogen species potently induce HO-1, and its products ferritin and bilirubin 
have potent anti-oxidant properties (Ryter et al., 2006). DFO and SIH are iron chelators which also 
have anti-oxidant properties and ROS can modulate several signaling pathways (Nathan, 2003). 
Therefore the importance of ROS in statin and rapamycin-induced DAF expression was initially 
explored using the free radical scavenger N-acetyl cysteine (NAC). Pre-treating ECs with NAC had 
no effect on basal or drug-induced DAF expression (figure 31a). Using the fluorescent hydrogen 
peroxide indicator DCF, atorvastatin and rapamycin had no effect on cellular ROS production 
(figure 31b). Finally as HO-1, ferritin and bilirubin have anti-oxidant properties the ability of 
atorvastatin and rapamycin to protect against hydrogen peroxide induced oxidative stress was 
explored. Exposing ECs to hydrogen peroxide for 30 minutes led to a 300% increase in DCF 
fluorescence, which was attenuated by 30% in ECs treated with the drug combination. Rapamycin 
treated ECs displayed a 20% increase in DCF fluorescence, while atorvastain reduced fluorescence 
by 10% following exposure to hydrogen peroxide (figure 31b). Hence, these results demonstrate 
that ROS are not involved in the regulation of basal or drug-induced DAF and the drug combination 
offers minimal protection against oxidative stress. 
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Figure 31. Role of oxidative stress in atorvastatin and rapamycin induced DAF. A HUVEC
were treated for 24 hours with atorvastatin 0.5µM (A) and/or rapamycin 1µM (R) in the
presence or absence of N-acetylcysteine 10mM (NAC) and assessed for DAF expression using
flow cytometry. Data is presented as a relative percentage compared to untreated cells (U). B
HUVEC were loaded with di-chloro-dihydro-fluorescin-diacetate (DCF) for 30 minutes and
were treated with atorvastatin and/ or rapamycin for 45 minutes or 24 hours and then
loaded with DCF for 30 minutes followed by exposure to hydrogen peroxide 5µM for 30
minutes. fluorescence was assessed using flow cytometry. Data is presented as percent of
untreated cells. All data is presented as mean +/- SEM of 3 independent experiments. ns- not
significant as shown.
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5.3 DISCUSSION 
Atorvastatin and rapamycin synergistically enhances DAF expression protecting ECs against 
complement-mediated injury in vitro. As HO-1 regulates DAF expression (Kinderlerer et al., 2009), 
and statin and rapamycin monotherapy are each known to induce HO-1, I explored the role of HO-
1 and its products in the synergistic induction of DAF by low dose combinations of atorvastatin and 
rapamycin. HO-1 expression is predominantly regulated at the transcriptional level and may be 
induced by several stimuli including hypoxia, thermal injury (Ewing et al., 1992), laminar shear 
stress (Dai et al., 2007), cytokines, growth factors (Bussolati et al., 2004), prostaglandins (Zhuang 
et al., 2003) and reactive oxygen species (Ryter et al., 2006). Statins and VEGF, which are known to 
enhance DAF expression, maximally induce HO-1 mRNA after 6 hours and protein levels between 
24 and 48 hours post-treatment (Mason et al., 2001;Mason et al., 2002a;Bussolati et al., 2004;Ali 
et al., 2007). Similar kinetics were observed in ECs treated with atorvastatin and rapamycin, with 
peak HO-1 mRNA expression at 6 hours post-treatment. Although ECs treated with low-dose 
atorvastatin or rapamycin alone increased HO-1 mRNA levels, rapamycin and the atorvastatin, 
rapamycin combination significantly increased both HO-1 protein and enzyme activity. HO-1 
protein induction in response to rapamycin was comparable to that induced by the drug 
combination, however HO-1 enzyme activity was far greater with combination therapy than with 
rapamycin alone. This suggests that rapamycin is the main component of the drug combination 
driving HO-1 expression, while both statin and rapamycin contribute to increased HO-1 enzyme 
activity. The ability of statins to regulate HO-1 mRNA, protein expression and enzyme activity 
varies with the statin formulation, drug concentration, cell type, species and experimental 
conditions. Simvastatin enhances HO-1 mRNA and protein in murine and human vascular smooth 
muscle cells but not in bovine or murine endothelial cells (Lee et al., 2004). In keeping with the 
current study, Dulak and colleagues showed that atorvastatin enhanced EC HO-1 mRNA but not 
protein (Dulak et al., 2005),  whilst Ali and colleagues (Ali et al., 2007) showed significant HO-1 
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protein expression and enzyme activity at concentrations exceeding 2.5µM. The regulation of HO-
1 by rapamycin is poorly understood with only one in vitro study by Visner and colleagues showing 
that rapamycin 1-10µM enhanced HO-1 mRNA and protein expression in human pulmonary artery 
ECs and SMC’s (Visner et al., 2003). 
Pharmacological induction and adenoviral over-expression of HO-1 in human EC increases cell 
surface DAF expression, protecting ECs from complement-dependent injury, whilst Hmox-1 
deficient ECs have less basal DAF expression than wildtype ECs and are more susceptible to 
complement-dependent cytotoxicity (Kinderlerer et al., 2009). As atorvastatin and rapamycin 
enhanced both HO-1 expression and enzyme activity, the role of HO-1 in enhanced DAF expression 
was assessed by antagonizing HO-1 with ZnPP, which attenuated synergistically enhanced DAF 
expression. Furthermore, the HO-1 agonist COPP in combination with atorvastatin also 
synergistically enhanced DAF expression. These findings suggested that HO-1 and/or its products 
were activating pathways which were interacting with a statin signaling cascade leading to the 
synergistic induction of DAF.  
The anti-inflammatory, anti-apoptotic and anti-thrombotic properties of HO-1 are attributed to its 
products biliverdin/bilirubin, carbon monoxide and ferritin. Each of these products can affect 
different aspects of the inflammatory response and may act in synergy to attenuate inflammation 
(Ryter et al., 2006). Hence the importance of each product in the synergistic induction of DAF 
when combined with statin was investigated. Biliverdin minimally enhanced DAF expression and in 
combination with atorvastatin a small synergistic increase in expression was observed. In contrast, 
bilirubin attenuated basal and atorvastatin-induced DAF expression. This was inconsistent with 
findings by Kinderlerer and colleagues who showed that bilirubin treatment enhanced EC DAF 
expression and inhibited C3 deposition and cytolysis (Kinderlerer et al., 2009). This discrepancy 
may be attributed to inadequate preparation of bilirubin, which is highly pH and light sensitive. In 
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initial experiments, bilirubin attenuated TNF-α induced VCAM-1 expression to a lesser extent than 
other studies, indicating possible inadequate preparation or batch variability (Soares et al., 2004). 
Moreover, at this time the Soares lab was also having problems with bilirubin (I. Pomo Grgoire, 
personal communication). Other anti-complement effects of bilirubin include inhibition of classical 
complement pathway-dependent hepatocytolysis and intra-vascular hemolysis (Arriaga et al., 
2002;Basiglio et al., 2007). In addition to modulating complement activation, biliverdin and 
bilirubin scavenge reactive oxygen and nitrogen species in vitro, inhibit neutrophil NADPH oxidase, 
suppresses cytokine-induced adhesion molecule expression and restore endothelial function in 
LDL-receptor knockout mice by increasing eNOS expression (Kaur et al., 2003;Soares et al., 
2004;Kawamura et al., 2005;Datla et al., 2007). Moreover, the clinical relevance of these 
atheroprotective properties are supported by epidemiological studies which show that moderately 
raised bilirubin levels protect against coronary artery disease (Vitek et al., 2002).  
HO-1 derived CO exerts anti-inflammatory and anti-apoptotic effects on endothelial cells and 
reproduces the cytoprotective effects of HO-1 in models of cardiac transplantation (Soares et al., 
1998;Sato et al., 2001), endotoxic shock (Sarady et al., 2002), acute lung injury (Otterbein et al., 
1999) and ischemia-reperfusion injury (Yet et al., 2001) . In contrast to biliverdin, bilirubin and 
ferritin, CO does not regulate basal EC DAF (Kinderlerer et al., 2009). Scavenging CO with 
haemoglobin attenuated synergistically enhanced DAF expression, while a short acting CO 
releasing molecule decreased statin-induced DAF. It is difficult to determine the precise 
contribution of CO from these experiments and more definitive experiments with long-acting 
CORMs and direct CO treatment are required. However they suggest that the carbon monoxide 
contribution is insufficient on its own to reproduce synergy with atorvastatin. 
Ferrous iron derived from heme potentiates the formation of reactive oxygen species and rapidly 
induces the ferritin heavy chain (FHC) which sequesters iron (Balla et al., 2005). Ferritin has a 
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potent antioxidant, cytoprotective profile and with bilirubin regulates EC DAF expression 
(Kinderlerer et al., 2009). Atorvastatin and rapamycin synergistically enhanced FHC mRNA which 
coincided with maximal HO-1 mRNA expression, and its importance in synergistic DAF expression 
was confirmed with ferritin RNAi. Ferritin expression is mainly regulated at the post-transcriptional 
level but may be induced transcriptionally by cytokines such as TNFα, or in response to ischemic 
preconditioning (Pham et al., 2004;Chevion et al., 2008). A study from our laboratory using DFO as 
a chemical inducer of hypoxia demonstrated synergistic enhancement of statin-induced DAF 
(Kinderlerer et al., 2006). The current study reproduced the same effects with DFO and a second 
iron chelator, SIH. Moreover, adeno-viral over expression of the FHC synergistically enhanced 
statin-induced DAF expression, confirming the importance of iron sequestration. These data were 
reinforced by a reduction in supernatant iron levels by the drug combination. Reactive oxygen 
species can regulate several signaling cascades and induce HO-1 and ferritin, whilst DFO and SIH 
are potent anti-oxidants as well as iron chelators (Nathan, 2003;Ryter et al., 2006). Hence the role 
of ROS on statin and rapamycin-induced DAF expression was investigated. Statins and rapamycin 
treatment had no effect on EC ROS generation. Likewise, NAc had no effect on statin and 
rapamycin-induced DAF expression supporting the findings by Abid and colleagues that DAF 
regulation is independent of ROS (Abid et al., 2007). Thus, the present study suggests that stains 
and rapamycin regulate DAF by influencing intracellular iron dynamics via ferritin induction, rather 
than by hypoxia and ROS formation. In support of these findings is the observation that rapamycin 
alters iron homeostasis in renal transplant patients and the PI-3 kinase mTOR signaling pathway 
regulates transferrin receptor expression (Maiorano et al., 2006;Galvez et al., 2007).  
At relative high concentrations, or in ECs conditioned by shear stress, statin-induced HO-1 and its 
products protect against oxidative stress in vitro and in vivo (Ali et al., 2007;Ali et al., 2009). 
However, although the combination of atorvastatin and rapamycin enhanced HO-1, bilirubin and 
ferritin expression, no significant protection against hydrogen peroxide-induced oxidative stress 
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was observed. Therefore, further in vitro and in vivo experiments are required to clarify the anti-
oxidant properties of this drug combination. 
At high concentrations, atorvastatin-induced DAF expression is regulated by a rho kinase, protein 
kinase Cα-dependent pathway (Mason et al., 2002a). The data in this chapter suggest that 
interactions between this pathway and those activated by biliverdin/bilirubin, ferritin and possibly 
CO results in the synergistic induction of EC DAF expression. The cytoprotective signaling 
mechanisms activated by biliverdin and bilirubin in ECs remain to be determined, but evidence in 
other cell types suggest it may involve inhibition of JNK kinase, protein kinase C and is unlikely to 
involve EC p38 MAP kinase (Kawamura et al., 2005;Nakao et al., 2005). Similarly, ferritin activated 
signaling pathways in ECs are poorly understood but alteration of intracellular iron levels might 
affect iron binding proteins, iron response elements and hence transcription. CO is the best 
characterized product of HO-1 and its role in the synergistic induction of DAF expression cannot be 
excluded in this study. Its anti-apoptotic and anti-inflammatory profile is linked to cGMP, p38 MAP 
kinase, HIF-1α and STAT-3 signaling pathways (Otterbein et al., 1999;Sato et al., 2001;Sarady et al., 
2002;Ryter et al., 2006;Silva et al., 2006;Zhang et al., 2006;Chin et al., 2007;True et al., 2007). 
Hence, the precise mechanisms involved in the synergistic induction of DAF by rapamycin, statins, 
HO-1 and its products remain unclear and require further investigation. 
Diseases of the vasculature including atherosclerosis, ischemia-reperfusion injury and transplant 
vasculopathy involve the interplay of different cellular and biochemical cascades including 
complement activation, coagulation, oxidative stress, leucocyte infiltration and acquired immune 
mechanisms (Eltzschig & Collard, 2004;Hansson, 2005;Wehner et al., 2007). HO-1 has an 
important vasoprotective role within the CV system. Thus, HO-1 protects against myocardial and 
renal ischemia-reperfusion injury, atherosclerosis, plaque instability and thrombosis, restenosis 
injury and transplant vasculopathy (Juan et al., 2001;Sato et al., 2001;Yet et al., 2001;Nakao et al., 
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2005;True et al., 2007;Cheng et al., 2009). The cytoprotective benefit observed in these models is 
attributed to HO-1-dependent down-regulation of leucocyte-adhesion molecule expression, 
enhanced resistance to apoptosis, inhibition of smooth muscle cell and fibroblast proliferation and 
anti-oxidant effects (Brouard et al., 2000;Berberat et al., 2003;Soares et al., 2004;Choi et al., 
2004;Ryter et al., 2006;Datla et al., 2007). The cytoprotective benefits of HO-1 parallel those of 
DAF observed in similar disease models, and the recent finding of DAF regulation by HO-1 is 
indirectly supported in vivo by excess complement deposition in HO-1-deficient cardiac allografts 
undergoing rejection (Soares et al., 1998;Yamada et al., 2004;Weeks et al., 2007;Gonzalez-
Stawinski et al., 2008). Therefore recent interest has focused on therapeutic enhancement of HO-1 
activity as a novel approach to managing inflammatory disease (Stocker & Perrella, 2006;Loboda 
et al., 2008). However, the response may rely on genetic factors including the presence of the GTn 
polymorphism in the HO-1 promoter. Individuals with a short GT repeat express higher levels of 
HO-1 and are protected from atherosclerosis and emphysema. Moreover, the shorter the 
polymorphism, the greater the magnitude of HO-1 induction following a specific stimulus (Exner et 
al., 2004).  
In summary, the findings in this chapter demonstrate that statins and rapamycin enhance EC HO-1, 
ferritin, bilirubin and DAF expression, potentially providing multiple anti-inflammatory, anti-
oxidant and anti-complement benefits which may be useful in the treatment of inflammatory 
vascular diseases. These findings are worthy of further investigation in vivo and in human clinical 
trials. 
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CHAPTER 6 
CELECOXIB ACTIVATES HEME OXYGENASE-1 
ACTIVITY IN VASCULAR ENDOTHELIUM  
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6.1 INTRODUCTION 
Traditional non-steroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase-2 (COX-2) 
selective inhibitors (COXIBs) are amongst the most frequently prescribed medications and 
constitute an important and effective class of drug for the treatment of pain and inflammation. 
However, following the APPROVE trial which demonstrated increased thrombotic cardiovascular 
events in patients taking rofecoxib, concerns were raised regarding a possible class effect of 
COXIBs, a concept reinforced by results from the use of parecoxib/valdecoxib in patients following 
cardiac surgery (Bresalier et al., 2005;Nussmeier et al., 2005). The prostanoid hypothesis, put 
forward as one potential explanation for the increased cardiovascular events, suggests that COX-2 
selectivity leads to an imbalance between the anti-thrombotic activity of endothelial-derived 
prostacyclin and the pro-thrombotic properties of platelet-derived thromboxane (Grosser et al., 
2006).  However, although the mechanism(s) remains to be established, COX-2 selectivity alone is 
now considered insufficient to account for the thrombotic risk (Warner & Mitchell, 2008). 
Moreover, evidence from meta-analyses, retrospective and prospective studies suggest that both 
NSAID and COXIB therapy may result in a small but measurable increase in cardiovascular risk 
(Farkouh et al., 2004;Graham et al., 2005a;Marwali & Mehta, 2006;Cannon et al., 
2006;McGettigan & Henry, 2006;Moore et al., 2007;Warner & Mitchell, 2008). Importantly, 
subgroup analysis may identify patient characteristics which increase risk, and expose agents more 
prone to induce cardiovascular events (Solomon et al., 2008).  
Although controversy remains over the relative risk of cardiovascular events between individual 
COXIBs and NSAIDs, clinical evidence from patients suffering from rheumatic diseases suggests 
that amongst the COXIBs, celecoxib (≤ 200mg daily) may have a more favorable cardiovascular 
profile (Marwali & Mehta, 2006;Strand, 2007). This observation has also been reported in 
comparison to traditional NSAIDs, and observed in some meta-analyses (Graham et al., 
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2005a;2006;McGettigan & Henry, 2006;Moore et al., 2007). The difference is particularly 
pronounced between celecoxib and rofecoxib and is supported by in vitro and in vivo studies 
(Graham et al., 2005a;Ray et al., 2002). Thus celecoxib, but not rofecoxib, inhibits TNFα-induced 
tissue factor expression in endothelial cells (Steffel et al., 2005a).. Similarly, in a rat model of 
hypertension celecoxib preferentially improved vascular function when compared to rofecoxib and 
diclofenac (Hermann et al., 2003), while celecoxib and naproxen were less likely than rofecoxib to 
increase 24-hour systolic BP in patients with osteoarthritis (Hermann et al., 2003;Sowers et al., 
2005) .  
Heme oxygenases (HO) are cytoprotective enzymes which degrade heme, generating carbon 
monoxide, bilirubin and ferrous iron which is sequestered by increased intracellular ferritin. The 
cytoprotective properties of HO are attributed to these products and include anti-oxidant, anti-
apoptotic, anti- thrombotic and anti-inflammatory actions. HO-1, the inducible form of heme 
oxygenase, is transcriptionally regulated in response to oxidative stress induced by heavy metals, 
hypoxia, cytokines and lipopolysaccharide (Ryter et al., 2006;Loboda et al., 2008). The importance 
of the anti-inflammatory, cytoprotective actions  of HO-1 are reflected in the severe sequelae of 
HO-1 deficiency, which include intravascular hemolysis, anemia, diffuse endothelial damage and 
accelerated atherosclerosis (Poss & Tonegawa, 1997b).  
Expression of HO-1 in atherosclerotic plaques, and its ability to inhibit vascular smooth muscle cell 
proliferation, exert anti-inflammatory and anti-oxidant effects, are likely to contribute to its 
protective role during atherogenesis (Stocker & Perrella, 2006;Cheng et al., 2009). Over-expression 
of HO-1 inhibited atherogenesis, while Hmox1-/-/ApoE-/- mice developed more extensive and 
complex atherosclerotic plaques (Juan et al., 2001). In addition, HO-1 activity may protect against 
thrombosis, as evidenced by a model of vascular injury in Hmox1-/- mice (True et al., 2007). In 
patients with rheumatoid arthritis, HO-1 is expressed in the inflamed synovium and HO-1 
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promoter polymorphisms increasing enzyme expression are associated with improved 
radiographic outcomes, while pharmacologic induction of HO-1 may attenuate murine 
inflammatory arthritis and glomerular lesions in lupus-prone mice (Takeda et al., 2004;Kobayashi 
et al., 2006;Benallaoua et al., 2007;Wagener et al., 2008).  
Aims of chapter 6:  
Recent interest has focused on the therapeutic potential of HO-1. In light of evidence suggesting 
that celecoxib may improve endothelial function and the importance of HO-1 as an anti-
inflammatory enzyme, I investigated the hypothesis that celecoxib enhances HO-1 expression and 
activity in vascular endothelial cells offering protection against vascular injury. 
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6.2 RESULTS 
6.2.1 Celecoxib increases HO-1 activity in human endothelial cells 
The effect of celecoxib on HO-1 expression was initially explored by concentration-response 
studies in HUVEC. Increasing concentrations of celecoxib enhanced steady-state HO-1 mRNA levels 
and protein expression after 24 hours of treatment. An increase in HO-1 expression was seen 
following treatment with 5µM celecoxib, with maximal induction of mRNA and protein at 
concentrations of 10-25µM (figure 32 a-b).  Time-kinetic studies demonstrated an initial increase 
in HO-1 protein expression by 18 hours, and maximal induction following 48 hours of celecoxib 
treatment (figure 32c). To assess HO-1 activity, an ELISA was used to quantify intracellular bilirubin 
IXα using mAb 24G7. Celecoxib increased intracellular bilirubin levels by 50% above that seen in 
vehicle-treated HUVEC (p<0.05), confirming an increase in HO-1 enzyme activity (figure 32d). 
Subsequent experiments performed with HAEC, to represent an endothelial surface affected by 
atherosclerosis, demonstrated that they responded similarly to HUVEC, with 10µM celecoxib 
inducing a 10-fold increase in HO-1 protein (figure 32e). Phase-contrast microscopy, trypan blue 
exclusion and MTT cell survival assays failed to demonstrate any cellular cytotoxicity at these 
concentrations (Figure 33). 
6.2.2 HO-1 is induced by celecoxib and NS-398 but not by rofecoxib or indomethacin 
To investigate whether HO-1 induction was celecoxib-specific, HUVEC were treated with the COX-2 
selective inhibitors NS-398 and rofecoxib. Concentration-response studies using NS-398 revealed a 
3.5 fold induction of HO-1 protein, whereas in contrast rofecoxib failed to significantly increase 
HO-1 expression over a broad concentration range (figure 34a and 34b). Although celecoxib and 
NS-398 specifically antagonize COX-2 activity, at high concentrations they may lose selectivity and 
inhibit COX-1.  Therefore HUVEC were cultured with increasing concentrations of indomethacin, 
which inhibits COX-1 and COX-2, and this failed to increase HO-1 expression (figure 34c),  
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Figure 32. Celecoxib enhances HO-1 expression and activity in human endothelial cells.
HUVEC were cultured with increasing concentrations of celecoxib for 24 hours prior to analysis of
A. HO-1 mRNA using quantitative PCR and B. HO-1 protein expression by immunoblotting.
C. Immunoblot showing the time-kinetics of HO-1 expression in HUVEC treated with 10µM
celecoxib. D. HUVEC were treated with 10µM celecoxib for 24 hours and HO-1 activity analysed
using an intracellular bilirubin IXα ELISA. E HO-1 expression in HAoECs treated with increasing
concentrations of celecoxib. All data show representative immunoblots along with a histogram
representing pooled quantification data with respect to α-tubulin (n=5). Data are represented as
fold change v’s untreated cells and presented as mean ± SEM. *p<0.05 compared to untreated
cells.
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Figure 33. A. Phase-contrast microscopy of celecoxib treated HUVEC. HUVEC
monolayers were cultured with increasing concentrations of celecoxib for 24 hours and
observed with a phase-contrast microscope and photographed at 20X magnification. No
significant toxicity is apparent. B. Cell viability of celecoxib treated HUVEC. HUVEC
monolayers were treated with celecoxib 10µM up to 48 hours and cell viability assessed
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Figure 34. HO-1 expression in human endothelial cells treated with NS-398,
rofecoxib and indomethacin. HUVEC were treated with increasing concentrations
of A NS-398, B rofecoxib or C indomethacin for 24 hours prior to analysis of HO-1 by
immunoblotting. All data show representative immunoblots along with a histogram
representing pooled quantification data with respect to α-tubulin (n=5). Data are
represented as fold-change v untreated cells and presented as mean ± SEM.
*p<0.05 compared to untreated cells.
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suggesting that induction of HO-1 by celecoxib and NS-398 is independent of any inhibition of 
COX-1. As described in chapter 5 and by others (Kinderlerer et al., 2009),HO-1 is involved in the 
regulation of EC DAF expression. Therefore I explored whether celecoxib enhanced DAF expression 
in ECs. Treating ECs with 5-25µM of celecoxib led to a minimal increase in DAF expression which 
was non-significant (not shown). 
6.2.3 Celecoxib induction of HO-1 is independent of prostaglandins  
I next investigated the role of COX-2 enzyme activity in the actions of celecoxib. As previously 
reported, low basal expression of COX-2 protein was detected in HUVEC (Syeda et al., 2006), and 
this was markedly enhanced by treatment with TNFα (figure 35a). To explore the role of reduced 
prostaglandin synthesis in HO-1 induction by celecoxib, HUVEC culture medium was supplemented 
with the prostaglandin precursor PGH2, or with prostaglandins PGI2 and PGE2  (both of which are 
synthesized by HUVEC), in the presence and absence of celecoxib. PGH2 alone led to a 
concentration-dependent 3-fold induction of HO-1, and in the presence of celecoxib enhanced HO-
1 expression in an additive manner (figure 35b). In contrast, PGE2 and iloprost, a stable analogue 
of PGI2, had no effect on HO-1 expression in the presence or absence of celecoxib (figure 35c-d). 
The failure of rofecoxib to induce HO-1, combined with the demonstration that HO-1 upregulation 
by celecoxib is independent of changes in prostaglandin synthesis, suggested that COX-2-
independent actions of celecoxib are required for the induction of HO-1.  
6.2.4 Celecoxib induces HO-1 by utilizing a PI-3K- and ROS-dependent pathway 
To explore the role of the PI-3K/Akt pathway, previously implicated in HO-1 induction (Ryter et al., 
2006), we initially used the PI-3K antagonist LY290042. Pre-treatment of HUVEC with LY290042 or 
DN-Akt adenoviruses inhibited basal and celecoxib-induced HO-1 expression (figure 36a and c). 
Moreover, celecoxib enhanced Akt Ser473 phosphorylation as early as 15 minutes post-treatment, 
achieving a maximal 3-fold increase in phosphorylation at 30 minutes (figure 36b). As ROS are 
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known to activate the Akt signaling cascade and induce HO-1, we hypothesized that they 
represent important signaling intermediaries in the regulation of HO-1 by celecoxib. This was 
initially demonstrated using the anti-oxidant N-acetylcysteine, which reduced both basal and 
celecoxib-induced HO-1 expression to below the level of detection (figure 357a). The ability of 
celecoxib and NS-398 to generate intracellular ROS was confirmed using a DCF assay, which 
demonstrated enhanced fluorescence following 30 minutes of treatment with either drug (figure 
37b). 
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Figure 35. The role of prostaglandins and COX-2 in celecoxib-induced HO-1.
A. HUVEC were left untreated (U) or cultured for 24 hours with 1ng/ml TNFα and analysed
for COX-2 expression by immunoblotting. B-D. HUVEC were left untreated or treated with
10µM celecoxib in the presence or absence of B. prostaglandin H2 (PGH2) (1-10 µM), C.
10µM PGE2, and D. 100nM iloprost (I) or vehicle (Veh) for 24h prior to analysis of HO-1 by
immunoblotting. Representative immunoblots are shown along with histograms
representing pooled quantification data with respect to α-tubulin (n=3). Data are shown
as fold change versus untreated cells (U) and presented as mean ± SEM. *p<0.05
compared to untreated cells.
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Figure 36. Celecoxib induces HO-1 via a PI-3 Kinase-dependent pathway.
A.HUVEC were cultured with 10µM celecoxib in the presence or absence of
LY290042 (20µM) for 24 hours prior to analysis of HO-1 expression by
immunoblotting. The histogram represents pooled quantification data with respect
to α-tubulin (n=3), presented as fold-change v untreated cells. B. HUVEC were
serum-starved for 2 hours prior to treatment with 10µM celecoxib and analysed for
phosphorylated Akt-Ser473 at the indicated time points using immunoblotting. The
histogram shows pooled quantification data presented as a ratio of phospho-
Akt:total Akt (n=3). C HUVEC were transfected with an adenovirus expressing DN-
Akt or the Ad0 control virus (MOI 200) and after 24 hours were treated with
celecoxib (10µM) for a further 24 hours, prior to analysis of HO-1 by
immunoblotting (n=3). All results are expressed as fold change v untreated cells
(U), presented as mean SEM. *p<0.05 compared to untreated cells unless where
indicated.
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Figure 37. Celecoxib induces HO-1 via a ROS-dependent pathway.
A. HUVEC were cultured with celecoxib in the presence or absence of N-
acetylcysteine (N-Ac) and analysed for HO-1 expression (n=5). B. HUVEC
were loaded with 5µM DCF for 60 minutes prior to treatment with 10μM
Celecoxib or NS-398 for 30 minutes and analyzed using fluorescent
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6.2.5 Celecoxib enhances HO-1 expression by generating mitochondrial-derived ROS 
NADPH oxidase and the mitochondrial electron transport chain (METC) are flavo-protein 
containing enzymes and the main source of ROS in mammalian cells (Zhang & Gutterman, 2007). 
Their role in HO-1 induction by celecoxib was initially investigated using the flavo-protein inhibitor 
di-phenyl-iodonium (DPI), which reduced HO-1 induction by celecoxib from 3.1 to 1.7 fold (figure 
38a). The importance of NADPH oxidase was further explored by using a selective inhibitor 
apocynin (APC), which had no effect on HO-1 induction by celecoxib (figure 38b). Therefore, I next 
investigated the role of the METC in more detail using rotenone, a mitochondrial complex I 
inhibitor, and antimycin A, a complex III inhibitor. As seen in Figure 38c-d, both antagonists 
significantly inhibited celecoxib-mediated HO-1 induction. Furthermore, uncoupling the 
mitochondrial respiratory chain with FCCP also attenuated HO-1 induction (figure 38e). Taken 
together these data suggest that celecoxib enhances EC HO-1 expression by increasing 
mitochondrial-derived rather than NADPH-dependent ROS. 
To explore this hypothesis, I used the mitochondrial dye Mitotracker™ to visualize mitochondria, 
and DCFH-DA as a fluorescent indicator of hydrogen peroxide formation. We observed an increase 
in EC DCF fluorescence within 15 mins of exposure to celecoxib (figure 39a). Of note, this was 
associated with a change in mitochondrial morphology from a linear appearance to a rounded, 
punctate form. The DCF fluorescence co-localized with mitochondria, suggesting that hydrogen 
peroxide generated by celecoxib was of mitochondrial origin (Figure 39c). To confirm this EC were 
loaded with Mitosox™, a triphenylphosphonium-linked dihydroethidium compound which is 
preferentially concentrated into mitochondria and specifically detects mitochondrial superoxide 
generation. Treatment with celecoxib led to a 50% increase in fluorescence. Laser confocal 
microscopy demonstrated a significant increase in EC fluorescence after treatment with celecoxib, 
reaching 50% above that in the control cells (figure 39b). 
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Figure 38. Celecoxib-induced HO-1 is dependent upon mitochondrial derived ROS.
HUVEC lysates were immunoblotted for HO-1 following 24 hours of treatment with 10μM
celecoxib in the presence or absence of A. Di-phenyl-iodonium (DPI, 10µM), B. Apocynin (Ap,
100µM), C. mitochondrial complex I inhibitor rotenone (2µM), D. complex III inhibitor antimycin A
(10µM) and E. mitochondrial uncoupler p-trifluoromethoxy carbonyl cyanide phenyl hydrazone
(FCCP) (1µM). A representative immunoblot with pooled quantitative analysis of 3 independent
experiments is shown. Data are expressed as fold change above untreated cells (U), mean ± SEM.
*p<0.05 compared to untreated cells or where indicated.
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Figure 39. Celecoxib-induced HO-1 is dependent upon mitochondrial derived ROS.
A. HUVEC were pre-loaded with 5µM DCF for 60 minutes and 5µM Mitotracker red
for 15 minutes followed by exposure to 10μM celecoxib and analysis by laser
confocal microscopy. DCF, Mitotracker and merged images are shown at 0 and 15
mins post-celecoxib, at 20X magnification and 63X magnification with 1.5X digital
zoom. B HUVEC were preloaded with 500 nM MitoSOX for 15 min followed by
exposure to 10 μM celecoxib and analysis by laser confocal microscopy (10× original
magnification). Results are expressed as mean percentage fluorescence over
control cells treated with vehicle alone (U) and presented as mean ± SEM. *p<0.05
compared to untreated cells.
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6.2.6 Celecoxib induces HO-1 by enhancing Nrf2 translocation 
The transcription factor Nrf2 is retained in the cytoplasm by kelch-like ECH-associated protein 
(Keap1). Oxidative stress results in dissociation of the Nrf2-Keap1 complex allowing Nrf2 
translocation to the nucleus, where it regulates phase II detoxification enzymes and anti-oxidant 
proteins including HO-1 via the antioxidant response element (ARE). Using confocal microscopy we 
observed a significant increase in nuclear localization of Nrf2 within 30 minutes of EC exposure to 
celecoxib (figure 40a), which was followed by a gradual decline to baseline by 4 hours (figure 40b). 
Pre-treating HUVEC with either N-acetylcysteine or the PI-3K antagonist LY290042 prevented 
celecoxib-induced Nrf2 nuclear translocation (figure 40c), further demonstrating the importance 
of PI-3K and ROS signaling. Finally, a recombinant adenovirus expressing DN-Nrf2 construct (MOI 
200) demonstrated the functional importance of Nrf2 by attenuating the induction of HO-1 by 
celecoxib, a response not seen with the control adenovirus (figure 41).   
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Figure 40. Celecoxib-induced HO-1 is dependent upon Nrf2 activation.
A. HUVEC were treated with celecoxib (10µM) for up to 240 minutes, fixed,
immunostained with anti-Nrf2, isotype-matched control Ig and nuclear dye DRAQ5 and
analyzed by confocal microscopy. The control Ab did not bind (not shown). (i) 40X
magnification and (ii) 63X magnification. B. Histogram representing nuclear Nrf2 as a
percentage of total Nrf2 from five independent experiments. C. HUVEC were left
untreated or pre-treated with LY290042 (LY) 20µM prior to the addition of celecoxib or
vehicle for 30 mins and analysis of Nrf2 nuclear localization as above. *p<0.05 where
indicated.
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Figure 41. Celecoxib-induced HO-1 is dependent upon Nrf2 activation.
HUVEC were transfected with an adenovirus expressing DN-Nrf 2 or the Ad0
control virus (MOI 200) and after 24 hours treated with celecoxib (10µM) for a
further 24 hours, prior to analysis of HO-1 by immunoblotting. Data are
expressed as fold change above untreated cells, and presented as mean SEM.
*p<0.05 where indicated.
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6.2.7 Celecoxib inhibits TNFα-induced VCAM-1 expression 
HO-1 is known to exert anti-inflammatory actions in EC including the inhibition of cellular adhesion 
molecule expression (Soares et al., 2004). To model an inflammatory state in vitro we exposed 
HUVEC to TNFα which increased cell surface expression of E-selectin by 20-fold and VCAM-1 by 10-
15 fold. Pre-treatment of HUVEC with celecoxib (10 μM) for 24 hours prior to the addition of TNFα 
for 16 hours led to a significant reduction in VCAM-1, while having no effect on the expression of 
E-selectin induced by 6 hours exposure to TNFα (figure 42a-b). Moreover, the ability of celecoxib 
to repress TNFα-induced VCAM-1 expression was significantly reduced by the HO antagonist 
ZnPPIX (figure 42c), supporting the importance of HO-1 activity for the anti-inflammatory actions 
of celecoxib. In contrast to celecoxib, pre-treatment of EC with rofecoxib (10 μM) for 24 hours 
failed to inhibit TNFα-induced VCAM-1 induction (figure 42d). 
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Figure 42. Celecoxib inhibits TNFα-induced VCAM-1 expression. HUVEC were pre-treated with
celecoxib (10µM) for 24 hours and then treated with 0.1 or 1 ng/ml TNFα. A. Flow-cytometric
analysis of E-selectin expression, following 6 hours TNFα stimulation. B. Flow-cytometric analysis
of VCAM-1 expression 16 hours post-TNFα stimulation. C. HUVEC were pre-treated with celecoxib
in the presence or absence of zinc protoporphyrin IX (ZnPP) (10µM) for 24 hours and then treated
with 1 ng/ml TNFα for 16 hours followed by flow-cytometric analysis of VCAM-1 expression. D.
HUVEC were pre-treated with rofecoxib (10µM) for 24 hours followed by TNFα (1 ng/ml) for 16
hours and analysis of VCAM-1 expression by flow-cytometry (n=3). Data are expressed as fold
change above untreated cells (U) and presented as mean SEM. *p<0.05 and ns- not significant as
indicated.
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6.3 DISCUSSION 
Concern regarding cardiovascular risk has significantly reduced the use of COXIBs and to a lesser 
extent traditional NSAIDs. It has also led to more considered prescribing, with physicians 
frequently recommending their use as required, rather than routine daily dosing. However, 
downsides include the use of traditional NSAIDs in place of COXIBs on the basis of a perceived 
improved cardiovascular profile, occasionally exposing susceptible patients to unnecessary 
gastrointestinal side-effects, or denial of anti-inflammatory drugs to those with inflammatory 
arthritis who might benefit significantly. Thus, it is important to consider data from the TARGET 
and MEDAL trials in OA and RA, which failed to demonstrate differences in cardiovascular risk 
between lumiracoxib and both naproxen and ibuprofen, or between etoricoxib and diclofenac 
(Farkouh et al., 2004;Cannon et al., 2006). Moreover, the cumulative incidence of thrombotic 
events, stroke, myocardial infarction or cardiovascular-related death was low. In contrast, the 
trials confirmed a reduced risk of serious gastrointestinal side-effects associated with the use of 
COXIBs (Farkouh et al., 2004;Cannon et al., 2006). However, the outstanding question remains 
whether there are differences between individual COXIBs and NSAIDs that might influence their 
cardiovascular profile. To this end, and in light of recent reports demonstrating that celecoxib and 
NS-398 enhance expression of the cytoprotective enzyme HO-1 in mesangial, epithelial and 
neuronal cells (Hou et al., 2005;Park et al., 2007), we chose to explore the effect of COXIBs on HO-
1 expression and activity in the vascular endothelium. 
Treatment of HUVEC and HAEC with celecoxib led to a significant and sustained upregulation of 
HO-1 expression and enzyme activity. Although maximal in vitro responses were evident at 
concentrations of celecoxib exceeding those achieved in the plasma following therapeutic dosing, 
increased HO-1 expression was also seen following exposure to 1-5μM which can be achieved 
therapeutically (Paulson et al., 1999). Comparable results were observed with NS-398, while in 
marked contrast rofecoxib failed to significantly increase HO-1 expression. Likewise, celecoxib but 
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not rofecoxib inhibited HUVEC proliferation in vitro, suggesting that these COXIBs affect different 
intracellular endothelial signaling pathways (Niederberger et al., 2004). This concept is also 
supported by the report that celecoxib but not rofecoxib reduced TNFα-induced tissue factor 
activity in human endothelial cells through inhibition of c-Jun terminal NH2 kinase and improved 
endothelial function in a model of salt-induced hypertension (Hermann et al., 2003;Steffel et al., 
2005a). In clinical use, rofecoxib and traditional NSAIDs are more likely than celecoxib to increase 
peripheral oedema (Whelton et al., 2001) and hospital admission for congestive cardiac failure 
(Mamdani et al., 2004). Furthermore, in contrast to rofecoxib (Title et al., 2003), celecoxib may 
improve vascular endothelial function in men with coronary artery disease, as measured by flow-
mediated dilatation (Chenevard et al., 2003).  
Prolonged treatment with celecoxib for 24-48 hours induced HO-1, while iloprost alone did not. In 
contrast, a recent report demonstrated some upregulation of EC HO-1 following treatment with a 
prostacyclin receptor agonist carbacyclin (Di et al., 2009). Supplementation of tissue culture media 
with PGE2 or iloprost failed to reverse HO-1 induction by celecoxib, while exogenous PGH2 
upregulated HO-1 and enhanced the effect of celexcoxib. Moreover, while NS-398 reproduced the 
effect of celecoxib, rofecoxib, a more selective COX-2 antagonist, and indomethacin, which inhibits 
COX-1 and COX-2, did not. These data suggest that the induction of HO-1 by celecoxib is 
predominantly COX-2 independent. Therefore, to investigate underlying mechanisms, we initially 
analyzed changes in PI-3K/Akt pathway activity and the intracellular redox milieu. Celecoxib 
treatment led to phosphorylation of Akt, while antagonizing PI-3K with LY290042 inhibited 
celecoxib-mediated induction of HO-1. Furthermore, the presence of the ROS scavenger N-
acetylcysteine abrogated HO-1 expression. Subsequent experiments confirmed that celecoxib 
treatment led to a rapid increase in intracellular oxidant generation. We propose that this leads to 
activation of PI-3K/Akt, Nrf2 translocation and HO-1 induction. This pathway is distinct to that 
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activated in proliferating endothelial cells, where prolonged exposure to celecoxib inhibits Akt 
phosphorylation and exerts an anti-angiogenic effect (Lin et al., 2004).  
Although in excess ROS may be damaging to the vasculature, it is now recognized that modest 
increases, such as that generated by low levels of oxidized-LDL, may be protective via activation of 
redox signaling which results in increased glutathione synthesis and HO-1 expression (Zmijewski et 
al., 2005;Gutierrez et al., 2006;Zhang & Gutterman, 2007). Inhibition of celecoxib-induced HO-1 
expression by DPI, but not apocynin (a selective NADPH oxidase inhibitor), implicated 
mitochondrial rather than NADPH-induced ROS in HO-1 upregulation. Furthermore, the 
fluorogenic dye MitoSOX™ demonstrated increased mitochondrial superoxide generation in 
response to celecoxib. Mitochondrial superoxide synthesis is regulated by Complexes I and III of 
the respiratory chain and use of their respective inhibitors rotenone and antimycin A, or 
uncoupling of the mitochondrial respiratory chain with FCCP, prevented celecoxib-mediated HO-1 
induction. Phosphoglycerate mutase 5 (PGAM5), a Keap1-binding protein, binds to the 
mitochondrial membrane through its N-terminal mitochondrial-localization sequence, forming a 
ternary complex with Nrf2 and suppressing Nrf2-dependent gene expression (Lo & Hannink, 2008). 
Thus, celecoxib may increase mitochondrial ROS which in turn bind Keap-1 so disrupting the 
ternary complex and allowing Nrf2 translocation and HO-1 induction. Intriguingly, HO-1 activity 
may itself inhibit COX-2, raising the possibility of a positive feedback loop (Haider et al., 2002;Choi 
et al., 2008). 
Nrf2, a member of the Cap’n’Collar-related basic leucine zipper family of proteins, is sequestered 
in the cytoplasm by Keap 1 and released upon activation, allowing translocation to the nucleus 
where Nrf2 binds the ARE. The ARE regulates expression of phase II detoxification enzymes and 
anti-oxidant proteins including HO-1. Thus, Nrf2 is considered an important cytoprotective 
transcription factor in the vasculature (Li & Kong, 2009). Celecoxib treatment led to rapid nuclear 
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translocation of Nrf2 which was inhibited by pre-treatment with either LY290042 or N-
acetylcysteine. The importance of Nrf2 in HO-1 induction by celecoxib was confirmed by inclusion 
of DN-Nrf2 which specifically reversed the response.  These data suggest that celecoxib may also 
induce expression of other important ARE anti-oxidant target genes including NAD(P)H:quinine 
oxidoreductase-1,  thioredoxin reductase 1, glutathione reductase and ferritin heavy chain.  
Although the therapeutic potential of HO-1 remains to be confirmed and exploited, areas of 
interest include RA (Kobayashi et al., 2006), SLE (Takeda et al., 2004) and atherosclerosis (Stocker 
& Perrella, 2006). HO-1 and its products exert a variety of vasculoprotective effects including anti-
inflammatory, anti-apoptotic, anti-thrombotic and anti-oxidant actions (Loboda et al., 2008). Thus, 
the ability of celecoxib to induce HO-1 may act to modulate its cardiovascular profile in patients 
with systemic inflammatory diseases. The functional relevance of HO-1 induction by celecoxib was 
demonstrated by its ability to inhibit TNFα-mediated upregulation of VCAM-1, a response 
significantly reduced by the presence of the HO antagonist ZnPPIX. However, in contrast rofecoxib 
failed to induce HO-1 and was unable to inhibit induction of VCAM-1 TNFα. Thus, celecoxib mimics 
an anti-inflammatory effect of HO-1 over-expression in EC reported by Soares et al, namely 
inhibition of TNFα-induced VCAM-1 expression (Soares et al., 2004). Although the suppression of 
VCAM-1 by celecoxib needs to be confirmed in vivo, it may be clinically relevant given the 
importance of VCAM-1 expression in RA, SLE and atherosclerosis.  
In conclusion, it is recognized that therapy with NSAIDs and COXIBs may lead to an increased risk of 
cardiovascular events (Graham et al., 2005a;McGettigan & Henry, 2006). However, the cardiovascular 
profile of celecoxib may be relatively favorable, particularly when compared to rofecoxib, and I propose 
that the ability of celecoxib to increase activity of the anti-inflammatory, anti-oxidant enzyme HO-1 is an 
important differentiating factor. The demonstration of celecoxib efficacy in SLE-prone mice(Zhang et al., 
2007), a good safety profile in patients with SLE (Lander et al., 2002), combined with data from a 
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prospective trial demonstrating reduced SLE disease activity without a significant change in serum 
coagulability (Wallace, 2008), should encourage rheumatologists to explore the potential uses of 
celecoxib further. Data from the current study will help inform clinical decisions and suggests that 
further investigation of both the mechanisms of action of celecoxib and its clinical utility are indicated.  
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CHAPTER 7 
SIGNALLING & TRANSCRIPTIONAL 
MECHANISMS IN STATIN & RAPAMYCIN 
ENHANCED DAF EXPRESSION IN VASCULAR 
ENDOTHELIUM 
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7.1 INTRODUCTION 
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase which regulates cellular 
growth and proliferation in response to growth factors and nutrients.  mTOR forms two distinct 
signaling complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Growth factors 
and nutrients activate mTORC1, which is composed of mTOR, raptor and Gβl which leads to 
translation initiation, ribosomal biogenesis, cellular growth and proliferation. The anti-proliferative 
drug rapamycin inhibits mTOR by disrupting raptor-mTOR interactions leading to 
hypophosphorylation of p70 S6 kinase and 4E-BP1 with resultant inhibition of growth factor-
induced cellular proliferation (figure 8) (Hay & Sonenberg, 2004). Hence rapamycin is used as an 
immunosuppressant following transplantation due to its potent anti-proliferative effects on T-
lymphocytes and is also eluted from coronary artery stents to inhibit neointimal proliferation 
following coronary angioplasty. The importance of mTORC2 in cellular physiology is less well 
understood. The mTORC2 protein complex consists of mTOR, rictor and Gβl which was recently 
shown to regulate growth factor and cytokine dependent Akt/protein kinase B phosphorylation 
(Sarbassov et al., 2005). Although it is well established that rapamycin rapidly inhibits mTORC1, it 
is now recognized that rapamycin by an unknown mechanism has a delayed inhibitory effect on 
mTORC2 leading to hypophosphorylation and inhibition of Akt/protein kinase B function 
(Sarbassov et al., 2006;Dormond et al., 2007). Previous studies from our group and others have 
demonstrated that pharmacological inhibition of PI-3 kinase in the presence of thrombin, statin, 
VEGF and PGE2 synergistically enhances DAF expression (Lidington et al., 2005;Holla et al., 
2005;Abid et al., 2007). As demonstrated in previous chapters, treating endothelial cells with 
rapamycin in combination with statins reproduced a similar synergistic induction of DAF 
expression. The importance of mTOR, Akt/protein kinase B and the inhibitory effects of rapamycin 
on mTORC1 and mTORC2 in the synergistic response remain to be determined. 
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Protein kinase C (PKC) is a family of serine/threonine kinases which are part of the inositol-
phospholipid signaling cascade and consist of 11 isozymes which are broadly classified into three 
groups defined by their structure and mechanism of activation. The classic PKCs (α, β and γ, cPKCs) 
are activated by calcium, phosphatidyl-serine (PS) and di-acyl-glycerol (DAG); novel PKCs (δ, ε, θ 
and η, nPKCs) are regulated by PS and DAG but are calcium independent, and the atypical PKCs (ι, 
ζ, λ, aPKCs) are activated by PS but are independent of calcium and DAG. PKC isozymes 
demonstrate cell type specificity with differential functions and may regulate cellular proliferation, 
differentiation, apoptosis and cell migration in response to various stimuli including growth factors 
(VEGF, basic fibroblast growth factor), cytokines (interlukin-1, interleukin-6, TNF-α) and hormones 
(insulin, glucagon) (Dempsey et al., 2000;Oliva et al., 2005). 
Endothelial cells are reported to express PKC α, β, δ, ε, ζ and θ and regulate different aspects of EC 
function during physiology and pathophysiology. PKCα, β and θ regulate VEGF-induced EC 
proliferation during angiogenesis, whilst PKCδ retards cell cycle progression and inhibits VEGF-
induced proliferation (Wang et al., 2002;Teicher et al., 2002;Shizukuda et al., 1999). PKCε co-
operates with Akt enhancing bcl-2 expression and protects ECs from apoptosis (Steinberg et al., 
2007). The cytoprotective importance of the PKCε isoform is demonstrated in models of ischemic 
pre-conditioning, and through the regulation of specific cytoprotective molecules including HO-1, 
eNOS and COX-2 (Xuan et al., 2005;Rojo et al., 2006;Rask-Madsen & King, 2008). 
The mitogen-activated protein kinases (MAPK) are serine/threonine kinases which are activated by 
a cascade of upstream MAP kinase kinases (MKK’s) and regulate diverse cellular processes 
including cell division, differentiation, apoptosis and migration. They transduce signals in response 
to growth factors, including VEGF, cytokines and hormones in various cell types and regulate 
several processes including inflammation, immunity, vascular function and angiogenesis 
(Garrington & Johnson, 1999;Lawrence et al., 2008). Three groups of MAP kinases are recognized: 
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the extracellular signal-regulated kinases (ERK), c-jun NH2-terminal protein kinases (JNK) and p38 
MAPK of which there are three recognized isoforms: α, β and γ (Blenis, 1993). ERK is activated in 
response to growth factors and phorbol esters and regulates EC proliferation and differentiation 
and confers resistance to complement-mediated cell lysis (Sugden & Clerk, 1997;Kraus et al., 
2001). p38 MAPKα has a central role in promoting vascular inflammation by increasing expression 
of pro-inflammatory cytokines, enhancing leucocyte adhesion, chemotaxis and by stimulating the 
oxidative burst and degranulation (Clark et al., 2003). In contrast, p38 MAP kinase β inhibits EC 
apoptosis in response to carbon monoxide generated by HO-1 (Silva et al., 2006). JNK is activated 
in response to growth factors (VEGF, basic-FGF), cytokines (TNF-α, interleukin-1, interleukin-4, 
interleukin-6) and stressful stimuli including heat shock and oxidative stress resulting in 
downstream activation of AP-1 leading to phosphorylation of c-jun (Westwick et al., 
1994;Moriguchi et al., 1995).  
The PKC isozymes are known to activate specific signaling pathways and regulate MAP kinase 
transcription of downstream target genes including ICAM-1 and DAF (Rahman et al., 
2001;Lidington et al., 2005). The intra-cellular signaling pathways regulating EC DAF expression are 
poorly understood but various PKC isozymes and the MAP kinases are involved in cytokine, VEGF, 
thrombin and statin-induced DAF expression (Mason et al., 1999;Mason et al., 2002a;Mason et al., 
2004;Lidington et al., 2005). Specifically, thrombin and VEGF employ PKCα/ε and p38 MAP kinase 
to enhance EC DAF expression (Mason et al., 2004;Lidington et al., 2005). Similarly, PKCα is 
involved in statin-induced DAF upregulation and combinations of TNFα and interferon-Υ induce 
DAF expression via a PKCα/ε and p38 MAP kinase dependent pathway (Mason et al., 1999;Mason 
et al., 2002a). In addition, thrombin- may also utilize ERK 1/2 and JNK MAP kinases to regulate cell-
surface DAF expression (Lidington et al., 2005).  
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In humans, DAF is encoded by a single 35 Kb gene located at q32 on chromosome 1 which is in 
close proximity to genes encoding other complement regulators including CR1, factor H and MCP. 
Collectively this region within the genome is named the regulators of complement activation (RCA) 
(Lublin et al., 1987). DAF is constitutively expressed in several cell types and is predominantly 
regulated transcriptionally, although post-transcriptional and post-translational mechanisms may 
be involved (Miwa & Song, 2001). Growth factors, cytokines, statins and prostaglandins enhance 
DAF expression in many cell types including endothelial cells, epithelial cells and fibroblasts, 
however the transcriptional mechanisms involved remian poorly understood (Mason et al., 
1999;Mason et al., 2001;Mason et al., 2002a;Lidington et al., 2005;Holla et al., 2005;Shao et al., 
2008). The human DAF promoter has previously been characterized and transcription and 
translation initiation sites mapped (Ewulonu et al., 1991). The promoter lacks conventional TATA 
and CAAT sequences but is rich in GC content and contains consensus sequences for several 
transcription factors including HIF, Sp1, KLFs, PRE and CRE (Medof et al., 1987;Thomas & Lublin, 
1993;Shao et al., 2008). Recently Sp1 was shown to be important in the constitutive expression of 
murine DAF, and PGE2 increased DAF promoter activity in epithelial cells by using KLF4/5 and the 
CRE (Holla et al., 2005;Cauvi et al., 2006;Shao et al., 2008). Furthermore, other studies using DAF 
promoter deletion constructs indicate that the CRE site is likely to be important in both 
constitutive and induced DAF expression (Ewulonu et al., 1991;Thomas & Lublin, 1993).  
The cAMP response element binding protein (CREB) is a member of the basic-leucine zipper family 
of transcription factors and binds to the CRE after phosphorylation of a serine-133 residue located 
within the kinase inducible domain of the protein. CREB is phosphorylated and activated in 
response to several stimuli including TNF and regulates the transcription of genes involved in 
cellular proliferation, growth, differentiation and migration (Shaywitz & Greenberg, 1999). CREB 
activation is modulated by upstream kinases including protein kinase C, p38 MAP kinase, ERK 1/2 
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and calcium/calmodulin dependent kinases (Shaywitz & Greenberg, 1999). The importance of 
CREB in the regulation of EC DAF is unknown.  
Aims of Chapter 7:  
As discussed above Akt, PKC isoforms and the MAP kinases control statin, VEGF and thrombin-
induced DAF expression. Therefore the role of these signaling proteins in statin and rapamycin 
enhanced DAF expression is investigated in the first part of this chapter by exploring the following 
hypotheses: 
1. The synergistic induction of DAF by statins and rapamycin is regulated by mTOR and AKT.  
2. Protein kinase C regulates statin and rapamycin-induced EC DAF expression. 
3. The MAP kinases are involved in statin and rapamycin-enhanced EC DAF expression. 
As statin and rapamycin induced-DAF expression is likely to be transcriptionally regulated and 
CREB, Sp1 and KLF 4/5 are involved in constitutive and PGE2 induced DAF expression in murine and 
human epithelial cells, the following hypotheses will also be explored:  
4. Synergistically-enhanced DAF expression requires de novo transcription and translation of 
the DAF gene. 
5. CREB activation and the CRE is important in regulating endothelial cell DAF expression 
following treatment with a combination of atorvastatin and rapamycin. 
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7.2 RESULTS 
7.2.1 Role of mTOR and AKT in synergistically enhanced DAF expression 
Treating endothelial cells with a combination of atorvastatin and rapamycin synergistically 
enhances DAF expression. Therefore, I first investigated whether a synergistic trend was observed 
when ECs were treated with rapamycin in combination with other known DAF inducers. 
Rapamycin in combination with thrombin led to a synergistic 400% increase in DAF expression, 
while combination treatment with VEGF increased expression by 300%, which was in turn 
comparable to DAF responses observed with the combination of atorvastatin and rapamycin 
(figure 43a). As rapamycin is an mTOR inhibitor I next explored the importance of mTOR using RNA 
interference (figure 43b). mTOR specific RNAi decreased mTOR mRNA expression by over 95%. If 
the synergistic response was due to rapamycin’s inhibitory effects on mTOR, then atorvastatin in 
combination with mTOR RNA interference should reproduce a synergistic induction of DAF. 
Surprisingly however, mTOR RNAi paradoxically attenuated atorvastatin-induced DAF mRNA 
expression and furthermore, mTOR RNAi had no effect on HO-1 mRNA expression.  
The effects of Ly294002 on synergistically enhanced DAF expression indicated a role for P-I-3 
kinase in the regulation of DAF. As AKT is predominantly regulated by P-I-3 kinase we next 
explored its role using a dominant-negative Akt adenovirus. Unexpectedly DN-AKT decreased 
basal, atorvastatin, rapamycin and synergistically enhanced DAF expression (figure 44a). Both 
statins and rapamycin are each known to phosphorylate and activate AKT (Dormond et al., 
2007;Ali et al., 2009). As pharmacological or adenoviral inhibition of AKT resulted in conflicting 
findings, the phosphorylation status of AKT(ser473) was investigated further.  Combined 
atorvastatin and rapamycin enhanced Akt (ser 473) phosphorylation within 15 minutes of treatment 
and this was sustained to 1 hour, however by 24 hours post-treatment AKT(ser473) was 
hypophosphorylated (figure 44b).  
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Figure 43. mTOR and the regulation of synergistically enhanced DAF. ECs were treated with
A rapamycin 1µM (R) alone or in combination with thrombin 10 units/ml (T), VEGF 25ng/ml
(V) or atorvastatin 0.5µM (A) for 24 hours and then analyzed for DAF expression using flow
cytometry. Data are expressed as percent change relative to untreated cells (U). B ECs were
treated with either 30nM of mTOR siRNA (RNAi) or scrambled control RNAi (C) for 48 hours
prior to the addition of atorvastatin 0.5µM (A) for 18 hours following which cells were lysed
and analyzed for mTOR, DAF or HO-1 mRNA using quantitative PCR. Data are expressed as
fold change relative to untreated cells and normalized to actin mRNA . All data is presented as
mean +/- SEM of 3-4 independent experiments. * p<0.05, **p<0.01, *** p<0.001 and ns- not
significant where indicated.
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Figure 44. Role of Akt in synergistically enhanced DAF. A ECs were transfected at an
MOI of 200 with dominant negative AKT (DN-AKT) or blank adenoviruses (Control-Ad)
and then treated with rapamycin 1µM (R) and/or atorvastatin 0.5µM (A) for 24 hours
and analyzed for DAF expression using flow cytometry. Data are expressed as percent
change relative to untreated cells. B ECs were lysed and assessed for AKT-ser473
phosphorylation using immunoblotting following treatment with atorvastatin 0.5µM (A)
and/or rapamycin 1µM (R) at the indicated time points. All data is presented as mean +/-
SEM of 3-4 independent experiments. * p<0.05 and **p<0.01 where indicated.
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Treating endothelial cells with the drug combination for 45 minutes synergistically enhanced AKT 
(ser473) phosphorylation while there was minimal phosphorylation in ECs treated by atorvastain or 
rapamycin alone (figure 44b).  
7.2.2 Protein kinase C regulates atorvastatin and rapamycin-induced DAF expression  
To initially explore the role of PKC in the synergistic up-regulation of DAF, ECs were treated with a 
broad spectrum PKC inhibitor, bisindolylmaleimide I (GF-109203X), prior to the addition of 
atorvastatin and rapamycin for 24 hours. Flow cytometry revealed that both basal and induced 
DAF expression was significantly inhibited by GF-109203X, suggesting the involvement of cPKC 
and/or nPKC isozymes (figure 45a). To further delineate the specific PKC isozymes responsible for 
synergistic DAF induction, the cPKC isozyme inhibitor Gö6976 was used. This inhibitor had little 
effect on basal, atorvastatin or rapamycin-induced DAF and attenuated DAF induction by the drug 
combination, although this was not significant (figure 45b). Although the result did not reach 
statistical significance, the role of cPKC and/or nPKC isozymes in synergistically enhanced DAF 
expression could not be excluded. Therefore, further experiments to determine the role of specific 
PKC isozymes involved using adenoviruses (Adv) expressing PKCα, δ and ε dominant-negative (DN) 
constructs were performed. Infection with DN-PKCα or DN-PKCδ alone resulted in a 30% decrease 
of constitutive DAF expression and complete abrogation of atorvastatin and rapamycin-induced 
DAF expression (figure 46a). In addition, although DN-PKCε had no effect on basal DAF expression, 
it suppressed the synergistic response to the additive level (figure 46a). These results suggest that 
PKCα, PKCδ and PKCε play a role in atorvastatin and rapamycin-induced DAF expression.  
The importance of PKCα was explored further using a specific myristoylated peptide inhibitor of 
PKCα (myr-ψ-PKCα). Myr-ψ-PKCα inhibited basal DAF expression and completely abolished 
synergistically enhanced DAF which was consistent with results obtained with the DN-PKCα 
adenovirus (figure 46b). Immunoblotting revealed that PKCα was rapidly phosphorylated at  
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Figure 45. Protein kinase C and the regulation of atorvastatin and rapamycin induced DAF.
ECs were treated with A the broad spectrum PKC inhibitor bisindolylmaleimide-1/ GF-
109203X (GF) 3µM or B the cPKC inhibitor Gö6976 (Gö) 5µM for 30 minutes prior to the
addition of atorvastatin 0.5µM (A) and/or rapamycin 1µM (R) for 24 hours. EC DAF
expression was then analyzed using flow cytometry. Concentrations of bisindolylmaleimide-
1/ GF-109203X and Gö6976 were previously optimized (Mason et al. 2004). Data are
expressed as percent change relative to untreated cells (U). All data is presented as mean
+/- SEM of 3-4 independent experiments. *** p<0.001 and ns- not significant where
indicated.
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Figure 46. Role of PKC isozymes in statin-rapamycin enhanced up-regulation of DAF. A ECs
were infected with adenoviruses expressing DN-PKCα (DNα), DN-PKCδ (DNδ), DN-PKCε (DNε),
or control Adv (Ad0) at an MOI of 200/cell (optimized previously) (Lidington et al., 2005) then
treated with atorvastatin (A) 0.5µM and rapamycin (R) 1µM for 24 hours. B ECs were exposed
to a myristoylated cPKC isozyme-specific peptide inhibitor (myr-cPKC) 100µM (concentration
optimized previously) for 30 minutes prior to the addition of A and R for 24 hours. DAF
expression was analyzed using flow cytometry. Data are expressed as percent change relative to
untreated cells and presented as mean +/- SEM of 3-5 independent experiments. * p<0.05,
**p<0.01, *** p<0.001 compared to Ad0-A+R unless where indicated, ns- not significant. Data is
presented as percent change relative to untreated cells (U).
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serine657 by the drug combination achieving a maximal 2-fold increase between 60 and 90 minutes 
of treatment (figure 47a). Further experiments were conducted to determine whether the 
individual drugs or the combination was responsible for PKCα phosphorylation after 60 minutes of 
treatment. Atorvastatin or rapamycin treatment alone had a minimal effect on PKCα 
phosphorylation. However, the drug combination yielded a synergistic 2-fold increase in 
phosphorylation status (figure 47b).  
As experiments with the DN-constructs also indicated a role for PKCδ and PKCε in atorvastatin and 
rapamycin-induced DAF expression, the phosphorylation status of these kinases was investigated. 
PKCε was phosphorylated at serine729 by atorvastatin and rapamycin achieving a 2-fold increase 
after 60 minutes of treatment (figure 48a). There was no change in PKCδ phosphorylation at 
threonine505 status in cells treated with the drug combination (figure 48b).  
7.2.3 Regulation of atorvastatin and rapamycin-induced DAF by MAP kinases  
p38 MAP kinase is known to be involved in the regulation of EC DAF expression (Mason et al., 
2002a;Mason et al., 2004;Lidington et al., 2005). Therefore the role of p38 MAP kinase in 
atorvastatin and rapamycin induced DAF was investigated using the inhibitor SB202190. This 
compound had no effect on basal or induced DAF expression by atorvastatin or rapamycin alone, 
but completely inhibited DAF induction by the drug combination (figure 49a). The activation state 
of p38 MAP kinase was explored by analysing threonine 180/ tyrosine 182 phosphorylation status 
using immunoblotting. p38 MAP kinase was phosphorylated by the drug combination as early as 
30 minutes and a peak 2-fold phosphorylation occurred between 45 and 60 minutes (figure 49b). 
Further analysis revealed that rapamycin had no effect on p38 phosphorylation status whilst 
atorvastatin resulted in a non-significant 1.5-fold increase and the drug combination enhanced 
phosphorylation by 2.5-fold (figure 49c). This suggests that p38 MAPK plays an important role in 
the pathway mediating synergistically enhanced DAF expression. 
Figure 47. Statins and rapamycin enhance PKCα phosphorylation. ECs were lysed and assessed
for PKCα-ser657 phosphorylation using immunoblotting following treatment with A atorvastatin
(A) 0.5µM in combination with rapamycin 1µM (R) for 15-120 minutes (n=4), or B with
atorvastatin (A) 0.5µM and/or rapamycin (R) 1µM for 60 minutes (n=3). A representative
immunoblot is shown with a histogram representing pooled quantification data relative to total
PKCα. Data are expressed as fold change relative to untreated cells (U) and presented as mean
+/- SEM of 3-5 independent experiments. *** p<0.001 compared to untreated cells.
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Figure 48. Effects of statins and rapamycin on PKCδ and PKCε phosphorylation. ECs were
treated with atorvastatin 0.5µM in combination with rapamycin 1µM (A+R) for 15-90 minutes,
then lysed and assessed for A PKCε-ser729 phosphorylation or B PKCδ-thre505 phosphorylation
using immunoblotting (n=2). A representative immunoblot is shown with a histogram
representing pooled quantification data relative to total PKCε pr PKCδ. Data are expressed as
fold change relative to untreated cells (U) and presented as mean +/- SEM. Statistical analysis
not possible as n=2.
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Figure 49. Role of p38 MAP kinase in statin and rapamycin-induced DAF expression. A ECs
were treated with the p38 MAP kinase inhibitor SB202190 (25µM) for 30 minutes prior to the
addition of atorvastatin (A) 0.5µM and/or rapamycin (R) 1µM for 24 hours and then analyzed
for DAF expression using flow cytometry. Results are presented as percent change above
untreated (U) cells (n=3). ECs were treated with B atorvastatin 0.5µM and rapamycin 1µM for
15-90 minutes, or C atorvastatin (A) 0.5µM and/or rapamycin (R) 1µM for 45 minutes then
lysed and assessed for phosphorylated p38-thr180/tyr182 and total p38 using
immunoblotting. A representative immunoblot is shown with a histogram representing
pooled quantification data compared to total p38 and data is presented as fold change
relative to untreated cells (n=3). All data are presented as mean +/- SEM. * p<0.05, **p<0.01,
and ns- not significant compared to untreated (U) cells unless indicated.
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The roles of other MAP kinases; ERK1/2 MAPK and JNK MAPK were also investigated using 
pharmacological antagonists. UO126 is an inhibitor of MEK-1/2 and inhibits phosphorylation of 
ERK1/2 MAPK. This compound had no effect on basal or drug-induced DAF expression (figure 50a). 
However, immunoblot analysis revealed that the drug combination induced maximal 
phosphorylation between 15 and 30 minutes of stimulation which decayed by 90 minutes of 
treatment (figure 50b). Of note, my colleague Dr Odile Dumont confirmed the efficacy of 5µM 
UO126 for the inhibition of ERK1/2 phosphorylation in separate experiments (not shown).The JNK 
MAPK inhibitor, JNK-I-II (Sp100625) significantly inhibited basal and drug-induced DAF expression 
(figure 51a). Moreover, the drug combination induced a maximal 2-fold increase in JNK 
phosphorylation by 60 minutes of treatment (figure 51b). The vehicle (DMSO) for atovastatin, 
rapamycin, PKC and MAPK inhibitors had no effect on DAF expression. 
These results suggest that ERK1/2 activation is not required for DAF expression induced by 
atorvastatin or rapamycin. In contrast, JNK MAPK is important for regulating constitutive 
expression and contributes to atorvastatin/rapamycin-induced DAF expression.  
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Figure 50. Role of ERK1/2 in statin and rapamycin-induced DAF expression. ECs were treated
with A the ERK 1/2 inhibitor UO126 (5µM) for 30 minutes prior to the addition of atorvastatin
0.5µM (A) and/or rapamycin 1µM (R) for 24 hours and then analysed for DAF expression using
flow cytometry. Results are presented as percent change above untreated (U) cells (n=3). B ECs
were treated with atorvastatin 0.5µM and rapamycin 1µM for 15-90 minutes, then lysed and
assessed for phosphorylated and total ERK 1/2 using immunoblotting. A representative
immunoblot is shown with a histogram representing pooled quantification data compared to
total ERK 1/2 and data is presented as fold change relative to untreated cells (n=3). All data are
presented as mean +/- SEM. *** p<0.001 compared to untreated cells. ns- not significant.
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Figure 51. Role of JNK in statin and rapamycin-induced DAF expression. ECs were treated
with A the JNK inhibitor-I-II (50µM) for 30 minutes prior to the addition of atorvastatin 0.5µM
(A) and/or rapamycin 1µM (R) for 24 hours and then analyzed for DAF expression using flow
cytometry. Results are presented as percent change above untreated (U) cells (n=3). B ECs
were treated with atorvastatin 0.5µM and rapamycin 1µM for 15-90 minutes, then lysed and
assessed for phosphorylated and total JNK using immunoblotting. A representative
immunoblot is shown with a histogram representing pooled quantification data compared to
total JNK and data is presented as fold change relative to untreated cells (n=3). All data are
presented as mean +/- SEM. * p<0.05 and ns- not significant compared to untreated cells (U).
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7.2.4 Inter-relationship of p38 and PKC in atorvastatin and rapamycin-induced DAF 
expression  
Having illustrated the importance of PKCα and p38 MAPK in atorvastatin and rapamycin-induced 
DAF expression, it was of interest to reveal their inter-relationship within the atorvastatin-
rapamycin-DAF signaling pathway. Previous studies have demonstrated that PKC and MAPK form 
part of a linear signaling pathway in thrombin-induced DAF upregulation (Lidington et al., 2005). 
Therefore the signaling relationship between p38 and protein kinase Cα was initially investigated 
by using p38 MAPK inhibitor SB202190 and measuring PKCα phosphorylation. Similarly, the effect 
of cPKC peptide inhibitor myc-ψ-PKC on p38 phosphorylation was analysed. ECs were pre-
incubated with myr-ψ-PKC for 24 h prior to addition of atorvastatin and rapamycin for 45 minutes.  
TNF-α (10ng/ml) and plain medium alone were used as positive and negative controls respectively. 
Atorvastatin and rapamycin induced p38 phosphorylation at 45 minutes, which was inhibited by 
myr-ψ-PKC (Figure 52a). Surprisingly, myr-ψ-PKC phosphorylated p38. However, further 
experiments led to inconsistent findings and the inhibitory effect of myr-ψ-PKC was not always 
observed. ECs were also pre-incubated with the p38 MAPK inhibitor SB202190 for 24 h before the 
addition of atorvastatin and rapamycin. VEGF 25ng/ml was used as positive control for PKCα 
phosphorylation, and plain HUVEC medium as a negative control. Although atorvastatin and 
rapamycin-induced PKCα phosphorylation at 60 min, the addition of SB202190 to the drug 
combination significantly enhanced phosphorylation. SB202190 alone also had a modest effect on 
PKCα phosphorylation (Figure 52b). However, inconsistent results were also obtained when 
repeating these experiments. Therefore a linear relationship between PKCα and p38 MAPK in this 
signaling pathway cannot be established and parallel pathways remain possible. 
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Figure 52. Inter-relationship between p38 MAP kinase and protein kinase C-α in statin and
rapamycin-induced DAF expression. A ECs were pre-treated with a PKCα inhibitory peptide
(PKCi- 100µM) for 24 hours followed by the the addition of atorvastatin (A) 0.5µM and
rapamycin (R) 1µM or TNFα 10ng/ml for 45 minutes then lysed and analyzed for phospho-
p38 (thr180/tyr182) and total p38 expression using immunoblotting (n=2). B ECs were pre-
treated with the p38 MAPK inhibitor SB202190 (25µM) for 24 hours followed by the the
addition of atorvastatin (A) 0.5µM and rapamycin (R) 1µM or VEGF (50ng/ml) for 60 minutes
then lysed and assessed for phosphorylated PKCα and total PKCα expression using
immunoblotting (n=2).
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7.3 TRANSCRIPTIONAL REGULATION OF DAF EXPRESSION 
7.3.1 DAF induction by atorvastatin and rapamycin requires de novo synthesis 
DAF induction in response to several agonists is known to be dependent on new transcription and 
translation of the DAF gene. Therefore the importance of new transcription and/or translation in 
statin and rapamycin-induced DAF was investigated using the transcriptional inhibitor, 
actinomycin D and the inhibitor of translation, cycloheximide. ECs were pre-treated with 
actinomycin D or cycloheximide for 30 minutes prior to the addition of atorvastain and/or 
rapamycin for 24 hours followed by analysis of DAF expression using flow cytometry. Actinomycin 
D attenuated DAF induction in cells treated with atorvastatin and/or rapamycin to basal levels 
whilst cycloheximide decreased atorvastatin and/or rapamycin induced-DAF expression to 50% of 
basal levels. The most striking response seen was the significant inhibition of atorvastatin and 
rapamycin-induced DAF expression. Interestingly, cycloheximide treatment decreased constitutive 
expression of DAF, while Actinomycin D did not have this effect (figure 53). These results suggest 
that DAF induction by atorvastatin and/or rapamycin is dependent on new transcription and 
translation whilst constitutive DAF expression may have a greater dependence on translation. 
Figure 53. Role of transcription and translation in statin and rapamycin-induced DAF
expression. ECs were treated with or without A actinomycin D 2μg/ml (Act D) or B
cycloheximide 3μg/ml (CHX) for 30 minutes prior to the addition of atorvastatin (A) 0.5µM
and/ or rapamycin (R) 1µM for 24 hours and DAF expression assessed using flow cytometry.
Data are expressed as percent change relative to untreated cells (U) and presented as mean
+/- SEM of 3-5 independent experiments. *** p<0.001 and ns- not significant as indicated.
0
50
100
150
200
250
300
U
ACT D
R A A + R
- + - + - + - +
***
ns
ns
R
el
at
iv
e 
D
A
F 
ex
pr
es
si
on
   
   
   
   
   
   
   
   
   
   
   
   
   
   
(P
er
ce
nt
 o
f U
)
ns
0
50
100
150
200
250
300
350
U
CHX
R A A + R
- + - + - + - +
ns
ns
R
el
at
iv
e 
D
A
F 
ex
pr
es
si
on
   
   
   
   
   
   
   
   
   
   
   
   
   
   
(P
er
ce
nt
 o
f U
)
ns
***
A
B
231 
 
7.3.2 Atorvastatin and rapamycin requires the cAMP response element to enhance DAF 
promoter activity 
The DAF promoter has previously been identified, characterized and several response elements 
identified (Ewulonu et al., 1991;Thomas & Lublin, 1993). Using Genomatix’s ElDorado software a 
601 nucleotide promoter sequence was identified within the human DAF gene. As previously 
described, sequence analysis confirmed that the DAF promoter lacked conventional TATA and 
CCAAT boxes, but had a GC content of  50-60%. Potential transcription factor binding sites were 
identified including those for HIF, PPARs, KLFs, and Sp1 as well as the phorbol myristate acetate 
(PRE) and cAMP response elements (CRE) (figure 54). To study the effects of atorvastain and 
rapamycin on human DAF promoter activity a group of 5’ DAF promoter deletion constructs were 
cloned into the Bgl II and Hind III sites of the pGL3 luciferase reporter vector (kindly provided by Dr 
V Holla, figure 55a). Denoting the most upstream transcription start site as +1, the construct with 
the full promoter extended from -724bp to +80bp (construct 1:-724/+80) and deletion constructs 
extended from -437 to +80bp (construct 2: -437/+80), -304 to +80bp (construct 3: -304/+80bp) 
and -126 to +80bp (construct 4: -126/+80bp). A restriction digest of each promoter construct using 
the restriction enzymes Hind III and Xho I yielded two DNA fragments; a large fragment of greater 
than 3000 bp which was the pGL3 vector and a smaller fragment which varied in size between 
each construct and correlated with the expected size of the DAF promoter inserts (figure 55b).   
Transfection of the complete DAF promoter construct (-724/+80) into ECs enhanced luciferase 
activity by 20-fold compared to the empty vector control. PBu and PGE2 are known to enhance 
DAF promoter activity and protein expression. Treating ECs with PBu or PGE2 following 
transfection with the complete DAF promoter enhanced luciferase activity to 500% and 300% 
respectively and confirmed the validity of the assay (figure 56). 
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Figure 55. pGL3 DAF luciferase reporter constructs. A Schematic representation of pGL3-
basic vector (Promega ©). DAF deletion promoter constructs were cloned between Bgl II and
Hind III sites. B 1µg of each deletion construct was dissolved in digestion buffer, BSA 1µg/µl
and double digested with Xho 1 and Hind III restriction enzymes for 2 hours at 370C. DNA
digestion products were then loaded onto a 1.5% agarose gel and separated at 150mV for 2
hours.
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Atorvastatin treatment increased luciferase activity to 140% and rapamycin maximally enhanced 
activity to 300% compared to untreated cells. Intriguingly, the drug combination increased 
luciferase activity to 280% which was comparable to rapamycin treatment alone (figure 56a).  
 
Endothelial cells transfected with the deletion constructs displayed a progressive decline in basal 
luciferase activity achieving a minimal 50% luciferase expression with deletion construct -126/+80 
(figure 56b). However, there was no significant difference in atorvastatin and rapamycin enhanced 
luciferase activity between each construct. DAF promoter activity has previously been studied in 
Hela, COS, EBV and epithelial cell lines, and the CRE site was shown to be critical in regulating DAF 
expression following stimulation with PGE2 (Ewulonu et al., 1991;Thomas & Lublin, 1993). As 
construct -126/+80 retained the CRE, a construct with a mutated CRE was derived from construct -
304/+80. The basal luciferase activity of the mutated construct was comparable to construct -
304/+80. In ECs transfected with the mutated construct and treated with atorvastatin and 
rapamycin, luciferase activity was attenuated and comparable to that in untreated cells 
transfected with the complete DAF promoter (figure 56b). Hence several transcription factor 
binding sites within the DAF promoter appear to be important in regulating constitutive DAF 
promoter activity, whilst the CRE site appears to regulate atorvastatin and rapamycin-induced DAF 
expression. 
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Figure 56. DAF promoter activity in response to atorvastatin and rapamycin. ECs were
transfected with atorvastatin and/or rapamycin for 16 hours following transfection with the
pGL4.73[hRluc/SV40] plasmid and either A the complete DAF promoter luciferase reporter
construct or, B DAF promoter deletion constructs. The cells were lysed and transcriptional
activity measured using the Dual Luciferase Reporter Assay. The pGL4 basic vector (control)
was used as a negative control. Phorbol dibutyrate (PBu) or prostaglandin E2 (PGE2) were
used as positive controls for enhancing DAF promoter activity. Results are expressed as a
ratio of luminescence generated by firefly luciferase produced by DAF promoter constructs
relative to Renilla luciferase produced by pGL4.73 [hRluc/SV40]. All results are normalised to
the untreated complete DAF promoter construct. All data are presented as mean +/- SEM. *
p<0.05 , *** p<0.001 and ns- not significant compared to untreated (U) or as indicated.
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7.3.3 DAF induction by atorvastatin and rapamycin is regulated by a protein kinase A 
and a CREB dependent pathway 
Protein kinase A phosphorylates a serine-133 residue within the cAMP response element binding 
protein (CREB) which subsequently leads to the assembley of a transcriptional complex at a cAMP 
response element (CRE) and enhances transcription of a target gene. A competitive antagonist of 
protein kinase A, attenuated synergistically enhanced DAF in ECs but had a non-significant effect 
on basal, atorvastatin or rapamycin-induced DAF (figure 57a). Immunoblotting showed that a 
maximal 2.5-fold increase in CREB phosphorylation at serine133 was achieved following 60 minutes 
treatment with the drug combination (figure 57b).  A further assessment showed that atorvastatin 
or rapamycin treatment alone had a minimal effect on CREB(ser133) phosphorylation but a 
synergistic 4.5-fold increase in phosphorylation was observed with the drug combination (figure 
57c). 
The interaction of CREB with the DAF promoter following treatment with atorvastatin and 
rapamycin was next investigated using chromatin immunopreciptation (figure 58). Primers 
flanking the CRE within the DAF promoter were designed for PCR of atorvastatin and rapamycin-
treated EC monolayers after immunoprecipitation with an anti-CREB mAb. Atorvastatin and 
rapamycin-treated ECs demonstrated a greater direct interaction between CREB and the CRE site 
within the DAF promoter than untreated ECs (figure 58b). In summary these results demonstrate 
that atorvastatin and rapamycin enhances CREB(ser133) phosphorylation and DAF promoter activity 
leading to super induction of DAF. 
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Figure 57. Role of protein kinase A and cAMP response element binding protein in statin
and rapamycin induced DAF expression. ECs were treated with A the protein kinase A
inhibitor H-89 (10µM) for 30 minutes prior to the addition of atorvastatin 0.5µM (A) and/or
rapamycin 1µM (R) for 24 hours and then analyzed for DAF expression using flow cytometry.
Results are presented as percent change above untreated (U) cells (n=3). ECs were treated
with B atorvastatin 0.5µM and rapamycin 1µM for 15-90 minutes, or C atorvastatin (A)
0.5µM and/or rapamycin (R) 1µM for 45 minutes then lysed and assessed for CREB-Ser133
phosphorylation and total CREB using immunoblotting. A representative immunoblot is
shown with a histogram representing pooled quantification data compared to total CREB and
data is presented as fold change relative to untreated cells (n=3). All data are presented as
mean +/- SEM. * p<0.05, **p<0.01, *** p<0.001 and ns- not significant compared to
untreated (U) cells unless indicated.
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Figure 58. Atorvastatin and rapamycin enhances CREB binding to the DAF promoter. A
Genomic DNA sequence of the proximal 5’ region of the human DAF gene. The approximate
transcription start site is designated +1 and ATG translation initiation site is indicated in bold.
The CRE binding site is over scored. Oligonucleotide sequences flanking the CRE and 3000
base pairs downstream from the DAF promoter used in the ChIP assay (see B) are indicated
by arrows. B Chromatin immunoprecipitation from a confluent HUVEC monolayer following
treatment with or without atorvastatin and rapamycin for 60 minutes. Genomic DNA
obtained after immunoprecipitation using a mouse anti-CREB mAb or negative control IgG,
was used as a template in a PCR reaction with primers spanning a region flanking the CREB
binding site within the DAF promoter. To ensure specificity of CREB binding to the DAF
promoter, PCR amplification was also performed on the same samples using primers specific
to the 3’ region of the DAF locus as negative control. Degree of binding was densitometrically
quantified relative to input DNA and expressed as fold change (n=3). All data are presented
as mean +/- SEM. * p<0.05 as indicated.
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-287 gagatattta ggtttctaga aggcaggtca tcgcaggccc cacccagcag tggagagagt
-227 gagtcccaga gggtgttgcc agcgagctcc tcctccttcc cctccccact ctccccgagt
-167 ctagggcccc cggggcgtat gacgccggag ccctctgacc gcacctctga ccacaacaaa
-107 cccctactcc acccgtcttg tttgtcccac ccttggtgac gcagagcccc agcccagacc
-47 ccgcccaaag cactcattta actggtattg cggagccacg aggcttctgc ttactgcaac
13 tcgctccggc cgctgggcgt agctgcgact cggcggagtc ccggcggcgc gtccttgttc
73 taacccggcg cgccATGacc…………………………………………………………………………………………………………....
.................................................................
3973 gaaatggtca gattgatgta ccaggtggca tattatttgg tgcaaccatc tccttctcat
4033 gtaacacagg gtaagtttgg gcatactaaa accctgtatt taggaaatga gaaaacaaat
4093 taggacttaa ggtgagattg ttagtttcat gactggtatt cacagctagt agcaattaaa
4153 acaatccctc tcctcaaaga cccttcatca tgagctcatc acagttaaat ttagtaaaat
+1
CRE
PCR Primers
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7.3.4 Interaction between protein kinase C, p38 MAP kinase and CREB 
CREB regulates several cellular responses including proliferation, differentiation and migration. 
CREB phosphorylation and activation is known to be regulated by several kinases including protein 
kinase C, ERK, p38 MAP kinase and calcium/calmodulin (Shaywitz & Greenberg, 1999). As already 
demonstrated, statin and rapamycin-induced DAF expression is regulated by protein kinase C and 
p38 MAP kinase in parallel pathways. As atorvastatin and rapamycin enhances CREB 
phosphorylation and binding to the DAF promoter, the role of PKC and p38 on statin-rapamycin-
induced CREB phosphorylation was explored. Although PKCα, PKCε and PKCδ regulate statin-
rapamycin induced DAF, the role of other PKC isozymes cannot be completely excluded. Therefore 
statin-rapamycin induced CREB phosphorylation was assessed in the presence of the non-specific 
PKC antagonist, bisindolylmaleimide and the p38 MAP kinase inhibitor, SB202190. Both 
antagonists abrogated statin-rapamycin induced CREB phosphorylation, suggesting that PKC and 
p38 act upstream of CREB in the regulation of statin and rapamycin-induced DAF expression 
(figure 59a) 
.
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7.3.5 Role of other transcription factors in statin and rapamycin induced DAF 
Analysis of the human DAF promoter using the genomatix promoter modeling program revealed 
several potential consensus sequences for HIF, Sp1, KLF 4/5 and NFkB and the role of these in DAF 
expression has been explored (Louis et al., 2005;Cauvi et al., 2006;Shao et al., 2008). The proximal 
HIF binding site was demonstrated to be important for DAF expression in epithelial cells exposed 
to hypoxia (Louis et al., 2005). Hypoxia enhances statin-induced DAF and HO-1 expression, and this 
is regulated by HIF during hypoxia (Lee et al., 1997;Kinderlerer et al., 2006). Moreover, a reduction 
in intracellular iron is known to stabilize HIF (Melillo et al., 1997;Hanson et al., 1999). As observed 
in chapter 3, statin and rapamycin-induced DAF expression is regulated by HO-1 and ferritin-
mediated reduction in intra-cellular iron. Therefore the effects of the combination of atorvastatin 
and rapamycin on HIF1 and HIF2 were investigated using immunoblotting. As expected, 
desferrioxamine stabilized HIF-1α and HIF-2α (figure 59b). However atorvastatin and/or rapamycin 
at concentrations known to synergistically enhance DAF expression had no effect on HIF 
expression (figure 59b). 
Sp1 is a ubiquitously expressed transcription factor and its consensus sequence within the DAF 
promoter is conserved in many species. Sp1 is known to be important for the constitutive 
expression of murine DAF and the human DAF promoter contains at least three Sp1 binding sites. 
Furthermore, deletion construct 4 (-126/+80) retained an Sp1 consensus sequence which may 
drive DAF promoter activity, and Sp1 is known to co-operate with CREB in transactivating several 
genes (Lu et al., 2008;Xia et al., 2008;Hong et al., 2008). Thus the role of Sp1 in statin-rapamycin 
induced EC DAF expression was explored (figure 60).  
Figure 59.
A. Protein kinase C and p38 MAPK regulate CREB phosphorylation. ECs were treated with
the broad spectrum protein kinase C inhibitor bisindolylmaleimide-1 (GF-109203X) (GF) 3µM
or the p38 MAPK inhibitor SB202190 (SB) 25µM for 30 minutes prior to the addition of
atorvastatin 0.5µM (A) and rapamycin 1µM (R) for 45 minutes and then lysed and assessed
for phosphorylated CREB-Ser133 and total CREB using immunoblotting. A representative
immunoblot is shown with a histogram representing pooled quantification data compared to
total CREB and data is presented as fold change relative to untreated cells (n=3). All data are
presented as mean +/- SEM. * p<0.05 and **p<0.01 compared to untreated (U) cells unless
indicated.
B. Hypoxia inducible factor expression endothelial cells treated with Atorvastatin and
Rapamycin. Endothelial cells were treated with atorvastatin (A) 0.5µM and/ or Rapamycin (R)
0.5-1µM and/or desferioxamine 100µM (D) for 24 hours. Cells were then lysed and assessed
for HIF1α or HIF2α expression using immunoblotting. Experiments performed in collaboration
with Sarah Hartnell.
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Mithramycin A, an Sp1 inhibitor attenuated DAF induction by atorvastatin, rapamycin and the drug 
combination to basal levels. However, mithramycin A had little effect on constitutive DAF 
expression (figure 60a). A commercially available binding ELISA was used to study the effects of 
the drug combination on EC nuclear Sp1 interactions with Sp1 consensus sequences. Untreated EC 
nuclear lysates demonstrated basal Sp1 binding activity which was enhanced by 50% after 30 
minutes treatment with the drug combination and although not reaching significance this steadily 
declined to baseline after 2 hours of treatment (figure 60b). These findings suggest that Sp1 is 
likely to have a role in constitutive and the induced DAF expression in response to statins and 
rapamycin. However, further experiments are needed to confirm this.  
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Figure 60. Role of Sp1 in statin-rapamycin enhanced up-regulation of DAF. A ECs were treated
with the Sp1 inhibitor mithramycin A 150 nM for 30 minutes prior to the addition of
atorvastatin 0.5µM (A) and/or rapamycin 1µM (R) for 24 hours. EC DAF expression was then
analyzed using flow cytometry. Data are expressed as percent change relative to untreated cells
(U). All data is presented as mean +/- SEM of 4 independent experiments. B Nuclear lysates
were prepared from endothelial cells treated with atorvastatin (A) 0.5µM and rapamycin (R)
1µM for 0 to 240minutes and nuclear Sp1 expression analyzed using an ELISA (Active Motif
TransAm ©). Data are expressed as relative Sp1 binding compared to untreated cells (0
minutes) and presented as mean +/- SEM of 5 independent experiments. Lipopolysaccharide
(LPS) 30µM was used as a positive control. + and – denote positive and negative controls
supplied with ELISA kit. * p<0.05, **p<0.01, *** p<0.001 compared to untreated cells
(U/0minutes), unless as indicated.
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7.4 DISCUSSION  
DAF and CD59 are GPI-anchored membrane-bound complement regulatory proteins which are 
highly expressed on vascular endothelium and limit complement-dependent vascular injury. The 
formation of the C3 convertase is a key step in the complement cascade and DAF inhibits its 
formation preventing the generation of several pro-inflammatory complement components 
including the C5b-9 membrane attack complex (Mollnes et al., 2002). DAF differs somewhat from 
CD59 as it is readily inducible on vascular endothelium by several stimuli including growth factors, 
cytokines, C-reactive protein, LPS and histamine which utilize specific signal transduction pathways 
(Tsuji et al., 1994;Mason et al., 1999;Mason et al., 2002b;Li et al., 2004). Hence during 
inflammation, DAF expression is readily modulated and protects endothelial cells from 
complement-dependant cellular injury. The intra-cellular signaling mechanisms which may be 
involved in DAF regulation are poorly understood. Therefore studies in this chapter explored the 
intra-cellular signaling pathways activated by atorvastatin and rapamycin in enhancing DAF 
expression.  
Rapamycin is an inhibitor of mTOR which in combination with statins synergistically enhanced 
endothelial DAF expression. A similar synergistic induction was observed when rapamycin was 
combined with VEGF or thrombin, suggesting that these stimuli employ similar DAF regulatory 
pathways to enhance DAF expression. Surprisingly, a synergistic increase in DAF expression was 
not observed when mTOR knockdown by siRNA was combined with statin therapy. Instead, mTOR 
siRNA attenuated statin enhanced DAF mRNA expression. The discrepancy in these observations 
could firstly be attributed to an mTOR independent property of rapamycin. Rapamycin inhibits the 
binding of FKBP12 to the FRB domain of mTOR with an IC50 of 10nM (Augustine et al., 2007), 
whereas the optimal synergistic concentration for DAF induction was 1µM raising the possibility of 
an ‘off target’ effect of rapamycin. Furthermore, mTOR RNAi failed to enhance HO-1 mRNA 
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expression which is known to regulate DAF expression. Moreover HO-1 is important in the 
synergistic induction of DAF by statins and rapamycin (chapter 3), and is known to be responsible 
for the anti-proliferative effects of rapamycin on pulmonary artery smooth muscle cells in vitro, 
albeit at concentrations up to 10µM (Visner et al., 2003;Zhou et al., 2006). Secondly, the 
mechanism of mTOR inhibition may be important in the synergistic induction of DAF. mTOR is a 
large protein which functions as a scaffold for the assembly of at least two distinct signaling 
complexes (Hay & Sonenberg, 2004). The results from experiments using mTOR siRNA suggest that 
an intact mTOR molecule is required for the induction of DAF and that different signaling motifs 
within mTOR may be necessary for DAF synthesis. Rapamycin by inhibiting FKBP12 binding to 
mTOR, may preserve other components of mTOR allowing them to function as a signaling 
intermediary in other pathways essential for DAF synthesis. Clearly further studies are necessary 
to explore these questions and might include experiments with alternative mTOR inhibitors such 
as everolimus and employing site-directed mutagenesis of the mTOR protein. 
Pharmacological inhibition of PI-3 kinase in the presence of statin, VEGF or thrombin 
synergistically enhanced DAF expression, suggesting that PI-3 kinase exerts a tonic inhibitory effect 
on a DAF regulatory pathway (Mason et al., 2004;Lidington et al., 2005). As PI-3 kinase is the main 
regulator of AKT phosphorylation and activation, its role in synergistically enhanced DAF 
expression was studied. AKT was expected to exert a similar tonic inhibitory effect on DAF 
expression; however studies with DN-AKT adenoviruses attenuated rather than enhanced DAF 
expression, suggesting an important role for AKT in the synergistic induction of DAF. These findings 
contrasted significantly with those observed with Ly294002. Further analysis of AKT (Ser473) 
phosphorylation status using immunoblotting showed both an early phosphorylation and delayed 
hypophosphorylation event which is accounted for by rapamycin’s well described effects on 
mTORC1 and mTORC2 function (Sarbassov et al., 2006;Dormond et al., 2007;Contreras et al., 
2008). P70-S6 kinase inhibits AKT(Ser473) under resting conditions (Asnaghi et al., 2004).  
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Inhibition of mTORC1 by rapamycin leads to the inhibition of p70-S6 kinase resulting in enhanced 
AKT phosphorylation. In contrast mTORC2 is known to phosphorylate AKT (Ser473) following 
stimulation with growth factors and cytokines (Sarbassov et al., 2005;Dormond et al., 2007). 
Prolonged rapamycin treatment leads to mTOR depletion and inhibition of mTORC2 function 
resulting in de- phosphorylation of AKT (Ser473) and becomes apparent 12 hours post-treatment in 
endothelial cells (Sarbassov et al., 2006;Dormond et al., 2007). Hence, endothelial DAF super-
induction by statins and rapamycin may rely on both AKT hyper-and hypophosphorylation. Other 
well described downstream effector molecules of PI-3 kinase include activation of GSK, PDK1 and 
monomeric cytoslic G-proteins including rac and rho-GTPases and each are worthy of further 
exploration in the regulation of DAF expression (Oudit et al., 2004). 
Ly294002 reversibly inhibits PI-3 kinase by competing with ATP for the active site of the enzyme’s 
catalytic subunit. The ic-50 of this enzyme is 1.4µM and at concentrations up to 50µM when 
enzyme activity is completely abolished there is little effect on other enzyme systems. 
Nevertheless, Ly294002 may have PI-3 kinase-independent effects including direct inhibitory 
effects on mTOR and casein kinase 2 (Oudit et al., 2004). Hence the observed synergistic induction 
of DAF expression in ECs treated with both Ly294002 and statin may be independent of PI-3 
kinase. This question may be specifically addressed by inhibiting PI-3 kinase using more targeted 
approaches such as RNA interference.  
A role for protein kinase C (PKC) in EC DAF expression was first established by Bryant and 
colleagues who showed that PKC activation with phorbol esters enhanced EC DAF expression by 3 
to 4 fold (Bryant et al., 1990). Moreover, studies from this laboratory have confirmed a role for 
PKC in cytokine induced DAF expression and by using a pharmacological and adenoviral approach, 
a role for both classic and novel PKC isozymes has also been established. Specifically VEGF and 
thrombin activate PKCα and ε (Mason et al., 2004;Lidington et al., 2005), whilst statins rely on 
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PKCα to upregulate EC DAF expression (Mason et al., 2002a). As PKC α, ε and δ are isozymes which 
are expressed in EC’s (Dempsey et al., 2000), we explored their role in the regulation of statin and 
rapamycin-induced EC DAF expression. Pharmacological antagonists, DN-adenoviruses and peptide 
inhibitors indicated a role for each of these isozymes. However, enhanced phosphorylation was 
observed for PKCα and PKCε, but not PKCδ. The increase in PKCα phosphorylation occurred in a 
synergistic manner following treatment with the drug combination, while treatment with statin or 
rapamycin alone had no effect on phosphorylation status. This differs from previous studies by 
Mason and colleagues demonstrating PKCα phosphorylation in response to statins leading to DAF 
induction. However, importantly their study utilized higher supratherapeutic concentrations of 
atorvastatin to demonstrate PKCα phosphorylation and DAF induction (Mason et al., 2004).  
Combined statin and rapamycin treatment resulted in an early increase in PKCε phosphorylation 
which paralleled PKCα phosphorylation time kinetics. The ability of statins or rapamycin alone to 
alter PKCε phosphorylation is unknown and further studies are necessary to establish which 
component of the drug combination is responsible for PKCε phosphorylation.  It is currently 
unknown whether rapamycin and mTOR can modulate PKCε phosphorylation and activity. 
However, a recent study has demonstrated a role for mTORC2 in the synthesis, folding and 
activation of PKCα and AKT (Facchinetti et al., 2008). Both PKCε and PKCα may have a 
cytoprotective role during inflammation (Dempsey et al., 2000). PKCε activates specific 
cytoprotective pathways during myocardial ischemic preconditioning and cerebral ischemic post-
conditioning following infarction (Xuan et al., 2005;Gao et al., 2008). Moreover PKCε inhibits 
endothelial cell apoptosis in vitro by co-operating with Akt (Steinberg et al., 2007). Similarly PKCα 
is known to be anti-apoptotic and functional co-operation is described between PKCα and PKCε. 
Both enzymes may regulate smooth muscle cell spreading, Grb2-associated binder-1 tyrosine 
phosphorylation and the EC response to mechanical strain (Haller et al., 1998;Cheng et al., 
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2001;Saito et al., 2002). Therefore, a similar co-dependence may exist between both isozymes in 
the regulation of statin-rapamycin and VEGF-induced DAF upregulation. 
PKCδ differs from the α and ε isozymes as it has a pro-apoptotic and pro-inflammatory role 
(Dempsey et al., 2000). Experiments with the DN-PKCδ adenovirus suggested a role for this 
isozyme in statin-rapamycin-induced DAF.  However the drug combination failed to phosphorylate 
PKCδ at early time points suggesting either delayed phosphorylation of PKCδThr505 or potential 
phosphorylation of other residues. Furthermore, my results might imply a lack of specificity of the 
PKCδ-DN construct and the importance of PKCδ needs to be explored with other approaches 
including RNA interference and by assessment of the phosphorylation status of other residues. 
Taken together these results indicate that both statins and rapamycin activate a DAF regulatory 
pathway which specifically involves PKCα and ε isozymes. 
The MAP kinases have several physiological and patho-physiological roles in regulating endothelial 
cell function. The p38 and JNK family of kinases transduce pro-inflammatory and stressful stimuli, 
whereas ERK 1/2 responds to mitogenic stimuli (Blenis, 1993;Dong et al., 2002;Lawrence et al., 
2008). Previous studies have identified p38 MAPK as the predominant MAPK in the regulation of 
endothelial cell DAF expression following treatment with VEGF, thrombin and cytokines such as 
TNF-α and interferon-γ (Mason et al., 1999;Mason et al., 2004;Lidington et al., 2005). These 
observations were determined using pharmacological antagonists of the MAP kinases and verified 
by enhanced p38 phosphorylation following treatment with VEGF. The findings in this study 
showed that the pharmacological inhibitor of p38, SB202190, decreased synergistically enhanced 
DAF to basal levels but had no effect on constitutive expression or statin-induced DAF expression. 
The drug combination also led to a synergistic increase in p38 phosphorylation which correlated 
with enhanced DAF expression. There are various isoforms of p38 MAPK; α, β and γ. p38α is the 
best characterized and has a pro-inflammatory, pro-apoptotic role and leads to the induction of 
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several pro-inflammatory molecules including TNFα, COX-2 and IL-1β. The p38 dependant 
induction of these molecules is related to enhanced mRNA stability which may be due to the 
presence of a characteristic 3’UTR within the gene (Clark et al., 2003). The DAF gene contains a 
similar p38 ‘stabilizing’ 3’ UTR and a role for mRNA stability in statin-induced DAF expression was 
previously shown (Mason et al., 2002a). A similar mechanism may be involved in synergistically 
enhanced DAF expression. In contrast to p38α, p38β has an anti-apoptotic and anti-inflammatory 
profile and is involved in the cytoprotective responses generated by HO-1 (Silva et al., 2006). The 
p38 inhibitor, SB202190, inhibits the p38α and p38β isoforms and the observed role for p38 in the 
regulation of statin and rapamycin-induced DAF could be attributed to p38β.  The role of p38α/β 
in DAF expression requires further verification using other approaches such as RNA interference 
and dominant negative constructs.  
Whilst p38 inhibition specifically attenuated synergistically enhanced DAF expression, the 
atorvastatin-rapamycin drug combination enhanced JNK phosphorylation and JNK inhibition had a 
global effect on DAF expression decreasing both basal and induced DAF expression in cells treated 
with atrovastatin and/or rapamycin. In contrast, ERK inhibition had no effect on statin and/or 
rapamycin-induced DAF expression, although increased ERK1/2 phosphorylation was observed 
following treatment with the drug combination. In summary, p38 is the predominant MAP kinase 
regulating synergistic induction of DAF by statins and rapamycin, whilst JNK may be additionally 
involved in the general influence of DAF regulation. The relative roles of p38α and p38β, as well as 
the p38-dependent effects on DAF mRNA stability in synergistically enhanced DAF upregulation 
require further investigation.  
Previous studies suggest that PKC and the MAP kinases form a linear signaling pathway in the 
regulation of ICAM-1 and VEGF induced EC DAF expression (Rahman et al., 2001;Clerk & Sugden, 
2001;Mason et al., 2004;Lidington et al., 2005). PKCα and ε phosphorylation occurred maximally 
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between 30 and 60 minutes which coincided with p38 and JNK phosphorylation. Employing PKCα 
inhibitory peptides or SB2020190 to explore the inter-relationship between p38 and PKCα failed to 
show a linear relationship between these signaling molecules. Taken together my data 
demonstrates that while p38 and PKCα/ε activation is involved in statin and rapamycin-induced 
DAF expression, most likely via parallel signaling pathways. 
Inhibition of statin and rapamycin-induced DAF by cycloheximide and actinomycin D indicating 
transcriptional regulation, led me to explore the regulation of the DAF promoter. The human DAF 
promoter is approximately 800bp upstream from the ATG initiation codon. The DAF promoter 
lacks conventional TATA and CAAT elements and has a high GC content, a characteristic feature of 
genes which are broadly and constitutively expressed (Ewulonu et al., 1991;Thomas & Lublin, 
1993;Cauvi et al., 2006). The location of the transcription start site is unclear. Studies by Ewolonu 
and colleagues using PCR extension analyses and nuclease digestion in HeLa cells suggested that 
the transcription start site was 82bp upstream of the ATG start codon, whilst Thomas and Lublin 
identified multiple start sites 87bp upstream from the start codon (Ewulonu et al., 1991;Thomas & 
Lublin, 1993). In the murine DAF promoter the transcription start site was located 47, 20 and 17bp 
upstream from the translation start codon (Cauvi et al., 2006). The discrepancy between these 
studies may be attributed to intercellular and interspecies differences which may affect DAF 
expression and complement regulation. We also found that the promoter had several response 
elements including those for HIF, KLFs, Sp1, CREB, AP-1 and NFKB.  
The regulation of the DAF promoter in endothelial cells has never been explored. Transfection of 
the complete DAF promoter into endothelial cells resulted in increased luciferase activity 
indicating that the DAF transcriptosome was active within these cells. Treatment with atorvastatin 
had no effect on promoter activity, whilst rapamycin enhanced activity by up to 3-fold, which was 
comparable to that seen in cells treated with the drug combination. Hence a synergistic increase in 
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promoter activity was not observed, suggesting an additional role for post-transcriptional 
mechanisms, including increased mRNA stability, in the synergistic induction of DAF by statins and 
rapamycin. Deletion analysis of the DAF promoter starting at the 5’ flanking region showed a 
successive decline in basal and drug-induced activity. These findings differ from studies by 
Ewulonu , Holla and Shioao et al where a 5’ deletion of a 500bp segment from the promoter led to 
enhanced basal and PGE2-induced promoter activity (Ewulonu et al., 1991;Holla et al., 2005;Shao 
et al., 2008). An observation which was reproduced in studies of the murine promoter (Cauvi et 
al., 2006). This indicates that a 5’ segment of the promoter contains response elements which 
negatively regulate DAF promoter activity. In contrast to this, I observed a stepwise decline in 
activity, also reported by Thomas and colleagues (Thomas & Lublin, 1993). It must be noted that in 
the latter study, like ours, the DAF promoter was transfected into human cells whereas the other 
studies used non-human cells. Thus there appears to be a cell-type and tissue-specific regulation 
of the DAF promoter, which may be dictated by the differential expression of specific transcription 
factors.  
In epithelial cells the cAMP response element (CRE) is essential for PGE2-induced DAF expression, 
and KLF binding sites within the DAF promoter appear to regulate the magnitude of DAF 
expression in response to PGE2 (Holla et al., 2005;Shao et al., 2008). Furthermore, co-operation 
between KLF4/KLF5 synergistically enhances DAF promoter activity (Shao et al., 2008). 
Transfection of EC with promoter constructs containing a mutated CRE resulted in loss of 
increased promoter activity in response to atorvastatin and rapamycin. This data suggests that the 
CRE site is important in the transcriptional upregulation of DAF. Inhibition of PKA with H89 
attenuated synergistically enhanced DAF protein expression but had no effect on DAF induced by 
either atorvastatin or rapamycin alone. Furthermore atorvastatin and rapamycin in combination 
synergistically enhanced CREBser133 phosphorylation and CREB binding to the CRE site as 
demonstrated using ChIP.  Recently Sp1 was shown to be important in the basal activity of the 
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murine DAF promoter, functionally co-operating with CRE (Cauvi et al., 2006). My preliminary 
studies with mithramycin and a Sp1 transcription factor binding assay suggest a role for this 
transcription factor in the regulation of human DAF. In conclusion, atorvastatin and rapamycin-
induced DAF is transcriptionally regulated by a CREB-CRE dependent pathway.  
PKC, calcium and p38 MAP kinase are known to regulate CREB activity (Shaywitz & Greenberg, 
1999;Gustin et al., 2004). Furthermore in endothelial cells PKC and PKA colocalise on the cytosolic 
protein gravin suggesting functional co-operation (Grove & Bruchey, 2001). As PKC and p38 MAP 
kinase regulate atorvastatin and rapamycin-induced DAF expression, their effects on CREB 
phosphorylation in response to statins and rapamycin was explored. I found that 
pharmacologically inhibiting p38 MAP kinase or PKC inhibited statin and rapamycin-induced CREB 
phosphorylation. Hence it appears that PKC and p38 are upstream of CREB and both co-operate in 
enhancing CREB phosphorylation which in turn activates DAF promoter activity and expression.  
This chapter has identified a specific endothelial cytoprotective signaling pathway which is 
stimulated by statins and rapamycin, which results in DAF superinduction. The signaling pathway 
involves AKT/protein kinase B and independently employs PKCα/ε and p38 MAP kinase which co-
operate in activating a PKA-CREB cascade leading to enhanced DAF gene transcription. HO-1, 
bilirubin and ferritin were shown in early chapters to be important in the superinduction of DAF, 
and both PKC and p38 MAP kinase are known to regulate HO-1 expression. The interplay between 
HO-1, PKC, p38 and PKA/CREB remains to be determined (figure 61).  
Statin
ferritin
R 
HO-1
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biliverdin
DAF 
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B
Figure 61- Signaling pathways in therapeutically regulated DAF expression
A. HO-1 and ferritin regulate synergistically enhanced DAF expression. Rapamycin (R)
treatment of endothelial cells increases HO-1 and ferritin heavy chain expression and activity,
which interacts with a statin sensitive signaling pathway super-enhancing DAF mRNA and
protein expression. B. Synergistically enhanced DAF expression is regulated by an AKT-p38
MAPK-PKCα and CREB dependent pathway. Combined atorvastatin (AT) and rapamycin
activates AKT, p38, PKCα and CREB increasing DAF expression. p38 MAPK and PKCα enhance
CREB phosphorylation and activity in parallel pathways which directly interacts with the DAF
promoter and stimulates DAF gene transcription. The interaction between AKT with p38
MAPK, PKCα and CREB remains to be determined. The effects of rapamycin in this pathway
appears to be independent of mTOR.
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8.1 DISCUSSION 
The vascular endothelium expresses several anti-inflammatory and cytoprotective proteins which 
limit local and systemic pathogenic responses following vascular injury. These include the 
elaboration of soluble anti-inflammatory molecules, cell surface proteins and receptors, 
intercellular adhesion molecules, protective intra-cellular signaling pathways and specific 
cytoprotective, anti-apoptotic and anti-inflammatory genes (figure 1). The basis of the research 
programme in our group is that a greater understanding of the mechanisms underlying endothelial 
cytoprotection may help to identify novel therapeutic targets with vasculoprotective potential 
(Tedgui & Mallat, 2001;Stoneman & Bennett, 2004). This is of particular importance in light of the 
increasingly recognized association between many diseases and accelerated atherosclerosis, 
above and beyond that linked to hyperlipidaemias and diabetes mellitus. Thus, SLE, RA, the 
vasculitides, chronic renal failure and post-transplant vasculopathy have all been associated with 
accelerated atherosclerosis. However, therapeutic intervention for atherosclerosis is largely 
directed at established symptomatic lesions and not at endothelial dysfunction. There is an 
outstanding need for therapeutic regimens that can combine immunosuppresion with 
vasculoprotection. 
The cytoprotective molecules studied in this thesis include decay accelerating factor (DAF) and the 
anti-inflammatory protein heme-oxygenase-1 (HO-1). DAF is a membrane bound complement 
regulatory protein which inhibits the formation and accelerates the decay of C3 convertases. It is 
expressed on vascular endothelium and is enhanced in response to cytokines, VEGF, basic-FGF and 
C-reactive protein (Mason et al., 1999;Mason et al., 2001;Mason et al., 2002b;Li et al., 2004). The 
cytoprotective importance of DAF within the vasculature is well illustrated in multiple animal 
models of disease and in patients with paroxysmal nocturnal hemoglobinuria (Mollnes et al., 
2002). Studies from this laboratory have previously shown that statins enhance EC DAF expression 
in a dose-dependent manner protecting endothelium from complement-mediated injury (Mason 
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et al., 2002a). However, as yet therapeutic induction of DAF in vivo has not been demonstrated. 
We and others have reported that pharmacological blockade of PI-3 kinase in the presence of 
statins or other DAF agonists leads to a synergistic induction in DAF expression (Mason et al., 
2002a;Holla et al., 2005;Abid et al., 2007). As the mTOR pathway is activated downstream from PI-
3 kinase, the above observations led us to hypothesize that statins in combination with the mTOR 
inhibitor rapamycin synergistically enhances EC DAF expression, which was investigated in chapter 
two.   
Treating endothelial cells with atorvastatin leads to a dose-dependent rise in EC DAF expression, 
whilst rapamycin only leads to a modest one. Combined atorvastatin and rapamycin treatment in 
vitro led to a synergistic increase in EC DAF expression which offered greater protection from 
complement than atorvastatin or rapamycin treatment alone. Optimum synergy was achieved 
when atorvastatin concentrations of 0.5µM were combined with rapamycin 1µM. Of note, the 
concentration of atorvastatin is feasible in human plasma following therapeutic dosing, whereas 
those for rapamycin are 50 times greater than those normally achieved in man (Augustine et al., 
2007). However, it is difficult to directly correlate in vitro studies and drug concentrations with 
those in clinical practice due to pharmacokinetic factors including protein binding and metabolism. 
Furthermore, laminar shear stress was recently shown to enhance atorvastatin induced HO-1 
expression in endothelial cells (Ali et al., 2009). Thus, laminar shear stress may alter the 
responsiveness of endothelial cells to drug therapy. The difficulties in translating in vitro 
concentrations and observations into clinically relevant ones are further indicated by experiments 
in mice, where intra-peritoneal atorvastatin or rapamycin for 48 hours reproduced a synergistic 
induction in DAF expression on murine aortic endothelium without any toxicity.   
Several in vitro, in vivo and clinical studies reveal that statins have multiple anti-inflammatory 
effects which may be independent of lipid-lowering. These properties are observed with both 
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hydrophilic and hydrophobic statins (Greenwood & Mason, 2007;Wang et al., 2008). We found 
that the synergistic response was also observed when simvastatin was combined with rapamycin, 
suggesting that all statins may synergistically enhance DAF expression. Rapamycin is an mTOR 
inhibitor which inhibits antigen driven T-cell proliferation, expands populations of regulatory T-
cells and is predominantly used as an immunosuppressant in transplantation, and anecdotally in 
various autoimmune diseases including rheumatoid arthritis and SLE (Young & Nickerson-Nutter, 
2005;Yoon, 2009).  Of particular interest to me, was the observation that combined dosing with 
atorvastatin with cyclosporin A failed to enhance DAF expression synergistically, whilst 
combinations involving mycophenolic acid lead to a small synergistic increase in DAF expression. 
The mechanisms for the latter are unclear. These data suggest that careful consideration of drug 
combinations may have additional therapeutic benefit. Cyclosporin A has multiple harmful effects 
on endothelial cells including impaired eNOS phosphorylation, disruption of VEGF signaling and 
predisposition to endothelial dysfunction, which may contribute to the observed decrease in DAF 
expression in cyclosporin treated endothelial cells (Kou et al., 2002;Mason et al., 2004;Caramelo et 
al., 2004).   
One factor underlying the differences between the combination of rapamycin, cyclosporine and 
myocophenolate with atorvastatin may be the induction of HO-1. HO-1 is a cytoprotective enzyme 
which degrades heme into equimolar amounts of biliverdin, carbon monoxide and ferrous iron 
which rapidly induces the ferritin heavy chain (FHC). Each of these products have multiple anti-
oxidant and anti-inflammatory effects which provide HO-1 with an anti-inflammatory profile and 
this is demonstrated in multiple models of disease and by several clinical studies (Loboda et al., 
2008). Recently, Kinderlerer and colleagues demonstrated that HO-1 derived FHC and bilirubin 
regulates endothelial cell DAF expression (Kinderlerer et al., 2009). Furthermore, many of the 
cytoprotective effects of statins and rapamycin may be accounted for by HO-1 induction (Visner et 
al., 2003;Hsu et al., 2006;Zhou et al., 2006;Ali et al., 2007;Lai et al., 2008;Hsu et al., 2009) . 
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Therefore, in Chapter 4 I explored the role of HO-1 in the synergistic expression of DAF in response 
to atorvastatin and rapamycin. In accordance with other studies, atorvastatin and rapamycin 
treatment enhanced HO-1 expression and activity in endothelial cells, whilst pharmacological 
antagonists of HO-1 attenuated synergistically enhanced DAF expression.   Importantly, rapamycin 
rather than atorvastatin was the main driver of HO-1, as iron chelators, which mimic the action of 
ferritin, in combination with atorvastatin reproduced the majority of the synergistic response. The 
role of the FHC was confirmed by mRNA time kinetic studies which showed that FHC mRNA 
expression preceded DAF mRNA, whilst FHC RNA interference attenuated DAF superinduction. 
Although bilirubin derived from biliverdin and carbon monoxide have multiple anti-oxidant, anti-
thrombotic, anti-inflammatory and cytoprotective effects, these products appear to have a minor 
role in synergistic DAF induction (Soares & Bach, 2009). Studies in chapter 6 demonstrated that 
celecoxib resulted in a significant induction in HO-1, but had little effect on DAF expression. This 
indicates that other factors are involved in the regulation of DAF by HO-1, which is likely to be 
stimulus specific. 
Therapeutic induction of HO-1 has received considerable recent attention. HO-1 is induced by 
several noxious and pharmacological stimuli including ROS, hypoxia, cytokines and growth factors 
(Loboda et al., 2008). Non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and 
COX-2 selective inhibitors (COXIBs) such as celecoxib are known to enhance HO-1 expression in 
different cell types (Hou et al., 2005;Aburaya et al., 2006). Concern exists regarding the 
cardiovascular safety of NSAIDs and COXIBs with celecoxib and naproxen having better 
cardiovascular profiles compared to other NSAIDs (McGettigan & Henry, 2006;Moore et al., 
2007;Warner & Mitchell, 2008). Furthermore celecoxib improves endothelial function in patients 
with stable coronary artery disease and attenuates neo-intimal proliferation following murine 
arterial injury (Chenevard et al., 2003;Yang et al., 2004b). Therefore, I explored the hypothesis that 
specific induction of HO-1 by celecoxib in vascular endothelial cells accounts for its relatively 
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favorable CV profile when compared to other NSAIDs and COXIBs. Dose-response studies 
confirmed that celecoxib enhanced HO-1 expression and activity in endothelial cells at 
concentrations which are therapeutically feasible in man (Niederberger et al., 2004). These 
observations were consistent with studies in other cell types (Hou et al., 2005). Furthermore HO-1 
induction by celecoxib attenuated TNF-α induced VCAM-1 expression confirming its functional 
relevance in vitro, which is consistent with the recognized anti-inflammatory profile of HO-1 
(Soares et al., 2004).  
 In contrast, COX-1 inhibition with indomethacin and the COX-2 inhibitor rofecoxib failed to induce 
HO-1. The inability of prostaglandin E2 or iloprost to reverse HO-1 induction by celecoxib indicated 
that this novel property was independent of COX-2 inhibition. Instead, celecoxib phosphorylated 
and activated Akt/protein kinase B, enhanced the formation of mitochondrial-derived ROS which 
in turn triggered Nrf-2 translocation into the nucleus enhancing HO-1 expression. Therefore, 
celecoxib appears to activate a cytoprotective pathway involving Akt and Nrf-2 which may have 
further cytoprotective consequences. Nrf-2 is known to bind to the anti-oxidant response element 
(ARE) and induces several anti-oxidant and de-toxifying enzymes such as NADPH quinine 
oxidoreductase, glutathione transferase and thioredoxin (Dai et al., 2007;Li & Kong, 2009). 
Furthermore Akt/protein kinase B transmits several protective signals involved in vascular 
homeostasis (Oudit et al., 2004). Although ROS are well recognized as being harmful to the 
vasculature it is increasingly recognized that low levels of ROS are required for modulating activity 
of signaling pathways which may have protective benefits (Gutierrez et al., 2006;Zhang & 
Gutterman, 2007). Recently laminar shear stress was shown to enhance mitochondrial ROS which 
mediated HO-1 expression (Han et al., 2009).  
Akt, protein kinase C and p38 MAP kinase are key signaling molecules involved in several cellular 
processes including cell division, apoptosis, angiogenesis, inflammation and neoplasia (Oudit et al., 
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2004;Dempsey et al., 2000;Lawrence et al., 2008). These signaling pathways are known to regulate 
statin, VEGF and cytokine-induced EC DAF expression (Mason et al., 1999;Mason et al., 
2002a;Mason et al., 2004), and their role in the synergistic induction of DAF was explored in 
Chapter 5.  
Looking at other signaling pathways, I found that atorvastatin and rapamycin treatment enhanced 
Akt phosphorylation, whilst DN-Akt adenoviruses attenuated synergistically enhanced DAF 
expression, indicating that the drug combination activates Akt.  These findings were discordant 
with those observed with PI-3 kinase blockade using Ly290042, which itself synergistically 
enhanced DAF expression in the presence of statin. This discrepancy questioned the regulatory 
role of mTOR in DAF expression, and this was further explored using RNA interference. Surprisingly 
mTOR RNA interference attenuated atorvastatin-induced DAF expression suggesting that 
atorvastatin and rapamycin-induced DAF expression is independent of mTOR. There is clearly a 
complex and relatively poorly understood relationship between mTOR and Akt which requires 
further investigation.  
Akt has an essential role in maintaining endothelial and vascular homeostasis. It enhances eNOS 
phosphorylation in response to laminar shear stress and regulates the expression and function of 
several cytoprotective molecules including HO-1, Nrf-2, CD59, COX-2 and bcl-2 (Dimmeler et al., 
1999;Boo & Jo, 2003;Salinas et al., 2004;Steinberg et al., 2007;Dai et al., 2007;Kinderlerer et al., 
2008). The anti-inflammatory importance of Akt is further supported by models of ischemia-
reperfusion injury and ischemic pre-conditioning (Hausenloy et al., 2005). Thus, the ability of 
combined atorvastatin and rapamycin treatment to activate Akt may provide additional benefits 
by enhancing the function of other cytoprotective proteins and pathways. 
Protein kinase C-α /ε are both known to be expressed in endothelial cells and may transmit both 
pro-inflammatory and anti-inflammatory signals (Dempsey et al., 2000). Both isozymes regulate 
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DAF expression in response to VEGF, thrombin, cytokines and statins (Mason et al., 1999;Mason et 
al., 2002a;Mason et al., 2004;Lidington et al., 2005). Pharmacological antagonists, DN-
adenoviruses and peptide inhibitors confirmed a role for PKC-α and PKC-ε in statin-rapamycin 
induced DAF. Furthermore the drug combination enhanced PKC-α and PKC-ε phosphorylation. The 
PKC family of enzymes are known to activate downstream MAP kinases including p38 MAP kinase 
(Rahman et al., 2001;Clerk & Sugden, 2001). Pharmacological antagonists of p38 attenuated 
synergistically enhanced DAF, whilst atorvastatin and rapamycin treatment synergistically 
enhanced p38 phosphorylation. A similar role for p38 MAPK is apparent in VEGF-induced DAF. 
Although PKCα is known to activate p38 MAPK following EC treatment with VEGF, a similar linear 
signaling pathway was not apparent following atorvastatin and rapamycin treatment (Mason et 
al., 2004). This suggests that regulatory pathways for DAF regulation are both cell type and 
stimulus specific. 
Finally, the synergistic induction of DAF was explored at the transcriptional level. Studies using 
actinomycin D and cycloheximide attenuated atorvastatin-rapamycin induced DAF expression, 
establishing the requirement for gene transcription and de novo protein synthesis. Using DAF 
promoter constructs the drug combination enhanced DAF promoter activity. Successive deletion 
constructs revealed that the cAMP response element (CRE) was essential for drug-induced 
transcriptional activity, and this was consistent with previous studies implicating CRE in DAF 
expression (Ewulonu et al., 1991;Thomas & Lublin, 1993;Holla et al., 2005). The importance of 
protein kinase A and the CRE binding protein (CREB) was supported by pharmacological 
antagonists and immunoblotting, which revealed a synergistic increase in CREB phosphorylation 
following treatment with atorvastatin and rapamycin, whilst chromatin immunoprecipitation 
demonstrated that atorvastatin and rapamycin increased CREB binding to the DAF promoter. 
Finally, blockade of PKC-α or p38 attenuated atorvastatin-rapamycin mediated CREB 
phosphorylation, indicating a linear signaling pathway between PKC-α or p38 and CREB. It follows, 
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that statins and rapamycin activate a unique cytoprotective pathway involving Akt, PKCα/ε, p38 
and PKA/CREB leading to enhanced endothelial cell DAF promoter activity and protection from 
complement-dependent injury.    
This study illustrates that combination therapy with statins and rapamycin activates multiple 
cytoprotective pathways involving Akt, protein kinase Cα/ε, p38 MAP kinase and protein kinase 
A/CREB. Each of these pathways results in the enhanced expression of HO-1 and intracellular 
ferritin resulting in the superinduction of DAF and EC protection against complement-mediated 
vascular injury. However, the targets of the drug combination may also exert broader 
cytoprotective actions and may potentially protect against oxidative stress, apoptosis and pro-
inflammatory cytokine-mediated injury. For example, Akt is known to directly regulate Nrf-2 and 
HO-1 in response to laminar shear stress, whilst p38 MAPKβ is known to be an anti-apoptotic 
effector molecule of HO-1 derived CO (Silva et al., 2006;Dai et al., 2007). Furthermore p38 MAPK 
may drive endothelial cell Nrf-2 and HO-1 expression in response to oxidized LDL, whilst 
simvastatin enhances VSMC HO-1 expression by activating Akt and p38 MAP kinase (Lee et al., 
2004;Anwar et al., 2005). Likewise, cAMP enhances HO-1 expression in vascular smooth muscle 
cells, whilst prostaglandin E2 enhances HO-1 employing a protein kinase A and Akt dependent 
pathway (Durante et al., 1997;Park et al., 2009). The precise pathways linking Akt-PKCα/ε-p38 and 
CREB with HO-1/ferritin induction remain to be determined and will require further investigation. 
Moreover, activation of Akt, protein kinase Cα/ε and the MAP kinases may also activate other 
vasoprotective pathways involving eNOS, thrombomodulin and bcl-2/bax, so improving vascular 
function and protecting from apoptosis and thrombosis.  
Several studies have clearly established an association between vascular injury, endothelial 
dysfunction and many vascular diseases including atherosclerosis, transplant vasculopathy, 
ischemia-reperfusion injury and systemic vasculitis. The pathogenesis of these diseases is multi-
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factorial and has an underlying inflammatory basis. Furthermore, an accelerated form of 
atherosclerosis is associated with the systemic inflammatory diseases including the autoimmune 
diseases such as rheumatoid arthritis and SLE (Sattar et al., 2003;Bruce, 2005). Oxidized LDL, 
reactive oxygen species, C-reactive protein, complement components and pro-inflammatory 
cytokines including TNF-α, IL-1 and IL-6 are amongst many noxious stimuli which may contribute 
to vascular injury (Ross, 1999). As discussed in Chapter 3, complement has an established role in 
the pathogenesis of atherosclerosis and other vascular diseases (Oksjoki et al., 2003;Riedemann & 
Ward, 2003;Wehner et al., 2007). The complement components C3a, C5a and the C5b-9 MAC 
activate endothelial cells, promoting a pro-inflammatory and pro-thrombotic endothelium 
(Fischetti & Tedesco, 2006). Similarly, oxidative stress within the vascular wall is associated with 
pro-atherogenic risk factors, leads to endothelial dysfunction and promotes vascular inflammation 
(Forstermann, 2008). My work suggests that in combination statins and rapamycin have the 
capacity to influence many of these pathogenic stimuli. 
The role of drug therapy in vascular disease is poorly understood. Although immunosuppressant 
drugs such as cyclosporin improve outcomes following transplantation, they may be harmful to 
the vasculature promoting endothelial dysfunction and contributing to transplant vasculopathy 
(Mudge, Jr. et al., 1992;Caramelo et al., 2004;Mudge, Jr., 2007). Similarly, certain NSAIDs are 
effective in the treatment of pain and inflammation in patients with inflammatory rheumatic 
disease but may perturb endothelial homeostasis by inhibiting COX-2 and promoting 
atherothrombosis (Warner & Mitchell, 2008). Furthermore, corticosteroids may also contribute to 
vascular dysfunction by augmenting the severity of traditional cardiovascular risk factors. In 
contrast, statins are highly vasculoprotective and are used in the primary and secondary 
prevention of atherosclerotic cardiovascular disease (Wang et al., 2008). Immunosuppressive 
treatment strategies are necessary for transplantation and autoimmune diseases. Drug therapy in 
these cases must provide both immunosuppression and vascular protection in order to prevent 
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morbidity and mortality from underlying immune disease and protect against transplant 
vasculopathy and accelerated atherogenesis respectively. The studies in this thesis demonstrate 
that combination therapies may activate specific endothelial cytoprotective pathways providing 
vasculoprotection. In particular, potentially deleterious effects of rapamycin on the vascular 
endothelium such as inhibition of proliferation, increased apoptosis and raised serum cholesterol 
may be balanced by opposite effects exerted by the statin, so allowing the cytoprotective actions 
of rapamycin to come to the fore. 
8.2 CONCLUSION 
The studies in this thesis demonstrate that combining statins with rapamycin leads to a synergistic 
induction in endothelial cell DAF expression in vitro and protects endothelial cells from 
complement-dependent lysis. Similarly atorvastatin and rapamycin synergistically enhances DAF 
expression on murine aortic endothelium. The superinduction of DAF is regulated by an 
Akt/protein kinase B, protein kinase Cα/ε, p38 MAP kinase and protein kinase A/CREB dependent 
pathway, which leads to enhanced cAMP response element driven DAF expression. DAF induction 
is also dependent on enhanced HO-1 and ferritin expression and activity. Moreover, the COX-2 
selective NSAID celecoxib enhances HO-1 expression and activity in endothelial cells by enhancing 
mitochondrial ROS formation and activating Akt and Nrf-2 translocation. Enhanced HO-1 
downregulates TNF-α induced VCAM-1 expression. In contrast other NSAIDs such as indomethacin 
and rofecoxib fail to induce HO-1. 
Taken together these findings demonstrate that the vascular endothelium can be therapeutically 
conditioned to enhance cytoprotective mechanisms, offering protection against vascular injury 
and disease.  
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8.3 FURTHER STUDIES 
Several questions arise from the studies in this thesis which are worthy of further investigation: 
1. How does Akt-protein kinase C-p38 interact with HO-1 and ferritin in the superinduction of 
DAF. This may be explored by using a combination of pharmacological antagonists, DN-
adenoviruses and RNAi, followed by assessment of phosphorylation status or protein 
expression using imunoblotting. 
2. Is mTOR and the complexes mTORC1/mTORC2 involved in synergistically enhanced DAF 
induction? This may be investigated by using site directed mutagenesis of mTOR or RNAi 
targeting of rictor/raptor and assessing DAF expression using quantitative PCR. 
3. What role does the 3’ UTR within the DAF gene have in synergistically enhanced DAF 
induction? This can initially be explored by assessing the importance of DAF mRNA 
stability in the presence of actinomycin D. 
4. Is statin and rapamycin-induced DAF functional in animal models of vascular disease? 
Possible models include those for atherosclerosis, ischemia-reperfusion injury and wire 
injury. 
5. What impact does laminar flow or oscillatory flow have on statin-rapamycin-induced DAF 
expression or celecoxib induced HO-1? This requires investigation in vitro and in vivo. 
6. Does celecoxib induce HO-1 in vivo and is this functionally relevant in the vasculature? 
7. What are the mechanisms by which celecoxib alters mitochondria morphology leading to 
Nrf-2 translocation? 
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CHAPTER 10 
PUBLICATIONS 
Disease-modifying anti-rheumatic
drugs: do they reduce cardiac
complications of RA?
Shahir S Hamdulay, Justin C Mason
RHEUMATOID, INFLAMMATION AND
CARDIOVASCULAR DISEASE
Our understanding of the pathogenesis of
atherosclerosis has evolved from a lipid
deposition disorder to a focal, chronic
inflammatory disease of medium-large
arteries characterised by inflammatory
plaques susceptible to rupture and throm-
bosis. Atherogenesis shares certain patho-
genic features with other inflammatory
diseases including the autoimmune disease
rheumatoid arthritis (RA). These include
macrophage-activating cytokines such as
tumour necrosis factor a (TNFa), inter-
leukin-1 (IL-1) and interleukin-6 (IL-6), the
presence of CD4+CD282 regulatory T-cells,
raised inflammatory markers including C-
reactive protein (CRP) and enhanced
expression of endothelial adhesion mole-
cules including VCAM-1.1 However, the
association between atherosclerosis and RA
extends beyond common pathogenic
mechanisms. Standardised mortality ratios
for cardiovascular disease in RA range from
1.2 to 5, and cardiovascular death accounts
for up to 50% of mortality with life
expectancy reduced by 10–15 years.2 A
similar alarming trend is observed in
systemic lupus erythematosus (SLE), with
a marked increase in stroke and myocardial
infarction (MI) reported.3 These outcome
data reflect the presence of increased
carotid artery intima thickening, vascular
stiffness and impaired flow-mediated vaso-
dilatation (FMD) in RA and SLE, indicating
endothelial dysfunction and subclinical
atherosclerosis.4
Atherosclerosis may be considered a
stereotypical inflammatory response to
vascular injury initiated and propagated
by traditional risk factors, and the latter
may be exacerbated by systemic inflam-
matory disease. RA and SLE patients
demonstrate insulin resistance and a pro-
atherogenic lipid profile characterised by
low high-density lipoprotein (HDL)
and apolipoprotein-AI levels, which may
be reversed by immunosuppression.2
However, traditional risk factors alone
do not explain the increased burden of
atherosclerosis, and disease-specific fac-
tors that predict RA severity are directly
associated with cardiovascular (CV) mor-
tality. Moreover, elevated acute phase
reactants in RA confer additional risk of
CV death, suggesting systemic inflamma-
tion contributes to the increase in CV
disease.2
Thus, the current challenge to clinicians
is the development of treatment regimens
that suppress underlying RA disease
activity, inhibit endothelial dysfunction
and retard progression of atherosclerosis.
ANTI-RHEUMATIC DRUGS AND
CARDIOVASCULAR DISEASE
Drug therapy of RA has undergone
remarkable evolution over 10 years, with
particular focus on biological therapies
and aggressive management of early dis-
ease. Undoubtedly this reaps benefit in
terms of reduction in structural damage.
Less clear is whether drugs aimed pre-
dominantly at synovitis also confer vas-
cular protection.
Since the introduction of methotrexate,
now the most widely used disease-mod-
ifying anti-rheumatic drug, mortality
from MI in RA has improved.5 Similar
observations have been made for both
sulfasalazine and hydroxychloroquine.6
Corticosteroid therapy may adversely
affect traditional risk factors such as
insulin resistance, hypertension and lipid
profiles, and is directly associated with
carotid plaque formation in RA and SLE.7
However, this relation is complex and
failure to use adequate immunosuppres-
sive therapy including corticosteroids may
predispose to accelerated atherogenesis.8
Non-steroidal anti-inflammatory drugs
(NSAIDs) and cyclo-oxygenase 2 selective
NSAIDs (coxibs), while effective anti-
inflammatory drugs may elevate blood
pressure and increase thrombotic CV
events, and caution surrounds their use
in patients with CV complications of
inflammatory disease.
BIOLOGICAL THERAPY AND CV DISEASE
IN RA
Biological therapies including TNFa
antagonists, interleukin-1 receptor
antagonist (IL-1ra), anti-IL-6 receptor
and B cell depletion may have vasculo-
protective potential in RA, but data to
date are preliminary. TNFa has a key role
in RA pathogenesis and TNFa antago-
nists, infliximab, etanercept and adalumi-
mab, markedly reduce systemic
inflammation, improve disease activity
and outcomes in RA.9 TNFa promotes
endothelial cell activation and endothelial
dysfunction and may lead to plaque
destabilisation. Infliximab therapy
improved FMD 4–12 weeks after infusion,
while etanercept reduced aortic stiffness
and this correlated with a beneficial effect
on disease activity.10 11 However, infliximab
therapy over three years had no effect on
carotid-intima media thickness in RA
patients compared to controls.12 Data from
the British Society of Rheumatology
Biologics register showed that although
there was no reduction in the incidence of
MI in patients treated with an anti-TNF
agent compared to conventional immuno-
suppressants (methotrexate, sulfasalzine
and hydroxychloroquine), MI was mark-
edly reduced in anti-TNF responders versus
non-responders.13
The interleukin 1 (IL-1) family com-
prises interleukin-1a (IL-1a), interleukin-
1b (IL-1b) and IL-1ra. IL-1a and IL-1b
exert comparable pro-inflammatory
effects by binding to IL-1 receptor type I.
IL-1ra, which binds the same receptor
without transmitting an activating signal,
acts as a competitive inhibitor of IL-1a
and IL-1b. IL-1 has a pivotal role in RA
pathogenesis, mediating synovial inflam-
mation, cartilage destruction and bone
resorption. Anakinra, a human, recombi-
nant form of IL-1ra, demonstrated effi-
cacy in RA when compared to placebo or
methotrexate. However, in combination
with etanercept there was no improve-
ment in efficacy compared to etanercept
alone. Furthermore partial responders to
anti-TNF agents derived no benefit when
switched to anakinra.14 15
IL-1 also plays a central part in ather-
ogenesis, increasing smooth muscle cell
proliferation, endothelin-1 release and
inducible nitric oxide synthase (iNOS),
leading to the formation of reactive
oxygen and nitrogen species directly con-
tributing to endothelial dysfunction.
Ikonomidis and colleagues have previously
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shown that anakinra decreases IL-1-
mediated nitro-oxidative stress, improves
FMD, coronary flow reserve (CFR), left
ventricular function and reduces IL-6 and
endothelin-1 levels in patients with RA.16
In the current issue of Heart (see page
1502), they extend their findings using
2D-speckle tracking echocardiography to
evaluate left ventricular myocardial defor-
mation.17 RA patients treated initially
with methotrexate, leflunomide and pre-
dnisolone were given either anakinra for
30 days, or had an escalation of predniso-
lone for the study period. Patients were
evaluated at baseline and day 30 for CFR,
FMD, nitro-oxidative stress and CRP
levels, and were compared with 23 con-
trols. Anakinra improved myocardial
deformation which correlated with
changes in nitro-oxidative stress, FMD
and CFR, compared to patients treated
with prednisolone. These findings high-
light the importance of IL-1 in mediating
vascular dysfunction in RA and suggest
that individual cytokine-directed thera-
pies may be useful in targeting specific
extra-articular manifestations of RA
including atherosclerosis. However, it
should be noted that the patients had
active RA and that escalation of predni-
solone to a higher dose, or alternative
biological therapies including anti-TNFa
might have exerted a similar beneficial
effect on CV function. Furthermore, this
is a short-term study and it would be
reassuring to know in due course that the
beneficial effects of anakinra persist after
12 months of treatment.
CONCLUSION
Our understanding of the pathogenesis of
inflammatory synovitis has led to the
development of specific biological thera-
pies with proved efficacy. Data are now
emerging to suggest that rigorous control
of rheumatoid disease activity may also
improve CV outcome and, importantly,
that combination biological therapy may
be the optimal approach for comprehensive
control of all aspects of this complex
disease. Large long-term clinical trials
which include primary cardiovascular end-
points are now required to establish this.
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inﬂammation, they have been overshadowed by concerns regarding atherothrombotic complications.
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ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Traditional nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
cyclooxygenase-2 (COX-2)-selective inhibitors (COXIBs) constitute
an important and effective class of drug for the treatment of pain
and inﬂammation. However, after the APPROVE trial demonstrating
increased thrombotic cardiovascular events in patients taking
rofecoxib, concerns were raised regarding a possible class effect
of COXIBs, a concept reinforced by results from the use ofparecoxib/valdecoxib in patients after cardiac surgery [1,2]. The
prostanoid hypothesis, put forward as one potential explanation for
the increased cardiovascular events, suggests that COX-2 selectivity
leads to an imbalance between the antithrombotic activity of
endothelial-derived prostacyclin and the prothrombotic properties
of platelet-derived thromboxane [3]. However, although the
mechanism(s) remains to be established, COX-2 selectivity alone
is now considered insufﬁcient to account for an increased
thrombotic risk [4]. Moreover, evidence from meta-analyses and
retrospective and prospective studies suggests that both NSAID and
COXIB therapy predisposes to a small but measurable increase in
cardiovascular risk [4–10]. Importantly, subgroup analysis may
identify patient characteristics that increase this risk and identify
those agents prone to inducing cardiovascular events [11].
Although controversy remains over the relative risk of cardio-
vascular events associated with individual COXIBs and NSAIDs,
clinical evidence from patients suffering from rheumatic diseases
suggests that among the COXIBs, celecoxib (≤200 mg daily) may
have a more favorable cardiovascular proﬁle [10,12]. This observa-
tion has also been reported in comparison to traditional NSAIDs
and observed in meta-analyses [5–7,13]. The difference in cardio-
vascular risk proﬁle is particularly pronounced between celecoxib
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[7,14]. Thus celecoxib, but not rofecoxib, inhibits TNFα-induced
tissue factor expression in endothelial cells [15]. Similarly, in a rat
model of hypertension, celecoxib preferentially improved vascular
function compared to rofecoxib and diclofenac [16], whereas
celecoxib and naproxen were less likely than rofecoxib to increase
24-h systolic blood pressure in patients with osteoarthritis [16,17].
Heme oxygenases (HO) are cytoprotective enzymes that degrade
heme, generating carbon monoxide, bilirubin, and ferrous iron, which
is sequestered by intracellular ferritin [18,19]. The cytoprotective
properties of HO are attributed to these products and include
antioxidant, antiapoptotic, antithrombotic, and anti-inﬂammatory
actions [18]. HO-1, the inducible form of heme oxygenase, is
transcriptionally regulated in response to oxidative stress induced
by heavy metals, hypoxia, cytokines, and lipopolysaccharide [19]. The
importance of the anti-inﬂammatory, cytoprotective actions of HO-1
is reﬂected in the severe sequelae of HO-1 deﬁciency, which include
intravascular hemolysis, anemia, diffuse endothelial damage, and
accelerated atherosclerosis [20].
Expression of HO-1 in atherosclerotic plaques and its ability to
inhibit vascular smooth muscle cell proliferation and exert anti-
inﬂammatory and antioxidant effects are likely to contribute to a
protective role during atherogenesis [21]. Overexpression of HO-1
inhibited atherogenesis, whereas Hmox1−/−/ApoE−/− mice devel-
oped more extensive and complex atherosclerotic plaques [22]. In
addition, HO-1 activity may protect against thrombosis, as
evidenced by a model of vascular injury in Hmox1−/− mice [23].
In patients with rheumatoid arthritis, HO-1 is expressed in the
inﬂamed synovium and HO-1 promoter polymorphisms increasing
enzyme expression are associated with improved radiographic
outcomes, whereas pharmacologic induction of HO-1 may attenuate
murine inﬂammatory arthritis and glomerular lesions in lupus-
prone mice [24–27].
In light of evidence suggesting that celecoxib may improve
endothelial function, and the importance of HO-1 as an anti-
inﬂammatory, antithrombotic enzyme, we explored the effects of
celecoxib on endothelial HO-1 activity. We show that celecoxib
signiﬁcantly increases HO-1 expression and activity in human EC, a
response not seen with either rofecoxib or indomethacin. HO-1
induction was independent of COX-2 and dependent on activation
of Akt, generation of mitochondrial-derived reactive oxygen species
(ROS), and nuclear translocation of NF-E2-related factor 2 (Nrf2)
and exerted a signiﬁcant anti-inﬂammatory effect as evidenced by
inhibition of TNFα-mediated VCAM-1 upregulation. Thus, induc-
tion of HO-1 may be an important factor in the relative freedom
from atherothrombotic complications associated with the use of
celecoxib.
Materials and methods
Reagents and antibodies
Monoclonal antibodies (mAb) against HO-1, COX-2, and Nrf2
were purchased from Stressgen (Ann Arbor, MI, USA), Cayman
Chemicals (Ann Arbor, MI, USA), and Santa Cruz Biotechnology
(Santa Cruz, CA, USA), respectively. Anti-Akt and anti-phospho-Akt
(Ser473) were from Cell Signaling (Danvers, MA, USA). Anti-E-
selectin mAb 1.2B6 and anti-VCAM-1 mAb 1.4C3 were generated
in-house. Celecoxib was donated by Pﬁzer (Groton, CT, USA) and
also purchased with rofecoxib from Toronto Research Chemicals
(Toronto, ON, Canada). Indomethacin, NS-398, prostaglandin H2,
and Iloprost were from Merck Biosciences (Nottingham, UK). TNFα
was from R&D Systems (Abingdon, UK). Prostaglandin E2,
LY290042, N-acetylcysteine, diphenyl iodonium, apocynin, rote-
none, antimycin A, carbonyl cyanide p-triﬂuoromethoxyphenylhy-
drazone (FCCP), and zinc protoporphyrin IX (ZnPPIX) were fromSigma–Aldrich (Poole, UK). In all experiments, EC were also treated
with the appropriate drug vehicle controls.
Endothelial cells
Human umbilical vein endothelial cells (HUVEC) and human aortic
EC (HAEC; purchased from Promocell, Heidelberg, Germany) were
cultured as described previously [28]. The use of human EC conforms
to the principles outlined in the Declaration of Helsinki and was
approved by Hammersmith Hospitals Research Ethics Committee
(Ref. No. 06/Q0406/21). Pharmacological antagonists, cytokines,
prostaglandins, or vehicle was added directly to the endothelial
culture medium 30–60 min before celecoxib.
Quantitative real-time PCR
Quantitative real-time PCR was performed using an iCycler (Bio-Rad,
Hercules, CA, USA). β-Actin was the housekeeping gene, with data
calculated in relation to β-actin and veriﬁed using glyceraldehyde-3-
phosphatedehydrogenase.DNase1-digested total RNA(1μg)was reverse
transcribed using 1 μM oligo(dT) and Superscript reverse transcriptase
(Invitrogen, Paisley, UK). cDNA was ampliﬁed in a 25 ml reaction
containing 5 μl of cDNA template, 12.5 μl of iSYBR supermix, 0.5 pM sense
and antisense gene-speciﬁc primers, and double-distilled H2O. Primer
sequences used were HO-1 forward 5′-CTTCTTCACCTTCCCCAACA-3′ and
HO-1 reverse 5′-TTCTATCACCCTCTGCCTGA-3′. Cycling parameters were
3 min at 95 °C and 40 cycles of 95°C for 10 s and 56°C for 45 s.
Immunoblotting
Immunoblotting was performed as previously described [29].
Immunoblots were probed with primary antibody overnight at 4°C,
followed by horseradish peroxidase (HRP)-labeled anti-rabbit Ig
(DAKO, Glostrup, Denmark) for 1 h, and developed with a
chemiluminescence substrate (Amersham–Pharmacia Biotech, Little
Chalfont, UK). To ensure equivalent sample loading, protein content
was determined using the Bio-Rad Dc protein assay (Bio-Rad) and
membranes were reprobed with anti-α-tubulin (Sigma–Aldrich).
Integrated density values were obtained with an Alpha Innotech
ChemiImager (Alpha Innotech, San Leandro, CA, USA).
Quantiﬁcation of HO-1 activity
HUVEC were treated with celecoxib for 24 h, ﬁxed in 1%
paraformaldehyde, and permeabilized with 0.1% Triton X-100.
After being washed, the EC were incubated with anti-bilirubin IXα
mAb (24G7), a gift from Dr. T. Yamaguchi (Tokyo Medical and
Dental University, Japan) [30], or isotype-matched control for
30 min, washed, and incubated with HRP-conjugated rabbit anti-
mouse Ig (Jackson ImmunoResearch, West Grove, PA, USA), before
washing and addition of tetramethyl benzidine substrate solution
(Sigma–Aldrich). The enzyme reaction was read at 405/630 nm
and recorded using a plate reader (Dynex Technologies, Worthing,
UK).
Adenovirus
The adenovirus expressing dominant-negative (DN) Nrf2 was
provided by J. Johnson, University of Wisconsin at Madison, and the
empty vector Ad0 control virus was a gift from E. Paleolog (Imperial
College). Adenoviruseswere ampliﬁed inHEK-293A cells, puriﬁed, and
titered using BD Adeno-X puriﬁcation and rapid titer kits (BD
Biosciences, Oxford, UK). After preliminary experiments for optimi-
zation, HUVEC were infected by incubation with Ad DN-Nrf2 and Ad
DN-Akt at amultiplicity of infection (m.o.i.) of 200 infectious units/cell
in serum-free M199 for 2 h at 37°C.
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2′,7′-Dichlorodihydroﬂuorescein diacetate (DCFH-DA) and Mito-
SOX (Invitrogen) were used to detect intracellular peroxides or
mitochondrial-derived superoxide, respectively. DCFH-DA is con-
verted to DCFH, generating a green-ﬂuorescent product, 2′,7′-
dichloroﬂuorescein (DCF; 514 nm excitation/585 nm emission).
MitoSOX, a speciﬁc detector of mitochondrial superoxide, generates
a red-ﬂuorescent product (514 nm excitation/585 nm emission).
HUVEC were preloaded with DCFH-DA (5 μM) for 60 min, or the
mitochondrial dyes MitoTracker 633 (5 μM) or MitoSOX (500 nM) for
15 minutes, before addition of celecoxib. Images were captured using
a confocal laser-scanning microscope (Zeiss, Oberkochen, Germany).
Cellular generation of ROS was quantiﬁed by ﬂow cytometry and by
image analysis of EC ﬂuorescence in 100 cells from three ﬁelds. Cell
ﬂuorescence was corrected for autoﬂuorescence and measured using
a threshold intensity deﬁned by background ﬂuorescence. Results are
expressed as percentage change compared to untreated cells.
Immunoﬂuorescence staining
HUVEC cultured on ﬁbronectin-coated slides (ThermoFisher
Scientiﬁc, Kamstrupvej, Denmark) were treated with celecoxib,
ﬁxed in methanol, and treated with 10% normal goat serum (DAKO)
for 1 h at room temperature. The EC were incubated at 4 °C
overnight with rabbit anti-Nrf2 (1:200) or an isotype-matched
control, washed, and incubated with goat anti-rabbit AlexaFluor 488
antibody (1:200; Invitrogen) for 1 h at room temperature. Cells
were washed, stained with nuclear dye Draq5, and mounted with
Hydromount (National Diagnostics, Atlanta, GA, USA). Nrf2 nuclear
translocation was analyzed by confocal microscopy using images
obtained at 40× magniﬁcation from 10 ﬁelds of view per
experiment. Nrf2 nuclear colocalization was quantiﬁed after
correcting for autoﬂuorescence and deﬁning threshold intensity
from background ﬂuorescence. Results are presented as mean
nuclear colocalization expressed as a percentage of total Nrf2
expression from three independent experiments.
Flow cytometry
EC were harvested and stained with the appropriate primary
mAb for 30 min at 4°C. After being washed, the EC were stained
with ﬂuorescein isothiocyanate-labeled rabbit anti-mouse Ig
(DAKO) at 4°C and analyzed on an Epics XL-MCL ﬂow cytometer
(Coulter, Luton, UK), and the results are expressed as the relative
ﬂuorescence intensity, representing mean ﬂuorescence intensity
(MFI) with test mAb divided by the MFI using an isotype-matched
irrelevant mAb.
Statistical analysis
All data are expressed as the means of the individual experi-
ments±standard error of the mean (SEM). Data were grouped
according to treatment and analyzed using the analysis of variance
with Bonferroni correction or an unpaired Student t test (GraphPad
Prism, San Diego, CA, USA). Differences were considered signiﬁcant
at pb0.05.
Results
Celecoxib increases HO-1 activity in human endothelial cells
The effect of celecoxib on HO-1 expression was initially explored
by concentration–response studies in HUVEC. Increasing concentra-
tions of celecoxib enhanced steady-state HO-1 mRNA levels and
protein expression after 24 h of treatment. An increase in HO-1expression was seen after treatment with 5 μM celecoxib, with
maximal induction of mRNA and protein at concentrations of 10–
25 μM (Figs. 1A and 1B). In light of the signiﬁcant induction of HO-1
protein expression in response to 10 μM celecoxib we chose this
concentration for further experiments. Phase-contrast microscopy,
trypan blue exclusion, and MTT cell survival assays failed to
demonstrate any cellular cytotoxicity at these concentrations in
the presence of 10% fetal bovine serum, with toxicity emerging only
at concentrations of celecoxib N25 μM (not shown). Time-kinetics
studies demonstrated an initial increase in HO-1 protein expression
by 18 h and maximal induction after 48 h of celecoxib treatment
(Fig. 1C). To assess HO-1 activity, an ELISA was used to quantify
intracellular bilirubin IXα using mAb 24G7. Celecoxib increased
intracellular bilirubin levels by 50% above that seen in vehicle-
treated HUVEC (Fig. 1D), conﬁrming an increase in HO-1 enzyme
activity. Subsequent experiments performed with HAEC, to repre-
sent an endothelial surface affected by atherosclerosis, demonstrat-
ed that they responded similarly to HUVEC, with 10 μM celecoxib
inducing a 10-fold increase in HO-1 protein (Fig. 1E).
Differential induction of HO-1 by celecoxib and rofecoxib
To investigate whether HO-1 induction was celecoxib-speciﬁc,
HUVEC were treated with the COX-2-selective antagonists NS-398
and rofecoxib. Concentration–response studies using NS-398 revealed
a 3.5-fold induction of HO-1 protein, whereas rofecoxib failed to
signiﬁcantly increase HO-1 expression over a broad concentration
range (Fig. 1F). Although celecoxib and NS-398 speciﬁcally antagonize
COX-2 activity, at high concentrations they may lose selectivity and
inhibit COX-1. Therefore HUVEC were cultured with increasing
concentrations of indomethacin, which inhibits COX-1 and COX-2,
and this failed to increase HO-1 expression (Fig. 1F), suggesting that
induction of HO-1 by celecoxib and NS-398 is independent of COX
inhibition.
Celecoxib induction of HO-1 is COX-2-independent
We next investigated the role of COX-2 enzyme activity in the
actions of celecoxib. As previously reported, low basal expression
of COX-2 protein was detected in HUVEC [31] and this was
markedly enhanced by treatment with TNFα (Fig. 2A). To explore
the role of reduced prostaglandin synthesis in HO-1 induction by
celecoxib, HUVEC culture medium was supplemented with the
prostaglandin precursor PGH2 or with prostaglandins PGI2 and
PGE2 (both of which are synthesized by HUVEC), in the presence
and absence of celecoxib. PGH2 alone led to a concentration-
dependent threefold induction of HO-1 and in the presence of
celecoxib enhanced HO-1 expression in an additive manner
(Fig. 2B). In contrast, PGE2 and iloprost, a stable analogue of
PGI2, had no effect on HO-1 expression in the presence or absence
of celecoxib (Figs. 2C and 2D). The failure of rofecoxib to induce
HO-1, combined with the demonstration that HO-1 upregulation by
celecoxib is independent of these prostanoids, suggests that COX-2-
independent actions of celecoxib are required for the induction of
HO-1.
Celecoxib induces HO-1 by utilizing a PI-3K- and ROS-dependent
pathway
To explore the role of the PI-3K/Akt pathway, previously
implicated in HO-1 induction [19], we used the PI-3K antagonist
LY290042 and an adenovirus expressing dominant-negative Akt
(DN-Akt). Pretreatment of HUVEC with LY290042 or transfection
with DN-Akt inhibited both basal and celecoxib-induced HO-1
expression compared with the control-treated EC (Fig. 3A).
Moreover, celecoxib enhanced Akt Ser473 phosphorylation as
Fig. 1. Celecoxib enhances HO-1 expression and activity in human endothelial cells. HUVEC were cultured with increasing concentrations of celecoxib for 24 h before analysis of (A)
HO-1 mRNA using quantitative PCR and (B) HO-1 protein expression by immunoblotting. (C) Immunoblot showing the time kinetics of HO-1 expression in HUVEC treated with
10 μM celecoxib. (D) HUVEC were treated with 10 μM celecoxib for 24 h and HO-1 activity was analyzed using an intracellular bilirubin IXα ELISA. Results are expressed as
percentage change relative to untreated cells (n=3). (E) HO-1 protein expression in HAEC treated for 24 h with celecoxib (5 and 10 μM). (F) HUVEC were treated with NS-398,
rofecoxib, indomethacin, or vehicle for 24 h before analysis of HO-1 by immunoblotting. Representative immunoblots alongwith a histogram representing pooled quantiﬁcation data
with respect to α-tubulin are shown (n=5). Data are represented as fold change versus untreated cells (UT) and presented as means±SEM. ⁎pb0.05.
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increase in phosphorylation at 30 min (Fig. 3B). As ROS are known
to activate the Akt signaling cascade and induce HO-1, we
hypothesized that they represent important signaling intermedi-
aries in the regulation of HO-1 by celecoxib. This was initially
demonstrated using the antioxidant N-acetylcysteine, which
reduced both basal and celecoxib-induced HO-1 expression tobelow the level of detection (Fig. 3C) [19]. No toxicity was seen in
HUVEC exposed to N-acetylcysteine (not shown). The ability of
celecoxib to generate intracellular ROS was conﬁrmed using a DCF
assay quantiﬁed by ﬂow cytometry, which revealed an increase in
ROS generation of up to 80% (not shown), and demonstrated by
confocal microscopy with enhanced ﬂuorescence seen after 30 min
of treatment (Fig. 3D).
Fig. 2. The role of prostaglandins and COX-2 in celecoxib-induced HO-1. (A) HUVEC were left untreated (UT) or cultured for 24 h with 1 ng/ml TNFα and analyzed for COX-2
expression by immunoblotting. (B–D) HUVEC were left untreated or treated with 10 μM celecoxib in the presence or absence of (B) 1–10 μM prostaglandin H2 (PGH2), (C) 10 μM
PGE2, (D) 100 nM iloprost or vehicle alone (Veh) for 24 h before analysis of HO-1 by immunoblotting. Representative immunoblots are shown along with histograms representing
pooled quantiﬁcation data with respect to α-tubulin (n=3). Data are shown as fold-change versus UT and presented as means±SEM. ⁎pb0.05.
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mitochondrial-derived ROS
NADPH oxidase and the mitochondrial electron transport chain
(METC) are ﬂavoprotein-containing enzymes and the main source of
ROS in mammalian cells [32]. Their role in HO-1 induction by
celecoxib was initially investigated using the ﬂavoprotein inhibitor
diphenyl iodonium (DPI), which reduced HO-1 induction by celecoxib
from 3.1- to 1.7-fold (not shown). The importance of NADPH oxidase
was further explored using the NADPH oxidase inhibitor apocynin
(100 μM), which had no effect on HO-1 induction by celecoxib (not
shown). Therefore, we next investigated the role of the METC in more
detail using rotenone, a mitochondrial Complex I inhibitor, and
antimycin A, a Complex III inhibitor. As seen in Fig. 4A, both
antagonists signiﬁcantly inhibited celecoxib-mediated HO-1 induc-
tion. Furthermore, uncoupling the mitochondrial respiratory chain
with FCCP also attenuated HO-1 induction (Fig. 4A). Taken together
these data suggest that celecoxib enhances EC HO-1 expression by
increasing mitochondrial-derived rather than NADPH-dependent
ROS.
To explore this hypothesis, we used the mitochondrial dye
MitoTracker to visualize mitochondria and DCFH-DA as a ﬂuores-
cent indicator of hydrogen peroxide formation. We observed an
increase in EC DCF ﬂuorescence within 15 min of exposure to
celecoxib (Fig. 4B). Of note, this was associated with a change in
mitochondrial morphology from a linear appearance to a rounded,punctate form. The DCF ﬂuorescence colocalized with mitochondria,
suggesting that ROS generated by celecoxib were of mitochondrial
origin (Fig. 4C). To conﬁrm this, EC were loaded with MitoSOX, a
triphenylphosphonium-linked dihydroethidium compound, which is
preferentially concentrated into mitochondria and speciﬁcally
detects mitochondrial superoxide generation. Laser confocal mi-
croscopy demonstrated a signiﬁcant increase in EC ﬂuorescence
after treatment with celecoxib, reaching 50% above that in the
control cells (Fig. 4D).
Celecoxib induces HO-1 by enhancing Nrf2 translocation
The transcription factor Nrf2 is retained in the cytoplasm by Kelch-
like ECH-associated protein (Keap1). Oxidative stress results in
dissociation of the Nrf2–Keap1 complex, allowing Nrf2 translocation
to the nucleus, where it controls the expression of phase II
detoxiﬁcation enzymes and antioxidant proteins, including HO-1, via
the antioxidant response element (ARE). We observed a signiﬁcant
increase in nuclear localization of Nrf2within 30min of EC exposure to
celecoxib (Fig. 5A), which was followed by a gradual decline to
baseline by 4 h (Fig. 5B). Pretreating HUVEC with either N-
acetylcysteine or the PI-3K antagonist LY290042 prevented cele-
coxib-induced Nrf2 nuclear translocation (Fig. 5C), further demon-
strating the importance of PI-3K and ROS signaling. Finally, a
recombinant adenovirus expressing DN-Nrf2 (m.o.i. 200) demonstrat-
ed the functional importance of Nrf2 by attenuating the induction of
Fig. 3. Celecoxib induces HO-1 via a PI-3K- and ROS-dependent pathway. (A) HUVEC were cultured with 10 μM celecoxib in the presence or absence of LY290042 (20 μM) for 24 h
before analysis of HO-1 expression by immunoblotting. The histogram represents pooled quantiﬁcation data with respect to α-tubulin (n=3), presented as fold change versus
untreated cells. (Bottom) HUVEC were left untreated or transfected with an adenovirus expressing dominant-negative Akt (DN-Akt; m.o.i. 200) or an empty vector control (Ad0; m.
o.i. 200) and after 24 h treated with celecoxib (10 μM) or vehicle alone for a further 24 h, before analysis of HO-1 by immunoblotting. (B) HUVEC were serum-starved for 2 h before
treatment with 10 μM celecoxib and analysis of phosphorylated Akt (Ser473) at the indicated time points using immunoblotting. The histogram shows pooled quantiﬁcation data
presented as a ratio of phospho-Akt:total Akt (n=3). (C) HUVEC were cultured for 24 h with celecoxib (10 μM) in the presence or absence of N-acetylcysteine (N-Ac, 5 and 10 mM)
and analyzed for HO-1 expression by immunoblotting. The histogram represents pooled quantiﬁcation data with respect to α-tubulin (n=5), presented as fold change versus
untreated cells. (D) HUVEC were loaded with 5 μM DCF for 60 min before treatment with 10 μM celecoxib for 30 min and analyzed using ﬂuorescence confocal microscopy (20×
original magniﬁcation), quantiﬁed by image analysis. Results are expressed as mean percentage ﬂuorescence above untreated cells (UT) and presented as means±SEM. ⁎pb0.05.
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(Fig. 5D).
Celecoxib inhibits TNFα-induced VCAM-1 expression
HO-1 is known to exert anti-inﬂammatory actions in EC including
the inhibition of cellular adhesionmolecule expression [33]. To model
an inﬂammatory state in vitro we exposed HUVEC to TNFα, which
increased cell-surface expression of E-selectin by 20-fold and VCAM-1
by 10- to 15-fold. Pretreatment of HUVEC with celecoxib (10 μM) for
24 h before the addition of TNFα for 16 h led to a signiﬁcant reduction
in VCAM-1, while having no effect on the expression of E-selectin
induced by 6 h exposure to TNFα (Figs. 6A and 6B). To explore the roleof HO-1 in this response we used the HO antagonist ZnPPIX, which did
not itself induce HO-1 expression in HUVEC (Fig. 6C). However, the
ability of celecoxib to repress TNFα-induced VCAM-1 expression was
signiﬁcantly reduced by ZnPPIX (Fig. 6D), supporting the importance
of HO-1 enzyme activity for the anti-inﬂammatory actions of
celecoxib. Finally, in contrast to celecoxib, pretreatment of EC with
rofecoxib (10 μM) for 24 h failed to inhibit TNFα-induced VCAM-1
induction (Fig. 6E).
Discussion
Since the withdrawal of rofecoxib, concern regarding cardiovas-
cular risk has signiﬁcantly reduced the use of COXIBs and, to a
Fig. 4. Celecoxib-induced HO-1 is dependent on mitochondrial-derived ROS. (A) HUVEC lysates were immunoblotted for HO-1 after 24 h of treatment with 10 μM celecoxib in the
presence or absence of the mitochondrial Complex I inhibitor rotenone (2 μM), Complex III inhibitor antimycin A (10 μM), or mitochondrial uncoupler FCCP (1 μM). A representative
immunoblot with pooled quantitative analysis of three independent experiments is shown. Data are expressed as fold change over untreated cells (UT), means±SEM. ⁎pb0.05. (B
and C) HUVEC were preloaded with 5 μM DCF for 60 min and 5 μMMitoTracker red for 15 min followed by exposure to 10 μM celecoxib and analysis by laser confocal microscopy.
DCF, MitoTracker, and merged images are shown at 0 and 15 min post-celecoxib at (B) 20× and (C) 63× original magniﬁcation with 1.5× digital zoom. (D) HUVEC were preloaded
with 500 nM MitoSOX for 15 min followed by exposure to 10 μM celecoxib and analysis by laser confocal microscopy (10× original magniﬁcation). Results are expressed as mean
percentage ﬂuorescence over control cells treated with vehicle alone (UT) and presented as means±SEM. ⁎pb0.05.
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pain control. It is therefore important to consider data from the
TARGET and MEDAL trials, which failed to demonstrate differences
in cardiovascular risk between lumiracoxib and either naproxen or
ibuprofen [8] or between etoricoxib and diclofenac [9]. Moreover,
the cumulative incidence of thrombotic events, stroke, myocardial
infarction, or cardiovascular-related death was low. In contrast, the
trials conﬁrmed a reduced risk of serious gastrointestinal side
effects associated with the use of COXIBs [8,9]. However, an
outstanding question remains, namely whether there are differences
between individual COXIBs and NSAIDs that inﬂuence theircardiovascular proﬁle. To this end, and in light of recent reports
demonstrating that celecoxib and NS-398 enhance expression of the
cytoprotective enzyme HO-1 in mesangial, epithelial, and neuronal
cells [34,35], we chose to explore the effects of COXIBs on HO-1
expression and activity in the vascular endothelium.
Treatment of HUVEC and HAEC with celecoxib led to a
signiﬁcant, sustained upregulation of HO-1 expression and
enzyme activity. Although maximal in vitro responses were
evident at concentrations of celecoxib exceeding those achieved
in the plasma after therapeutic dosing, increased HO-1 expression
was also seen after exposure to 1–5 μM, which can be achieved
Fig. 5. Celecoxib-induced HO-1 is dependent on Nrf2 activation. (A) HUVEC were treated with celecoxib (10 μM) for up to 240 min; ﬁxed; immunostained with anti-Nrf2, isotype-
matched control Ig, and nuclear dye DRAQ5; and analyzed by confocal microscopy. The control Ab did not bind (not shown). (i) 20× and (ii) 63× original magniﬁcation with 1.5×
digital zoom. (B) Histogram representing nuclear Nrf2 as a percentage of total Nrf2 from ﬁve independent experiments. (C) HUVEC were left untreated or pretreated with 20 μM
LY290042 (LY) before the addition of celecoxib or vehicle for 30min and analysis of Nrf2 nuclear localization as above. (D)HUVECwere transfectedwith an adenovirus expressing DN-
NrfF2 or the Ad0 control virus (m.o.i. 200) and after 24 h treated with celecoxib (10 μM) for a further 24 h, before analysis of HO-1 by immunoblotting. Data are expressed as fold
change over untreated cells and presented as means±SEM. ⁎pb0.05.
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Fig. 6. Celecoxib inhibits TNFα-induced VCAM-1 expression. HUVECwere pretreated with celecoxib (10 μM) for 24 h and then treatedwith 0.1 or 1 ng/ml TNFα. (A) Flow-cytometric
analysis of E-selectin expression, after 6 h TNFα stimulation. (B) Flow-cytometric analysis of VCAM-1 expression 16 h post-TNFα stimulation. (C) HUVEC were left untreated (UT) or
treated with celecoxib (10 μM) in the presence or absence of zinc protoporphyrin IX (ZnPP; 10 μM) for 40 h before analysis of HO-1 by immunoblotting. (D) HUVEC were pretreated
with celecoxib in the presence or absence of ZnPP (10 μM) for 24 h and then treated with 1 ng/ml TNFα for 16 h followed by ﬂow-cytometric analysis of VCAM-1 expression. (E)
HUVEC were pretreated with rofecoxib (10 μM) for 24 h followed by TNFα (1 ng/ml) for 16 h and analysis of VCAM-1 expression by ﬂow cytometry. Data are expressed as fold
change over UT. ⁎pb0.05, n=3, presented as means±SEM.
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NS-398, whereas in marked contrast rofecoxib failed to signiﬁ-
cantly increase HO-1 expression. Likewise, celecoxib but not
rofecoxib inhibited HUVEC proliferation in vitro, suggesting that
these COXIBs affect different intracellular endothelial signaling
pathways [36–38]. This concept is also supported by the report
that celecoxib but not rofecoxib reduced TNFα-induced tissue
factor activity in human endothelial cells through inhibition of
the c-Jun terminal NH2 kinase and improved endothelial functionin a model of salt-induced hypertension [15,16]. In clinical use,
rofecoxib and traditional NSAIDs are more likely than celecoxib to
increase peripheral edema [39] and hospital admission for
congestive cardiac failure [40]. Furthermore, in contrast to
rofecoxib [41], celecoxib may improve vascular endothelial
function in men with coronary artery disease, as measured by
ﬂow-mediated dilatation [42]. These observations may also reﬂect
structural differences between the two COXIBs, as evidenced by
the report that the sulfone rofecoxib increases the susceptibility
1022 S.S. Hamdulay et al. / Free Radical Biology & Medicine 48 (2010) 1013–1023of lipids to nonenzymatic oxidative modiﬁcation, a response not
seen with the sulfonamide celecoxib [37].
Prolonged treatment with celecoxib for 24–48 h induced HO-1,
whereas iloprost alone did not. In contrast, a recent report
demonstrated some upregulation of EC HO-1 after treatment with a
prostacyclin receptor agonist carbacyclin [43]. Supplementation of
tissue culture medium with PGE2 or iloprost failed to reverse HO-1
induction by celecoxib, whereas exogenous PGH2 upregulated HO-1
and enhanced the effect of celecoxib. Moreover, whereas NS-398
reproduced the effect of celecoxib, rofecoxib, a more selective COX-2
antagonist, and indomethacin, which inhibits COX-1 and COX-2, did
not. These data suggest that the induction of HO-1 by celecoxib is
predominantly COX-2-independent. Therefore, to investigate under-
lying mechanisms, we initially analyzed changes in PI-3K/Akt
pathway activity and the intracellular redox milieu. Celecoxib
treatment led to phosphorylation of Akt, whereas antagonizing PI-
3K with LY290042 or transfection of DN-Akt inhibited celecoxib-
mediated induction of HO-1. Furthermore, the presence of the ROS
scavenger N-acetylcysteine abrogated HO-1 expression. Subsequent
experiments conﬁrmed that celecoxib treatment led to a rapid
increase in intracellular oxidant generation. We propose that this
leads to activation of PI-3K/Akt, Nrf2 translocation, and HO-1
induction. Of note, this pathway is distinct from that activated in
proliferating endothelial cells, in which prolonged exposure to
celecoxib inhibits Akt phosphorylation and exerts an antiangiogenic
effect [38].
Although ROS in excess induce endothelial dysfunction, it is now
recognized that modest increases, such as that generated by low
levels of oxidized low-density lipoprotein, may elicit protective
responses via activation of redox signaling, resulting in increased
glutathione synthesis and HO-1 expression [32,44]. Inhibition of
celecoxib-induced HO-1 expression by DPI, but not apocynin (a
selective NADPH oxidase inhibitor), implicated mitochondrial rather
than NADPH-induced ROS in HO-1 upregulation, a conclusion
supported by the demonstration of increased mitochondrial super-
oxide generation using MitoSOX. Mitochondrial superoxide synthe-
sis is regulated by Complexes I and III of the respiratory chain, and
the use of their respective inhibitors rotenone and antimycin A, or
uncoupling of the mitochondrial respiratory chain with FCCP,
prevented celecoxib-mediated HO-1 induction. Phosphoglycerate
mutase 5, a Keap1-binding protein, binds to the mitochondrial
membrane through its N-terminal mitochondrial-localization se-
quence, forming a ternary complex with Nrf2 and suppressing Nrf2-
dependent gene expression [45]. Thus, celecoxib may increase
mitochondrial ROS, which in turn bind Keap-1, so disrupting the
ternary complex and allowing Nrf2 translocation and HO-1
induction. Intriguingly, HO-1 activity may itself inhibit COX-2 [46],
raising the possibility of a positive feedback loop.
After release from Keap 1, Nrf2 translocates to the nucleus
where it binds the ARE, thereby regulating expression of phase II
detoxiﬁcation enzymes and antioxidant proteins including HO-1.
The importance of celecoxib-induced Nrf2 nuclear translocation in
HO-1 induction was demonstrated by inclusion of DN-Nrf2, which
speciﬁcally reversed the response. Although beyond the scope of
this report, these data suggest that celecoxib may also induce
expression of other important ARE antioxidant target genes
including NAD(P)H:quinine oxidoreductase-1, thioredoxin reductase
1, glutathione reductase, and ferritin heavy chain.
Although the therapeutic potential of HO-1 remains to be
conﬁrmed and exploited, areas of interest include RA [25], SLE [27],
and atherosclerosis [18]. HO-1 and its products exert a variety of
vasculoprotective effects, including anti-inﬂammatory, antiapoptotic,
antithrombotic, and antioxidant actions [21]. Thus, the ability of
celecoxib to induce HO-1 may act to modulate its cardiovascular
proﬁle in patients with systemic inﬂammatory diseases. The func-
tional relevance of HO-1 induction by celecoxib was demonstrated byits ability to inhibit TNFα-mediated upregulation of VCAM-1, a
response known to be redox sensitive [47]. In contrast rofecoxib
failed to induce HO-1 and was unable to inhibit induction of VCAM-1
TNFα. Although the suppression of VCAM-1 by celecoxib needs to be
conﬁrmed in vivo, it may be clinically relevant given the importance
of VCAM-1 expression in RA, SLE, and atherosclerosis. Intriguingly, a
recent report suggests that HO-1 agonists prevent the progression of
atherosclerotic plaques from stable to unstable in ApoE−/−mice [21].
In conclusion, it is recognized that therapy with NSAIDs and
COXIBs may lead to an increased risk of cardiovascular events.
However, the risk of atherothrombotic complications associated with
celecoxib is relatively low, particularly compared to rofecoxib, and we
propose that HO-1 induction represents a molecular mechanism for
these clinical observations. Thus, these data combined with the
demonstration that celecoxib treatment improves ﬂow-mediated
dilatation in patients with coronary artery disease [42] and the reports
of clinical efﬁcacy and relative safety of celecoxib in patients with RA,
osteoarthritis [6,12], and SLE [48], may help guide prescribing
decisions and suggest that further investigation of the mechanisms
of action of celecoxib and its clinical utility are indicated.Acknowledgments
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